

# SIMONA SOVERINI

CV

## GENERALITA'

---

Data di nascita: 03-09-1975  
Luogo di nascita: Bologna  
Nazionalità: Italiana  
Residenza: Via Camillo Torres, 8 – 40013 Castel Maggiore (BO)  
Stato civile: coniugata  
CF: SVRSMN75P43A944E

## CONTATTI

---

Cellulare: 339 7688671  
E-mail: [simona.soverini@unibo.it](mailto:simona.soverini@unibo.it)

## POSIZIONE ATTUALE

---

Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), Università di Bologna:  
Professoressa Associata, SSD MED/15 Malattie del Sangue

## TITOLI ACCADEMICI E CERTIFICAZIONI

---

- 1999 Università degli Studi di Bologna  
**Laurea in Scienze Biologiche ad Indirizzo Biomolecolare**, conseguita con la votazione di **110/110 e lode**.  
Titolo della Tesi: "Valutazione dell'espressione della ciclina A nel carcinoma primitivo infiltrante della mammella. Un nuovo ed affidabile indicatore della frazione di crescita".
- 2000 Università degli Studi di Bologna  
**Abilitazione all'esercizio della professione di Biologo**.
- 2002 Università degli Studi di Bologna  
**Specializzazione in Chimica e Tecnologie Alimentari**, conseguita la votazione di **70/70 e lode**.  
Titolo della Tesi: "Gli alimenti funzionali: aspetti chimici e nutrizionali".
- 2007 Università degli Studi di Bologna  
**Dottorato di Ricerca in Ematologia Clinica e Sperimentale ed Ematopatologia**.  
Titolo della Tesi: "Le mutazioni puntiformi del gene ABL come meccanismo di resistenza agli inibitori delle tirosin-chinasi nei pazienti con leucemie Philadelphia-positive: significato biologico, clinico e prognostico".
- 2015 Iscrizione all'Ordine Nazionale dei Biologi.

## FORMAZIONE

---

- Marzo 1998 - Luglio 1999

Dipartimento di Scienze Radiologiche ed Istocitopatologiche, Sezione di Anatomia Patologica, Università di Bologna, Policlinico S. Orsola

***Internato di Laurea presso il Laboratorio di Immunocitopatologia Oncologica***

- Settembre 1999 – Settembre 2000

Istituto di Ematologia ed Oncologia Medica “L. e A. Seràgnoli”, Università di Bologna, Policlinico S. Orsola

***Tirocinio post-lauream propedeutico all’ammissione all’Esame di Stato per l’abilitazione alla professione di Biologo presso il Laboratorio di Biologia Molecolare***

- Agosto 2000 - Agosto 2001

Istituto di Ematologia ed Oncologia Medica “L. e A. Seràgnoli”, Università di Bologna, Policlinico S. Orsola

***Titolare di Borsa di Studio erogata dall’Azienda Ospedaliera S.Orsola*** per effettuare ricerche su “Impiego cellule staminali periferiche con e senza purging in vitro”

- Settembre 2001 - Agosto 2009

Istituto di Ematologia ed Oncologia Medica “L. e A. Seràgnoli”, Università di Bologna, Policlinico S. Orsola

***Titolare di Assegno di Ricerca dell’Università di Bologna***, con progetto dal titolo “Basi molecolari della resistenza a imatinib e a nuovi inibitori delle tirosin-chinasi nelle leucemie philadelphia-positive”

- Settembre 2009 – Agosto 2011

Dipartimento di Ematologia e Scienze Oncologiche “L. e A. Seràgnoli”, Università di Bologna, Policlinico S. Orsola

***Titolare di Borsa di Studio dell’Università di Bologna*** destinata ad attività di ricerca sul tema “Valutazione dell’impatto clinico e terapeutico delle mutazioni puntiformi del gene BCR-ABL”

- Settembre 2011 – Aprile 2012

Dipartimento di Ematologia e Scienze Oncologiche “L. e A. Seràgnoli”, Università di Bologna, Policlinico S. Orsola

***Titolare di Assegno di Ricerca dell’Università di Bologna***, con progetto dal titolo “Il sequenziamento di nuova generazione per la caratterizzazione della resistenza agli inibitori delle tirosino-chinasi nei pazienti con leucemie Philadelphia- positive”

- dal 2 Aprile 2012

Dipartimento di Ematologia e Scienze Oncologiche “L. e A. Seràgnoli”, successivamente Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES), Università di Bologna

***Ricercatrice Universitaria (MED/15- Malattie del Sangue)***

- dal 2 Aprile 2015

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES), Università di Bologna

***Ricercatrice Universitaria Confermata (MED/15- Malattie del Sangue)***

- dall’11 Aprile 2022

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale (DIMES), Università di Bologna

***Professoressa Associata (MED/15- Malattie del Sangue)***

## POSSESSO DEI REQUISITI ASN

### SECONDA FASCIA:

Settore concorsuale	Conseguimento	Scadenza
<b>06/D3 - Ematologia, Oncologia e Reumatologia</b>	<b>03/12/2013*</b>	<b>21/01/2029*</b>
06/B1 - Medicina Interna	23/12/2013	23/12/2024
06/A2 - Patologia Generale e Patologia Clinica	08/01/2014	08/01/2025
05/F1 - Biologia Applicata	24/11/2014	24/11/2025
06/A1 - Genetica Medica	07/01/2014	07/01/2025
06/N1 - Scienze delle Professioni Sanitarie e delle Tecnologie Mediche Applicate	31/03/2017	31/03/2028
05/E3 - Biochimica Clinica e Biologia Molecolare Clinica	05/04/2017	05/04/2028
05/E2 - Biologia Molecolare	10/01/2020	10/01/2031

### PRIMA FASCIA:

Settore concorsuale	Conseguimento	Scadenza
05/F1 - Biologia Applicata	24/11/2014	24/11/2025
06/D3 - Ematologia, Oncologia e Reumatologia	06/04/2017	06/04/2028
06/N1 - Scienze delle Professioni Sanitarie e delle Tecnologie Mediche Applicate	13/01/2020	13/01/2031

\*Conseguita nella tornata 2012 e di nuovo nella tornata 2018

## ATTIVITA' DI RICERCA

### Organizzazione, direzione e coordinamento di gruppi di ricerca nazionali

- **Principal Investigator** del progetto **AIRC IG GRANT 2015** "High throughput technologies for improved diagnosis, molecular profiling and therapy of systemic mastocytosis" (Project Id.16996); durata, 36 mesi.
- **Principal Investigator** del Progetto **AIRC IG GRANT 2019** "ReSETting SETD2/H3K36Me3 deficiency in advanced systemic mastocytosis and chronic myeloid leukemia" (Project Id.23001); durata, 60 mesi.
- **Responsabile di un gruppo di ricerca** sulla leucemia mieloide cronica e la mastocitosi sistemica (2012-2017) e sulle leucemie mieloidi acute e croniche (2018-presente) presso l'Istituto di Ematologia "L. e A. Seràgnoli", Università di Bologna.

### Organizzazione, direzione e coordinamento di gruppi di ricerca internazionali

- **Coordinatrice** dello **European LeukemiaNet Expert Panel** for BCR-ABL KD mutation analysis in CML (2010-2011).
- **Coordinatrice del workpackage (WP) "BCR-ABL" dello studio internazionale IRON-II** (Interlaboratory RObustness of Next Generation Sequencing)(2012-2014).
- **Coordinatrice del WP 'BCR-ABL mutation registry'** nell'ambito del progetto EUTOS-CML ("European Treatment and Outcome Study on the therapy of patients with Chronic Myeloid Leukemia (CML) and the optimization of CML management") (2007-2010, rinnovato 2011-2012).

- **Co-coordinatrice del WP ‘New Technologies’** nell’ambito del progetto EUTOS 2016
- **Coordinatrice del WP ‘BCR-ABL mutation profiling in patients with unstable MMR’** nell’ambito del progetto EUTOS 2018.

### **Partecipazione a centri/gruppi di ricerca nazionali**

- Membro del gruppo di ricerca del progetto **PRIN 2007**: “Le cellule staminali emopoietiche nella leucemia mieloide cronica: effetti biologici e clinici dell’esposizione agli inibitori delle tirosino-chinasi”, prot 2007F7AE7B\_002; coordinatore scientifico del progetto, Prof. Fabrizio Pane; responsabile scientifico dell’unità di ricerca, Prof. Michele Bacarani; durata, 24 mesi.
- Membro del gruppo di ricerca del progetto **AIRC IG GRANT 2007**: “Mechanisms responsible for sensitivity and resistance of Ph-positive cells to tyrosine kinase inhibitors”, coordinatore scientifico del progetto, Prof. Giovanni Martinelli; durata, 36 mesi.
- Membro del gruppo di ricerca del progetto **PRIN 2009**: “Meccanismi di controllo delle cellule staminali Ph1+: implicazioni prognostiche e applicazioni terapeutiche” prot 2009JSMKYE; coordinatore scientifico del progetto, Prof. Michele Bacarani sostituito da Dott.ssa Simona Soverini dal 12/12/2012; durata, 24 mesi.
- Membro del comitato scientifico della **Rete Italiana Mastocitosi (RIMA)**.
- **Componente del Gruppo di Ricerca** del Professor Giovanni Martinelli (Biologia Molecolare e Terapia Molecolare delle Leucemie) presso l’Istituto di Ematologia “L. e A. Seràgnoli”, Università di Bologna (1999-2012).

### **Partecipazione a centri/gruppi di ricerca internazionali**

- Membro di **European LeukemiaNet (ELN)** (2004-presente).
- Membro del **network EICML** (European Investigators on CML)(2004-presente).
- Partecipante dell’**FP7-HEALTH-2012-INNOVATION-1** – Seventh Framework Programme 2011 “Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia” – (Acronym: NGS-PTL). Responsabile scientifico del progetto, Prof. Giovanni Martinelli; durata, 36 mesi.
- **Collaborazioni internazionali** comprovate da pubblicazioni scientifiche: Prof. Andreas Hochhaus, Prof. Thomas Ernst (University of Jena, Germany); Prof. Torsten Haferlach (University of Munich, Germany); Prof. Nick Cross (University of Southampton, UK); Prof. Michael Deininger and Prof. Thomas O’Hare, (University of Utah, Salt Lake City, USA); Prof. Jerald Radich (University of Washington, Seattle, USA); Prof. Timothy Hughes (University of Adelaide, Australia); Prof. Peter Valent (Medical University of Vienna, Austria); Dr. Katerina Machova Polakova (Institute of Hematology and Blood Transfusion, Prague, Czech Republic); Prof Thomas Lion, (Medical University of Vienna, Austria); Dr Franck-Emmanuel Nicolini (Centre Hospitalier Universitaire de Lyon, France).

### **Affiliazione a società scientifiche nazionali**

- Membro del **Consiglio Direttivo della Società Italiana di Ematologia Sperimentale (SIES)**(2020-presente)

- Membro della **Società Italiana di Ematologia (SIE)**

### **Affiliazione a società scientifiche internazionali**

- **Membro dell'American Society of Hematology (ASH)**
- **Membro dell'American Association for Cancer Research (AACR)**
- **Membro della Society of Hematological Oncology (SOHO)**
- **Membro della European Hematology Association (EHA)**

### **Partecipazione a comitati editoriali di riviste**

- **Associate Editor** nella sezione 'Hematologic Malignancies' della rivista *Frontiers in Oncology* (IF 6.244; 2021-presente)
- **Membro dell'Editorial Board** delle riviste:
  - *Cancer Medicine* (IF 4.711; 2022-presente)
  - *Journal of Hematology & Oncology* (IF 23.168; 2016-presente)
  - *International Journal of Molecular Sciences* (IF 6.208; 2017-presente)
  - *Stem Cell Investigation* (2016-presente)
  - *TheScientificWorld Journal* (last IF 1.219; 2012-2017)
- **Guest Editor** di:
  - Special Issue: "Advances in the Molecular Biology and Targeted Therapy of Leukemias" della rivista *International Journal of Molecular Sciences* (IF 6.208) (2018-2019)
  - Special Issue: "Advances in the Molecular Biology and Targeted Therapy of Leukemias 2.0" della rivista *International Journal of Molecular Sciences* (IF 6.208) (2020)
  - Special Issue: "Advances in the Molecular Biology and Targeted Therapy of Leukemias 3.0" della rivista *International Journal of Molecular Sciences* (IF 6.208) (2021)
  - Special Issue: "Hematologic Diseases: Molecular Insights and Novel Methods" della rivista *International Journal of Molecular Sciences* (IF 6.208) (2024)
  - Special Issue "Prognosis and Therapy of Chronic Myeloid Leukemia" della rivista *Journal of Clinical Medicine* (IF 4.964) (2020)
  - Research Topic "Next-Generation Sequencing in Hematologic Malignancies" della rivista *Frontiers in Oncology* (IF 6.244)
  - Research Topic "Chronic Myeloid Leukemia: From Targeted Therapy to Treatment-Free Remission" della rivista *Frontiers in Pharmacology* (IF 5.81)

### **Attività di revisore scientifico**

- **Revisore di articoli** per riviste scientifiche internazionali con IF: *Blood*; *Blood Advances*; *Leukemia*; *Haematologica*; *Clinical Cancer Research*; *Cancer*; *Leukemia Research*; *Cancer Letters*; *Annals of Hematology*; *Acta Haematologica*; *Clinical and Experimental Medicine*; *Drug Discovery Today*; *Cancer Treatment Reviews*; *Leukemia Treatment and Research*; *Anti-Cancer Drugs*; *European Journal of Haematology*, ecc
- **Revisore di abstracts** per lo della **European Hematology Association** (EHA; 2008, 2009, 2013, 2015 [coordinating reviewer], 2016 [coordinating reviewer], 2017 [coordinating reviewer], 2021, 2023), dell'**American Society of Hematology** (ASH; 2009, 2015; 2023),

della **Società Italiana di Ematologia Sperimentale** (SIES; 2010, 2012, 2014, 2016, 2018, 2020, 2022, 2024) e per l'**European School of Hematology** (ESH) International Conference on CML (2011, 2012, 2016)

- **Revisore di grant applications** per l'Università di Malta (2023, 2024)
- **Revisore di grant applications** per l'Israeli Ministry of Health (2021)
- **Revisore di grant applications** per la Fundació La Caixa (2021, 2023)
- **Revisore di grant applications** per l'Agency for Health Quality and Assessment of Catalonia (2019)
- **Revisore di grant applications** per il Czech Health Research Council (2017; 2020)
- **Revisore di Special Research Programmes** per l'Austrian Science Fund (2016; 2017)
- **Revisore di grant applications** per la Kay Kendall Leukemia Foundation (KKLF)(2009; 2017)
- **Revisore di grant applications** per la Leuka Foundation (2016)
- **Revisore di grant applications** per il National Science Center (Narodowe Centrum Nauki – NCN), Poland (2014)
- **Revisore di grant applications** per la German-Israeli Foundation for Scientific Research and Development (GIF) (2013)
- **Revisore di richieste di finanziamento per assegni di ricerca** per l'Università degli Studi di Padova (2012) e per l'Università dell'Insubria (2013)
- **Revisore di progetti per il Bando MIUR Futuro in Ricerca 2013**

## **Premi e riconoscimenti internazionali**

- **2007 AACR-GlaxoSmithKline Outstanding Clinical Scholar Award**  
assegnato per l'Highly Rated Abstract: Soverini et al, "Mutations at contact residues in the ATP-binding site are the main cause of upfront or acquired resistance to dasatinib in Philadelphia chromosome-positive (Ph+) leukemia patients" presentato al 2007 AACR Annual Meeting.
- **2010 AACR-Pezcoller Foundation Scholar-in-Training Award**  
assegnato per l'abstract: Soverini et al, "First Application of Whole-Transcriptome Sequencing to a High-Risk Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time of Disease Progression to Blast Crisis (BC)" presentato al 2010 AACR Annual Meeting.
- **2010 ASCO Cancer Foundation Merit Award**  
assegnato per l'abstract: Soverini et al, "Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients" presentato al 2010 ASCO Annual Meeting.
- **2012 ASCO Cancer Foundation Merit Award**  
assegnato per l'abstract: Soverini et al, "Bcr-Abl kinase domain mutations and resistance in Philadelphia-chromosome positive acute lymphoblastic leukemia from the imatinib to the second-generation TKI era" presentato al 2012 ASCO Annual Meeting.

## **Partecipazione in qualità di relatrice a congressi nazionali e internazionali**

- Ha partecipato a **292** congressi di **interesse nazionale e internazionale** in qualità di **relatrice su invito (Allegato 4)**. Tra questi, in particolare:
- è stata **invited speaker** a congressi nazionali delle **Società Brasiliana** (2009), **Coreana** (2009; 2019; 2022), **Cinese** (2015), **Rumena** (2012, 2017), **Greca** (2015), **Spagnola** (2019), **Giapponese** (2020) e **Francese** (2023) di **Ematologia**, della **Società Rumena di Genetica Medica** (2014), della **Società Russa di Genetica** (2015).

- E' stata **keynote speaker** al "**16th Annual John Goldman Conference on CML: Biology and Therapy**" (Philadelphia, Pennsylvania, 4-7 settembre 2014) e al "**25th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy**" (Mandelieu-La Napoule, Francia, 6-8 ottobre 2023).
- E' stata **invited speaker** nell'**Educational Session: "Chronic Myeloid Leukemia"** del **20th Meeting della European Hematology Association (EHA)** (Vienna, 11-14 giugno 2015) con una presentazione dal titolo "New methodologies and monitoring tools for chronic myeloid leukemia" e nuovamente nell'**Educational Session "Current challenges in Chronic Myeloid Leukemia treatment"** del **25th Meeting della European Hematology Association (EHA)** (virtual, 2020) con una presentazione dal titolo "Resistance to TKIs and new treatment targets".
- E' stata **invited speaker** nell'**Educational Session: "How Do We Tackle Remaining Clinical Challenges in CML?"** del **65th Annual Meeting of the American Society of Hematology (ASH)** (San Diego, CA, 2023) con una presentazione dal titolo "Resistance mutations and how we approach them".
- E' stata **keynote speaker** al **19th annual Symposium of the European Leukemia Net** con una lecture dal titolo "ELN Laboratory Recommendations for the diagnosis and management of CML".
- Ha tenuto **seminari** in Università, Unità di Ematologia/Medicina Interna o centri di ricerca a **Vienna, Praga, Copenhagen, Lund, Stockholm, Bern, Basel, Zurich, Mannheim, Berlin, Aachen, Freiburg, Essen, Wurzburg, Buenos Aires, Seoul, Toronto, Calgary, Windsor (Ontario), Hamilton (Ontario), Vancouver, Edmonton.**
- E' stata **chairman** di sessioni scientifiche a diversi congressi nazionali ed internazionali, inclusi gli Annual Meetings dell'American Society of Hematology (ASH; 2009, 2015, 2023) e della European Hematology Association (EHA; 2008, 2015, 2016), l'Annual Meeting della Society of Hematologic Oncology (SOHO; 2016). In particolare, è stata **chairman dell'Educational Session: "Chronic Myeloid Leukemia"** del **Meeting della European Hematology Association (EHA)** a Copenhagen nel 2016 e a Madrid nel 2017.
- Ha partecipato ad altri **95** congressi nazionali ed internazionali in qualità di **discente (Allegato 6)**.

## **Organizzazione di congressi nazionali ed internazionali**

- Membro del **Scientific Program Committee** dell'**Annual Meeting of the Society of Hematological Oncology (SOHO)** (2014 - presente)
- Membro del **Scientific Program Committee Advisory Board** del **2015 Annual Meeting della European Hematology Association (EHA)**
- Membro della **Scientific Program Committee** del **2016 e 2017 Annual Meetings della European Hematology Association (EHA)**
- Membro dell'**Advisory Committee** dell'**Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy**, organizzato dalla **European School of Heematology (ESH)** (2016 - presente)
- **Responsabile Scientifico/membro della Segreteria Scientifica** di **11** congressi nazionali (**Allegato 5**)

## **Produzione scientifica**

- **Contributi in volume: 5**
  - Tura  
“Corso di malattie del sangue e degli organi emolinfopoietici” quarta (2007), quinta (2011), sesta (2015) e settima (2020) Edizione. Casa Editrice Esculapio, Bologna
  - Tura, Cavo, Zinzani  
“Hematology: pathophysiology, diagnosis and treatment” prima edizione in inglese (2018). Casa Editrice Esculapio, Bologna
  - “Chronic Myeloid Leukemia Diagnosis and Treatment”. Editor, Rüdiger Hehlmann. 1st ed. Springer International Publishing Switzerland: Springer International. 2016
  - “Oxford Specialist Handbooks in Oncology: Myeloproliferative Neoplasms” Editors, Tariq I Mughal and Tiziano Barbui. Oxford University Press. 2020
  - “Next generation sequencing nelle leucemie Ph+”. Mattioli 1885. Fidenza. 2018
- **Pubblicazioni su riviste internazionali peer-reviewed: 181 (Allegato 1).**  
**Citazioni totali: 12317; h-index: 55** (fonte: Scopus Database, 16/06/2024).
- **Abstracts** presentati a congressi nazionali o internazionali come **first o senior author: 150**, di cui 66 selezionati come comunicazione orale (**Allegato 2**).
- **Abstracts** presentati a congressi nazionali o internazionali come **contributing author: 456** (**Allegato 3**).

## ATTIVITA' DIDATTICA

---

### Attività didattica frontale

- Modulo 1 e 2 “**Molecular Basis of Haematological Disorders**” (cod. 90936)(CFU: 3; ore: 16 lezioni frontali +15 esercitazioni di laboratorio; lingua: inglese; SSD: MED/15) del **Corso integrato 90933 – “Normal and Leukemic Stem Cells” – Università di Bologna, Scuola di Farmacia e Biotecnologie, Laurea Magistrale in Medical Biotechnology** (a.a. 2023-2024)
- Modulo “**Biologia delle cellule staminali emopoietiche e concetti di immunoterapia**” (cod. 85555)(CFU: 1; ore: 8; lingua: italiano; SSD: MED/15) del corso elettivo integrato **85554 – TRAPIANTO DI CELLULE STAMINALI EMOPOIETICHE C.I. – Università di Bologna, Scuola di Medicina e Chirurgia, Laurea Magistrale a Ciclo Unico in Medicina e Chirurgia** (a.a. 2017-2018 - presente)
- Modulo “**Biologia molecolare degli oncogeni e delle lesioni delle emopatie**” (cod. 78632)(CFU: 1; ore: 8; lingua: italiano; SSD: MED/15) del corso elettivo integrato **78629 – GENETICA ONCO- EMATOLOGICA C.I. – Università di Bologna, Scuola di Medicina e Chirurgia, Laurea Magistrale a Ciclo Unico in Medicina e Chirurgia** (a.a. 2012-2013 - presente)
- Modulo “**Patologia molecolare dei linfomi**” (70793)(CFU: 1; ore 8; lingua: italiano; SSD: MED/08) del **corso elettivo integrato: 70792 - EMATOPATOLOGIA C.I. – Università di Bologna, Scuola di Medicina e Chirurgia, Laurea Magistrale a Ciclo Unico in Medicina e Chirurgia** (a.a. 2015-2016) in sostituzione del Prof. Pier Paolo Piccaluga
- Modulo “**Biologia e Genetica**” (**frazionamento b e d**) (cod.15950)(CFU totali: 9; ore 48; lingua: italiano; SSD: BIO/13) del corso integrato **21197 - BIOLOGIA E GENETICA C.I. – Università di Bologna, Scuola di Medicina e Chirurgia, Laurea Magistrale a Ciclo Unico in Medicina e Chirurgia, canale di recupero** (a.a. 2014-2015)



- Modulo **“Laboratorio di Biologia e Genetica” (frazionamento c)** (cod. 90171)(CFU: 1; ore: 8; lingua: italiano; SSD: BIO/13) del corso integrato **21197 - BIOLOGIA E GENETICA C.I. – Università di Bologna, Scuola di Medicina e Chirurgia, Laurea Magistrale a Ciclo Unico in Medicina e Chirurgia, canale di recupero** (a.a. 2014-2015)
- Modulo **80117 - EMATOLOGIA II - DIDATTICA FRONTALE - Mod. 4 - Leucemia mieloide cronica 1** (CFU: 2; ore: 16; lingua: italiano; SSD: MED/15) per la **Scuola di Specializzazione 8914-EMATOLOGIA, Università di Bologna** (a.a. 2014-2015 – presente)
- Modulo **80129 - DIAGNOSTICA EMATOLOGICA II** (CFU: 1; ore: 8; lingua: italiano; SSD: MED/15) per la **Scuola di Specializzazione 8914-EMATOLOGIA, Università di Bologna** (a.a. 2014-2015, 2015-2016)
- Modulo **80117 - EMATOLOGIA II - DIDATTICA FRONTALE - Mod. 5 "Leucemia mieloide acuta"** - (CFU: 2; ore: 16; lingua: italiano; SSD: MED/15) per la **Scuola di Specializzazione 8914-EMATOLOGIA, Università di Bologna** (a.a. 2019-2020 – presente)
- Modulo **5157 – MALATTIE DEL SANGUE** (CFU: 1; ore: 8; lingua: italiano; SSD: MED/15) per la **Scuola di Specializzazione 7121-GENETICA MEDICA, Università di Bologna** (a.a. 2019-2020 – presente)
- Componente della Commissione d’esame del C.I. Ematologia, Immunologia Clinica e Reumatologia, Laurea Magistrale a Ciclo Unico in Medicina e Chirurgia, Università di Bologna.

### **Attività didattica integrativa**

- **Relatrice** per la preparazione di **tesi di Laurea Magistrale di 11 studenti del CdL in Biologia della Salute** (Luana Bavaro; Sara De Santis; Cecilia Monaldi; Margherita Martelli; Sara Malfatto; Angela Sergi; Carlotta Calitri; Francesco Tedeschi; Marzia Costanzo; Angelica Marina Bove; Cristina Mosca), **3 studentesse del CdL in Biotecnologie Mediche** (Angela Maria Bruno; Serena Chimenti; Sara Russo), **1 studente del CdL in Medical Biotechnology** (Alessandro Claudio Taccini) dell’Università di Bologna.
- **Tutor** di **8 Assegnisti di Ricerca** (Dr.ssa Caterina De Benedittis; Dott.ssa Daria Sollazzo, Dott.ssa Gabriella Chirumbolo, Dott.ssa Luana Bavaro, Dott.ssa Margherita Martelli, Dott.ssa Sara De Santis, Dott.ssa Cecilia Monaldi, Dott.ssa Samantha Bruno, DIMES) e di **2 Borsisti** (Dott.ssa Margherita Martelli, Dott.ssa Cecilia Monaldi - DIMES).
- **Co-supervisore di 1 Tesi di Dottorato di Ricerca in Scienze Biomediche, 27° Ciclo** (Dott.ssa Caterina de Benedittis).
- **Supervisore di 5 Tesi di Dottorato in Patologia, Oncologia ed Ematologia** (Dott.ssa Maria Chiara Fontana, 31° ciclo; Dott.ssa Michela Rondoni, Dott.ssa Samantha Bruno, Dott.ssa Valentina Robustelli, 32° ciclo; Dott.ssa Cecilia Monaldi, 36° ciclo).
- **Seminari per il Dottorato in Patologia, Oncologia ed Ematologia:** “Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy” (36° ciclo-presente).
- Membro del **Collegio Docenti del Dottorato in Oncologia, Ematologia e Patologia** (33° Ciclo-presente)
- **Membro interno della commissione giudicatrice per il conferimento del titolo di Dottore di Ricerca in ‘Oncologia, Ematologia e Patologia’, 30° ciclo, Università degli studi di Bologna** (9/5/2018)

- **Membro esterno della commissione giudicatrice per il conferimento del titolo di Dottore di Ricerca in 'Genetica Molecolare Applicata alle Scienze Mediche', 28° ciclo, Università degli Studi di Brescia (16/12/2016)**
- **Membro esterno della commissione giudicatrice per il conferimento del titolo di Dottore di Ricerca in 'Medicina e Terapia Sperimentale', 30° ciclo, Università degli Studi di Torino (23/7/2020)**
- **Revisore esterno di Tesi di Dottorato in 'Genetica Molecolare Applicata alle Scienze Mediche' dell'Università degli Studi di Brescia (Dott.ssa Simona Bernardi, 28° ciclo); in 'Trapianti di Tessuti ed Organi e Terapie Cellulari' dell'Università degli Studi di Bari (Dott. Cosimo Cumbo, Dott.ssa Angela Minervini, Dott.ssa Maria Rosa Conserva, 30°, 31° e 35° ciclo); in 'Genetica Molecolare, Biotecnologie e Medicina Sperimentale' dell'Università degli Studi di Brescia (Dott.ssa Camilla Zanaglio, 32° ciclo); in 'Medicina e Terapia Sperimentale' dell'Università degli Studi di Torino (Dott.ssa Elisabetta Signorino, 30° ciclo)**

## **ATTIVITÀ ISTITUZIONALI, ORGANIZZATIVE E DI SERVIZIO ALL'ATENEO**

- **Membro della Commissione VRA (2022-presente)**
- **Commissario ai test di ammissione ai Corsi di Laurea in Medicina e Chirurgia e Odontoiatria dell'Università di Bologna (2013, 2014, 2015, 2017, 2018, 2019; 2023)**
- **Membro di 17 Commissioni Giudicatrici per l'attribuzione di Assegni di Ricerca L. 240/2010**
- **Membro di 3 Commissioni di Valutazione per proroga biennale RTD-A**

La sottoscritta, consapevole delle responsabilità penali previste dagli artt. 75 e 76 del D.P.R. n.445 del 28/12/2000 per le ipotesi di falsità negli atti e dichiarazioni mendaci, dichiara di aver redatto il presente curriculum sotto la propria personale responsabilità, ai sensi degli artt. 46 e 47 del predetto D.P.R. n.445/2000.

Ai sensi del D.LGS. 196/03 e s.m.i. dichiara inoltre il consenso al trattamento dei dati personali contenuti nel presente documento.

Bologna, 16/06/2024

In fede



## Allegato 1

### ELENCO DELLE PUBBLICAZIONI SU RIVISTE PEER-REVIEWED

---

1. : Sciumè M, Serpenti F, Zanotti R, Bonadonna P, Tanasi I, Crosera L, Elena C, Mannelli F, Crupi F, Papayannidis C, Sartor C, **Soverini S**, Rondoni M, Eller-Vainicher C, Pravettoni V, Rivolta F, Alberti Violetti S, Croci GA, Migliorini AC, Bolli N, Giannarelli D, Grifoni FI. Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis. *Hematol Oncol*. 2024 May;42(3):e3277. [IF 2020: 5,271]
2. Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, Monaldi C, Klamova H, Srbova D, Zizkova H, Hochhaus A, **Soverini S**, Machova Polakova K (co-last author). Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia. *Am J Hematol*. 2024 Feb 5. Epub ahead of print. doi: 10.1002/ajh.27232. [IF 2020: 13,268]
3. **Soverini S**. Resistance mutations in CML and how we approach them. *Hematology Am Soc Hematol Educ Program*. 2023 Dec 8;2023(1):469-475.
4. Cross NCP, Ernst T, Branford S, Cayuela JM, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R, Hochhaus A, Apperley JF, **Soverini S**. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. *Leukemia*. 2023 Nov;37(11):2150-2167. [IF 2020: 12,897]
5. Iezza M, Cortesi S, Ottaviani E, Mancini M, Venturi C, Monaldi C, De Santis S, Testoni N, **Soverini S**, Rosti G, Cavo M, Castagnetti F. Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights. *Cells*. 2023 Jun 23;12(13):1703. [IF 2020: 6,000]
6. Mancini M, De Santis S, Monaldi C, Castagnetti F, Lonetti A, Bruno S, Dan E, Sinigaglia B, Rosti G, Cavo M, Gugliotta G, **Soverini S**. Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. *Front Oncol*. 2022 Aug 5;12:901132. [IF 2020: 6,244]
7. **Soverini S**, De Santis S, Martelli M, Monaldi C, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Bruno S, Venturi C, Machova Polakova K, Ernst T, Maar D, Corner A, Cavo M. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia. *Leukemia*. 2022 Sep;36(9):2250-2260. [IF 2020: 11,528]
8. Bruno S, Ghelli Luserna di Rorà A, Napolitano R, **Soverini S**, Martinelli G, Simonetti G. CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies. *J Exp Clin Cancer Res*. 2022 Apr 30;41(1):159. doi: 10.1186/s13046-022-02363-9. [IF 2020: 11,161]

9. Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D'Adda M, Salvucci M, Stagno F, Rege-Cambrin G, Tiribelli M, Martino B, Bocchia M, Cedrone M, Trabacchi E, Cavazzini F, Porretto F, Sorà F, Simula MP, Albano F, **Soverini S**, Foà R, Pane F, Cavo M, Saglio G, Baccarani M, Rosti G. Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. *Haematologica*. 2022 Oct 1;107(10):2356-2364. **[IF 2020: 9,941]**
10. Baccarani M, Bonifazi F, **Soverini S**, Castagnetti F, Gugliotta G, Saber W, Estrada-Merly N, Rosti G, Gale RP. Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia. *Leukemia*. 2022 May;36(5):1227-1236. **[IF 2020: 11,528]**
11. Mancini M, Monaldi C, De Santis S, Rondoni M, Papayannidis C, Sartor C, Curti A, Bruno S, Cavo M, **Soverini S**. Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells. *Cancers (Basel)*. 2022 Jan 31;14(3):738. **[IF 2020: 6,639]**
12. De Santis S, Monaldi C, Mancini M, Bruno S, Cavo M, **Soverini S**. Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia. *Onco Targets Ther*. 2022 Jan 25;15:103-116. **[IF 2020: 4,147]**
13. Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, **Soverini S**, Terragna C, Marconi G, Lemoli RM, Guolo F, Fornaro A, Lunghi M, de Fabritiis P, Candoni A, Selleri C, Simonetti F, Bocchia M, Vitale A, Frison L, Tedeschi A, Cuneo A, Bonifacio M, Martelli MP, D'Ardia S, Trappolini S, Tosi P, Galieni P, Fabbiano F, Abbenante MC, Granier M, Zhu Z, Wang M, Sartor C, Paolini S, Cavo M, Foà R, Fazi P, Vignetti M, Baccarani M. INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia. *Blood Adv*. 2022 Mar 22;6(6):1742-1753. **[IF 2020: 6,686]**
14. Bruno S, Bandini L, Patuelli A, Robustelli V, Venturi C, Mancini M, Forte D, De Santis S, Monaldi C, Grassi A, Chiurumbolo G, Paolini S, Cristiano G, Papayannidis C, Sartor C, Nanni J, Ottaviani E, Curti A, Cavo M, **Soverini S**. Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia. *Front Oncol*. 2021 Sep 30;11:728613. **[IF 2020: 6,244]**
15. Monaldi C, De Santis S, Mancini M, Bruno S, Cavo M, **Soverini S**. Systemic Mastocytosis: Molecular Landscape and Implications for Treatment. *Mediterr J Hematol Infect Dis*. 2021 Jul 1;13(1):e2021046. **[IF 2020: 2,576]**
16. **Soverini S**, De Santis S, Monaldi C, Bruno S, Mancini M. Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort? *Int J Mol Sci*. 2021 Jun 30;22(13):7093. **[IF 2020: 5,923]**
17. Bruno S, Mancini M, De Santis S, Monaldi C, Cavo M, **Soverini S**. The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities. *Int J Mol Sci*. 2021 Jun 25;22(13):6857. **[IF 2020: 5,923]**

18. Papayannidis C, Sartor C, Dominietto A, Zappone E, Arpinati M, Marconi G, Cristiano G, Nanni J, Parisi S, Barbato F, Paolini S, **Soverini S**, Terragna C, Robustelli V, Testoni N, Chirumbolo G, Curti A, Cavo M, Bonifazi F. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant. *Hematol Oncol*. 2021 Oct;39(4):580-583. **[IF 2020: 5,271]**
19. Fontana MC, Nanni J, Ghelli Luserna di Rorà A, Petracci E, Padella A, Ghetti M, Ferrari A, Marconi G, **Soverini S**, Iacobucci I, Papayannidis C, Curti A, Audisio E, Giannini MB, Rondoni M, Lanza F, Cavo M, Martinelli G, Simonetti G. Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. *Biomedicines*. 2021 Apr 6;9(4):388. **[IF 2020: 6,081]**
20. Schäfer V, White HE, Gerrard G, Möbius S, Saussele S, Franke G-N, Mahon F-X, Talmaci R, Colomer D, **Soverini S**, Machova Polakova K, Cross NCP, Hochhaus A, Ernst T. Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts. Recommendations by the EUTOS cooperative network. *J Cancer Res Clin Oncol*. 2021 Oct;147(10):3081-3089. **[IF 2020: 4,553]**
21. **Soverini S**. Improving prognostication and management of Systemic Mastocytosis. *Lancet Haematol*. 2021 Mar;8(3):e164-e166. **[IF 2020: 18,959]**
22. **Soverini S**, Martelli M, Bavaro L, De Benedittis C, Papayannidis C, Sartor C, Sorà F, Albano F, Galimberti S, Abruzzese E, Annunziata M, Russo S, Stulle M, Imovilli A, Bonifacio M, Maino E, Stagno F, Basilico CM, Borlenghi E, Fozza C, Mignone F, Minari R, Stella S, Baccarani M, Cavo M, Martinelli G. Next generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukemia. *Br J Haematol*. 2021 Apr;193(2):271-279. **[IF 2020: 6,998]**
23. **Soverini S**, Martelli M, Bavaro L, De Benedittis C, Sica S, Sorà F, Iurlo A, Bonifacio M, Pregnò P, Galimberti S, Lunghi F, Albano F, D'Adda M, Crugnola M, Capodanno I, Castagnetti F, Gugliotta G, Papayannidis C, Rosti G, Percesepe A, Mignone F, Baccarani M, Martinelli G, Cavo M. BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. *Leukemia*. 2021 Jul;35(7):2102-2107. **[IF 2020: 11,528]**
24. **Soverini S**, Bernardi S, Galimberti S. Molecular Testing in CML between Old and New Methods: Are We at a Turning Point? *J Clin Med*. 2020 Nov 27;9(12):E3865. **[IF 2020: 3.303]**
25. Russo D, Garcia-Gutierrez JV, **Soverini S**, Baccarani M. Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives. *J Clin Med*. 2020 Jun 2;9(6): E1709. **[IF 2020: 3.303]**
26. Martelli M, Monaldi C, De Santis S, Bruno S, Mancini M, Cavo M, **Soverini S**. Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for

Diagnosis, Prognosis, and Therapy. *Int J Mol Sci.* 2020 Jun 2;21(11): E3987. [IF 2020: 5,923]

27. **Soverini S**, Albano F, Bassan R, Fabbiano F, Ferrara F, Foà R, Olivieri A, Rambaldi A, Rossi G, Sica S, Specchia G, Venditti A, Barosi G, Pane F. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position paper. *Cancer Med.* 2020 May;9(9):2960-2970. [IF 2020: 4,452]
28. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rouselot P, Saglio G, Sauße S, **Soverini S**, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. *Leukemia.* 2020 Apr;34(4):966-984. [IF 2020: 11,528]
29. **Soverini S**, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, Sica S, Sorà F, Lunghi F, Ciceri F, Galimberti S, Baratè C, Bonifacio M, Scaffidi L, Castagnetti F, Gugliotta G, Albano F, Russo Rossi AV, Stagno F, di Raimondo F, D'Adda M, di Bona E, Abruzzese E, Binotto G, Sancetta R, Salvucci M, Capodanno I, Girasoli M, Coluzzi S, Attolico I, Musolino C, Calistri E, Annunziata M, Bocchia M, Stella S, Serra A, Errichiello S, Saglio G, Pane F, Vigneri P, Mignone F, Laginestra MA, Pileri SA, Percesepe A, Tenti E, Rosti G, Baccarani M, Cavo M, Martinelli G. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. *Blood.* 2020 Feb 20;135(8):534-541. [IF 2020: 22,113]
30. Mancini M, De Santis S, Monaldi C, Bavaro L, Martelli M, Gugliotta G, Castagnetti F, Rosti G, Santucci MA, Martinelli G, Cavo M, **Soverini S**. Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis. *Hematol Oncol.* 2020 Apr;38(2):201-203. [IF 2020: 5,271]
31. Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, Beltrami G, Bergamaschi M, Binotto G, Bocchia M, Caocci G, Capodanno I, Cavazzini F, Cedrone M, Cerrano M, Crugnola M, D'Adda M, Elena C, Fava C, Fazi P, Fozza C, Galimberti S, Gai V, Gozzini A, Gugliotta G, Iurlo A, La Barba G, Levato L, Lucchesi A, Luciano L, Lunghi F, Lunghi M, Malagola M, Marasca R, Martino B, Melpignano A, Miggiano MC, Montefusco E, Musolino C, Palmieri F, Pugno P, Rapezzi D, Rege-Cambrin G, Rupoli S, Salvucci M, Sancetta R, Sica S, Spadano R, Stagno F, Tiribelli M, Tomassetti S, Trabacchi E, Bonifacio M, Breccia M, Castagnetti F, Pane F, Russo D, Saglio G, **Soverini S**, Vigneri P, Rosti G. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. *Blood Adv.* 2019 Dec 23;3(24):4280-4290. [IF 2020: 6,686]
32. Bavaro L, Martelli M, Cavo M, **Soverini S**. Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update. *Int J Mol Sci.* 2019 Dec 5;20(24):6141. [IF 2020: 5,923]

- 33.** Padella A, Simonetti G, Paciello G, Giotopoulos G, Baldazzi C, Righi S, Ghetti M, Stengel A, Guadagnuolo V, De Tommaso R, Papayannidis C, Robustelli V, Franchini E, Rorà AGLD, Ferrari A, Fontana MC, Bruno S, Ottaviani E, **Soverini S**, Storlazzi CT, Haferlach C, Sabattini E, Testoni N, Iacobucci I, Huntly BJP, Ficarra E, Martinelli G. Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia. *Cancers (Basel)*. 2019 Dec 5;11(12):1951. [IF 2020: 6,639]
- 34.** **Soverini S**, Abruzzese E, Bocchia M, Bonifacio M, Galimberti S, Gozzini A, Iurlo A, Luciano L, Pugno P, Rosti G, Saglio G, Stagno F, Tiribelli M, Vigneri P, Barosi G, Breccia M. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. *J Hematol Oncol*. 2019 Dec 5;12(1):131. [IF 2020: 17,388]
- 35.** Bruno S, Bochicchio MT, Franchini E, Padella A, Marconi G, Ghelli Luserna di Rorà A, Venturi C, Raffini M, Prisinzano G, Ferrari A, Bandini L, Robustelli V, Pazzaglia M, Fontana MC, Sartor C, Abbenante MC, Papayannidis C, **Soverini S**, Ottaviani E, Simonetti G, Martinelli G. Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia. *J Oncol*. 2019 Oct 30;2019:5985923. [IF 2020: 4,375]
- 36.** Moisiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghea M, Dima D, Precup R, Tomuleasa C, **Soverini S**. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology. *Front Oncol*. 2019 Sep 23;9:863. [IF 2020: 6,244]
- 37.** Bacarani M, Rosti G, **Soverini S**. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. *Leukemia*. 2019 Oct;33(10):2358-2364. [IF 2020: 11,528]
- 38.** Mancini M, De Santis S, Monaldi C, Bavaro L, Martelli M, Castagnetti F, Gugliotta G, Rosti G, Santucci MA, Martinelli G, Cavo M, **Soverini S**. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. *J Exp Clin Cancer Res*. 2019 May 23;38(1):216. [IF 2020: 11,161]
- 39.** **Soverini S**, Martelli M, Bavaro L. BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now? *Lancet Haematol*. 2019 May;6(5):e236-e237. [IF 2020: 18,959]
- 40.** **Soverini S**, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. *J Hematol Oncol*. 2019 Apr 23;12(1):39. [IF 2020: 17,388]
- 41.** Bacarani M, Castagnetti F, Gugliotta G, Rosti G, **Soverini S**, Albeer A, Pffirmann M; International BCR-ABL Study Group. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. *Leukemia*. 2019 May;33(5):1173-1183. [IF 2020: 11,528]

42. Fontana MC, Marconi G, Feenstra JDM, Fonzi E, Papayannidis C, Ghelli Luserna di Rorá A, Padella A, Solli V, Franchini E, Ottaviani E, Ferrari A, Baldazzi C, Testoni N, Iacobucci I, **Soverini S**, Haferlach T, Guadagnuolo V, Semerad L, Doubek M, Steurer M, Racil Z, Paolini S, Manfrini M, Cavo M, Simonetti G, Kralovics R, Martinelli G. Chromothripsis in acute myeloid leukemia: biological features and impact on survival. *Leukemia*. 2018 Jul;32(7):1609-1620. [IF 2020: 11,528]
43. **Soverini S**, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. *Mol Cancer*. 2018 Feb 19;17(1):49. [IF 2020: 27,401]
44. Cargnin S, Ravegnini G, **Soverini S**, Angelini S, Terrazzino S. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis. *Pharmacol Res*. 2018 May;131:244-254. [IF 2020: 7,658]
45. Martinelli G, Mancini M, De Benedittis C, Rondoni M, Papayannidis C, Manfrini M, Meggendorfer M, Calogero R, Guadagnuolo V, Fontana MC, Bavaro L, Padella A, Zago E, Pagano L, Zanotti R, Scaffidi L, Specchia G, Albano F, Merante S, Elena C, Savini P, Gangemi D, Tosi P, Ciceri F, Poletti G, Riccioni L, Morigi F, Delledonne M, Haferlach T, Cavo M, Valent P, **Soverini S**. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. *Leukemia*. 2018 Jan;32(1):139-148. [IF 2020: 11,528]
46. Mancini M, **Soverini S**, Gugliotta G, Santucci MA, Rosti G, Cavo M, Martinelli G, Castagnetti F. Chibby 1: a new component of  $\beta$ -catenin-signaling in chronic myeloid leukemia. *Oncotarget*. 2017 Sep 22;8(50):88244-88250. [IF 2016: 5,168]
47. Bucelli C, Cattaneo D, Ferla V, Zappa M, de Benedittis C, **Soverini S**, Iurlo A. Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case. *Case Rep Hematol*. 2017;2017:6167345.
48. De Benedittis C, Papayannidis C, Venturi C, Abbenante MC, Paolini S, Parisi S, Sartor C, Cavo M, Martinelli G, **Soverini S**. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report. *BMC Cancer*. 2017 Aug 5;17(1):523. [IF 2020: 4,430]
49. Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, **Soverini S**, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto - Chronic Myeloid Leukemia Working Party. Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. *Haematologica*. 2017 Sep;102(9):1530-1536. [IF 2020: 9,941]
50. Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, **Soverini S**,



Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. *Am J Hematol*. 2017 Aug;92(8):797-805. [IF 2020: 10,047]

51. Luatti S, Baldazzi C, Marzocchi G, Ameli G, Bochicchio MT, **Soverini S**, Castagnetti F, Tiribelli M, Gugliotta G, Martinelli G, Baccarani M, Cavo M, Rosti G, Testoni N. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. *Oncotarget*. 2017 May 2;8(18):29906-29913. [IF 2016: 5,168]
52. Mancini M, Castagnetti F, **Soverini S**, Leo E, De Benedittis C, Gugliotta G, Rosti G, Bavaro L, De Santis S, Monaldi C, Martelli M, Santucci MA, Cavo M, Martinelli G. FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage. *J Cell Biochem*. 2017 Nov;118(11):3968-3975. [IF 2020: 4,429]
53. Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, **Soverini S**, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. *Am J Hematol*. 2017 Jan;92(1):82-87. [IF 2020: 10,047]
54. **Soverini S**, Baccarani M, Martinelli G. Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia. *Lancet Haematol*. 2016 Dec;3(12):e554-e555. [IF 2020: 18,959]
55. Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, **Soverini S**, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. *Haematologica*. 2016 Oct;101(10):1200-1207. [IF 2020: 9,941]
56. **Soverini S**, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. *BMC Cancer*. 2016 Aug 2;16:572. [IF 2020: 4,430]
57. Lewis M, Copland M, **Soverini S**, Sadovnik I, Bedel A, Prost S, Italiano A, Mahon F-X. What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer? *Hematol Oncol*. 2017 Dec;35(4):420-423. [IF 2020: 5,271]

58. Catherwood M, McGrattan P, Lawless S, McConville C, Robson N, Lundy B, Humphreys M, **Soverini S**, Mills KI, McMullin MF. Coexistence of inversion1 6 in chronic myeloid leukemia in blast crisis. *J. Hematopathol.* 2016;9:155. [IF 2020: 0,196]
59. **Soverini S**, De Benedittis C, Machova Polakova K, Linhartova J, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Klamova H, Salvucci M, Crugnola M, Iurlo A, Albano F, Russo D, Rosti G, Cavo M, Baccarani M, Martinelli G. Next-Generation Sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. *Oncotarget.* 2016 Apr 19;7(16):21982-90. [IF 2016: 5,168]
60. Polivkova V, Rohon P, Klamova H, Cerna O, Divoka M, Curik N, Zach J, Novak M, Marinov I, **Soverini S**, Faber E, Machova Polakova K. Interferon- $\alpha$  Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients. *PLoS One.* 2016 May 23;11(5):e0155959. [IF 2020: 3,240]
61. Pieri L, Bonadonna P, Elena C, Papayannidis C, Grifoni FI, Rondoni M, Girlanda S, Mauro M, Magliacane D, Elli EM, Iorno ML, Almerigogna F, Scarfi F, Salerno R, Fanelli T, Gesullo F, Fattori GC, Bonifacio M, Perbellini O, Artuso A, **Soverini S**, De Benedittis C, Muratori S, Pravettoni V, Cova V, Cortellini G, Ciceri F, Cortelezzi A, Martinelli G, Triggiani M, Merante S, Vannucchi AM, Zanotti R. Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. *Am J Hematol.* 2016 Jul;91(7):692-9. [IF 2020: 10,047]
62. **Soverini S**, De Benedittis C., Mancini M, Martinelli G. Best practices in chronic myeloid leukemia monitoring and management. *Oncologist.* 2016 May;21(5):626-33. [IF 2020: 5.025]
63. Gugliotta G, Castagnetti F, Breccia M, Gozzini A, Usala E, Carella AM, Rege-Cambrin G, Martino B, Abruzzese E, Albano F, Stagno F, Luciano L, D'Adda M, Bocchia M, Cavazzini F, Tiribelli M, Lunghi M, Falcone AP, Musolino C, Levato L, Venturi C, **Soverini S**, Cavo M, Alimena G, Pane F, Martinelli G, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. *Am J Hematol.* 2016 Jun;91(6):617-22. [IF 2020: 10,047]
64. **Soverini S**, De Benedittis C, Papayannidis C, Machova Polakova K, Venturi C, Russo D, Bresciani P, Iurlo A, Mancini M, Vitale A, Chiaretti S, Foà R, Abruzzese E, Sorà F, Kohlmann A, Haferlach T, Baccarani M, Cavo M, Martinelli G. Clinical impact of low burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. *Leukemia.* 2016 Jul;30(7):1615-9. [IF 2020: 11,528]
65. **Soverini S**, De Benedittis C., Mancini M, Martinelli G. Present and future of molecular monitoring in chronic myeloid leukaemia. *Br J Haematol.* 2016 May;173(3):337-49. [IF 2020: 6,998]

66. **Soverini S**, Martinelli G. Interferon in CML: back to the past, or towards the future? *Lancet Haematol.* 2015 Jan;2(1):e8-9. [IF 2020: 18,959]
67. Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, **Soverini S**, Hochhaus A, Hughes TP, Rivera VM, Branford S. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. *Blood.* 2016 Feb 11;127(6):703-12. [IF 2020: 22,113]
68. Russo D, Malagola M, Skert C, Cancelli V, Turri D, Pregno P, Bergamaschi M, Fogli M, Testoni N, De Vivo A, Castagnetti F, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Cambrin GR, Nicolini G, Abruzzese E, Tiribelli M, Bigazzi C, Usala E, Russo S, Russo-Rossi A, Lunghi M, Bocchia M, D'Emilio A, Santini V, Girasoli M, Lorenzo RD, Bernardi S, Palma AD, Cesana BM, **Soverini S**, Martinelli G, Rosti G, Baccarani M. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. *Blood Cancer J.* 2015 Sep 18;5:e347. [IF 2020: 11,037]
69. **Soverini S**, De Benedittis C, Mancini M, Martinelli G. Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia. *Clin Lymphoma Myeloma Leuk* 2015 Jun;15 Suppl S120-8. [IF 2020: 3,231]
70. Mancini M, Leo E, Takemaru K, Campi V, Castagnetti F, **Soverini S**, De Benedittis C, Rosti G, Cavo M, Santucci MA, Martinelli G. 14-3-3 Binding and Sumoylation Concur to the Down-Modulation of  $\beta$ -catenin Antagonist chibby 1 in Chronic Myeloid Leukemia. *PLoS One.* 2015 Jul 6;10(7):e0131074. [IF 2020: 3,240]
71. Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, **Soverini S**, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. *Haematologica.* 2015 Sep;100(9):1146-50. [IF 2020: 9,941]
72. Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, **Soverini S**, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. *Leukemia.* 2015 Sep;29(9):1823-31. [IF 2020: 11,528]
73. Linhartova J, Hovorkova L, **Soverini S**, Benesova A, Jaruskova M, Klamova H, Zuna J, Machova Polakova K. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing. *Mol Cancer.* 2015 Apr 18;14:89. [IF 2020: 27,401]
74. Savini P, Rondoni M, Poletti G, Lanzi A, Quercia O, **Soverini S**, De Benedittis C, Musardo G, Martinelli G, Stefanini GF. Serum total tryptase level confirms itself as a more

reliable marker of mast cells burden in mast cell leukaemia (aleukaemic variant). Case Rep Hematol. 2015;2015:737302.

75. De Matteis G, Zanotti R, Colarossi S, De Benedittis C, Garcia-Montero A, Bonifacio M, Sartori M, Aprili F, Caruso B, Paviati E, Carli G, Perbellini O, Zamò A, Bonadonna P, Pizzolo G, Guidi G, Martinelli G, **Soverini S**. The impact of sensitive KIT D816V detection on recognition of Indolent Systemic Mastocytosis. Leuk Res. 2015 Mar;39(3):273-8. **[IF 2020: 3,156]**
76. Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, de Benedittis C, Haferlach T, Baccharani M, Martinelli G, Stopka T, Ernst T, Hochhaus A, Kohlmann A, **Soverini S**. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015 May;141(5):887-99. **[IF 2020: 4,553]**
77. Zheng Q, Wu H, Yu Q, Kim DH, Lipton JH, Angelini S, **Soverini S**, Vivona D, Takahashi N, Cao J. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis. Pharmacogenomics J. 2015 Apr;15(2):127-34. **[IF 2020: 3,550]**
78. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada JC, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton J, Rea D, Stenke L, Barbany G, Lange T, Hernandez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccharani M, **Soverini S**, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton, WL, Eiring AE, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Philadelphia Chromosome-Positive Leukemia. Cancer Cell 2014 Sep 8;26(3):428-42. **[IF 2020: 31,743]**
79. Mughal TI, Vannucchi AM, **Soverini S**, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, Goldman JM. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Haematologica 2014 May;99(5):797-801. **[IF 2020: 9,941]**
80. Baccharani M, **Soverini S**, De Benedittis C. Molecular Monitoring and Mutations in Chronic Myeloid Leukemia: How to Get the Most out of Your Tyrosine Kinase Inhibitor. Am Soc Clin Oncol Educ Book. 2014;34:167-75.
81. Iacobucci I, Lonetti A, Venturi C, Ferrari A, Papayannidis C, Ottaviani E, Abbenante MC, Paolini S, Bresciani P, Potenza L, Parisi S, Cattina F, **Soverini S**, Russo D, Luppi M, Martinelli G. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response. Leuk Res 2014 May;38(5):581-5. **[IF 2020: 3,156]**
82. **Soverini S**, Rosti G, Baccharani M, Martinelli G. Molecular Monitoring. Curr Hematol Malig Rep. 2014 Mar;9(1):1-8. **[IF 2020: 3,952]**

- 83. Soverini S**, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, Luppi M, Bresciani P, Salvucci M, Russo D, Sica S, Orlandi E, Intermesoli T, Gozzini A, Bonifacio M, Rigolin GM, Pane F, Baccarani M, Cavo M, Martinelli G. Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. *Cancer*. 2014 Apr 1;120(7):1002-9. [IF 2020: 6,860]
- 84.** Baccarani M, **Soverini S**. Molecular response in CML: where is the bar? *Blood*. 2014 Jul 24;124(4):469-71. [IF 2020: 22,113]
- 85. Soverini S**, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Müller MC, Radich JP, Shah NP. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. *Leuk Res*. 2014 Jan;38(1):10-20. [IF 2020: 3,156]
- 86.** Malagola M, Breccia M, Skert C, Cancelli V, **Soverini S**, Iacobucci I, Cattina F, Liberati AM, Tiribelli M, Annunziata M, Trabacchi E, De Vivo A, Castagnetti F, Martinelli G, Fogli M, Stagno F, Pica G, Iurlo A, Pregno P, Abruzzese E, Pardini S, Bocchia M, Russo S, Pierri I, Lunghi M, Barulli S, Merante S, Mandelli F, Alimena G, Rosti G, Baccarani M, Russo D. Long term outcome of ph+ cml patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. *Am J Hematol*. 2014 Feb;89(2):119-24. [IF 2020: 10,047]
- 87.** Leo E, Mancini M, Aluigi M, Luatti S, Castagnetti F, Testoni N, **Soverini S**, Santucci MA, Martinelli G. BCR-ABL1-Associated Reduction of Beta Catenin Antagonist Chibby1 in Chronic Myeloid Leukemia. *PLoS One*. 2013 Dec 10;8(12):e81425. [IF 2020: 3,240]
- 88.** Baccarani M, Deininger MW, Rosti G, Hochhaus A, **Soverini S**, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Sauße S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*. 2013 Aug 8;122(6):872-84. [IF 2020: 22,113]
- 89. Soverini S**, De Benedittis C, Machova Polakova K, Brouckova A, Horner D, Iacono M, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Iacobucci I, Venturi C, Bochicchio MT, Klamova H, Cattina F, Russo D, Bresciani P, Binotto G, Giannini B, Kohlmann A, Haferlach T, Roller A, Rosti G, Cavo M, Baccarani M, Martinelli G. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. *Blood*. 2013 Aug 29;122(9):1634-48. [IF 2020: 22,113]
- 90.** Nicolini FE, Ibrahim AR, **Soverini S**, Martinelli G, Müller MC, Hochhaus A, Dufva IH, Kim DW, Cortes J, Mauro MJ, Chuah C, Labussière H, Morisset S, Roche-Lestienne C, Lippert E, Hayette S, Peter S, Zhou W, Maguer-Satta V, Michallet M, Goldman J, Apperley JF, Mahon FO, Marin D, Etienne G. The BCR-ABL1 T315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase

inhibitors, in a matched pair analysis. *Haematologica*. 2013 Oct;98(10):1510-6. [IF 2020: 9,941]

91. Russo D, Martinelli G, Malagola M, Skert C, **Soverini S**, Iacobucci I, De Vivo A, Testoni N, Castagnetti F, Gugliotta G, Turri D, Bergamaschi M, Pregno P, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Fava C, Abruzzese E, Tiribelli M, Bigazzi C, Cesana BM, Rosti G, Baccarani M. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. *Blood*. 2013 Jun 27;121(26):5138-44. [IF 2020: 22,113]
92. Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, **Soverini S**, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. *Leuk Lymphoma*. 2013 Jun;54(6):1151-8. [IF 2020: 2.969]
93. Angelini S\*, **Soverini S\***, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. *Haematologica*. 2013 Feb;98(2):193-200. [IF 2020: 9,941] \*co-first authors
94. Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, **Soverini S**, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. *BMC Cancer*. 2013 Apr 2;13(1):173. [IF 2020: 3.15]
95. Khorashad JS, Kelley TW, Szankasi P, Mason CC, **Soverini S**, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. *Blood*. 2013 Jan 17;121(3):489-98. [IF 2020: 22,113]
96. Baccarani M, Pileri S, Steegmann JL, Muller M, **Soverini S**, Dreyling M; ESMO Guidelines Working Group. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012 Oct;23 Suppl7:vii72-7. [IF 2020: 32,976]
97. Branford S, Kim DW, **Soverini S**, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. *J Clin Oncol*. 2012 Dec 10;30(35):4323-9. [IF 2020: 44,544]

98. **Soverini S**, Martinelli G, Rosti G, Iacobucci I, Baccarani M. Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. *Pharmacogenomics*. 2012 Aug;13(11):1271-84. [IF 2020: 2,533]
99. Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E, Ferrari A, Papayannidis C, Paoloni F, Vitale A, Storlazzi CT, Ottaviani E, Guadagnuolo V, Durante S, Vignetti M, **Soverini S**, Pane F, Foà R, Baccarani M, Müschen M, Perini G, Martinelli G. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. *PLoS One*. 2012;7(7):e40934. [IF 2020: 3,240]
100. Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti A, Xumerle L, Ferrari A, Papayannidis C, Malerba G, Luiselli D, Boattini A, Garagnani P, Vitale A, **Soverini S**, Pane F, Baccarani M, Delledonne M, Martinelli G. Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia. *Blood Cancer J*. 2012 Mar;2(3):e61. [IF 2020: 11,037]
101. Abate F, Acquaviva A, Paciello G, Foti C, Ficarra E, Ferrarini A, Delledonne M, Iacobucci I, **Soverini S**, Martinelli G, Macii E. Bellerophon: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model. *Bioinformatics*. 2012 Aug 15;28(16):2114-21. [IF 2020: 6,937]
102. Martínez-Serra J, Gutiérrez A, Marcús TF, **Soverini S**, Amat JC, Navarro-Palou M, Ros T, Bex T, Ballester C, Bauça JM, SanFelix S, Novo A, Vidal C, Santos C, Besalduch J. Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL kinase domain mutations. *Clin Biochem*. 2012 Mar;45(4-5):345-51. [IF 2020: 3,281]
103. White DL, Radich J, **Soverini S**, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G, Hughes TP. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. *Haematologica*. 2012 Jun;97(6):907-14. [IF 2020: 9,941]
104. Intermesoli T, Castagnetti F, **Soverini S**, Bussini A, Spinelli O, Gnani A, Bassan R, Rosti G. Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib. *Leuk Res*. 2012 Jan;36(1):e10-1. [IF 2020: 3,156]
105. Iacobucci I, Ferrari A, Lonetti A, Papayannidis C, Paoloni F, Trino S, Storlazzi CT, Ottaviani E, Cattina F, Impera L, Abbenante MC, Vignetti M, Vitale A, Potenza L, Paolini S, **Soverini S**, Pane F, Luppi M, Foà R, Baccarani M, Martinelli G. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. *Clin Cancer Res*. 2011 Dec 1;17(23):7413-23. [IF 2020: 12,531]
106. Foà R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propriis MS, Elia L, Paoloni F, Fazi P, Cimino G, Nobile F, Ferrara F, Castagnola C, Sica S, Leoni P, Zuffa E, Fozza C, Luppi M, Candoni A, Iacobucci I, **Soverini S**, Mandelli F, Martinelli G, Baccarani M.

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood*. 2011 Dec 15;118(25):6521-8. [IF 2020: 22,113]

107. Nicolini FE, Basak GW, **Soverini S**, Martinelli G, Mauro MJ, Müller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussière H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. *Blood*. 2011 Nov 17;118(20):5697-700. [IF 2020: 22,113]
108. **Soverini S**, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Iacobucci I, Palandri F, Rosti G, Testoni N, Luatti S, Marzocchi G, Baccharani M, Martinelli G. Low-level BCR-ABL mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. *Leuk Res*. 2011 Nov;35(11):1527-9. [IF 2020: 3,156]
109. Porro A, Iraci N, **Soverini S**, Diolaiti D, Gherardi S, Terragna C, Durante S, Valli E, Kalebic T, Bernardoni R, Perrod C, Haber M, Norris MD, Baccharani M, Martinelli G, Perini G. c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells. *Mol Cancer Res*. 2011 Aug;9(8):1054-66. [IF 2020: 5,852]
110. **Soverini S**, Rosti G, Iacobucci I, Baccharani M, Martinelli G. Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? *Oncologist*. 2011;16(6):868-76. [IF 2020: 5,025]
111. **Soverini S**, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Müller MC, Ernst T, Rosti G, Porkka K, Baccharani M, Cross NC, Martinelli G. Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. *Blood*. 2011 Aug 4;118(5):1208-15. [IF 2020: 22,113]
112. Oyekunle AA, Castagnetti F, Gugliotta G, **Soverini S**, Baccharani M, Rosti G. F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib. *Leuk Res*. 2011 Jul;35(7):e118-20. [IF 2020: 3,156]
113. Abate F, Acquaviva A, Ficarra E, Paciello G, Macii E, Ferrarini A, Delledonne M, **Soverini S**, Martinelli G. A novel framework for chimeric transcript detection based on accurate gene fusion model. 2011 IEEE International Conference on Bioinformatics and Biomedicine Workshops, BIBMW 2011. 34-41.
114. Iacobucci I, Sazzini M, Garagnani P, Ferrari A, Boattini A, Lonetti A, Papayannidis C, Mantovani V, Marasco E, Ottaviani E, **Soverini S**, Girelli D, Luiselli D, Vignetti M, Baccharani M, Martinelli G. A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia. *Leuk Res*. 2011 Aug;35(8):1052-9. [IF 2020: 3,156]



- 115.** Soverini S, Vitale A, Poerio A, Gnani A, Colarossi S, Iacobucci I, Cimino G, Elia L, Lonetti A, Vignetti M, Paolini S, Meloni G, di Maio V, Papayannidis C, Amabile M, Guarini A, Bacarani M, Martinelli G, Foà R. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. *Haematologica*. 2011 Apr;96(4):552-7. [IF 2020: 9,941]
- 116.** Soverini S, Gnani A, Colarossi S, Castagnetti F, Rosti G, Amabile M, Palandri F, Gugliotta G, Bacarani M, Martinelli G. The T212R Bcr-Abl mutation is extremely rare in imatinib-resistant chronic myeloid leukemia patients. *Blood* 2010. E-letter [IF 2020: 22,113]
- 117.** Soverini S, Score J, Iacobucci I, Poerio A, Lonetti A, Gnani A, Colarossi S, Ferrari A, Castagnetti F, Rosti G, Cervantes F, Hochhaus A, Delledonne M, Ferrarini A, Sazzini M, Luiselli D, Bacarani M, Cross NC, Martinelli G. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. *Leukemia*. 2011 Jan;25(1):178-81. [IF 2020: 11,528]
- 118.** Della Peruta M, Martinelli G, Moratti E, Pintani D, Vezzalini M, Mafficini A, Grafone T, Iacobucci I, Soverini S, Murineddu M, Vinante F, Tecchio C, Piras G, Gabbas A, Monne M, Sorio C. Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. *Cancer Res*. 2010 Nov 1;70(21):8896-906. [IF 2020: 12,701]
- 119.** Iacobucci I, Lonetti A, Paoloni F, Papayannidis C, Ferrari A, Storlazzi CT, Vignetti M, Cilloni D, Messa F, Guadagnuolo V, Paolini S, Elia L, Messina M, Vitale A, Meloni G, Soverini S, Pane F, Bacarani M, Foà R, Martinelli G. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. *Haematologica*. 2010 Oct;95(10):1683-90. [IF 2020: 9,941]
- 120.** Baruzzi A, Iacobucci I, Soverini S, Lowell CA, Martinelli G, Berton G. c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration. *FEBS Lett*. 2010 Jan 4;584(1):15-21. [IF 2020: 4,124]
- 121.** Iacobucci I, Lonetti A, Messa F, Ferrari A, Cilloni D, Soverini S, Paoloni F, Arruga F, Ottaviani E, Chiaretti S, Messina M, Vignetti M, Papayannidis C, Vitale A, Pane F, Piccaluga PP, Paolini S, Berton G, Baruzzi A, Saglio G, Bacarani M, Foà R, Martinelli G. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. *Leukemia*. 2010 Jan;24(1):66-73. [IF 2020: 11,528]
- 122.** Martinelli G, Iacobucci I, Papayannidis C, Soverini S. New targets for Ph+ leukaemia therapy. *Best Pract Res Clin Haematol*. 2009 Sep;22(3):445-54. [IF 2020: 3,020]
- 123.** Martinelli G, Iacobucci I, Soverini S, Piccaluga PP, Cilloni D, Pane F. New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia. *Expert Rev Hematol*. 2009 Jun;2(3):297-303. [IF 2020: 2,929]

- 124.** Baccarani M, Castagnetti F, Gugliotta G, Palandri F, **Soverini S**; European Leukemia Net. Response definitions and European Leukemianet Management recommendations. *Best Pract Res Clin Haematol*. 2009 Sep;22(3):331-41. **[IF 2020: 3,020]**
- 125.** Nicolini FE, Mauro MJ, Martinelli G, Kim DW, **Soverini S**, Muller MC, Hochhaus A, Cortes J, Chuah C, Dufva IH, Apperley JF, Yagasaki F, Pearson JD, Peter S, Sanz Rodriguez C, Preudhomme C, Giles F, Goldman JM, Zhou W. Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation. *Blood*. 2009 Dec 17;114(26):5271-8. **[IF 2020: 22,113]**
- 126.** Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Rege Cambrin G, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, **Soverini S**, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. *Blood*. 2009 Dec 3;114(24):4933-8. **[IF 2020: 22,113]**
- 127.** Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, **Soverini S**, Vitale A, Chiaretti S, Cimino G, Papayannidis C, Paolini S, Elia L, Fazi P, Meloni G, Amadori S, Saglio G, Pane F, Baccarani M, Foà R. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. *J Clin Oncol*. 2009 Nov 1;27(31):5202-7. **[IF 2020: 44,544]**
- 128.** Hughes T, Saglio G, Branford S, **Soverini S**, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. *J Clin Oncol*. 2009 Sep 1;27(25):4204-10. **[IF 2020: 44,544]**
- 129.** Jabbour E, **Soverini S**. Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. *Semin Hematol*. 2009 Apr;46(2 Suppl 3):S22-6. PubMed PMID: 19621546. **[IF 2020: 3,851]**
- 130.** Palandri F, Castagnetti F, **Soverini S**, Poerio A, Gugliotta G, Luatti S, Amabile M, Martinelli G, Rosti G, Baccarani M. Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. *Haematologica*. 2009 Dec;94(12):1758-61. **[IF 2020: 9,941]**
- 131.** Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, **Soverini S**, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Foà R, Martinelli G. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). *Blood*. 2009 Sep 3;114(10):2159-67. **[IF 2020: 22,113]**

- 132.** Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A, Iacobucci I, Palandri F, Gugliotta G, Papayannidis C, Poerio A, Amabile M, Cilloni D, Rosti G, Baccarani M, Martinelli G. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. *Blood*. 2009 Sep 3;114(10):2168-71. [IF 2020: 22,113]
- 133.** Potenza L, Volzone F, Riva G, Soverini S, Martinelli S, Iacobucci I, Gnani A, Barozzi P, Forghieri F, Morselli M, Zanetti E, Maccaferri M, Baccarani M, Martinelli G, Torelli G, Luppi M. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. *Br J Haematol*. 2009 Jul;146(2):227-30. [IF 2020: 6,998]
- 134.** Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. *Blood*. 2009 Apr 9;113(15):3428-34. [IF 2020: 22,113]
- 135.** Merante S, Colombo AA, Calatroni S, Rocca B, Boni M, Bernasconi P, Bonvini L, Soverini S, Alessandrino EP. Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation. *Bone Marrow Transplant*. 2009 Aug;44(4):263-4. [IF 2020: 5,483]
- 136.** Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. *Clin Cancer Res*. 2009 Feb 1;15(3):1059-63. [IF 2020: 12,531]
- 137.** Breccia M, Frustaci AM, Cannella L, Soverini S, Stefanizzi C, Federico V, Grammatico S, Santopietro M, Alimena G. Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? *Cancer Chemother Pharmacol*. 2009 Jun;64(1):195-7. [IF 2020: 3,333]
- 138.** Martinelli G, Soverini S, Iacobucci I, Baccarani M. Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy. *Nat Clin Pract Oncol*. 2009 Feb;6(2):68-9. [IF 2011: 8]
- 139.** Cross NC, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughal T, Perrotti D, Radich J, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval JL, Goldman JM. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. *Leukemia*. 2009 Nov;22(11):1975-89. [IF 2020: 11,528]

- 140.** Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A, Zuntini R, Ferrari S, Ottaviani E, Arruga F, Paolini S, Papayannidis C, Piccaluga PP, **Soverini S**, Saglio G, Pane F, Baruzzi A, Vignetti M, Berton G, Vitale A, Chiaretti S, Müschen M, Foà R, Baccarani M, Martinelli G. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. *Haematologica*. 2008 Dec;93(12):1814-21. [IF 2020: 9,941]
- 141.** Monteghirfo S, Tosetti F, Ambrosini C, Stigliani S, Pozzi S, Frassoni F, Fassina G, **Soverini S**, Albini A, Ferrari N. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. *Mol Cancer Ther*. 2008 Sep;7(9):2692-702. [IF 2020: 6,261]
- 142.** Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F, Ottaviani E, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, **Soverini S**, Amabile M, Poerio A, Saglio G, Pane F, Berton G, Baruzzi A, Vitale A, Chiaretti S, Perini G, Foà R, Baccarani M, Martinelli G. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. *Blood*. 2008 Nov 1;112(9):3847-55. [IF 2020: 22,113]
- 143.** **Soverini S**, Martinelli G, Iacobucci I, Baccarani M. Imatinib mesylate for the treatment of chronic myeloid leukemia. *Expert Rev Anticancer Ther*. 2008 Jun;8(6):853-64. [IF 2020: 4,512]
- 144.** Martinelli G, **Soverini S**, Iacobucci I. What we don't know about resistance to tyrosine kinase inhibitors in CML: what makes CML cells a tougher enemy than expected? *Clin Leuk*. 2008 May; 2 (2): 86-87.
- 145.** Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, **Soverini S**, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M; GIMEMA Working Party on CML. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. *J Clin Oncol*. 2008 Jan 1;26(1):106-11. [IF 2020: 44,544]
- 146.** Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, **Soverini S**, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. *Haematologica*. 2007 Sep;92(9):1173-9. [IF 2020: 9,941]
- 147.** Martinelli G, Iacobucci I, **Soverini S**, Palandri F, Castagnetti F, Rosti G, Baccarani M. Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. *Biologics*. 2007 Jun;1(2):121-7.
- 148.** Cilloni D, Messa F, Martinelli G, Gottardi E, Arruga F, Defilippi I, Carturan S, Messa E, Fava M, Giugliano E, Rosso V, Catalano R, Merante S, Nicoli P, Rondoni M, Ottaviani E, **Soverini S**, Tiribelli M, Pane F, Baccarani M, Saglio G. WT1 transcript

amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. *Leukemia*. 2007 Jul;21(7):1442-50. [IF 2020: 11,528]

149. **Soverini S**, Iacobucci I, Bacarani M, Martinelli G. Targeted therapy and the T315I mutation in Philadelphia-positive leukemias. *Haematologica*. 2007 Apr;92(4):437-9. [IF 2020: 9,941]
150. Iacobucci I, Galletti L, Amabile M, **Soverini S**, Bacarani M, Martinelli G. Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio. *Haematologica*. 2007 Mar;92(3):429-30. [IF 2020: 9,941]
151. **Soverini S**, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Bacarani M, Martinelli G. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. *Haematologica*. 2007 Mar;92(3):401-4. [IF 2020: 9,941]
152. **Soverini S**, Martinelli G, Colarossi S, Gnani A, Rondoni M, Castagnetti F, Paolini S, Rosti G, Bacarani M. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. *Lancet Oncol*. 2007 Mar;8(3):273-4. [IF 2020: 41,316]
153. Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, **Soverini S**, Palandri F, Rege Cambrin G, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane F, Saglio G, Bacarani M, Martinelli G. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. *Haematologica*. 2007 Jan;92(1):101-5. [IF 2020: 9,941]
154. **Soverini S**, Bacarani M, Iacobucci I, Martinelli G. Resistance to tyrosine kinase inhibitors in Philadelphia chromosome-positive leukemias: which mutations matter? *Clin Leuk*. 2007 Dec;1(4):223-8.
155. Bussolari R, Candini O, Colomer D, Corradini F, Guerzoni C, Mariani SA, Cattelani S, Silvestri C, Pecorari L, Iacobucci I, **Soverini S**, Fasano T, Martinelli G, Cervantes F, Calabretta B. Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients. *Leuk Res*. 2007 Feb;31(2):163-7. [IF 2020: 3,156]
156. Martinelli G, **Soverini S**, Iacobucci I, Bacarani M. MK-0457: a light at the end of the tunnel? *Blood* 2007;109:396-397. [IF 2020: 22,113]
157. **Soverini S**, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Bacarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the

GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006 Dec 15;12(24):7374-9. [IF 2020: 12,531]

- 158.** Soverini S, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol. 2006 Nov 20;24(33):e51-2. [IF 2020: 44,544]
- 159.** Martinelli G, Iacobucci I, Soverini S, Cilloni D, Saglio G, Pane F, Baccarani M. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. Hematol Oncol. 2006 Dec;24(4):196-204. [IF 2020: 5,271]
- 160.** Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006 May 15;12(10):3037-42. [IF 2020: 12,531]
- 161.** Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006 Jul 1;108(1):28-37. [IF 2020: 22,113]
- 162.** Merante S, Chichino G, Boveri E, Gottardi E, Soverini S, Cilloni D, Martinelli G. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy. J Clin Oncol. 2006 Feb 1;24(4):e6-7. [IF 2020: 44,544]
- 163.** Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol. 2006 Jan 20;24(3):454-9. [IF 2020: 44,544]
- 164.** Martinelli G, Iacobucci I, Rosti G, Pane F, Amabile M, Castagnetti F, Cilloni D, Soverini S, Testoni N, Specchia G, Merante S, Zaccaria A, Frassoni F, Saglio G, Baccarani M. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. Ann Oncol. 2006 Mar;17(3):495-502. [IF 2020: 32,976]

165. Martinelli G, **Soverini S**, Rosti G, Baccarani M. Dual tyrosine kinase inhibitors in chronic myeloid leukemia. *Leukemia*. 2005 Nov;19(11):1872-9. [IF 2020: 11,528]
166. **Soverini S**, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. *J Clin Oncol*. 2005 Jun 20;23(18):4100-9. [IF 2020: 44,544]
167. Martinelli G, **Soverini S**, Rosti G, Cilloni D, Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. *Haematologica*. 2005 Apr;90(4):534-41. [IF 2020: 9,941]
168. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, **Soverini S**, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G; GIMEMA Working Party on Chronic Myeloid Leukemia. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. *Blood*. 2004 Dec 15;104(13):4245-51. [IF 2020: 22,113]
169. Zinzani PL, Pulsoni A, Perrotti A, **Soverini S**, Zaja F, De Renzo A, Storti S, Laut VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. *J Clin Oncol*. 2004 Jul 1;22(13):2654-61. [IF 2020: 44,544]
170. **Soverini S**, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G, Pane F, Saglio G, Baccarani M; Italian Cooperative Study Group on Chronic Myeloid Leukemia; European LeukemiaNet-6th Framework Program of the European Community. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. *Clin Chem*. 2004 Jul;50(7):1205-13. [IF 2020: 8,327]
171. Piccaluga PP, Malagola M, Rondoni M, Amabile M, Paolini S, **Soverini S**, Gaitani S, Visani G, Baccarani M, Martinelli G. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. *Eur J Haematol*. 2004 Apr;72(4):302-3. [IF 2020: 2,997]
172. Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, Cilloni D, Izzo B, De Vivo A, Testoni N, Cambrin GR, Bonifazi F, **Soverini S**, Luatti S, Gottardi E, Alberti D, Pane F, Salvatore F, Saglio G, Baccarani M; Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. *Blood*. 2004 Mar 15;103(6):2284-90. [IF 2020: 22,113]

- 173.** Bianchini M, Ottaviani E, Grafone T, Giannini B, **Soverini S**, Terragna C, Amabile M, Piccaluga PP, Malagola M, Rondoni M, Bosi C, Baccarani M, Martinelli G. Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC. *Clin Chem*. 2003 Oct;49(10):1642-50. [IF 2020: 8,327]
- 174.** **Soverini S**, Martinelli G, Cavo M. Relevance of cyclin D1 level in the pathogenesis of multiple myeloma. *Blood*. 2003 Dec 1;102(12):4245-46. [IF 2020: 22,113]
- 175.** **Soverini S**, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Bonifazi F, Neri A, Fabris S, Tura S, Baccarani M, Martinelli G. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. *Blood*. 2003 Sep 1;102(5):1588-94. [IF 2020: 22,113]
- 176.** Martinelli G, Buonamici S, Visani G, Malagola M, Piccaluga PP, Isidori A, Bosi C, Bonifazi F, **Soverini S**, Terragna C, Amabile M, Giannini B, Baccarani M. Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely. *Leukemia*. 2003 Mar;17(3):650-1; author reply 651-2. [IF 2020: 11,528]
- 177.** **Soverini S**, Terragna C, Testoni N, Ruggeri D, Tosi P, Zamagni E, Cellini C, Cavo M, Baccarani M, Tura S, Martinelli G. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. *Haematologica*. 2002 Oct;87(10):1036-40. [IF 2020: 9,941]
- 178.** Martinelli G, Amabile M, Giannini B, Terragna C, Ottaviani E, **Soverini S**, Saglio G, Rosti G, Baccarani M. Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one. *Haematologica*. 2002 Jul;87(7):688-94; discussion 694. [IF 2020: 9,941]
- 179.** Martinelli G, Tosi P, Ottaviani E, **Soverini S**, Tura S. Molecular therapy for multiple myeloma. *Haematologica*. 2001 Sep;86(9):908-17. [IF 2020: 9,941]
- 180.** Amabile M, Giannini B, Testoni N, Montefusco V, Rosti G, Zardini C, Terragna C, Buonamici S, Ottaviani E, **Soverini S**, Fiacchini M, Bassi S, de Vivo A, Trabacchi E, Saglio G, Pane F, Baccarani M, Tura S, Martinelli G. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. *Haematologica*. 2001 Mar;86(3):252-9. [IF 2020: 9,941]
- 181.** Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli R, Bandini G, Testoni N, Amabile M, Ottaviani E, Buonamici S, **Soverini S**, Montefusco V, de Vivo A, Bonifazi F, Tura S, Cavo M. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. *Haematologica*. 2000 Sep;85(9):930-4. [IF 2020: 9,941],





## Allegato 2

### ELENCO ABSTRACTS A PRIMO O ULTIMO NOME

---

1. **Soverini S**, Tosi P, Zamagni E, Ronconi S, Amabile M, Ottaviani E, Terragna C, Buonamici S, Martinelli G, Tura S, Cavo M: Analysis of p53 gene mutations in multiple myeloma. *Haematologica* 85 (9): 32, 2000. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETÀ ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2000**
2. **Soverini S**, Terragna C, Testoni N, Ruggeri D, Neri A, Tosi P, Ottaviani E, Amabile M, Giannini B, Buonamici S, Zardini C, Cavo M, Tura S, Martinelli G: New mechanisms of fibroblast growth factor receptor 3 (FGFR3) deregulation in multiple myeloma. *The Hematology Journal* 1 (1): 201, 2001. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2001**
3. **Soverini S**, Terragna C, Testoni N, Ruggeri D, Tosi P, Zamagni E, Cellini C, Cavo M, Tura S, Baccarani M, Martinelli G: New mechanisms of fibroblast growth factor receptor 3 deregulation in multiple myeloma patients. *Haematologica* 86(supplement to 10): 56, 2001. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETÀ ITALIANA DI EMATOLOGIA (SIE) - 2001**
4. **Soverini S**, Terragna C, Martinelli G, Ruggeri D, Testoni N, Ottaviani E, Amabile M, Giannini B, Buonamici S, Zamagni E, Cellini C, Tosi P, Cavo M, Tura S, Baccarani M: Two Novel Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations in Newly Diagnosed Multiple Myeloma Patients With and Without the t(4;14) Translocation. *Blood* 98 (11): 572, 2001. **Sottomesso al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2001**
5. **Soverini S**, Terragna C, Martinelli G, Ruggeri D, Testoni N, Ottaviani E, Amabile M, Giannini B, Buonamici S, Zardini C, Bonifazi F, Zamagni E, Cellini C, Tosi P, Cavo M, Tura S, Baccarani M. Cyclin D1 Overexpression in Newly Diagnosed Multiple Myeloma Identifies a Subset of Patients Who Are Refractory to Conventional-Dose Chemotherapy. *Blood* 98 (11): 573, 2001 **Sottomesso al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2001**
6. **Soverini S**, Terragna C, Martinelli G, Ottaviani E, Amabile M, Giannini B, Buonamici S, Zardini C, Zamagni E, Cellini C, Tosi P, Cavo M, Tura S, Baccarani M: N-RAS and K-RAS Mutational Analysis in Newly Diagnosed Multiple Myeloma Patients: Evidence for Novel Mutation Hotspots. *Blood* 98 (11): 172-173, 2001. **Sottomesso al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2001**
7. **Soverini S**, Terragna C, Martinelli G, Ottaviani E, Amabile M, Giannini B, Zardini C, Buonamici S, Zamagni E, Cellini C, Tosi P, Cavo M, Tura S, Baccarani M: P53 Gene Mutation Are a Rare Event and Devoid of Prognostic Significance in Newly Diagnosed Multiple Myeloma Patients. *Blood* 98 (11): 304-305, 2001. **Sottomesso al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2001**

**8. Soverini S**, Martinelli G, Terragna C, Ruggeri D, Testoni N, Bonifazi F, Ottaviani E, Amabile M, Giannini B, Zamagni E, Cellini C, Tosi P, Cavo M, Tura S, Baccarani M: Real-Time quantification of cyclin D1 overexpression in newly diagnosed multiple myeloma identifies a subset of patients who are refractory to conventional chemotherapy. *The Hematology Journal* 3 (1): 348, 2002. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2002**

**9. Soverini S**, Martinelli G, Terragna C, Rossi M, Ottaviani E, Amabile M, Giannini B, Testoni N, Ruggeri D, Zamagni E, Cellini C, Tosi P, Cavo M, Tura S, Baccarani M: mutational analysis of N-RAS and K-RAS genes in newly diagnosed multiple myeloma patients: evidence for two novel activating mutations. *The Hematology Journal* 3 (1): 359, 2002. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2002**

**10. Soverini S.**, Terragna C., Rossi M., Ottaviani E., Amabile M., Giannini B., Testoni N., Ruggeri D., Zamagni E., Cellini C., Tosi P., Cavo M., Tura S., Baccarani M., Martinelli G. Mutational Analysis Of N-Ras And K-Ras Genes In Newly Diagnosed Multiple Myeloma Patients: Evidence For Two Novel Activating Mutations. *Haematologica* 2002 Sept;87 suppl.1 to(9): 114-115 **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2002**

**11. Soverini S.**, Terragna C., Ruggeri D., Testoni N., Bonifazi F., Ottaviani E., Amabile M., Giannini B., Zamagni E., Cellini C., Tosi P., Cavo M., Tura S., Baccarani M., Martinelli G. Real-time quantification of cyclin d1 overexpression in newly diagnosed multiple myeloma identifies a subset of patients who are refractory to conventional chemotherapy. *Haematologica* 2002 Sept;87 suppl. 1 to(9): 37 **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2002**

**12. Soverini S**, Cavo M, Terragna C, Ruggeri D, Testoni N, Cellini C, De Vivo A, Neri A, Fabris S, Amabile M, Grafone T, Ottaviani E, Giannini B, Tosi P, Zamagni E, Bonifazi F, Cangini D, Tura S, Baccarani M, Martinelli G. Cyclin D1 overexpression is not an adverse prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy. *The Hematology Journal* 4(S1): 164-165, 2003. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2003**

**13. Soverini S**, Cavo M, Cellini C, Terragna C, Ruggeri D, Testoni N, Neri A, Fabris S, De Vivo A, Tosi P, Zamagni E, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Tacchetti P, Tura S, Baccarani M, Martinelli G. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double peripheral blood stem cell autotransplants. *Haematologica* 88:50-51, 2003. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA (SIE) - 2003**

**14. Soverini S**, Rosti G, Amabile M, Poerio A, Bassi S, Trabacchi E, Izzo B, Fava M, Pane F, Saglio G, Alberti D, Baccarani M, Martinelli G. ABL mutations detected by a novel D-HPLC-based assay in late-chronic phase chronic myeloid leukemia patients resistant to imatinib are strongly associated to subsequent progression to blast crisis. *The Hematology Journal*, 5(S2): 100, 2004. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2004**

**15. Soverini S**, Cavo M, Tosi P, Terragna C, Zamagni E, Cellini C, Ottaviani E, Amabile M, Renzulli M, Poerio A, Grafone T, Cangini D, Tacchetti P, Tura S, Baccarani M, Martinelli G. N-RAS and K-RAS mutational analysis in newly diagnosed multiple myeloma patients: evidence for two novel activating mutation. *Haematologica* 89(supplement to 6): 104, 2004. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2004**

**16. Soverini S**, Rosti G, Amabile M, Poerio A, Bassi S, Trabacchi E, Giannini B, Ottaviani E, Renzulli M, Grafone T, Terragna C, Testoni N, Luatti S, Castagnetti F, Pane F, Izzo B, Fava M, Saglio G, Alberti D, Baccarani M, Martinelli G on behalf meeting della European Hematology Association (EHA) of the GIMEMA CML Working Party. Abl kinase mutations detected by a novel D-HPLC-based assay in late-chronic phase chronic myeloid leukemia patients resistant to imatinib are strongly associated to subsequent progression to blast crisis. *Haematologica* 89(supplement to 6): 131, 2004. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2004**

**17. Soverini S**, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Ottaviani E, Grafone T, Terragna C, Renzulli M, Testoni N, Luatti S, Castagnetti F, Cilloni D, Fava M, Izzo B, Pane F, Saglio G, Baccarani M. ABL Mutations In Late-Chronic Phase Chronic Myeloid Leukemia Patients With Cytogenetic Refractoriness To Imatinib Are Associated With A Greater Likelihood Of Progression To Blast Crisis And Shorter Survival. On behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia. *Blood* 104(11):287, 2004. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2004**

**18. Soverini S**, Colarossi S, Rosti G, Amabile M, Poerio A, Bassi S, Castagnetti F, Testoni N, Iacobucci I, Izzo B, Fava M, Pane F, Saglio G, Baccarani M, Martinelli G. ABL mutations in CP-CML patients resistant to imatinib are associated with significantly shorter time to progression and survival, with P-loop mutations conferring a particularly poor prognosis. *Haematologica* S2:45, 2005. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2005**

**19. Soverini S**, Colarossi S, Rosti G, Amabile M, Poerio A, Giovannini M, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G. Frequency, distribution and prognostic value of abl mutations in different subsets of imatinib-resistant chronic myeloid leukemia patients: an Italian multicenter study by the GIMEMA-CML Working Party. *Haematologica* S2:152, 2005. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) 2005**

**20. Soverini S**, Colarossi S, Rosti G, Amabile M, Poerio A, Bassi S, Castagnetti F, Testoni N, Iacobucci I, Izzo B, Fava M, Pane F, Saglio G, Baccarani M, Martinelli G. Abl kinase domain mutations in CP-CML patients resistant to imatinib are associated with significantly shorter time to progression and survival, with P-loop mutations conferring a particularly poor prognosis. *Haematologica* 90(S3):43-44, 2005. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' DI EMATOLOGIA (SIE) - 2005**

**21. Soverini S**, Colarossi S, Rosti G, Amabile M, Poerio A, Giovannini M, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, Caracciolo C, Izzo B, Pane F, Saglio G, Di Lorenzo R, Abruzzese E, Baccarani M, Martinelli G. Frequency, distribution and prognostic value of Abl mutations in different subsets of imatinib-resistant chronic myeloid leukemia patients: an italian multicenter study by the GIMEMA-CML Working Party. *Haematologica* 90(S3):136-137, 2005. **Accettato come POSTER al meeting della SOCIETA' DI EMATOLOGIA (SIE) - 2005**

**22. Soverini S**, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Giannoulia P, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, Caracciolo C, Pane F, Saglio G, Baccarani M, Martinelli G. Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the GIMEMA Working Party on CML. *Blood* 106(11): 131, 2005. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2005**

**23. Soverini S**, Tasco G, Grafone T, Colarossi S, Gnani A, Rosti G, Castagnetti F, Palandri F, Rondoni M, Poerio A, Iacobucci I, Amabile M, Baccarani M, Martinelli G. Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies. *Haematologica* 91(s1):27, 2006. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2006**

**24. Soverini S**, Tasco G, Grafone T, Colarossi S, Gnani A, Rosti G, Castagnetti F, Palandri F, Rondoni M, Poerio A, Iacobucci I, Amabile M, Baccarani M, Casadio R, Martinelli G. Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies. *Haematologica* 91(s3):31, 2006. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2006**

**25. Soverini S**, Rosti G, Gnani A, Colarossi S, Castagnetti F, Bosi C, Iacobucci I, Rondoni M, Poerio A, Amabile M, Giannoulia P, Abruzzese E, Saglio G, Baccarani M, Martinelli G. T315I AND F317L are the only BCR-ABL Mutants Which Seem To Confer Resistance To Dasatinib (BMS-354825) Treatment In Philadelphia-Positive Leukemia Patients Resistant To Or Intolerant Of Previous Imatinib Treatment. *Haematologica* 91(s3):32, 2006. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2006**

**26. Soverini S**, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Giannoulia P, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, Caracciolo C, Pane F, Saglio G, Baccarani M, Martinelli G. Impact of ABL Kinase Domain (KD) Mutations In Different Subsets of Imatinib (IM)-Resistant Philadelphia (PH)-Positive Patients (PTS) – By The GIMEMA-CML Working Party. *Haematologica* 91(s3):34, 2006. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2006**

**27. Soverini S**, Martinelli G, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Abruzzese E, Iacobucci I, Testoni N, Baccarani M. Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+)

Leukemia Patients (pts). *Blood* 108(11):251, 2006. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2006**

**28. Soverini S**, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Abruzzese E, Iacobucci I, Testoni N, Baccarani M, Lollini PL, Martinelli G. Mutations at contact residues in the ATP-binding site are the main cause of upfront or acquired resistance to dasatinib in Philadelphia chromosome-positive (Ph+) Leukemia Patients. *Cancer Res* 2007;67(S9):2636. **Accettato come POSTER al meeting della AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) - 2007**

**29. Soverini S**, Tasco G, Grafone T, Colarossi S, Gnani A, Baccarani M, Casadio R, Martinelli G. Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies. *J Clin Oncol* 18S: 7049, 2007. **Accettato come POSTER al meeting dell'AMERICAN ASSOCIATION OF CLINICAL ONCOLOGY (ASCO) - 2007**

**30. Soverini S**, Saglio G, Brandford S, Radich J, Kim DW, Hughes T, Mueller M, Erben P, Hochhaus A, Shou Y, Weitzman A, Baccarani M, Martinelli G. In Patients With Chronic Myelogenous Leukemia (CML), Response Dynamics To Nilotinib After Imatinib Failure Depend On The Type Of Bcr-Abl Mutations. *Haematologica* 91(s):320, 2007. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2007**

**31. Soverini S**, Gnani A, Colarossi S, Castagnetti F, Palandri F, Giannoulia P, Paolini S, Abruzzese E, Merante S, Rondoni M, Iacobucci I, Poerio A, Rosti G, Baccarani M, Martinelli G. Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors. *Blood* 110(11):101a, 2007. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2007**

**32. Soverini S**, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Merante S, Breccia M, Capucci A, Specchia G, Radaelli F, Palandri F, Poerio A, Iacobucci I, Amabile M, Rosti G, Baccarani M, Martinelli G. In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations. *Blood* 110(11): 574a, 2007. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2007**

**33. Soverini S**, Angelini S, Turrini E, Gnani A, Colarossi S, Perini G, Iacobucci I, Hrelia P, Cantelli Forti G, Cilloni D, Saglio G, Pane F, Baccarani M, Kalebic T, Martinelli G. Multidrug Resistance Gene (MDR1) Polymorphisms May Serve as Predictors of Resistance to Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients. *Blood* 110(11): 578a, 2007. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2007**

**34. Soverini S**, Gnani A, Colarossi S, Castagnetti F, Palandri F, Paolini S, Abruzzese E, Merante S, Rondoni M, Iacobucci I, Poerio A, Amabile M, Papayannidis C, Giannoulia P, Rosti G, Baccarani M, Martinelli G. Philadelphia-positive leukemia patients already harbouring ABL kinase domain mutations have a higher likelihood of developing further

mutations under the selective pressure of novel tyrosine kinase inhibitors. *Haematologica* 93(s1): 40, 2008. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2008**

**35. Soverini S**, Gnani A, Colarossi S, Castagnetti F, Palandri F, Abruzzese E, Orlandi E, Breccia M, Specchia G, Gherlinzoni F, Poerio A, Amabile M, Iacobucci I, Rosti G, Baccarani M, Martinelli G. ABL kinase domain mutations are infrequent in early-chronic phase chronic myeloid leukemia patients resistant to imatinib. *Haematologica* 93(s1): 43, 2008. **Accettato come POSTER, al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2008**

**36. Soverini S**, Colarossi S, Gnani A, Castagnetti F, Abruzzese E, Orlandi E, Tiribelli M, Breccia M, Specchia G, Palandri F, Poerio A, Amabile M, Iacobucci I, Ciccarese F, Rosti G, Baccarani M, Martinelli G. Incidence of abl kinase domain mutations in chronic phase chronic myeloid leukemia patients with failure or suboptimal response to frontline imatinib treatment – an analysis by the GIMEMA working party on CML. *Haematologica* 93(s2): S71, 2008. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2008**

**37. Soverini S**, Turrini E, Gnani A, Colarossi S, Perini G, Iacobucci I, Hrelia P, Cantelli Forti G, Saglio G, Pane F, Baccarani M, Kalebic T, Martinelli G, Angelini S. Multidrug resistance gene haplotype may be a predictor of upfront resistance to imatinib in chronic phase chronic myeloid leukemia patients. *Haematologica* 93(s2): S68, 2008. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2008**

**38. Soverini S**, Gnani A, Colarossi S, Castagnetti F, Palandri F, Giannoulia P, Paolini S, Abruzzese E, Merante S, De Matteis S, Gozzini A, Ciccarese F, Poerio A, Amabile M, Iacobucci I, Rosti G, Baccarani M, Martinelli G. Dynamics of BCR-ABL kinase domain mutations in philadelphia-positive leukemia patients after sequential treatment with multiple tyrosine kinase inhibitors. *Haematologica* 93(s2): 68, 2008. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2008**

**39. Soverini S**, Martinelli G, Vitale A, Gnani A, Colarossi S, Paolini S, Iacobucci I, Papayannidis C, Vignetti M, Lonetti A, Elia L, Leone G, Lazzarino M, Torelli G, Fanin R, Cimino G, Meloni G, Guarini A, Mandelli F, Baccarani M, and Foà R. Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party. *Blood* 112(11):268, 2008. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2008**

**40. Soverini S**, Gnani A, Colarossi S, Castagnetti F, Palandri F, Paolini S, Papayannidis C, Gozzini A, Santini V, Cilloni D, Orlandi E, Merante S, Radaelli F, Rondoni M, Malagola M, Poerio A, Amabile M, Iacobucci I, Gugliotta G, Rosti G, Martinelli G and Baccarani M. Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly

Detected during the First Year. *Blood* 112(11):737-8, 2008. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2008**

**41. Soverini S**, Gnani A, Colarossi S, Vitale A, Castagnetti F, Palandri F, Paolini S, Papayannidis C, Amabile M, Iacobucci I, Poerio A, Scotlandi K, Lonetti A, Mandelli F, Baccarani M, Foà R, Martinelli G. Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia. *Cancer Res* 2009;69(S9):3871. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) - 2009**

**42. S. Soverini**, A. Gnani, S. Colarossi, F. Castagnetti, E. Abruzzese, S. Paolini, S. Merante, E. Orlandi, S. De Matteis, A. Gozzini, I. Iacobucci, F. Palandri, G. Gugliotta, C. Papayannidis, A. Poerio, M. Amabile, C. Cilloni, G. Rosti, M. Baccarani, G. Martinelli. Long-term mutation follow-up of Philadelphia-chromosome positive leukemia patients treated with second-generation tyrosine kinase inhibitors after imatinib failure shows that newly acquired Bcr-Abl kinase domain mutations leading to relapse mainly arise during the first year. *Haematologica* 2009; 94[suppl.2]:216. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2009**

**43. S. Soverini**, A. Poerio, A. Vitale, A. Gnani, S. Colarossi, F. Castagnetti, I. Iacobucci, A. Lonetti, F. Palandri, G. Rosti, M. Amabile, S. Paolini, C. Papayannidis, G. Gugliotta, M. Vignetti, F. Mandelli, M. Baccarani, R. Foà, G. Martinelli. At the time of diagnosis, Ph+ cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour Bcr-Abl kinase domain mutations. *Haematologica* 2009; 94[suppl.2]:212. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2009**

**44. Soverini S**, Poerio A, Vitale A, Gnani A, Colarossi C, Castagnetti F, Palandri F, Paolini S, Papayannidis C, Amabile M, Iacobucci I, Lonetti A, Vignetti M, Mandelli F, Baccarani M, Foà R, Martinelli G. In newly diagnosed chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients, imatinib-resistant BCR-ABL mutations are already detectable at low levels but do not correlate with subsequent clinical outcome – A study by the GIEMA ALL and GIMEMA-CML Working Parties. *Haematologica* 94(s4): 94, 2009. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA (SIE) - 2009**

**45. Soverini S**, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A, Iacobucci I, Palandri F, Gugliotta G, Papayannidis C, Poerio A, Amabile M, Cilloni D, Rosti G, Baccarani M, Martinelli G. Long-term mutation follow-up of Philadelphia-chromosome positive leukemia patients treated with second-generation tyrosine kinase inhibitors after imatinib failure shows that newly acquired BCR-ABL kinase domain mutations leading to relapse mainly arise during the first year. *Haematologica* 94(s4): 94-95, 2009. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA (SIE) - 2009**

**46. Soverini S**, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A, Iacobucci I, Palandri F, Gugliotta G, Papayannidis C, Poerio A, Amabile M, Cilloni D, Rosti G, Baccarani M, Martinelli G. Second-and third-line



tyrosine kinase inhibitor therapy in imatinib-resistant Philadelphia-positive leukemias: patients who already harbour BCR-ABL kinase domain mutations have a higher likelihood of developing further mutations leading to relapse after an initial response. *Haematologica* 94(s4): 95, 2009. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA (SIE) - 2009**

**47. Soverini S**, Turrini E, Pane F, Quarantelli F, Hughes T, Kim DW, Radich J, Saglio G, Cilloni D, Terragna C, Iacobucci I, Hrelia P, Cantelli Forti G, Kalebic T, Thornquist M, Baccarani M, Martinelli G, Angelini S. ABCB1 and CYP3A5 genetic variants correlate with response to imatinib in newly diagnosed chronic myeloid leukemia patients. *Haematologica* 94(s4): 165, 2009. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA (SIE) - 2009**

**48. Soverini S**, Colarossi S, Gnani A, Castagnetti F, Astolfi A, Formica S, Palandri F, Iacobucci I, Gugliotta G, Poerio A, Amabile M, Marzocchi G, Testoni N, Abruzzese E, Rosti G, Baccarani M, Martinelli G. High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. *Blood* 114(22): 2176, 2009. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2009**

**49. Soverini S**, Colarossi S, Gnani A, Astolfi A, Formica S, Castagnetti F, Palandri F, Gugliotta G, Poerio A, Iacobucci I, Amabile M, Marzocchi G, Luatti S, Terragna C, Durante S, Testoni N, Rosti G, Baccarani M, Martinelli G. High-Resolution Genome Wide Copy Number Alteration (CNA) and Loss of Heterozygosity (LOH) Analysis in Chronic Myeloid Leukemia (CML) Shows That High and Intermediate Sokal Risk Pts (Pts) Have Multiple Losses Targeting Genes Involved in DNA Repair. *Blood* 114(22): 3262, 2009. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2009**

**50. Soverini S**, Angelini S, Turrini E, Pane F, Quarantelli F, Hughes TP, White DL, Kim DW, Goh H, Radich J, Beppu L, Saglio G, Cilloni D, Terragna C, Durante S, Iacobucci I, Perini G, Hrelia P, Cantelli Forti G, Kalebic T, Barnett M, Thornquist M, Baccarani M, Martinelli G. Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity. *Blood* 114(22): 3283, 2009. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2009**

**51. Soverini S**, Giacomelli E, Ferrarini A, Xumerle L, Colarossi S, Gnani A, Castagnetti F, Terragna C, Durante S, Astolfi A, Formica S, Marzocchi G, Testoni N, Iacobucci I, Poerio A, Palandri F, Gugliotta G, Amabile M, Rosti G, Baccarani M, Delledonne M, Martinelli G. Whole-Transcriptome Sequencing of a Chronic Myeloid Leukemia (CML) Patient at Diagnosis and at the Time of Progression to Blast Crisis (BC). *Blood* 114(22): 4259, 2009. **Sottomesso al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2009**

**52. Soverini S**, Giacomelli E, Ferrarini A, Xumerle L, Colarossi S, Gnani A, Castagnetti F, Terragna C, Durante S, Astolfi A, Formica S, Marzocchi G, Testoni N, Iacobucci I, Poerio A, Palandri F, Gugliotta G, Amabile M, Rosti G, Baccarani M, Delledonne M, Martinelli G. First Application of Whole-Transcriptome Sequencing to a High-Risk Chronic Myeloid Leukemia

(CML) Patient at Diagnosis and at the Time of Disease Progression to Blast Crisis (BC). *Cancer Res* 2010;70(S8):1138. **Accettato come POSTER al meeting dell'AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) - 2010**

**53. S. Soverini**, S. Angelini, M. Barnett, M. Thornquist, E. Turrini, G. Rosti, P. Hrelia, T. Kalebic, M. Baccarani, G. Martinelli. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients. *J Clin Oncol* 28(15s):500s, 2010. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - 2010**

**54. S Soverini**, S Colarossi, A Gnani, A Astolfi, S Formica, F Castagnetti, F Palandri, G Gugliotta, G Rosti, A Poerio, I Iacobucci, M Amabile, G Marzocchi, S Luatti, S Durante, C Terragna, N Testoni, M Baccarani, G Martinelli. High-resolution genome-wide analysis of copy number alterations/loss of heterozygosity in chronic myeloid leukemia shows that high Sokal risk patients have multiple losses targeting DNA repair genes. *Haematologica* 95[suppl.2]:243, 2010. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2010**

**55. S Soverini**, A Poerio, A Ferrarini, I Iacobucci, M Sazzini, E Giacomelli, L Xumerle, S Colarossi, A Gnani, F Castagnetti, F Palandri, G Gugliotta, M Amabile, G Rosti, M Baccarani, M Delledonne, G Martinelli. Whole-transcriptome sequencing in chronic myeloid leukemia at diagnosis and at the time of progression to blast crisis reveals novel gene mutations. *Haematologica* 95[suppl.2]:242, 2010. **accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2010**

**56. S Soverini**, S Colarossi, A Gnani, A Poerio, F Castagnetti, A Astolfi, S Formica, F Palandri, I Iacobucci, M Amabile, G Marzocchi, S Luatti, N Testoni, G Gugliotta, G Rosti, M Baccarani, G Martinelli. high-resolution molecular karyotyping of chronic myeloid leukemia patients in blast crisis by 6.0 SNP-Arrays identifies focal copy number alterations affecting oncogenes and tumor suppressor genes. *Haematologica* 95[suppl.2]:49, 2010. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2010**

**57. S Soverini**, S Angelini, M Barnett, E Turrini, M Thornquist, G Ravegnini, G Rosti, A Gnani, S Colarossi, P Hrelia, T Kalebic, M Baccarani, G Martinelli. Pharmacogenetics of imatinib in newly diagnosed chronic myeloid leukemia patients shows evidence of association between imatinib transporters and metabolizing enzymes genotype and molecular response. *Haematologica* 95[suppl.2]:60, 2010. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2010**

**58. S Soverini**, A Poerio, A Gnani, S Colarossi, G Rosti, F Castagnetti, F Palandri, G Gugliotta, M Amabile, M Baccarani, G Martinelli. In chronic myeloid leukemia patients who are in major molecular response after 12 months of first-line nilotinib therapy, low-level Bcr-Abl kinase domain mutations are very rare. *Haematologica* 95[suppl.2]:341, 2010. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2010**

**59. Soverini S**, Poerio A, Ferrarini A, Iacobucci I, Sazzini M, Xumerle L, Colarossi S, Gnani A, Castagnetti F, Palandri F, Gugliotta G, Amabile M, Rosti G, Baccarani M, Delledonne M, Martinelli G. Novel gene mutations revealed by massively parallel sequencing of the transcriptome of a chronic myeloid leukemia patient at diagnosis and at the time of

progression to blast crisis. *Haematologica* 95[suppl.3]:S57, 2010. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2010**

**60. Soverini S**, Poerio A, Debenedittis C, Iacobucci I, Colarossi S, Gnani A, Castagnetti F, Palandri F, Gugliotta G, Amabile M, Rosti G, Baccarani M, Martinelli G. In chronic myeloid leukemia patients who are in major molecular response after 12 months of first-line nilotinib therapy, low-level Bcr-Abl kinase domain mutations are very rare. *Haematologica* 95[suppl.3]:S122, 2010. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2010**

**61. Soverini S**, Angelini S, Turrini E, Burnett M, Ravegnini G, Thornquist M, Pane F, Quarantelli F, Hughes TP, White DL, Kim D-W, Goh H, Radich JP, Beppu L, Saglio G, Cilloni D, Iacobucci I, Perini G, Cantelli Forti G, Rosti G, Hatfield A, Baccarani M, Hrelia P, Martinelli G. Specific Drug Transporter Genotypes Are Significantly Associated with Increased Rates of Major and Complete Molecular Responses In Newly Diagnosed Chronic Myeloid Leukemia Patients Treated with Imatinib – A TOPS Correlative Substudy. *Blood* 2010; 116: 670. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2010**

**62. Soverini S**, Poerio A, Ferrarini A, Iacobucci I, Sazzini M, Score J, Giacomelli E, Xumerle L, Colarossi S, Gnani A, Castagnetti F, Palandri F, Gugliotta G, Amabile M, Rosti G, Baccarani M, Cross NCP, Delledonne M, Martinelli G. Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression. *Blood* 2010; 116: 885. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2010**

**63. Soverini S**, Gnani A, Colarossi S, Castagnetti F, Iacobucci I, Breccia M, Abruzzese E, Pane F, Saglio G, Russo D, Specchia G, Pregno P, Sorà F, Tiribelli M, Palandri F, Gugliotta G, Amabile M, Rosti G, Baccarani M, Martinelli G. Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. *Blood* 2010; 116: 2279. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2010**

**64. Soverini S**, Poerio A, Ferrarini A, Iacobucci I, De Benedittis, Sazzini M, Giacomelli E, Xumerle L, Colarossi S, Gnani A, Castagnetti F, Palandri F, Gugliotta G, Amabile M, Baccarani M, Delledonne M, Martinelli G. Whole-transcriptome sequencing in chronic myeloid leukemia reveals novel gene mutations that may be associated with disease pathogenesis and progression. *Cancer Res* 2011;71(S8):309. **Accettato come POSTER al meeting dell'AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) - 2011**

**65. Soverini S**, Angelini S, Burnett M, Ravegnini G, Pane F, Hughes TP, White DL, Kim D-W, Saglio G, Rosti G, Woodman R, Hrelia P, Biasco G, Baccarani M, Martinelli G. Pharmacogenetics of drug transporters may be useful to identify chronic myeloid leukemia patients who are less likely to achieve molecular responses to imatinib: Implications for treatment optimization in the era of new tyrosine kinase inhibitors. *Cancer Res* 2011;71(S8):5448. **Accettato come POSTER al meeting dell'AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) - 2011**

**66. Soverini S**, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Breccia M, Abruzzese E, Sorà F, Pregno P, Baratè C, Orlandi E, Merante S, Gangemi D, Specchia G, Capucci A, Russo D, Giannini B, Iacobucci I, Amabile M, Bochicchio MT, Palandri F, Pane F, Saglio G, Rosti G, Baccarani M, Martinelli G. BCR-ABL kinase domain mutations in imatinib and in second- generation tyrosine kinase inhibitor eras: a review of seven years of mutation analysis by the GIMEMA CML working party. *Haematologica* 96[suppl.2]:204-5, 2011. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2011**

**67. Soverini S**, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Breccia M, Pregno P, Abruzzese E, Sorà F, Baratè C, Gangemi D, Capucci A, Girasoli M, Orlandi E, Specchia G, Russo D, Giannini B, Poletti G, Iacobucci I, Bochicchio MT, Pane F, Saglio G, Rosti G, Baccarani M, Martinelli G. Seven year-experience of BCR-ABL mutation analysis in Philadelphia-chromosome positive (Ph+) patients on imatinib (IM) or 2nd-generation tyrosine kinase inhibitors (TKIs): by the GIMEMA CML working party. *Haematologica* 96[suppl.3]:39, 2011. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA (SIE) - 2011**

**68. Soverini S**, Angelini S, Ravegnini G, Barnett M, Thornquist M, Pane F, Hughes TP, Kim D-W, Radich J, Saglio G, Cilloni D, Iacobucci I, Perini G, Iraci N, Forti GC, Rosti G, Baccarani M, Woodman R, Hrelia P, Martinelli G. Pharmacogenetics of drug transporters may be useful to identify chronic myeloid leukemia patients who are less likely to achieve molecular responses to imatinib: Implications for treatment optimization in the era of new tyrosine kinase inhibitors. Pharmacogenetics for the optimization of chronic myeloid leukemia (CML) therapy in the era of second-generation tyrosine kinase inhibitors (TKIs): specific drug transporter genotypes are associated with decreased rates of major molecular response (MMR) and complete molecular response (CMR) in patients receiving imatinib (IM). *Haematologica* 96[suppl.3]:78, 2011. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA (SIE) - 2011**

**69. Soverini S**, Gnani A, De Benedittis C, Iacobucci I, Lonetti A, Papayannidis C, Potenza L, Luppi M, Merante S, Malagola M, Russo D, Tiribelli M, Salvucci M, Zaccaria A, Giannini B, Poletti G, Vitale A, Elia L, Vignetti M, Foà R, Baccarani M, Martinelli G. Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement. *Blood* 2011; 118: 575. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2011**

**70. Soverini S**, Gnani A, De Benedittis C, Castagnetti F, Gugliotta G, Bochicchio MT, Palandri F, Arpinati M, Bonifazi F, Abruzzese E, Sorà F, Alimena G, Pregno P, Specchia G, Russo D, Pane F, Saglio G, Salvucci M, Zaccaria A, Poletti G, Giannini B, Iacobucci I, Lonetti A, Durante S, Rosti G, Baccarani M, Martinelli G. Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies. *Blood* 2011; 118: 112. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2011**

**71. Soverini S**, De Benedittis C, Gnani A, Iacobucci I, Russo D, Cattina F, Castagnetti F, Gugliotta G, Papayannidis C, Vitale A, Elia L, Foà R, Palandri F, Lonetti A, Bochicchio MT, Durante S, Rosti G, Baccharani M, Martinelli G. Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients. *Blood* 2011;118(21):3775. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2011**

**72. Soverini S**, De Benedittis C, Gnani A, Iacobucci I, Castagnetti F, Gugliotta G, Papayannidis C, Cattina F, Russo D, Pantaleo MA, Rosti G, Baccharani M, Martinelli G. Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology. *Cancer Res* 2012;72(S8):1884. **Accettato come POSTER al meeting dell'AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) - 2012**

**73. Soverini S**, Gnani A, C De Benedittis C, Iacobucci I, Venturi C, Papayannidis C, Luppi M, Merante S, Malagola M, Russo D, Tiribelli M, Salvucci M, Vitale A, Elia L, Vignetti M, Foà R, Baccharani M, Martinelli G. Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era. *J Clin Oncol* 30 (suppl), 2012. **Accettato come SELECTED ORAL POSTER PRESENTATION al meeting dell'AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) - 2012**

**74. Soverini S**, De Benedittis C, Cattina F, Broučková A, Machová Poláková K, Russo D, Gnani A, Iacobucci I, Bochicchio MT, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Klamová H, Vitale A, Vignetti M, Foà R, Rosti G, Baccharani M, Martinelli G. High sensitivity mutation screening and clonal analysis allowed by ultra-deep amplicon sequencing uncover the complexity of BCR-ABL mutation status in patients treated with tyrosine kinase inhibitors. *Haematologica* 97[suppl.1]:452, 2012 **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2012**

**75. Soverini S**, De Benedittis C, Castagnetti F, Papayannidis C, Gugliotta G, Iacobucci I, Venturi C, Bochicchio MT, Cattina F, Russo D, Rosti G, Baccharani M, Martinelli G. High sensitivity mutation monitoring and clonal analysis by ultra-deep amplicon sequencing uncover the complexity of BCR-ABL mutation status in Philadelphia+ patients treated with tyrosine kinase inhibitors. *Haematologica* 97[suppl.2]:S17, 2012 **Accettato come COMUNICAZIONE ORALE SELEZIONATA al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2012**

**76. Soverini S**, De Benedittis C, Papayannidis C, Vitale A, Iacobucci I, Venturi C, Luppi M, Bresciani P, Coluccio V, Vignetti M, Foà R, Baccharani M, Martinelli G. BCR-ABL kinase domain mutation monitoring by ultra deep amplicon sequencing may anticipate emerging inhibitor-resistant mutations in philadelphia-positive acute lymphoblastic leukemia patients. *Haematologica* 97[suppl.2]:S20-21, 2012 **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) - 2012**

**77. Soverini S**, C De Benedittis, K Machova Polakova, A Brouckova, F Castagnetti, C Papayannidis, G Gugliotta, F Palandri, H Klamova, I Iacobucci, C Venturi, F Cattina, P

Bresciani, V Coluccio, M Salvucci, M Tiribelli, G Binotto, T Intermesoli, M Luppi, M Teresa Bochicchio, E Ottaviani, D Russo, G Rosti, M Bacarani, G Martinelli. Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications. *Blood* 2012; 120(21): 692. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2012**

**78. S Soverini**, C De Benedittis, K Machova Polakova, A Brouckova, C Papayannidis, P Bresciani, V Coluccio, I Iacobucci, C Venturi, M Luppi, E Ottaviani, F Cattina, R Foà, A Vitale, D Russo, M Bacarani, G Martinelli. Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies. *Blood* 2012; 120(21): 284. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2012**

**79. Simona Soverini**, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Fausto Castagnetti, Cristina Papayannidis, Gabriele Gugliotta, Francesca Palandri, Hana Klamova, Iliaria Iacobucci, Claudia Venturi, Federica Cattina, Paola Bresciani, Valeria Coluccio, Marzia Salvucci, Mario Tiribelli, Gianni Binotto, Tamara Intermesoli, Mario Luppi, Maria Teresa Bochicchio, Emanuela Ottaviani, Domenico Russo, Rosti Gianantonio, Michele Bacarani and Giovanni Martinelli. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain in Philadelphia-positive leukemias. *Cancer Res* 2013;73(8S):2082. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) - 2012**

**80. S Soverini**, C De Benedittis, K Polakova, A Brouckova, C Papayannidis, M Abbenante, I Iacobucci, C Venturi, A Ferrari, F Cattina, D Russo, M Luppi, P Bresciani, A Vitale, R Foà, M Bacarani, M Cavo, G Martinelli. Dynamics of expansion of tyrosine kinase inhibitor-resistant mutants as assessed by deep sequencing of the BCR-ABL kinase domain: implications for routine mutation testing. *Haematologica* 2013; 98(S1):S257. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) - 2013**

**81. Soverini S**, De Benedittis C, Machova Polakova K, Brouckova A, Alikian M, Foroni L, Ozbek U, Lion T, Hernandez JM, Hochhaus A, Pane F, Kohlmann A, Haferlach T, Castagnetti F, Rosti G, Papayannidis C, Iacobucci I, Cattina F, Russo D, Bacarani M, Martinelli G. Sensitivity, reproducibility and clinical utility of ultra-deep sequencing for BCR-ABL kinase domain mutation screening: results from the IRON II (Interlaboratory ROBustness of Next-Generation Sequencing) international study. *Haematologica* 2013; 98(S3):S129. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA (SIE) - 2013**

**82. S Soverini**, C De Benedittis, K Machova Polakova, A Brouckova, F Castagnetti, C Papayannidis, G Gugliotta, F Palandri, Hana Klamova, I Iacobucci, C Venturi, F Cattina, Paola Bresciani, Valeria Coluccio, Marzia Salvucci, M Tiribelli, G Binotto, T Intermesoli, Mario Luppi, MT Bochicchio, E Ottaviani, D Russo, Rosti Gianantonio, M Bacarani, G Martinelli. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain in Philadelphia-positive leukemias.

*Cancer Res* 2013;73(S8):4632. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) - 2013**

**83. S Soverini**, T Ernst, A Kohlmann, C De Benedittis, M Alikian, L Foroni, K Machova Polakova, A Brouckova, Y Erbilgin, O Hatirnaz, U Ozbek, C Robledo, JM Hernandez, M Musilova, S Barrio, J Martinez-Lopez, R Kastner, T Lion, T Haferlach, A Hochhaus, G Martinelli. Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study. *Blood* 2013; 122(21): 3824. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) - 2013**

**84. S Soverini**, C De Benedittis, K Machova Polakova, A Brouckova, F Castagnetti, G Gugliotta, F Palandri, C Papayannidis, I Iacobucci, C Venturi, M Mancini, E Leo, Hana Klamova, S Paolini, D Russo, G Rosti, M Bacarani, M Cavo, G Martinelli. Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy. *Blood* 2013; 122(21): 380. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2013**

**85. S Soverini**, C De Benedittis, M Rondoni, M Mancini, C Papayannidis, V Guadagnuolo, E Leo, L Zazzeroni, R Calogero, E Zago, A Scandola, M Garonzi, A Ferrarini, P Savini, O Quercia, L Pagano, R Zanotti, O Perbellini, G Specchia, S Merante, C Elena, D Gangemi, G Poletti, M Delledonne, S Cerny-Reiterer, M Cavo, P Valent, G Martinelli. Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. *Blood* 2014; 124(21):1881. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2014**

**86. S Soverini**, C De Benedittis, L Zazzeroni, K Machova Polakova, F Castagnetti, G Gugliotta, MT Bochicchio, I Iacobucci, M Salvucci, M Crugnola, G Binotto, M Bonifacio, G Leonardi, A Iurlo, G Specchia, D Russo, F Pane, G Saglio, G Rosti, M Cavo, M Bacarani, G Martinelli. In Chronic Myeloid Leukemia Patients on 2nd-Line Tyrosine Kinase Inhibitor Therapy, Deep Sequencing at the Time of Warning May Allow Sensitive Detection of Emerging BCR-ABL1 Mutants. *Blood* 2014; 124(21): 815. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2014**

**87. S Soverini**, C De Benedittis, C Papayannidis, L Zazzeroni, C Venturi, I Iacobucci, D Russo, P Bresciani, M Luppi, M Bacarani, M Cavo, G Martinelli. Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing. *Blood* 2014; 124(21): 2259 **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2014**

**88. S Soverini**, C De Benedittis, M Rondoni, M Mancini, C Papayannidis, L Zazzeroni, V Guadagnuolo, E Zago, F Griggio, A Ferrarini, M Garonzi, M Delledonne, G Specchia, R Zanotti, O Perbellini, L Pagano, M Cavo, P Valent, Giovanni Martinelli. Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor

suppressor gene. *Cancer Res* 2015;75(S15):3957. **Accettato come POSTER al meeting dell'AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) – 2015**

**89. S. Soverini**, M. Mancini, C. De Benedittis, L. Zazzeroni, C. Papayannidis, V. Guadagnuolo, R. Calogero, E. Zago, A. Scandola, M. Garonzi, P. Savini, L. Pagano, R. Zanotti, O. Perbellini, P. Bonadonna, G. Specchia, S. Merante, C. Elena, D. Gangemi, F.I. Grifoni, A. Ferrarini, M. Delledonne, P. Valent, M. Cavo, M. Rondoni, G. Martinelli. Recurrent loss of function of the SETD2 gene in aggressive systemic mastocytosis and mast cell leukemia. *Haematologica* 2015; 100(Suppl3)110. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA (SIE) - 2015**

**90. S Soverini**, C De Benedittis, F Castagnetti, G Gugliotta, M Mancini, G Specchia, Domenico Russo, Alessandra Iurlo, Massimiliano Bonifacio, Marzia Salvucci, T Intermesoli, P Avanzini, S Galimberti, B Martino, E Maino, AR Scortechini, K Machova Polakova, G Saglio, F Pane, G Rosti, M Bacarani, M Cavo, G Martinelli. BCR-ABL Mutations in Chronic Myeloid Leukemia (CML) Patients (pts) with Failure and Warning to First- and Second-Line Tyrosine Kinase Inhibitor (TKI) Therapy: What Is the Advantage of Next-Generation Sequencing (NGS) over Conventional Sequencing? *Blood* 2015; 126(23):346. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2015**

**91. S. Soverini**, C De Benedittis, M Mancini, M Rondoni, C Papayannidis, A Padella, G Specchia, R Zanotti, L Pagano, V Guadagnuolo, MC Fontana, M Delledonne, A Ferrarini, I Do Valle, D Remondini, G Castellani, R Calogero, S Merante, C Elena, P Valent, M Cavo, G Martinelli. Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. *Blood* 2015; 126(23): 4085. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2015**

**92. S Soverini**, C De Benedittis, C Venturi, C Papayannidis, M Mancini, K Machova Polakova, D Russo, P Bresciani, A Iurlo, E Abruzzese, F Sorà, M Bacarani, M Cavo, T Haferlach, G Martinelli. Clinical Relevance of Low Burden BCR-ABL1 Mutations Detectable By Amplicon Deep Sequencing (DS) in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients (pts): The Type of Mutation Matters. *Blood* 2015; 126(23): 2489. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2015**

**93. Soverini S**, de Benedittis C, Bavaro L, Serra A, Carnuccio F, Stella S, Vigneri P, Errichiello S, Mottadelli F, Mancini M, Iurlo A, Sorà F, Sica S, Galimberti S, Baratè C, Coluzzi S, Attolico I, di Bona E, Novella E, Specchia G, Abruzzese E, Castagnetti F, Gugliotta G, Papayannidis C, Cazzaniga G, Saglio G, Pane F, Cavo M, Rosti G, Martinelli G. Next generation sequencing (NGS) versus sanger sequencing (SS) for BCR-ABL kinase domain (KD) mutation screening: first results of the "NEXT-IN-CML" Italian multicenter study. *Haematologica* 2016;101(S3):S28. **Accettato come COMUNICAZIONE ORALE al meeting dell'ASSOCIAZIONE ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2016**

**94. S Soverini**, C De Benedittis, S Stella, A Serra, F Carnuccio, S Errichiello, L Bavaro, F Castagnetti, A Iurlo, N Orofino, F Sorà, S Sica, S Galimberti, C Baratè, F Mottadelli, M Martelli, E Novella, E Di Bona, G Specchia, F Albano, E Abruzzese, F Ciceri, F Lunghi, C Fava, G Rege Cambrin, L Luciano, M Breccia, C Caracciolo, M Santoro, F Di Raimondo, G



Gugliotta, C Papayannidis, G Cazzaniga, M Mancini, Rosaria Sancetta, R Bassan, C Musolino, G Spinosa, S Franca Capalbo, M Annunziata, M Cavo, G Rosti, M Bacarani, P Vigneri, G Saglio, F Pane, G Martinelli. The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. *Blood* 2016;128(22):3097. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2016**

**95. S Soverini**, C De Benedittis, M Rondoni, C Papayannidis, E Ficarra, G Paciello, M Manfrini, M Mancini, R Zanotti, L Scaffidi, G Specchia, F Albano, S Merante, C Elena, L Pagano, D Gangemi, P Tosi, L Bavaro, MC Fontana, V Guadagnuolo, A Ferrarini, E Zago, M Cavo, M Delledonne, P Valent, G Martinelli. The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. *Blood* 2016; 128(22):3136. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2016**

**96. Soverini S**, De Benedittis C, Bavaro L, Martelli M, Stella S, Vigneri P, Serra A, Carnuccio F, Errichiello S, Galimberti S, Barate C, Lunghi F, Ciceri F, Iurlo A, Orofino N, Albano F, Russo Rossi A, Sica S, Sorà F, Tenti E, Rosti G, Castagnetti F, Gugliotta G, Stagno F, Abruzzese E, Bonifacio M, Di Bona E, Sancetta R, Salvucci M, Pane F, Saglio G, Bacarani M, Cavo M, Martinelli G. Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the 'NEXT-IN-CML' Study. *Clin Lymphoma Myeloma Leuk* 2017;17(S2):S310-S311. **Accettato come POSTER al meeting della SOCIETY OF HEMATOLOGICAL ONCOLOGY (SOHO) – 2017**

**97. S Soverini**, C De Benedittis, L Bavaro, M Martelli, S Stella, A Iurlo, N Orofino, C Baratè, S Galimberti, S Sica, F Sorà, A Russo Rossi, F Albano, F Ciceri, F Lunghi, F Castagnetti, G Gugliotta, E Tenti, G Rosti, C Papayannidis, F Stagno, P Vigneri, A Serra, G Saglio, F Carnuccio, F Pane, S Errichiello, M Annunziata, M Breccia, E Abruzzese, M Bonifacio, E Novella, E Di Bona, R Sancetta, E Calistri, G Spinosa, M D'Adda, I Capodanno, M Bacarani, M Cavo, G Martinelli. Establishing a national network of laboratories using next generation amplicon deep sequencing for BCR-ABL1 kinase domain mutation screening: the 'NEXT-IN-CML' study. *Haematologica* 2017;102(S2):182. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2017**

**98. S Soverini**, L Bavaro, C De Benedittis, M Martelli, S Stella, P Vigneri, A Iurlo, N Orofino, S Sica, F Sorà, S Galimberti, C Baratè, MD, F Albano, A Russo Rossi, F Ciceri, F Lunghi, F Castagnetti, G Gugliotta, G Rosti, E Tenti, F Stagno, E Novella, E Di Bona, M Bonifacio, E Abruzzese, M Salvucci, M D'Adda, R Sancetta, E Calistri, M Bocchia, I Capodanno, G Spinosa, MA Laginestra, S Errichiello, A Serra, F Carnuccio, S Coluzzi, M Annunziata, C Musolino, F Pane, G Saglio, M Bacarani, M Cavo, and G Martinelli. What's Next in CML – a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening. *Blood* 2017; 130(S1):248. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2017**

**99.** M Mancini, C Monaldi, S De Santis, C Papayannidis, M Rondoni, MC Abbenante, L Bavaro, M Martelli, R Zanotti, L Pagano, M Cavo, P Valent, G Martinelli and **S Soverini**.

Polo-like Kinase-1 and Aurora Kinase A As Novel Therapeutic Targets in Neoplastic Mast Cells. *Blood* 2017;130(S1):5290 **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2017**

**100.** M Mancini, S DeSantis, C Monaldi, F Castagnetti, L Bavaro, M Martelli, G Gugliotta, G Rosti, E Tenti, MA Santucci, M Cavo, G Martinelli and **S Soverini**. Targeting WEE1 Kinase after G2/M Checkpoint Arrest Induces Apoptosis in Chronic Myeloid Leukemia Progenitors. *Blood* 2017; 130(S1):1588. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2017**

**101.** M Mancini, S De Santis, C Monaldi, L Bavaro, M Martelli, F Castagnetti, G Gugliotta, G Rosti, A Iurlo, E Abruzzese, M Salvucci, P Pregno, A Gozzini, M Crugnola, F Albano, M Bonifacio, E Calistri, M Tiribelli, G Binotto, A Imovilli, E Trabacchi, S Galimberti, C Baratè, E Tenti, M Bacarani, M Cavo, G Martinelli and **S Soverini**. SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia. *Blood* 2017;130(S1):43. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2017**

**102.** M Mancini, C Monaldi, S De Santis, C Papayannidis, M Rondoni, MC Abbenante, L Bavaro, M Martelli, E Ficarra, G Paciello, V Guadagnuolo, MC Fontana, M Manfrini, R Zanotti, L Pagano, F Albano, F Ciceri, C Elena, P Tosi, M Delledonne, P Valent, M Cavo, G Martinelli and **S Soverini**. SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications. *Blood* 2017;130(S1):2944. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2017**

**103.** Manuela Mancini, Cecilia Monaldi, Sara De Santis, Cristina Papayannidis, Michela Rondoni, Maria Chiara Abbenante, Luana Bavaro, Margherita Martelli, Roberta Zanotti, Livio Pagano, Michele Cavo, Peter Valent, Giovanni Martinelli, **Simona Soverini**. Polo-like kinase-1, Aurora kinase A and Wee1: new therapeutic targets in systemic mastocytosis. *Haematologica* 2018;103(S3):S93. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2018**

**104.** M. Mancini, S. De Santis, C Monaldi, L. Bavaro, M. Martelli, F. Castagnetti, G Gugliotta, G. Rosti, A. Iurlo, E. Abruzzese, M. Salvucci, P. Pregno, A. Gozzini, M. Crugnola, F. Albano, M. Bonifacio, E. Calistri, M. Tiribelli, G. Binotto, A. Imovilli, E. Trabacchi, S. Galimberti, C. Baratè, E. Tenti, M. Bacarani, M. Cavo, G. Martinelli, **S. Soverini**. Loss of function of the SETD2 tumor suppressor is a recurrent event in advanced-phase chronic myeloid leukemia, is due to post-translational mechanisms and fosters genetic instability. *Haematologica* 2018;103(S3):S47 **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2018**

**105.** **S. Soverini**, L. Bavaro, M. Martelli, C. De Benedittis, S. Stella, A. Iurlo, N. Orofino, C. Baratè, S. Galimberti, S. Sica, F. Sorà, A. Russo Rossi, F. Albano, F. Ciceri, F. Lunghi, F. Castagnetti, G. Gugliotta, E. Tenti, G. Rosti, C. Papayannidis, F. Stagno, P. Vigneri, A. Serra, G. Saglio, F. Carnuccio, F. Pane, S. Errichiello, M. Annunziata, M. Breccia, E. Abruzzese, M. Bonifacio, E. Novella, E. Di Bona, R. Sancetta, E. Calistri, G. Spinosa, M. D'Adda, I. Capodanno, M. Bocchia, M. Salvucci, C. Musolino, M.A. Laginestra, S.A. Pileri, A.

Percesepe, M. Baccarani, M. Cavo, G. Martinelli. NGS-Based Prospective Assessment of Low Burden Mutation Dynamics in Chronic Myeloid Leukemia Patients with Failure and Warning Responses: The 'NEXT-in-CML' Study. *Haematologica* 2018;103(S3):S49. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2018**

**106.** M. Mancini, C. Monaldi, S. De Santis, C. Papayannidis, M. Rondoni, MC. Abbenante, L. Bavaro, M. Martelli, R. Zanotti, L. Pagano, M.Cavo, P. Valent, G. Martinelli, S. Soverini. Polo-like kinase-1, Aurora kinase A and Wee1: new therapeutic targets in systemic mastocytosis. *Haematologica* 2018;103(S3):S93. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2018**

**107.** M. Mancini, S. De Santis, C. Monaldi, F. Castagnetti, L. Bavaro, M. Martelli, G. Gugliotta, G. Rosti, E. Tenti, M.A. Santucci, M. Cavo, G. Martinelli, S. Soverini. Association of Plk1 and Aurora kinase inhibitors with Wee1 inhibitors: a novel therapeutic approach for advanced phases-CML. *Haematologica* 2018;103(S3):S95. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2018**

**108.** M. Mancini, C. Monaldi, S. De Santis, C. Papayannidis, M. Rondoni, M.C. Abbenante, L. Bavaro, M. Martelli, E. Ficarra, G. Paciello, M.C. Fontana, M. Manfrini, R. Zanotti, L. Pagano, F. Albano, F. Ciceri, C. Elena, P. Tosi, M. Delledonne, P. Valent, M. Cavo, G. Martinelli, S. Soverini. SETD2 non-genomic loss of function in advanced systemic mastocytosis (SM): pathogenetic and therapeutic implications. *Haematologica* 2018;103(S3):S48. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2018**

**109.** Soverini, S, Bavaro, L, Martelli, M, De Benedittis, C, Iurlo, A, Orofino, N, Pagano, L, Criscuolo, M, Bonifacio, M, Scaffidi, L, Sica, S, Sora, F, Maino, E, Rondoni, M, Laginestra, MA, Lunghi, F, Ermacora, A, D'adda, M, Gugliotta, G, Castagnetti, F, Rosti, G, Papayannidis, C, Marconi, G, Curti, A, Miggiano, MC, Galimberti, S, Percesepe, A, Stagno, F, Sancetta, R, Annunziata, M, Falzetti, F, Capodanno, I, Pregno, P, Maffioli, M, Intermesoli, T, Di Bona, E, Caocci, G, Attolico, I, Binotto, G, Bocchia, M, Angelucci, E, Sgherza, N, Luciano, L, Mignone, F, Pileri, SA, Martinelli, G, Cavo, M. Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. *Blood* 2018;132(S1):789. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2018**

**110.** S Soverini, L Bavaro, M Martelli, C De Benedittis, C Papayannidis, A Percesepe, MA Laginestra, S Sica, F Sorà, F Albano, MD, Livio Pagano, Marianna Criscuolo, Sara Galimberti, M Salvucci, M Annunziata, GMarconi, A Curti, S Russo, A Imovilli, D Mannina, D Ferrero, M Stulle, C Basilico, E Abruzzese, F Mignone, SA Pileri, G Martinelli, M Cavo. Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. *Blood* 2018;132(S1):4078. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2018**

**111.** Mancini, M, De Santis, S, Monaldi, C, Bavaro, L, Martelli, M, Castagnetti, F, Gugliotta, G, Rosti, G, Fontana, MC, Dan, E, Sinigaglia, B, Iurlo, A, Orofino, N, Abruzzese, E, Salvucci,

M, Pregno, P, Gozzini, A, Crugnola, M, Albano, F, Bonifacio, M, Calistri, E, Tiribelli, M, Binotto, G, Imovilli, A, Trabacchi, E, Galimberti, S, Barate, C, Tenti, E, Baccarani, M, Martinelli, G, Cavo, M, **Soverini, S**. Aurora Kinase  $\alpha$ /MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. *Blood* 2018;132(S1):1726. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2018**

**112.** Mancini, M, Monaldi, C, De Santis, S, Papayannidis, C, Rondoni, M, Bavaro, L, Martelli, M, Abbenante, MC, Curti, A, Ficarra, E, Paciello, G, Fontana, MC, Zanotti, R, Bonifacio, M, Scaffidi, L, Pagano, L, Criscuolo, M, Albano, F, Ciceri, F, Elena, C, Tosi, P, Delledonne, M, Avanzato, C, Xumerle, L, Valent, P, Martinelli, G, Cavo, M, **Soverini, S**. MDM2 and Aurora Kinase  $\alpha$  Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment. *Blood* 2018;132(S1):1779. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2018**

**113. Simona Soverini**, Margherita Martelli, Luana Bavaro, Cristina Papayannidis, Simona Sica, Federica Sorà, Francesco Albano, Sara Galimberti, Claudia Barate', Michela Rondoni, Elisabetta Abruzzese, Mario Annunziata, Sabina Russo, Daniele Mannina, Manuela Stulle, Annalisa Imovilli, Antonio Curti, Massimiliano Bonifacio, Dario Ferrero, Claudia Basilico, Giovanni Reddiconto, Giuseppe Mineo, Maria Antonella Laginestra, Stefano Aldo Pileri, Flavio Mignone, Antonio Percesepe, Giovanni Martinelli, Michele Cavo Prospective comparison of Sanger sequencing vs Next Generation Sequencing for routine BCR-ABL1 kinase domain mutation screening in Philadelphia-positive acute lymphoblastic leukemia patients. *HemaSphere* 2019;3(S1):37-38. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2019**

**114.** M Mancini, C Monaldi, S De Santis, C Papayannidis, M Rondoni, L Bavaro, M Martelli, E Ficarra, G Paciello, MC Fontana, R Zanotti, L Pagano, F Albano, F Ciceri, C Elena, Patrizia Tosi, M Delledonne, P Valent, G Martinelli, M Cavo, **S Soverini**. SETD2 non-genomic loss of function in advanced systemic mastocytosis (SM): pathogenetic and therapeutic implications. *HemaSphere* 2019;3(S1):662-663. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2019**

**115.** M Mancini, S De Santis, C Monaldi, L Bavaro, M Martelli, F Castagnetti, G Gugliotta, G Rosti, MC Fontana, E Dan, BSinigallia, A Iurlo, N Orofino, E Abruzzese, M Salvucci, Patrizia Pregno, A Gozzini, M Crugnola, F Albano, M Bonifacio, E Calistri, M Tiribelli, G Binotto, A Imovilli, E Trabacchi, S Galimberti, C Baratè, E Tenti, M Baccarani, G Martinelli, M Cavo, **S Soverini**. SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia induced by post-translational mechanisms that can be therapeutically targeted. *HemaSphere* 2019;3(S1):13-14. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2019**

**116.** M. Mancini, S. De Santis, C Monaldi, L. Bavaro, M. Martelli, F. Castagnetti, Gabriele Gugliotta, G. Rosti, A. Iurlo, E. Abruzzese, M. Salvucci, P. Pregno, A. Gozzini, M. Crugnola, F. Albano, M. Bonifacio, E. Calistri, M. Tiribelli, G. Binotto, A. Imovilli, E. Trabacchi, S. Galimberti, C. Baratè, E. Tenti, M. Baccarani, G. Martinelli, M. Cavo, **S. Soverini**. Aurora kinase  $\alpha$ /MDM2-mediated SETD2 loss of function in chronic myeloid leukemia patients in blast crisis induces genetic instability and can be therapeutically targeted. *Haematologica*

2019;104(S2):23. **Accettato come COMUNICAZIONE ORALE al meeting dell'ASSOCIAZIONE ITALIANA DI EMATOLOGIA (SIE) – 2019**

**117.** M. Mancini, C. Monaldi, S. De Santis, C. Papayannidis, M. Rondoni, L. Bavaro, M. Martelli, M.C. Abbenante, A. Curti, M.C. Fontana, R. Zanotti, M. Bonifacio, Luigi Scaffidi, L. Pagano, M. Criscuolo, F. Albano, F. Ciceri, C. Elena, P. Tosi, M. Delledonne, C. Avanzato, L. Xumerle, P. Valent, G. Martinelli, M. Cavo, **S. Soverini**. In systemic mastocytosis, midostaurin targets both KIT and Aurora kinase A reverting H3K36Me3 deficiency and synergizes with second-generation tyrosine kinase inhibitors. *Haematologica* 2019;104(S2):39. **Accettato come COMUNICAZIONE ORALE al meeting dell'ASSOCIAZIONE ITALIANA DI EMATOLOGIA (SIE) – 2019**

**118. S. Soverini**, M. Martelli, L. Bavaro, C. Papayannidis, S. Sica, F. Sorà, F. Albano, S. Galimberti, C. Barate', M. Rondoni, E. Abruzzese, M. Annunziata, S. Russo, D. Mannina, M. Stulle, A. Imovilli, A. Curti, M. Bonifacio, L. Scaffidi, D. Ferrero, C. Basilico, G. Reddiconto 15, G. Mineo, M. A. Laginestra, S. A. Pileri, F. Mignone, A. Percesepe, G. Martinelli, M. Cavo. Prospective comparison of Sanger sequencing vs Next Generation Sequencing for routine BCR-ABL1 kinase domain mutation screening in Philadelphia-positive acute lymphoblastic leukemia patients. *Haematologica* 2019;104(S2):35. **Accettato come COMUNICAZIONE ORALE al meeting dell'ASSOCIAZIONE ITALIANA DI EMATOLOGIA (SIE) – 2019**

**119.** M. Martelli, L. Bavaro, G. De Matteis, M. Rondoni, R. Zanotti, M. Bonifacio, C. Papayannidis, A. Curti, C. Monaldi, S. De Santis, M. Mancini, M. Cavo, **S. Soverini**. Digital PCR is a promising method for sensitive detection of the KIT D816V mutation in patients with suspected systemic mastocytosis. *Haematologica* 2019;104(S2):106. **Accettato come POSTER al meeting dell'ASSOCIAZIONE ITALIANA DI EMATOLOGIA (SIE) – 2019**

**120.** Manuela Mancini, Cecilia Monaldi, Sara De Santis, Cristina Papayannidis, Michela Rondoni, Luana Bavaro, Margherita Martelli, Antonio Curti, Maria Chiara Fontana, Samantha Bruno, Roberta Zanotti, Massimiliano Bonifacio, Luigi Scaffidi, Livio Pagano, Marianna Criscuolo, Francesco Albano, Fabio Ciceri, Chiara Elena, Patrizia Tosi, Massimo Delledonne, Carla Avanzato, Luciano Xumerle, Peter Valent, Giovanni Martinelli, Michele Cavo, **Simona Soverini**. In Systemic Mastocytosis, Midostaurin Targets Both KIT and Aurora Kinase A Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors. *Blood* 2019;134(S1):4204. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2019**

**121.** Manuela Mancini, Sara De Santis, Cecilia Monaldi, Luana Bavaro, Margherita Martelli, Gabriele Gugliotta, Fausto Castagnetti, Gianantonio Rosti, Maria Chiara Fontana, Samantha Bruno, Elisa Dan, Barbara Sinigaglia, Alessandra Iurlo, Nicola Orofino, MD, Elisabetta Abruzzese, Marzia Salvucci, Patrizia Pregno, Antonella Gozzini, Monica Crugnola, Francesco Albano, Massimiliano Bonifacio, Elisabetta Calistri, Mario Tiribelli, Gianni Binotto, Annalisa Imovilli, Elena Trabacchi, Sara Galimberti, Claudia Baratè, Elena Tenti, Michele Bacarani, Giovanni Martinelli, Michele Cavo, **Simona Soverini**. Aurora Kinase A/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. *Blood* 2019;134(S1):4142. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2019**

**122. Soverini S**, Martelli M, Bavaro L, De Benedittis C, Iurlo A, Galimberti S, Pregno P, Bonifacio M, Lunghi F, Castagnetti F, Gugliotta G, Rosti G, Tiribelli M, Velotta V, Stagno F, Russo Rossi A, D'Adda M, Barate' C, Crugnola M, Luciano L, Laginestra MA, Corner AS, Maar D, Percesepe A, Pileri S, Pane F, Saglio G, Baccarani M, Martinelli G, Cavo M. Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. *Blood* 2019;134(S1):661. **Accettato come COMUNICAZIONE ORALE al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2019**

**123.** P Vannuffel, L Bavaro, F Nollet, A Aynaci, M Martelli, H Devos, C De Rop, **S Soverini**. Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). *Blood* 2019;134(S1):14660. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2019**

**124.** Manuela Mancini, Cecilia Monaldi, Sara De Santis, Cristina Papayannidis, Michela Rondoni, Chiara Sartor, Luana Bavaro, Margherita Martelli, Samantha Bruno, Antonio Curti, Maria Chiara Fontana, Roberta Zanotti, Massimiliano Bonifacio, Luigi Scaffidi, Livio Pagano, Marianna Criscuolo, Francesco Albano, Fabio Ciceri, Chiara Elena, Patrizia Tosi, Peter Valent, Michele Cavo, **Simona Soverini**. In systemic mastocytosis, midostaurin targets both KIT and Aurora kinase A reverting H3K36Me3 deficiency and synergizes with nilotinib and dasatinib. *HemaSphere* 2020;4(S1):488. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2020**

**125.** Manuela Mancini, Sara De Santis, Cecilia Monaldi, Luana Bavaro, Margherita Martelli, Samantha Bruno, Gabriele Gugliotta, Fausto Castagnetti, Gianantonio Rosti, Maria Chiara Fontana, Elisa Dan, Barbara Sinigaglia, Alessandra Iurlo, Cristina Bucelli, Elisabetta Abruzzese, Marzia Salvucci, Patrizia Pregno, Antonella Gozzini, Monica Crugnola, Francesco Albano, Massimiliano Bonifacio, Elisabetta Calistri, Mario Tiribelli, Gianni Binotto, Isabella Capodanno, Elena Trabacchi, Sara Galimberti, Claudia Baratè, Michele Baccarani, Michele Cavo, **Simona Soverini**. SETD2/KDM4A-mediated H3K36Me3 loss in chronic myeloid leukemia patients in blast crisis can be therapeutically targeted. *HemaSphere* 2020;4(S1):321. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2020**

**126.** K. Machova Polakova, A. Benesova, M. Martelli, V. Polivkova, J. Koblihova, P. Pecherkova, H. Klamova, D. Srbova, H. Zizkova, A. Hochhaus, **S. Soverini**. Major molecular response is the threshold for NGS analysis and resistant BCR-ABL1 mutation detection in CML. *HemaSphere* 2020;4(S1):40. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2020**

**127.** S. Galimberti, F. Guerrini, S. Grassi, M. Bocchia, L. Bavaro, E. Ciabatti, M. Dragani, E. M. Gottardi, B. Izzo, F. Lunghi, M. Martelli, F. Quarantelli, A. Serra, A. Sicuranza, G. Rege Cambrin, **S. Soverini**. Digital droplet PCR is a fast and effective tool for detecting T315I mutation in chronic myeloid leukemia. *HemaSphere* 2020;4(S1):324. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2020**

**128.** M. Rondoni, M. Mancini, C. Papayannidis, M. Martelli, R. Zanotti, C. Elena, L. Pagano, E. Petracci, C. Sartor, F. I. Grifoni, P. Bonadonna, M. Rosetti, E. Massari, P. Benvenuti, M. Criscuolo, C. Monaldi, S. De Santis, G. Poletti, G. Martinelli, M. Cavo, F. Lanza, **S. Soverini**. SETD2 protein levels are a novel predictor of overall survival in systemic mastocytosis. *HemaSphere* 2020;4(S1):489. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2020**

**129.** M Martelli, L Bavaro, G De Matteis, M Rondoni, R Zanotti, FI Grifoni, M Bonifacio, C Papayannidis, C Sartor, C Monaldi, S De Santis, M Mancini, A Curti, M Cavo, **S Soverini**. Digital PCR for Sensitive Detection and Accurate Quantification of KIT D816V Allele Burden in Patients with Suspected Systemic Mastocytosis. *Clin Lymphoma Myeloma Leuk* 2020;20(S1):S320. **Accettato come POSTER al meeting della SOCIETY OF HEMATOLOGICAL ONCOLOGY (SOHO) – 2020**

**130.** S De Santis, M Mancini, C Monaldi, M Martelli, F Castagnetti, G Gugliotta, G Rosti, E Dan, B Sinigaglia, A Iurlo, E Abruzzese, M Salvucci, P Pregno, A Gozzini, M Crugnola, F Albano, M Bonifacio, E Calistri, M Tiribelli, G Binotto, A Imovilli, E Trabacchi, S Galimberti, C Barate, M Baccarani, G Martinelli, M Cavo, **S Soverini**. ReSETting SETD2/H3K36Me3 Deficiency as a New Therapeutic Strategy in Blast Crisis Chronic Myeloid Leukemia Patients. *Clin Lymphoma Myeloma Leuk* 2020;20(S1):S236-S237. **Accettato come POSTER al meeting della SOCIETY OF HEMATOLOGICAL ONCOLOGY (SOHO) – 2020**

**131.** C Monaldi, M Mancini, S De Santis, M Martelli, M Rondoni, C Papayannidis, C Sartor, R Zanotti, M Bonifacio, FI Grifoni, S Bruno, A Curti, C Elena, L Pagano, M Criscuolo, M Cavo, **S Soverini**. Midostaurin Synergizes with Nilotinib and Dasatinib Restoring SETD2 Expression and Activity in Advanced Systemic Mastocytosis. *Clin Lymphoma Myeloma Leuk* 2020;20(S1):S334. **Accettato come POSTER al meeting della SOCIETY OF HEMATOLOGICAL ONCOLOGY (SOHO) – 2020**

**132.** S. Galimberti, F. Guerrini, S. Grassi, M. Bocchia, L. Bavaro, M. Dragani, E.M. Gottardi, B. Izzo, F. Lunghi, F Quarantelli, A. Serra, A. Sicuranza, G. Rege Cambrin, **S. Soverini**. Digital droplet PCR is a promising tool for detecting ABL1 T315I mutation in chronic myeloid leukemia patients: the experience of Italian “CML CAMPUS”. *Haematologica* 2020;105(S2):S53. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2020**

**133.** M. Martelli, L. Bavaro, G. De Matteis, M. Rondoni, R. Zanotti, F. Grifoni, M. Bonifacio, C. Papayannidis, C. Sartor, A. Curti, C. Monaldi, S. De Santis, M. Mancini, M. Cavo, **S. Soverini**. Digital pcr is a precise, accurate and sensitive method for the detection of the KIT D816V mutation in patients with suspected systemic mastocytosis. *Haematologica* 2020;105(S2):S76. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2020**

**134.** M. Mancini, C. Monaldi, S. De Santis, C. Papayannidis, M. Rondoni, C. Sartor, L. Bavaro, M. Martelli, S. Bruno, A. Curti, M.C. Fontana, R. Zanotti, M. Bonifacio, L. Scaffidi, L. Pagano, M. Criscuolo, F. Albano, F. Ciceri, C. Elena, P. Tosi, P. Valent, M. Cavo, **S. Soverini**. In systemic masocytosis, midostaurin targets both KIT and Aurora kinase A reverting H3K36ME3 deficiency and synergizes with nilotinib and dasatinib. *Haematologica*

2020;105(S2):S78. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2020**

**135.** S. Bruno, M. Mancini, M. Martelli, C. Monaldi, S. De Santis, M. Cavo, S. Soverini. Pan-Aurora kinase inhibitor tozasertib induces the activation of DNA damage repair network in acute myeloid leukemia. *Haematologica* 2020;105(S2):S86. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2020**

**136.** S. Bruno, M. Mancini, C. Monaldi, S. De Santis, M. Cavo, S. Soverini. Deep hypoxia reduces sensitivity of acute myeloid leukemia cell lines to the pan-aurora inhibitor tozasertib. *Hemasphere* 2021;5(S2):167. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2021**

**137.** S. Bruno, M. Mancini, C. Monaldi, S. De Santis, M. Cavo, S. Soverini. The Anti-Leukemic Effects of the Pan-Aurora Inhibitor Tozasertib Are Negatively Influenced by Hypoxia in Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk* 2021;21(S1):S297. **Accettato come POSTER al meeting della SOCIETY OF HEMATOLOGICAL ONCOLOGY (SOHO) – 2021**

**138.** C. Monaldi, M. Mancini, S De Santis, S Bruno, M Rondoni, C Papayannidis, C Sartor, R Zanotti, M Bonifacio, F Grifoni, A Curti, C Elena, L Pagano, M Criscuolo, M Cavo, S Soverini. *Clin Lymphoma Myeloma Leuk* 2021;21(S1):S356-357. **Accettato come POSTER al meeting della SOCIETY OF HEMATOLOGICAL ONCOLOGY (SOHO) – 2021**

**139.** S De Santis, M Mancini, C Monaldi, S Bruno, F Castagnetti, G Gugliotta, G Rosti, E Dan, B Sinigaglia, A Iurlo, E Abruzzese, P Pregno, F Albano, M Bonifacio, M Tiribelli, G Binotto, S Galimberti, M Baccarani, G Martinelli, M Cavo, S Soverini. SETD2 Loss of Function Induces Genomic Instability in CML and May Contribute to Disease Progression to Blast Crisis. *Clin Lymphoma Myeloma Leuk* 2021;21(S1):S329-330. **Accettato come POSTER al meeting della SOCIETY OF HEMATOLOGICAL ONCOLOGY (SOHO) – 2021**

**140.** C. Monaldi, M. Mancini, S. De Santis, M. Rondoni, S. Bruno, C. Papayannidis, C. Sartor, M. Cavo, S. Soverini. Rescue of SETD2 tumor suppressor functions is a novel mechanism of action of midostaurin in systemic mastocytosis (SM) and may serve as a biomarker of response. *Haematologica* 2022;107(S1):S23. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2022**

**141.** M. Mancini, C. Monaldi, S. De Santis, C. Papayannidis, M. Rondoni, C. Sartor, S. Bruno, A. Curti, R. Zanotti, M. Bonifacio, L. Scaffidi, L. Pagano, M. Criscuolo, F. Ciceri, C. Elena, P. Tosi, P. Valent, M. Cavo, S. Soverini. SETD2 is a bona fide tumor suppressor in systemic mastocytosis. *Haematologica* 2022;107(S1):S42. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2022**

**142.** S. Soverini, S. De Santis, C. Monaldi, M. Martelli, M. Mancini, S. Bruno, F. Castagnetti, G. Gugliotta, G. Rosti, C. Papayannidis, A. Curti, K. Machova Polakova, T. Ernst, D. Maar, A. Corner, M. Cavo. A novel, rapid and straightforward droplet digital pcr (ddPCR) strategy for the detection of bcr-abl1 kinase domain (KD) mutations impacting on tyrosine kinase inhibitor (TKI) selection in Philadelphia chromosome-positive patients. *Haematologica*



2022;107(S1):S42. **Accettato come COMUNICAZIONE ORALE al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2022**

**143.** S. De Santis, M. Mancini, C. Monaldi, S. Bruno, F. Castagnetti, G. Gugliotta, G. Rosti, A. Iurlo, E. Abruzzese, M. Cerrano, M. Bonifacio, S. Galimberti, S. Balducci, F. Stagno, M. Baccarani, M. Cavo, S. Soverini. In advanced phase CML, the SETD2 histone methyltransferase shows tumor suppressor functions and is responsible for BCR-ABL1-independent genomic instability. *Haematologica* 2022;107(S1):S61. **Accettato come POSTER al meeting della SOCIETA' ITALIANA DI EMATOLOGIA SPERIMENTALE (SIES) – 2022**

**144.** M Mancini, S De Santis, C Monaldi, S Bruno, F Castagnetti, G Gugliotta, A Iurlo, M Cerrano, S Galimberti, S Balducci, F Stagno, G Rosti, M Cavo, **S Soverini**. SETD2/H3K36Me3 deficiency sustains genomic instability and enhances clonogenic potential of chronic myeloid leukemia (CML) progenitors. *HemaSphere* 2022;6(S3):108. **Accettato come COMUNICAZIONE ORALE al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2022**

**145.** M Mancini, C Monaldi, S De Santis, C Papayannidis, M Rondoni, C Sartor, S Bruno, A Curti, R Zanotti, M Bonifacio, L Scaffidi, L Pagano, M Criscuolo, F Ciceri, C Elena, P Tosi, P Valent, M Cavo, S Soverini. SETD2 is a bona fide tumor suppressor in systemic mastocytosis. *HemaSphere* 2022;6(S3):1698. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2022**

**146.** S de Santis, C Monaldi, M Martelli, M Mancini, S Bruno, F Castagnetti, G Gugliotta, K Machova Polakova, T Ernst, D Maar, A Corner, M Cavo, **S Soverini**. A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors. *Clin Lymphoma Myeloma Leuk* 2022;22(S1):S289-290. **Accettato come POSTER al meeting della SOCIETY OF HEMATOLOGICAL ONCOLOGY (SOHO) – 2022**

**147.** C Monaldi, S De Santis, M Mancini, C Papayannidis, C Sartor, M Rondoni, M Cavo, S Soverini. Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis. *Clin Lymphoma Myeloma Leuk* 2022;22(S1):S328. **Accettato come POSTER al meeting della SOCIETY OF HEMATOLOGICAL ONCOLOGY (SOHO) – 2022**

**148.** S De Santis, M Mancini, C Monaldi, G Gugliotta, S Bruno, F Castagnetti, M Iezza, M Cerrano, A Iurlo, S Galimberti, S Balducci, F Stagno, M Cavo, **S Soverini**. Loss of Function of SETD2 Tumor Suppressor in Chronic Myeloid Leukemia (CML) Progenitors Fosters Genomic Instability and Enhances Clonogenic Potential. *Blood* 2023;142(Supplement 1):1785. **Accettato come POSTER al meeting dell'AMERICAN SOCIETY OF HEMATOLOGY (ASH) – 2023**

**149.** C Monaldi, S De Santis, M Mancini, D Pietra, G De Matteis, S Fabris, N Bolli, S Errichiello, B Izzo, F Gesullo, P Guglielmelli, G Minnella, P Chiusolo, C Papayannidis, C Sartor, C Elena, I Tanasi, M Bonifacio, FI Grifoni, M Sciumè, M Triggiani, F Mannelli, L Pagano, AM Vannucchi, NCP Cross, M Cavo, R Zanotti, **S Soverini**. Performance and Interlaboratory Reproducibility of Droplet Digital Polymerase Chain Reaction (ddPCR) and

Real Time PCR for KIT D816V Mutation Detection: A Nationwide Pilot Study By the RIMA (Rete Italiana Mastocitosi) Association. *Blood* 2023;142 (Supplement 1):6393.

**150.** S Bruno, 2, C Mosca, M Mancini, D Forte, S De Santis, C Monaldi, M Cavo, **S Soverini**. Autophagy inhibition boosts midostaurin efficacy on hypoxic leukemic stem cells in acute myeloid leukemia. *HemaSphere* 2024;8(S1):832. **Accettato come POSTER al meeting della EUROPEAN HEMATOLOGY ASSOCIATION (EHA) – 2024**

## Allegato 3

### ALTRI ABSTRACTS

---

1. Buonamici S, Ottaviani E, Testoni N, **Soverini S**, Giannini B, Terragna C, Amabile M, Martinelli G: New and unfrequent CBF $\beta$ -MYH11 fusion transcripts: clinical and molecular findings in acute leukemia patients. *Haematologica* 85 Vol. 1 (9): 111, 2000.
2. Buonamici S, Ottaviani E, Testoni N, Visani G, Saglio G, Montefusco V, Bonifazi F, Amabile M, Terragna C, **Soverini S**, Isidori A, Fiacchini M, Tura S, Martinelli G: Real Time quantification of minimal residual disease in inv(16) positive acute myeloid leukemia can predict clinical relapse and identify patients in durable remission. *Haematologica* 85 Vol. 1 (9): 80, 2000.
3. Martinelli G, Terragna C, Amabile M, Ottaviani E, **Soverini S**, Buonamici S, Tosi P, Testoni N, Cavo M, Tura S: Real-Time quantitative polymerase chain reaction for the detection of minimal residual disease in multiple myeloma using junctional region specific Taqman probe and patient specific primer set. *Haematologica* 85 Vol. 1 (9): 106, 2000.
4. Martinelli G, Amabile M, Terragna C, Montefusco V, Testoni N, Ottaviani E, De Vivo A, Mianulli A, Saglio G, **Soverini S**, Buonamici S, Tura S: Novel type of chimeric bcr-abl transcript e8-int-a2 found in a philadelphia chromosome positive myeloid leukemia patient retains the dbl- and CDC24-like domains but not the ph-like domain of the bcr gene. *The Pezcoller Foundation Journal* 15: 19, 2000.
5. Martinelli G, Ottaviani E, Testoni N, Visani G, Terragna C, Buonamici S, **Soverini S**, Amabile M, Montefusco V, Tura S: Role of bone marrow transplantation procedures for inducing molecular remission in inv(16) positive acute myeloid leukemia patients. *The Hematology Journal* 1 (1): 56, 2000.
6. Martinelli G, Terragna C, Amabile M, Montefusco V, Testoni N, Ottaviani E, De Vivo A, Mianulli A, Saglio G, **Soverini S**, Buonamici S, Bregoli M, Tura S: Rare transcripts and abnormal breakpoints in Philadelphia chromosome positive chronic myeloid leukemia patients. *The Hematology Journal* 1 (1): 84, 2000.
7. Martinelli G, Testoni N, Piccaluga P, Ottaviani E, Terragna C, **Soverini S**, Buonamici S, Amabile M, Pastano R, Cavo M, Visani G, Tura S: Molecular analysis in alpha-Interferon treated P-190BCR-ABL positive adult acute lymphoblastic leukemia. *The Hematology Journal* 1 (1): 117, 2000.
8. Montefusco V, Martinelli G, Amabile M, Ottaviani E, Stanzani M, **Soverini S**, Buonamici S, Terragna C, Bandini G, Tura S: Clinical relevance of molecular monitoring after allogeneic bone marrow transplantation for chronic myelogenous leukemia. *The Hematology Journal* 1 (1): 212, 2000.
9. Martinelli G, Montefusco V, Testoni N, Amabile M, Saglio G, Ottaviani E, Terragna C, Bonifazi F, Rosti G, Bandini G, **Soverini S**, Buonamici S, Tura S: Clinical value of quantitative long-term assessment of BCR-ABL chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. *Haematologica*, 85 Vol. 1 (7): 36, 2000.
10. Martinelli G, Amabile M, Montefusco V, Testoni N, Giannini B, de Vivo A, Bonifazi F, Ottaviani E, Saglio G, Terragna C, Buonamici S, **Soverini S**, Gambacorti-Passerini C, Russo D, Trabacchi E, Bassi S, Rosti G, Baccarani M, Tura S: Predictive value of quantitative Real-Time evaluation of molecular response in CML patients treated with  $\alpha$ IFN. *Haematologica* 85 (Vol. 1): 7, 2000.

11. Martinelli G, Amabile M, Giannini B, Montefusco V, Testoni N, de Vivo A, Bonifazi F, Ottaviani E, Saglio G, Terragna C, Buonamici S, **Soverini S**, Trabacchi E, Bassi S, Rosti G, Baccarani M, Tura S: Characteristics of Real-Time and competitive RT-PCR quantification of BCR-ABL transcripts in CML patients. *Haematologica* 85 (Vol. 1): 7, 2000.
12. Amabile M, Martinelli G, Giannini B, Montefusco V, Testoni N, De Vivo A, Bonifazi F, Ottaviani E, Saglio G, Terragna C, Buonamici S, **Soverini S**, Trabacchi E, Bassi S, Rosti G, Baccarani M, Tura S: Characteristics of Real-Time and competitive RT-PCR quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia. *Haematologica* 85 (9): 30, 2000.
13. Bonifazi F, Ottaviani E, Saglio G, Terragna C, Buonamici S, **Soverini S**, Gambacorti-Passerini C, Russo D, Trabacchi E, Bassi S, Rosti G, Baccarani M, Tura S: Predictive value of quantitative Real-Time evaluation of molecular response in chronic myeloid leukemia patients treated with alpha-interferon. *Haematologica* 85 Vol. (9): 77, 2000.
14. Martinelli G, Amabile M, Giannini B, Montefusco V, Testoni N, De Vivo A, Bonifazi F, Ottaviani E, Saglio G, Terragna C, Buonamici S, **Soverini S**, Gambacorti-Passerini C, Russo D, Trabacchi E, Bassi S, Rosti G, Baccarani M, Tura S: Predictive value of quantitative real-time evaluation of molecular response in CML patients treated with  $\alpha$ -IFN. *Blood* 96 (11): 737, 2000.
15. Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, Bandini G, Testoni N, Amabile M, Ottaviani E, Buonamici S, **Soverini S**, Montefusco V, de Vivo A, Bonifazi F, Tura S, Cavo M: PCR-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. *Blood* 96 (11): 155, 2000.
16. Martinelli G, Amabile M, Giannini B, Montefusco V, Testoni N, De Vivo A, Bonifazi F, Ottaviani E, Saglio G, Terragna C, Buonamici S, **Soverini S**, Trabacchi E, Bassi S, Rosti G, Baccarani M, Tura S: Characteristics of real-time and competitive RT-PCR quantification of bcr-abl transcripts in CML patients. *Blood* 96 (11): 256, 2000.
17. Amabile M, Giannini B, Testoni N, Montefusco V, Rosti G, Zardini C, Terragna C, Buonamici S, Ottaviani E, **Soverini S**, Fiacchini M, Bassi S, de Vivo A, Trabacchi E, Saglio G, Pane F, Baccarani M, Tura S, Martinelli G: Real-time quantification of different types of *bcr-abl* transcript in chronic myeloid leukemia. *Haematologica* 86 (3): 252-259, 2001.
18. Martinelli G, Giannini B, Amabile M, Zardini C, Montefusco V, Testoni N, Rosti G, Terragna C, **Soverini S**, Buonamici S, Ottaviani E, Bassi S, Gottardi E, De Micheli D, Izzo B, Saglio G, Pane F, Fiacchini M, Baccarani M, Tura S: Innovative therapies: Monitoring the response of CML patients treated with STI571 by cytogenetic analysis and quantitative RT-PCR. *2<sup>nd</sup> International Symposium on Minimal Residual Disease – Europe Against Cancer Program*. Vol.1: 47, 2001.
19. Buonamici S, Ottaviani E, Testoni N, Montefusco V, Amabile M, Terragna C, Giannini B, **Soverini S**, Ruggeri D, Visani G, Isidori A, Malagola M, Bassi S, Bonifazi F, Baccarani M, Tura S, Martinelli G: Real-Time quantification of minimal residual disease in inv(16) positive acute myeloid leukemia can predict clinical relapse and identify patients in a curable state. *2<sup>nd</sup> International Symposium on Minimal Residual Disease – Europe Against Cancer Program*. Vol.1: 93, 2001.
20. Martinelli G, Buonamici S, Ottaviani E, Testoni N, Visani G, Saglio G, Montefusco V, Bonifazi F, Amabile M, Terragna C, **Soverini S**, Isidori A, Fiacchini M, Tura S: Real-Time quantification of minimal residual disease in inv(16) positive acute myeloid leukemia can predict clinical relapse and identify patients in durable remission. *Bone Marrow Transplantation* 27 (Suppl. 1): 319, 2001.

- 21.** Martinelli G, Giannini B, Amabile M, Testoni N, De Vivo A, Bonifazi F, Ottaviani E, Saglio G, Terragna C, Buonamici S, **Soverini S**, Trabacchi E, Bassi S, Rosti G, Baccarani M, Tura S: Real-Time and competitive RT-PCR quantification of BCR-ABL transcripts in CML patients during  $\alpha$ -IFN therapy. *Bone Marrow Transplantation* 27 (Suppl. 1): 426, 2001.
- 22.** Martinelli G, Terragna C, Zamagni E, Ronconi S, Tosi P, Lemoli RM, Bandini G, Testoni N, Amabile M, Ottaviani E, Buonamici S, **Soverini S**, Tura S, Cavo M: Absence of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation is associated with a very low rate of clinical relapse. *Bone Marrow Transplantation* 27 (Suppl. 1): 615, 2001.
- 23.** Martinelli G, Buonamici S, Ottaviani E, Testoni N, Terragna C, Amabile M, Giannini B, **Soverini S**, Zardini C, Luatti S, Visani G, Isidori A, Piccaluga P, Baccarani M, Tura S: Single-center experience of detection of minimal residual disease in patients with AML1/ETO-Associated acute myeloid leukemia by real-time RT-PCR. *The Hematology Journal* 1 (1): 231, 2001.
- 24.** Martinelli G, Terragna C, Tosi P, **Soverini S**, Cavo M, Tura S: A very low rate of clinical relapse in multiple myeloma patients receiving allogeneic stem cell transplantation is associated with absence of minimal residual disease. *The Hematology Journal* 1 (1): 216, 2001.
- 25.** Martinelli G, Buonamici S, Ottaviani E, Testoni N, Terragna C, Amabile M, Giannini B, **Soverini S**, Zardini C, Visani G, Isidori A, Malagola M, Ruggeri D, Piccaluga P, Baccarani M, Tura S: Rare CBF $\beta$ -MYH11 fusion transcripts in patients with acute myeloid leukemia associated with inversion of chromosome 16. *The Hematology Journal* 1 (1): 115-116, 2001.
- 26.** Martinelli G, Terragna C, Zamagni E, Tosi P, **Soverini S**, Cavo M, Tura S: Prolonged relapse free survival and a favorable clinical outcome in multiple myeloma patients are predicted by molecular analysis after allogeneic or autologous stem cells transplantation. *The Hematology Journal* 1 (1): 96, 2001.
- 27.** Martinelli G, Tosi P, Ottaviani E, **Soverini S**, Terragna C, Buonamici S, Giannini B, Amabile M, Zamagni E, Testoni N, Ruggeri D, Cavo M, Baccarani M, Tura S: Molecular therapy for multiple myeloma. *XXV corso nazionale di aggiornamento in ematologia clinica*. Vol. 1: 108-117, 2001.
- 28.** Martinelli G, Rosti G, Trabacchi E, Amabile M, Giannini B, Cardini C, Montefusco V, Testoni N, Terragna C, Buonamici S, Ottaviani E, **Soverini S**, Bassi S, De Vivo A, Bonifazi F, Alberti D, Tura S, Baccarani M: Clinical and molecular response analyzed by Real-Time quantification of BCR-ABL transcripts in chronic myeloid leukemia patients after STI-571 therapy. *Haematologica* 86(10): 9, 2001.
- 29.** Buonamici S, Ottaviani E, Testoni N, Terragna C, Amabile M, Giannini B, **Soverini S**, Ruggeri D, Luatti S, Zardini C, Visani G, Piccaluga P, Isidori A, Malagola M, Baccarani M, Tura S, Martinelli G: Single-center experience of detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia by Real-Time RT-PCR. *Haematologica* 86(10): 170, 2001.
- 30.** Martinelli G, Rosti G, Trabacchi E, Amabile M, Zardini C, Giannini B, Montefusco V, Testoni N, Terragna C, Buonamici S, Ottaviani E, **Soverini S**, Bassi S, De Vivo A, Baccarani M, Alberti D, Tura S: Real-Time Quantification of BCR-ABL Transcripts in Chronic Myeloid Leukemia after Glivec® (Formerly STI571) Treatment: Relationship with Cytogenetic Response. *Blood* 98 (11): 262, 2001.
- 31.** Ottaviani E, Martinelli G, Rosti G, Grafone T, Amabile M, Giannini B, Terragna C, Zardini C, Buonamici S, **Soverini S**, Trabacchi E, Bassi S, De Vivo A, Bonifazi F, Alberti D, Tura S, Baccarani M: Simultaneous In Vitro Exposure to STI-571, Apo2L/TRAIL and Interferon-

Alpha, with or without Prior Ara-C Treatment, Apo2L/TRAIL-Induced Cytotoxicity and Apoptosis in BCR/ABL + Leukemic Blasts. *Blood* 98 (11): 265, 2001.

**32.** Ottaviani E, Giannini B, Amabile M, Martinelli G, Bonifazi F, Zardini C, Grafone T, Trabacchi E, Bassi S, Rosti G, Terragna C, Buonamici S, **Soverini S**, De Vivo A, Alberti D, Tura S, Bacarani M: Effects of Glivec® (Formerly STI571) Alone and in Combination with  $\alpha$ -IFN and Ara-C on the Amount of BCR/ABL Transcript in CML cells. *Blood* 98 (11): 265, 2001.

**33.** Terragna C, Martinelli G, Rossi M, **Soverini S**, Amabile M, Giannini B Ottaviani E, Buonamici S, Zamagni E, Cellini C, Tosi P, Cangini D, Tura S, Bacarani M, Cavo M: Molecular remission of multiple myeloma after allogeneic or autologous transplantation of hematopoietic stem cells. *6° International Symposium on Predictive Oncology & Intervention Strategies*. Vol. 1: 80, 2002.

**34.** Martinelli G, Ottaviani E, Rosti G, Grafone T, Amabile M, Giannini B, Terragna C, Zardini C, Buonamici S, **Soverini S**, Trabacchi E, Bassi S, De Vivo A, Bonifazi F, Alberti D, Tura S, Bacarani M: Simultaneous In Vitro Exposure to STI-571, Apo2L/TRAIL and Interferon-Alpha, with or without Prior Ara-C Treatment, Apo2L/TRAIL-Induced Cytotoxicity and Apoptosis in BCR/ABL + Leukemic Blasts. *Bone Marrow Transplantation* 29 (Suppl. 2): 0241, 2002.

**35.** Martinelli G, Setola E, Tosi P, Ottaviani E, **Soverini S**, Terragna C, Buonamici S, Giannini B, Amabile M, Zamagni E, Testoni N, Ruggeri D, Cavo M, Bacarani M, Tura S: I pathways della mielomagenesi: "Passaggi fragili che possono essere interrotti da farmaci". *Conferenza Nazionale sul Mieloma*. Vol. 1: 209-14, 2002.

**36.** Terragna C, Martinelli G, Bonifazi F, Motta MR, Zamagni E, **Soverini S**, Amabile M, Ottaviani E, Giannini B, Buonamici S, Cavo M, Tura S, Bacarani M: Valutazione qualitativa e quantitativa della malattia minima residua nel mieloma multiplo. *Conferenza Nazionale sul Mieloma*. Vol. 1: 47-52, 2002.

**37.** Martinelli G, Rosti G, Trabacchi E, Amabile M, Giannini B, Testoni N, Terragna C, Buonamici S, Ottaviani E, **Soverini S**, Bassi S, Bonifazi F, Tura S, Alberti D, Bacarani M: CML patients with resistance to STI-571 therapy could be monitored by real-time quantification of bcr-abl transcripts. *The Hematology Journal* 3 (1): 296-7, 2002.

**38.** Terragna C, Rossi M, Zamagni E, Bonifazi F, Amabile M, **Soverini S**, Giannini B, Ottaviani E, Buonamici S, Cellini C, Tosi P, Cavo M, Tura S, Bacarani M, Martinelli G: Molecular remission of multiple myeloma patients after allogeneic or autologous transplantation of hematopoietic stem cells. *The Hematology Journal* 3 (1): 333, 2002.

**39.** Martinelli G, Amabile M, Giannini B, Terragna C, Ottaviani E, **Soverini S**, Saglio G, Rosti G, Bacarani M. Novel types of *bcr-abl* transcript with breakpoints in BCR exon 8 found in Philadelphia-positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24-homology domains but not the pleckstrin homology one. *Haematologica* 87(7):688-94, 2002.

**40.** Terragna C, Martinelli G, Rossi M, **Soverini S**, Amabile M, Giannini B, Ottaviani E, Buonamici S, Zamagni E, Cellini C, Tosi P, Cangini D, Tura S, Bacarani M, Cavo M. Molecular Remission Of Multiple Myeloma Patients After Allogeneic Or Autologous Transplantation Of Hematopoietic Stem Cells. *Haematologica* 2002;87 (suppl. to 9): 38

**41.** Grafone T., Martinelli G., Ottaviani E., Rosti G., Amabile M., Giannini B., Terragna C., Buonamici S., **Soverini S**, Trabacchi E., Bassi S., De Vivo A., Bonifazi F., Alberti D., Tura S., Bacarani M. Simultaneous In Vitro Exposure To STI-571, APO2L/TRAIL And Interferon-Alpha, With Or Without Prior Ara-C Treatment, APO2L/TRAIL-Induced Cytotoxicity And Apoptosis In BCR/ABL+ Leukemic Blasts. *Haematologica* 2002;87 (suppl. to 9): 38

42. Martinelli G., Rosti G., Trabacchi E, Amabile M., Giannini B., Testoni N., Terragna C., Buonamici S., Ottaviani E., **Soverini S.**, Bassi S., De Vivo A., Tura S., Alberti D., Baccarani M. CML patients with resistance to sti-571 therapy could be monitored by real-time quantification of bcr-abl transcripts. *Haematologica* 2002;87 (suppl. to 9): 40
43. Giannini B, Martinelli G, Rosti G, Amabile M, Trabacchi E, Testoni N, Buonamici S, Ottaviani E, **Soverini S**, Bassi S, Pane F, Izzo B, Saglio G, Alberti D, Baccarani M. CML Patients With Complete Karyotypic Response To Sti-571 (Glivec) Therapy Shows Rapid Reduction Of Bcr-Abl Transcripts. *Haematologica* 2002;87 (suppl. to 9): 126
44. Ottaviani E., Giannini B., Amabile M., Martinelli G., Bonifazi F., Grafone T., Trabacchi E., Bassi S., Rosti G., Terragna C., Buonamici S., **Soverini S.**, De Vivo A., Alberti D., Tura S., Baccarani M. Effects Of Glivec (Formerly Sti571) Alone And In Combination With Alpha-Ifn And Ara-C On The Amount Of Bcr/Abl Transcript In CML Cells. *Haematologica* 2002;87 (suppl. to 9): 117
45. Martinelli G., Amabile M., Giannini B., Terragna C., Ottaviani E., **Soverini S.**, Saglio G., Rosti G., Baccarani M. Novel types of *BCR-ABL* transcript with breakpoints in bcr exon 8 found in philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 –homology domains but not the ph one. *Haematologica* 2002;87(suppl. to 9): 117-118.
46. Terragna C, **Soverini S**, Martinelli G, Bonifazi F, Testoni N, Amabile M, Giannini B, Ottaviani E, Grafone T, Cellini C, Zamagni E, Tosi P, Tura S, Cavo M, Baccarani M. Analysis of MMSET and Fibroblast Growth Factor Receptor 3 Expression in Multiple Myeloma Patients with t(4;14). *Blood* 100 (11): 392, 2002.
47. Terragna C, Martinelli G, Rossi M, de Vivo A, Bonifazi F, **Soverini S**, Amabile M, Giannini B, Ottaviani E, Buonamici S, Zamagni E, Cellini C, Tosi P, Tura S, Cavo M, Baccarani M. Clinical Relevance and Prognostic Value of Minimal Residual Disease in Multiple Myeloma. *Blood* 100 (11): 599, 2002.
48. Giannini B, Martinelli G, Rosti G, Amabile M, Bassi S, Trabacchi E, Testoni N, Buonamici S, Ottaviani E, **Soverini S**, Terragna C, Grafone T, Trabacchi E, Pane F, Saglio G, Alberti D, Baccarani M. CML patients with complete karyotypic response to STI571 (glivec) therapy show rapid reduction of bcr-abl transcripts. *Blood* 100 (11): 785-6, 2002.
49. Grafone T, Martinelli G, Ottaviani E, Giannini B, Ferraretti L, Terragna C, **Soverini S**, Amabile M, Baccarani M. Different effects of the Farnesyl Protein Transferase Inhibitors (FTI) *in vitro* against MK2 and MK1 Philadelphia chromosome (Ph)-positive cell lines. *Blood* 100 (11): 788, 2002.
50. Amabile M, Martinelli G, Trabacchi E, Giannini B, Testoni N, Terragna C, Buonamici S, Ottaviani E, **Soverini S**, Bassi S, De Vivo A, Tura S, Alberti D, Baccarani M. CML Patients with Resistance to STI-571 Therapy Could Be Monitored by Real-Time Quantification of BCR-ABL Transcripts. *Blood* 100 (11): 320, 2002.
51. Martinelli G, Bianchini M, Giannini B, Grafone T, Ottaviani E, Amabile M, Terragna C, **Soverini S**, Piccaluga PP, Isidori A, Malagola M, Rondoni M, Buonamici S, Baccarani M. Rapid Detection of Flt3-ITD in Acute Myeloid Leukemia Patients by D-HPLC. *Blood* 100 (11): 229, 2002.
52. Martinelli G, **Soverini S**, Cavo M, Terragna C, Ruggeri D, Testoni N, Cellini C, De Vivo A, Amabile M, Grafone T, Tosi P, Zamagni E, Bonifazi F, Cangini D, Tura S, Baccarani M. Significance of cyclin D1 overexpression in multiple myeloma patients. *The Hematology Journal*, 4(S2): 167-168, 2003.

- 53.** Martinelli G, Piccaluga PP, Malagola M, **Soverini S**, Rondoni M, Isidori A, Bonifazi F, Giannini B, Grafone T, Ottaviani E, De Vivo A, Bosi C, Bianchini M, Terragna C, Fiacchini M. Other targets for imatinib therapy. *The Hematology Journal*, 4(S2): 181, 2003.
- 54.** Grafone T, Martinelli G, Ottaviani E, Giannini B, Ferraretti L, Terragna C, **Soverini S**, Amabile M, Bacarani M. Different effects of the farnesyl protein transferase inhibitors in vitro against MK2 and MK1 cell lines Philadelphia chromosome (PH)-positive. *The Hematology Journal*, 4(S2): 181, 2003.
- 55.** Martinelli G, Bianchini M, Giannini B, Grafone T, Ottaviani E, Amabile M, Terragna C, **Soverini S**, Piccaluga PP, Isidori A, Malagola M, Rondoni M, Bacarani M. Rapid detection of FLT3-ITD in acute myeloid leukemia patients by D-HPLC. *The Hematology Journal*, 4(S2): 208, 2003.
- 56.** Martinelli G, Rosti G, Piccaluga PP, Malagola M, Rondoni M, Trabacchi E, Bassi S, Amabile M, Giannini B, Grafone T, Terragna C, Bianchini M, Poerio A, **Soverini S**, Ottaviani E, Vigna E, Bosi C, Testoni N, Luatti S, Tonelli M, Nicci C, Tura S, Bacarani M. The clinical efficacy of imatinib in hematology and oncology. *XXVI corso nazionale di aggiornamento in ematologia clinica*. Vol. 1: 134-144, 2003.
- 57.** Terragna C, Cavo M, **Soverini S**, Cellini C, Testoni N, De Vivo A, Amabile M, Giannini B, Ottaviani E, Grafone T, Zamagni E, Tosi P, Cangini D, Tocchetti P, Tura S, Bacarani M, Martinelli G. Frequency and prognostic relevance of t(4;14) in previously untreated Multiple Myeloma (MM) patients receiving either single or double autotransplantations. *The Hematology Journal* 4(S1): 110-111, 2003.
- 58.** Martinelli G, Bianchini M, Grafone T, Giannini B, Ottaviani E, Terragna C, **Soverini S**, Amabile M, Piccaluga PP, Malagola M, Rondoni M, Bosi C, Bacarani M. Rapid detection of FLT3 mutations in acute myeloid leukemia patients by denaturing high-performance liquid chromatography. *Haematologica* 88:83-84, 2003.
- 59.** Grafone T, Martinelli G, Ottaviani E, Bianchini M, Giannini B, Ferraretti L, Terragna C, **Soverini S**, Amabile M, Russo D, Bacarani M. Different effects of the farnesyl protein transferase inhibitors in vitro against MK2 and MK1 Philadelphia chromosome-positive chronic leukemia cell lines. *Haematologica* 88:419-420, 2003.
- 60.** Martinelli G, Piccaluga PP, Malagola M, **Soverini S**, Rondoni M, Isidori A, Giannini B, Grafone T, Ottaviani E, De Vivo A, Bonifazi F, Bosi C, Bianchini M, Terragna C, Fiacchini M, Ricci P, Visani G, Russo D, Bassi S, Trabacchi E, Rosti G, Buonamici S, Alberti D, Bacarani M. Other targets for imatinib therapy. *Haematologica* 88:208, 2003.
- 61.** Bosi C, Piccaluga PP, Malagola M, Rondoni M, Bianchini M, Testoni N, Luatti S, Amabile M, **Soverini S**, Ottaviani E, Giannini B, Gaitani S, Vigna E, Dizdari A, Visani G, Pileri SA, Fiacchini M, Martinelli G, Bacarani M. de novo acute B-Cell acute lymphoblastic leukemia with t(14;18) and BCR/ABL rearrangement. a case report. *Haematologica* 88:246, 2003.
- 62.** Martinelli G, Ottaviani E, Testoni N, Rosti G, **Soverini S**, Malagola M, Piccaluga PP, Giannini B, Luatti S, Grafone T, Amabile M, Bianchini M, Terragna C, Poerio A, Tonelli M, Nicci C, Bacarani M Hypereosinophilic syndrome treated with imatinib therapy: clinical and biological analysis. *Haematologica* 88:40, 2003.
- 63.** Terragna C, Cavo M, **Soverini S**, Cellini C, Testoni N, De Vivo A, Amabile M, Giannini B, Ottaviani E, Grafone T, Zamagni E, Tosi P, Cangini D, Tocchetti P, Tura S, Bacarani M and Martinelli G. Frequency And Prognostic Relevance Of t(4;14) In Previously Untreated Multiple Myeloma (MM) Patients Receiving Either Single Or Double Autotransplants. *Haematologica* 88:99, 2003.
- 64.** Terragna C, Cavo M, **Soverini S**, Cellini C, Testoni N, De Vivo A, Amabile M, Giannini B, Ottaviani E, Grafone T, Poerio A, Bianchini M, Zamagni E, Tosi P, Cangini D, Tacchetti P, Tura S, Bacarani M, Martinelli G. The translocation t(4;14) in Multiple Myeloma (MM):



frequency and prognostic relevance in previously untreated patients receiving either single or double autotransplants. *Blood* 102(11): 149, 2003.

**65.** Martinelli G, Ottaviani E, Malagola M, Cross N, Rosti G, Gaitani S, Pane F, Giannini B, Testoni N, Mecucci C, **Soverini S**, Piccaluga PP, Rondoni M, Amabile M, Tirabelli M, Bosi C, Poerio A, Zuffa E, Zaccaria A, Grafone T, De Vivo A, Ascani S, Pileri S, Visani G, Fattori PP, Bocchia M, Serra A, Gottardi E, Maurillo L, Merante S, Cazzola M, Fanin R, Saglio G, Bertieri R, Baccharani M. Italian Cooperative Study on Idiopathic Hypereosinophilic Syndrome (HES): FIP1-L1/PDGFR $\alpha$  rearrangement can be effectively treated with imatinib. *Blood* 102(11): 386, 2003.

**66.** Martinelli G, Bianchini M, Ottaviani E, Grafone T, Giannini B, **Soverini S**, Terragna C, Rondoni M, Piccaluga PP, Malagola M, Baccharani M. Molecular therapy of AML: A new and rapid method to characterize novel genetic variants in FLT3 gene. *Blood* 102(11): 387, 2003.

**67.** Piccaluga PP, Malagola M, Amabile M, Bianchini M, Bosi C, Gaitani S, Giannini B, Isidori A, Pane F, Paolini S, Rondoni M, Russo D, **Soverini S**, Vigna E, Visani G, Martinelli G, Baccharani M. The achievement of molecular complete remission during treatment with imatinib mesylate correlates with bcr/abl-positive acute lymphoblastic leukemia. *Blood* 102(11): 870, 2003.

**68.** Martinelli G, Piccaluga PP, Malagola M, Rondoni M, **Soverini S**, Amabile M, Pane F, Bianchini M, Ottaviani E, Giannini B, Vigna E, Bosi C, Gaitani S, Paolini S, Russo D, Visani G, Fiacchini M, Baccharani M. Minimal Residual Disease Monitoring By Quantitative Real Time-Pcr During Treatment With STI571 For Bcr/Abl-Positive Acute Lymphoblastic Leukemia. *Blood* 102(11): 245b, 2003.

**69.** Martinelli G, **Soverini S**, Rosti G, Bassi S, Amabile M, Trabacchi E, Giannini B, Cilloni D, Izzo B, De Vivo A, Testoni N, Rege Cambrin G, Bonifazi F, Luatti S, Gottardi E, Alberti D, Pane F, Salvatore F, Saglio G and Baccharani M. Molecular Resistance To Imatinib In Chronic Myeloid Leukemia. From the Italian Cooperative Study Group on Chronic Myeloid Leukemia. *Blood* 102(11): 312b, 2003.

**70.** Rondoni M, **Soverini S**, Malagola M, Ottaviani E, Piccaluga P.P, Bosi C, Gentili S, Gozzetti A, Lauria F, Bertoldero G, Minotto C, Vinante O, Vivaldi P, Gitani S, Martinelli G and Baccharani M. Imatinib Seems To Be Ineffective In Patients With Systemic Mastocytosis Carrying The Asp816Val C-Kit Mutation. *Blood* 102(11): 335b, 2003.

**71.** Piccaluga PP, Malagola M, Rondoni M, Amabile M, Paolini S, **Soverini S**, Gaitani S, Visani G, Baccharani M, Martinelli G. Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukemia. *European Journal of Haematology*, 72: 302-303, 2004.

**72.** Martinelli G, Bianchini M, Ottaviani E, Grafone T, Giannini B, **Soverini S**, Terragna C, Rondoni M, Piccaluga PP, Malagola M, Baccharani M. Molecular therapy of AML: a new and rapid method to characterize novel genetic variants in FLT3 gene. *The Hematology Journal*, 5(S2): 108, 2004.

**73.** Terragna C, Renzulli M, Cavo M, **Soverini S**, Cellini C, Testoni N, De Vivo A, Amabile M, Giannini B, Ottaviani E, Grafone T, Zamagni E, Tosi P, Cangini D, Tacchetti P, Tura S, Baccharani M, Martinelli G. Frequency and prognostic relevance of t(4;14) in previously untreated multiple myeloma (MM) patients receiving either single or double autotransplants. *The Hematology Journal*, 5(S2): 201, 2004.

**74.** Martinelli G, Cilloni D, Ottaviani E, Malagola M, Rondoni M, Messa F, Bosi C, Gottardi E, Rosti G, Emilia G, Gaitani S, Pane F, Giannini B, Testoni N, Mecucci C, **Soverini S**, Piccaluga PP, Amabile M, Tirabelli M, Poerio A, Zuffa E, Zaccaria A, Grafone T, De Vivo A, Ascani S, Pileri S, Vivaldi P, Visani G, Fattori P, Bocchia M, Serra A, Maurillo L, Fanin R, Cross N,

Reiter A, Bertieri R, Bacarani M, Saglio G. New therapeutic approaches for the therapy of idiopathic hypereosinophilic syndrome (HES). *Congresso Interannuale della Società Italiana di Allergologia ed Immunologia Clinica. Libro degli Atti (1):47-48, 2004*

**75.** Martinelli G, **Soverini S**, Rosti G, Cilloni D, Bassi S, Amabile M, Izzo B, Poerio A, Castagnetti F, Ottaviani E, Grafone T, Terragna C, Renzulli M, Testoni N, Santucci MA, de Vivo A, Pane F, Saglio G, Bacarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. *Haematologica* 89(supplement to 6): 12, 2004.

**76.** Rondoni M, Malagola M, Piccaluga PP, Gaitani S, **Soverini S**, Ottaviani E, Rosti G, Ricci P, Testoni N, Poerio A, Grafone T, De Vivo A, Amabile M, Bosi C, Bacarani M, Martinelli G. Imatinib-mesylate as experimental therapy in systemic mastocytosis with d816v c-kit mutation but without FIP1L1-PDGFR fusion transcript. *Haematologica* 89(supplement to 6): 46-47, 2004.

**77.** Martinelli G, Rosti G, Pane F, Amabile M, **Soverini S**, Izzo B, Giannini B, Poerio A, Cilloni D, Terragna C, Ottaviani E, Grafone T, De Vivo A, Testoni N, Bassi S, Rege Cambrin G, Bonifazi F, Gottardi E, Trabacchi E, Alberti D, Salvatore F, Saglio G, Bacarani M (Study and writing committee for the Italian Cooperative Study Group on Chronic Myeloid Leukemia) Prediction of response to imatinib by prospective quantitation of Bcr-Abl transcript in late chronic phase chronic myeloid leukemia patients. *Haematologica* 89(supplement to 6): 59-60, 2004.

**78.** Martinelli G, Ottaviani E, Cilloni D, Malagola M, Rondoni M, Bosi C, Gottardi E, Rosti G, Ricci P, Gaitani S, Pane F, Testoni N, Mecucci C, **Soverini S**, Piccaluga PP, Amabile M, Tiribelli M, Poerio A, Zuffa E, Zaccaria A, Grafone T, De Vivo A, Ascani S, Pileri S, Vivaldi P, Giuseppe V, Fattori P, Bocchia M, Serra A, Maurillo L, Fanin R, Cross N, Bertieri R, Bacarani M, Saglio G, Merante S, Cazzola M, Alimena G, Frassoni F, Galieni P, Ballerini PF, Danesin C, Tecchio C, Morandi S, De Biase E, Russo D, Gobbi M, Gugliotta L, Lauria F, Mazza P, Ferrara F, Gherlinzoni F, Leoni P, Musto P, Bernasconi C, Majolino I, Liberati M. FIP1L1-PDGFR fusion gene as a therapeutic target of imatinib in hypereosinophilic syndrome: clinical and biological features. *Haematologica* 89(supplement to 6): 132, 2004.

**79.** Renzulli M, Terragna C, Cavo M, **Soverini S**, Cellini C, Testoni N, Poerio A, De Vivo A, Amabile M, Giannini B, Ottaviani E, Grafone T, Zamagni E, Tosi P, Cangini D, Tacchetti P, Tura S, Bacarani M, Martinelli G. Frequency and prognostic relevance of t(4;14) in previously untreated multiple myeloma (MM) patients receiving either single or double autotransplants. *Haematologica* 89(supplement to 6): 49-50, 2004.

**80.** Bassi S, Amabile M, Martinelli G, Rosti G, Trabacchi E, Castagnetti F, Giannini B, Cilloni D, Izzo B, De Vivo A, Testoni N, Rege Cambrin G, **Soverini S**, Luatti S, Iacobucci I, Gottardi E, Dorigo A, Pane F, Salvatore F, Saglio G, Bacarani M (on behalf of the GIMEMA CML Working Party). Imatinib in late chronic phase CML patients. Long-term molecular evaluation in complete cytogenetic responders. *Haematologica* 89 (supplement to 6): 136, 2004.

**81.** Palandri F, Martinelli G, Bandini G, Benedetti F, Amabile M, Bonifazi F, Usala L, Angelucci E, Tiribelli M, Fanin R, Pizzolo G, Arpinati M, Falconi S, Giannini MB, Angela P, Rosti G, **Soverini S**, Bacarani M. Imatinib therapy is the first therapeutic option for chronic myeloid leukemia patients relapsed after allogeneic stem cell transplantation. *Haematologica* 89(supplement to 6): 146, 2004.

**82.** Martinelli G, Cilloni D, Ottaviani E, Malagola M, Messa F, Rondoni M, Bosi C, Gottardi E, Rosti G, Ricci P, Gaitani S, Pane F, Testoni N, Mecucci C, **Soverini S**, Piccaluga PP, Amabile M, Tiribelli M, Zaccaria A, Grafone T, De Vivo A, Pileri S, Fattori PP, Bocchia M, Serra A, Maurillo L, Fanin R, Cross NCP, Merante S, Cazzola M, Alimena G, Frassoni F, Galieni P, Russo D, Gobbi M, Gugliotta L, Lauria F, Mazza P, Ferrara F, Gherlinzoni F, Leoni P, P Musto

- P, Baccarani M, Saglio G. Idiopathic Hypereosinophilic Syndrome (HES) With FIP1L1-PDGFR $\alpha$  Rearrangement Can Be Effectively Treated With Imatinib. *Blood* 104(11):421, 2004.
- 83.** Grafone T, Mancini M, Ottaviani E, Matteo Renzulli M, Boschelli F, Ferraretti L, Santucci MA, Amabile M, **Soverini S**, Terragna C, Poerio A, Rosti G, Taccioli C, Baccarani M, Martinelli G. A Novel 4-anilino-3-quinolinecarbonitrile dual Src And Abl Kinase Inhibitor (SKI-606) Has In Vitro Activity On CML Ph+Blast Cells Resistant To Imatinib. *Blood* 104(11):549-550, 2004.
- 84.** Walz C, Cilloni D, **Soverini S**, Roche C, Ottaviani E, Martinelli G, Saglio G, Preudhomme C, Paschka P, Apperley J, Hochhaus A, Hehlmann R, Cross NCP, Grimwade D, Reiter A. Molecular heterogeneity of the FIP1L1-PDGFR $\alpha$  fusion gene in chronic eosinophilic leukemia (CEL) and systemic mastocytosis with eosinophilia (SME): a study of 43 cases. *Blood* 104(11):667, 2004.
- 85.** Poerio A, Amabile M, **Soverini S**, Renzulli M, Rosti G, Bassi S, Ottaviani E, Grafone T, Terragna C, Taccioli C, Rondoni M, Bosi C, Testoni N, Luatti S, Castagnetti F, Malagola M, Pane F, Saglio G, Baccarani M, Martinelli G. Down Regulation of TOPK, PBX3, SRPK, DDX21 and CLC Genes in Newly Diagnosed, Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated With Imatinib Mesylate. *Blood* 104(11):246, 2004.
- 86.** Palandri F, Martinelli G, Amabile M, Bonifazi F, Bandini G, Benedetti F, Usala E, Angelucci E, Tiribelli M, Fanin R, Sorio M, Arpinati M, Testoni N, Falcioni S, Giannini MB, Poerio A, **Soverini S**, Pane F, Rosti G, Tura S, Baccarani M. Imatinib Therapy For Chronic Myeloid Leukemia Patients Who Relapse After Allogeneic Stem Cell Transplantation: A Molecular Analysis. *Blood* 104(11):247, 2004.
- 87.** Martinelli G, Rosti G, Pane F, Amabile M, Bassi S, Izzo B, Poerio A, Giannini B, Cilloni D, **Soverini S**, Terragna C, Ottaviani E, Grafone T, De Vivo A, Testoni N, Trabacchi E, Alberti D, Salvatore F, Saglio G, Baccarani M. Prediction Of Response To Imatinib By Prospective Quantitation Of BCR-ABL Transcript In Late Chronic Phase Chronic Myeloid Leukemia Patients, By GIMEMA Working Party on CML. *Blood* 104(11):252, 2004.
- 88.** Martinelli G, Martelli AM, Grafone T, Rosti G, Mantovani I, Cappellini A, Tazzari PL, Ottaviani E, Renzulli M, Amabile M, Poerio A, **Soverini S**, Terragna C, Taccioli C, Bassi S, Baccarani M. A New Abl kinase Inhibitor (AMN107) Has In Vitro Activity On CML Ph+Blast Cells Resistant To Imatinib. *Blood* 104(11):255, 2004.
- 89.** Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, **Soverini S**, Castagnetti F, Cilloni D, Izzo B, De Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G. Imatinib and pegylated human recombinant interferon- $\alpha$ 2b in early chronic phase chronic myeloid leukemia. *Blood*. 104(13): 4245-4251, 2004.
- 90.** Martinelli G, **Soverini S**, Rosti G, Cilloni D, Baccarani M. Molecular targets in chronic myeloid leukemia. *Libro degli Atti, Diagnosi e terapia molecolare delle neoplasie ematologiche*. 1:87-99, 2005.
- 91.** Grafone T, Mancini M, Ottaviani E, Renzulli M, Boschelli F, Ferraretti L, Santucci MA, Amabile M, **Soverini S**, Terragna C, Poerio A, Colarossi S, Rosti G, Baccarani M, Martinelli G. A novel 4-anilino-3-quinolinecarbonitrile dual src and abl kinase inhibitor (SKI-606) has in vitro pro-apoptotic activity on CML ph blast cells resistant to imatinib. *Haematologica* S2:46, 2005.
- 92.** Iacobucci I, Martinelli G, Amabile M, Poerio A, Castagnetti F, Testoni N, Cilloni D, Izzo B, **Soverini S**, Colarossi S, Terragna C, Pane F, Saglio G, Rosti G, Baccarani M. Comparison between patients with Ph chronic phase CML who obtained complete cytogenetic

response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. *Haematologica* S2:46, 2005.

**93.** Iacobucci I, Martinelli G, Amabile M, Bassi S, Poerio A, Luatti S, **Soverini S**, Colarossi S, Terragna C, Grafone T, Renzulli M, Pane F, Saglio G, Rosti G, Baccarani M. BCR-ABL RNA levels at the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib-treated chronic myeloid leukemia patients. *Haematologica* S2:47, 2005.

**94.** Poerio A, Martinelli G, Amabile M, Trabacchi E, **Soverini S**, Iacobucci I, Colarossi S, Terragna C, Grafone T, Luatti S, Castagnetti F, Pane F, Saglio G, Baccarani M, Rosti G. Molecular response to a imatinib plus alpha-interferon therapy in newly diagnosed, early chronic phase chronic myeloid leukemia. *Haematologica* S2:213, 2005.

**95.** Martinelli G, A. Martelli, T. Grafone, I. Mantovani, A. Cappellini, P.L. Tazzari, E. Ottaviani, **S. Soverini**, M. Amabile, M. Baccarani. A new Abl kinase inhibitor (AMN107) has in vitro activity on chronic myeloid leukaemia (CML) ph cells resistant to imatinib. *Haematologica* S2:215, 2005.

**96.** Terragna C, Renzulli M, Calcoli F, Martinelli G, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Amabile M, Rossi M, **Soverini S**, Tura S, Baccarani M, Cavo M. Predictive value of minimal residual disease (MRD) quantitative detection in multiple myeloma (MM) patients in complete remission after stem cell transplantation. *Haematologica* S2:253-254, 2005.

**97.** Rondoni M, Piccaluga PP, **Soverini S**, Malagola M, Amabile M, Pileri S, Baccarani M, Martinelli G. Imatinib-mesylate therapy is not effective in systemic mastocytosis with D816V c-kit mutation. *Haematologica* S2:264, 2005.

**98.** Renzulli M, Grafone T, Taccioli C, Terragna C, Mancini M, Boschelli F, Creo P, Amabile M, **Soverini S**, Poerio A, Ottaviani E, Iacobucci I, Rosti G, Baccarani M, Martinelli G. Identification of gene expression profiling in a CML cell line, K562, after treatment with SKI606, a dual inhibitor of src/abl kinase. *Haematologica* S2:401, 2005.

**99.** Iacobucci I, Martinelli G, Amabile M, Bassi S, Poerio A, Luatti S, **Soverini S**, Colarossi S, Terragna C, Grafone T, Renzulli M, Pane F, Saglio G, Rosti G, Baccarani M. Bcr-Abl RNA levels at the time of a complete cytogenetic response predict the duration of CCR in imatinib-treated chronic myeloid leukemia patients. *Haematologica* 90(S3):44-45, 2005.

**100.** Poerio A, Martinelli G, Amabile M, Trabacchi E, **Soverini S**, Iacobucci I, Colarossi S, Terragna C, Grafone T, Luatti S, Castagnetti F, Pane F, Saglio G, Baccarani M, Rosti G. Molecular response to a imatinib plus alpha-interferon therapy in newly diagnosed, early chronic phase chronic mieloid leukemia. *Haematologica* 90(S3):137, 2005.

**101.** Iacobucci I, Martinelli G, Amabile M, Poerio A, Castagnetti F, Testoni N, Cilloni D, Izzo B, **Soverini S**, Colarossi S, Terragna C, Pane F, Saglio G, Rosti G, Baccarani M. Comparison between patients with Ph+ chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. *Haematologica* 90(S3):137-138, 2005.

**102.** Renzulli M, Terragna C, Calboli F, Martinelli G, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Amabile M, Rossi M, **Soverini S**, Tura S, Baccarani M, Cavo M. Predictive value of minimal residual disease quantitative detection in multiple myeloma patients in complete remission after stem cell transplantation. *Haematologica* 90(S3):354, 2005.

**103.** Martinelli G, Cilloni D, Rondoni M, Messa F, Ottaviani E, Gottardi E, Piccaluga PP, Malagola M, **Soverini S**, Merante S, Alimena G, Bosi C, De Vivo A, Rosti G, Giugliano E, Pane F, Izzo B, Testoni N, Paolini S, Rancati F, Bassan R, Mecucci C, Baccarani M, Saglio G.

Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). *Blood* 106(11): 113-114, 2005.

**104.** Poerio A, Amabile M, Iacobucci I, **Soverini S**, Colarossi S, Ottaviani E, Terragna C, Grafone T, Luatti S, Castagnetti F, Pane F, Saglio G, Russo D, Rosti G, Baccarani M, Martinelli G. Better Molecular Response (MR) to Imatinib (IM) in Early Chronic Phase (CP) Versus Late CP Chronic Myeloid Leukemia (CML) Patients (pts) in Complete Cytogenetic Response (CCR): A Comparison at 24 Months of 2 Clinical Trials of the GIMEMA Working Party on CML on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML). *Blood* 106(11): 319, 2005.

**105.** Iacobucci I, Testoni N, Rosti G, Amabile M, Poerio A, **Soverini S**, Colarossi S, Gnani A, Ottaviani E, Castagnetti F, Terragna C, Renzulli M, Grafone T, Cilloni D, Pane F, Saglio G, Baccarani M, Martinelli G. Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia (CML) on Behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML). *Blood* 106(11): 320, 2005.

**106.** Martinelli G, Martelli AM, Grafone T, Mantovani I, Cappellini A, Tazzari PL, Ottaviani E, **Soverini S**, Amabile M, Renzulli M, Terragna C, Colarossi S, Iacobucci I, Poerio A, Baccarani M. A New Abl Kinase Inhibitor (AMN107) Has In Vitro Activity on Chronic Myeloid Leukaemia (CML) Ph+ Cells Resistant to Imatinib. *Blood* 106(11): 567, 2005.

**107.** Grafone T, Ferraretti L, Ottaviani E, Mancini M, Palmisano M, Malagola M, Terragna C, Renzulli M, Poerio A, Amabile M, **Soverini S**, Colarossi S, Iacobucci I, Baccarani M, Martinelli G. SU11657, a FLT3-Targeted Tyrosine Kinase, Has Pro-Apoptotic Activity on Leukemia Cells In Vitro. *Blood* 106(11): 784, 2005.

**108.** Renzulli M, Grafone T, Taccioli C, Terragna C, Boschelli F, Mancini M, Creo P, Ottaviani E, Colarossi S, Amabile M, **Soverini S**, Poerio A, Iacobucci I, Baccarani M, Martinelli G. Gene Expression Profile in the CML Cell Line K562 Treated with SKI-606, a Dual Inhibitor of Src/Abl Kinase. *Blood* 106(11): 297-298, 2005.

**109.** Terragna C, Renzulli M, Testoni N, Nicci C, Grafone T, Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Perrone G, **Soverini S**, Martinelli G, Baccarani M, Cavo M. Prognostic Relevance of t(4;14) and Expression of FGFR3 and TACC3 in Newly Diagnosed Patients with Multiple Myeloma. *Blood* 106(11): 350, 2005.

**110.** Rondoni M, Cilloni D, Ottaviani E, Piccaluga PP, Malagola M, Messa F, Gottardi E, **Soverini S**, Merante S, Alimena G, Pane F, Apolini S, Rancati F, Saglio G, Baccarani M, Martinelli G. Imatinib mesylate can induce molecular complete remission in idiopathic hypereosinophilic syndrome. A phase II multicentric Italian clinical trial. *Haematologica* 91(S1): 26-27, 2006.

**111.** Grafone T, Ottaviani E, Palmisano M, Mancini M, Testoni N, Amabile M, Terragna C, Poerio A, Renzulli M, **Soverini S**, Colarossi S, Iacobucci I, Baccarani M, Martinelli G. Single-agent SU11657, a novel FLT3 inhibitor, shows biologic activity in acute leukaemia cells in vitro. *Haematologica* 91(S1):28, 2006.

**112.** Poerio A, Rosti G, Amabile M, Iacobucci I, **Soverini S**, Colarossi S, Gnani A, Ottaviani E, Terragna C, Grafone T, Luatti S, Castagnetti F, Pane F, Saglio G, Baccarani M, Martinelli G. Molecular response to imatinib in early chronic phase versus late chronic phase CML patients in complete cytogenetic response: a comparison at 24 months of 2 clinical trials of the GIMEMA-CML WP. *Haematologica* 91(S1):61, 2006.

**113.** Castagnetti F, Rosti G, Iacobucci I, Testoni N, Amabile M, Usala E, Russo D, Orlandi E, **Soverini S**, Montefusco E, Rege-Cambrin G, Rupoli S, Martinelli G, Pane F, Saglio G, Baccarani M. Imatinib and aging: preliminary results of a sub-analysis within 3 trials of the GIMEMA CML WP. *Haematologica* 91(S1):64, 2006.

- 114.** Iacobucci I, Martinelli G, Rosti G, Castagnetti F, Amabile M, Poerio A, **Soverini S**, Colarossi S, Gnani A, Amadori S, Abruzzese E, Cilloni D, Saglio G, Baccarani M, Pane F. The e19a2 Bcr-Abl breakpoint: more frequent than other atypical Bcr-Abl variants in chronic myelogenous leukemia (CML)? *Haematologica* 91(S1):251-252, 2006.
- 115.** Musto P, Rondoni M, Piccaluga PP, **Soverini S**, Paolini S, Falcone A, Sanpaolo G, Barone ML, Guariglia R, Ciuffreda L, Pietrantuono G, Vivaldi P, Lauria F, Baccarani M, Martinelli G. Imatinib-mesylate therapy for systemic mastocytosis: relationship to c-kit mutational status. *Haematologica* 91(S1):354, 2006.
- 116.** Martinelli G, **Soverini S**, Iacobucci I, Cilloni D, Rosti G, Baccarani M. Novel tyrosine kinase inhibitors for Ph+ leukemia patients resistant to imatinib. *Haematologica* 91(S3):4-5, 2006.
- 117.** Iacobucci I, Rosti G, Castagnetti F, Testoni N, Amabile M, Poerio A, Usala E, Russo D, Orlandi E, **Soverini S**, Montefusco E, Rege Cambrin G, Rupoli S, Pane F, Saglio G, Martinelli G, Baccarani M. Imatinib And Aging In Chronic Myeloid Leukaemia In Early Chronic Phase: Results Of A Sub-Analysis Within 3 Trials of The GIMEMA CML Working Party. *Haematologica* 91(S3):34-35, 2006.
- 118.** Poerio A, Rosti G, Amabile M, Iacobucci I, **Soverini S**, Colarossi S, Gnani A, Ottaviani E, Terragna C, Grafone T, Luatti S, Castagnetti F, Pane F, Saglio G, Baccarani G, Martinelli G. Molecular Response To Imatinib In Early Chronic Phase Versus Late Chronic Phase CML Patients In Complete Cytogenetic Response: A Comparison At 24 Months of 2 Clinical Trials of The GIMEMA-CML WP. *Haematologica* 91(S3):35, 2006.
- 119.** Grafone T, Ottaviani E, Palmisano M, Mancini M, Testoni N, Amabile M, Terragna C, Poerio A, Renzulli M, **Soverini S**, Colarossi S, Iacobucci I, Baccarani M, Martinelli G. Single agent SU11657, a novel FLT3 inhibitor, show a biologic activity in acute myeloid leucemia cells in vitro. *Haematologica* 91(S3):79-80, 2006.
- 120.** Bussolari R, Candini O, Colomer D, Corradini F, Guerzoni C, Mariani SA, Cattelani S, Silvestri C, Pecorari L, Iacobucci I, **Soverini S**, Fasano T, Martinelli G, Cervantes F, Calabretta B. Coding sequence and intro-exon junctions of the C-myc gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients. *Haematologica* 91(S3):94, 2006.
- 121.** Rondoni M, Musto P, Paolini S, **Soverini S**, Colarossi S, Piccaluga PP, Palmerini E, Falcone A, Sanpaolo G, Barone ML, Pierantuono G, Guariglia R, Vivaldi F, Lauria F, Baccarani M, Martinelli G. Imatinib-mesylate therapy for systemic mastocytosis: relationship to c-kit mutational status. *Haematologica* 91(S3):120, 2006.
- 122.** Hochhaus A, Erben P, Branford S, Radich J, Kim DW, Martinelli G, Saglio G, Mueller MC, Hoffmann J, Palandri F, **Soverini S**, Hughes T, Shou Y, Weitzman A, Baccarani M. Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogenous Leukemia (CML) after Imatinib Failure. *Blood* 108(11):225, 2006.
- 123.** Abruzzese E, Marfe' G, Di Stefano C, Trawinska MM, Russo MA, Silvestri R, Del Poeta G, Martinelli G, **Soverini S**, de Fabritiis P, Amadori S, Sinibaldi Salimei P. Pyrrolo[1,2-B][1,2,5] benzodiazepines (PBTDS) Compounds Induce Apoptosis in Chronic Myeloid Leukaemia Cells from Patients at Onset, Imatinib and Second Generation TK Inhibitors (Dasatinib, Nilotinib) Resistant. *Blood* 108(11):403-404, 2006.
- 124.** Iacobucci I, Martinelli G, Amabile M, Poerio A, **Soverini S**, Castagnetti F, Colarossi S, Gnani A, Testoni N, Breccia M, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Rosti G, Baccarani M. Imatinib Treatment of Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML). For Late Chronic Phase Patients Who Achieve a Complete Cytogenetic

Response 5-Year Survival Is as High as for Early Chronic Phase Patients. *Blood* 108(11):611-12, 2006.

**125.** Grafone T, **Soverini S**, Tasco G, Mancini M, Boschelli F, Golas J, Frauling D, Colarossi S, Ottaviani E, Gnani A, Panagiota G, Castagnetti F, Casadio R, Rosti G, Martinelli G, Baccarani M. A Study of the Binding Mode and the *In Vitro* Activity of the Protein Tyrosine Kinase Inhibitor SKI-606 in the BCR-ABL Positive Cells. *Blood* 108(11):661-62, 2006.

**126.** Porro A, **Soverini S**, Diolaiti D, Grafone T, Ottaviani E, Iraci N, Terragna C, Kalebic T, Baccarani M, Martinelli G, Della Valle G, Perini G. Direct and Coordinate Regulation of Multidrug Resistance Genes by the c-Myc Oncoprotein. *Blood* 108(11):732-33, 2006.

**127.** Martinelli G, Palandri F, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, Poerio A, **Soverini S**, Rege-Cambrin G, Franco Iuliano, G Alimena, Roberto Latagliata, N Testoni, F Pane, G Saglio, G Rosti, and M Baccarani Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party. *Blood* 108(11):4805, 2006.

**128.** Colarossi S, **Soverini S**, Gnani A, Rondoni M, Gatto S, Merante S, Enrico Gottardi, D Cilloni, P Musto, M Tiribelli, Roberta Zanotti, G Martinelli, and M Baccarani A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants. *Blood* 108(11):4849, 2006.

**129.** Martinelli G, Iacobucci I, **Soverini S**, Ottaviani E, Paolini S, Piccaluga PP, Grafone T, Rondoni M, Amabile M, Poerio A, Colarossi S, Gnani A, Cilloni D, Saglio G, Pane F, Rosti GA, Baccarani M. Expression of a dominant-negative IKAROS splice variant IK6 in Ph-positive Acute Lymphoblastic Leukemia: implications for a new mechanism of resistance to tyrosine kinase inhibitors. *Cancer Res* 2007;67(S9):2638.

**130.** Iacobucci I, Martinelli G, Amabile M, Poerio A, **Soverini S**, Castagnetti F, Colarossi S, Gnani A, Testoni N, Breccia M, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Rosti GA, Biasco G, Baccarani M, on behalf of the GIMEMA Working Party on CML. Imatinib treatment of Philadelphia positive (Ph+) chronic myeloid leukemia (CML). For late chronic phase patients who achieve a complete cytogenetic response 5-year survival is as high as for early chronic phase patients. *Cancer Res* 2007;67(S9):2639.

**131.** Iacobucci I, Ottaviani E, Astolfi A, **Soverini S**, Testoni N, Paolini S, Piccaluga PP, Papayannidis C, Cilloni D, Pession A, Pane F, Vitale A, Foà R, Baccarani M, Martinelli G, Genome wide analysis of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) identified novel recurrent copy number variations involved in both pathogenesis and resistance to tyrosine kinase inhibitors. *AACR-NCI-EORT Conference, Program and Proceedings*, 217, 2007.

**132.** Iacobucci, F. Palandri, M. Amabile, A. Poerio, **S. Soverini**, F. Castagnetti, N. Testoni, G. Rosti, M. Baccarani, G. Martinelli, F. Palandri. Five-year follow-up results of imatinib 400 mg in late chronic phase chronic myeloid leukemia (CML) patients. *J Clin Oncol* 2007; 18S: 7041.

**133.** S. Colarossi, **S. Soverini**, A. Gnani, M. Rondoni, S. Gatto, S. Merante, R. Zanotti, G. Martinelli, M. Baccarani, M. Tiribelli. A novel denaturing high-performance liquid chromatography (D-HPLC) based method for KIT mutation screening of patients (pts) with systemic mastocytosis (SM). *J Clin Oncol* 2007; 18S: 7085.

**134.** Gnani A, **Soverini S**, Colarossi S, Turrini E, Iacobucci I, Castagnetti F, Baccarani M, Hrelia P, Martinelli G, Angelini S. Genetic Polymorphisms In The Methylenetetrahydrofolate Reductase Gene Associated With Chronic Myeloid Leukemia. *Haematologica* 2007;92(S1):199.

- 135.** Iacobucci I, **Soverini S**, Paolini S, Pccaluga PP, Rondoni M, Ottaviani E, Amabile M, Poerio A, Castagnetti F, Giannoulia P, Colarossi S, Gnani A, Saglio G, Pane F, Rosti G, Bacarani M, Martinelli G. Identification of a new mechanism of resistance to imatinib and dasatinib in Ph-positive acute lymphoblastic leukemia: overexpression of aberrantly spliced oncogenic Ikaros isoforms. *Haematologica* 2007; 92(S1):2-3.
- 136.** Colarossi S, **Soverini S**, Gnani A, Rodoni M, Gatto S, Merante S, Gottardi E, Cilloni D, Musto P, Tiribelli M, Zanotti R, Martinelli G, Bacarani M. A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method For KIT Mutation Screening Of Patients With Systemic Mastocytosis. *Haematologica* 2007; 92(S1):212-213.
- 137.** Palandri F, Iacobucci I, Castagnetti F, Testoni N, Amabile M, Bassi S, **Soverini S**, Saglio G, Pane F, Breccia M, Bassan R, Martino B, Merante S, Giannoulia P, Martinelli G, Rosti G, Bacarani M. Imatinib 400 Mg In Late Chronic Phase CML Patients: Long Term Evaluation Of Responses And Survival Of A Phase Ii Study Of The GIMEMA CML WP. *Haematologica* 2007; 92(S1):208.
- 138.** Castagnetti F, Palandri F, Marzocchi G, Luatti S, testoni N, Amabile M, **Soverini S**, Kerim S, Giugliano E, Specchia G, Cuneo A, Martinelli G, Alimena G, Bacarani M, Rosti G. Deletions Of The Derivative Chromosome 9 Do Not Influence Response to Imatinib In Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis). *Haematologica* 92(S1):338, 2007.
- 139.** Pane F, Esposito N, Izzo B, Quarantelli F, Colavita I, Buonomo T, Roberti V, **Soverini S**, Melo JV, Martinelli G, Martinelli R, Ruoppolo M, Rotoli B, Pane F. Multiple molecular mechanism may account for resistance to imatinib in resistant cell lines. *Haematologica* 2007;92(S1):418.
- 140.** Iacobucci I, **Soverini S**, Paolini S, Pccaluga PP, Rondoni M, Ottaviani E, Amabile M, Poerio A, Castagnetti F, Giannoulia P, Colarossi S, Gnani A, Saglio G, Pane F, Rosti G, Bacarani M, Martinelli G. Identification of a new mechanism of resistance to imatinib and dasatinib in Ph-positive acute lymphoblastic leukemia: overexpression of aberrantly spliced oncogenic Ikaros isoforms. *Haematologica* 2007; 92(S3):4.
- 141.** Gnani A, **Soverini S**, Colarossi S, Turrini E, Iacobucci I, Castagnetti F, Bacarani M, Hrelia P, Martinelli G, Angelini S. Genetic Polymorphisms In The Methylenetetrahydrofolate Reductase Gene Associated With Chronic Myeloid Leukemia. *Haematologica* 2007;92(S3):182.
- 142.** Colarossi S, **Soverini S**, Gnani A, Rodoni M, Gatto S, Merante S, Gottardi E, Cilloni D, Musto P, Tiribelli M, Zanotti R, Martinelli G, Bacarani M. A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method For Kit Mutation Screening Of Patients With Systemic Mastocytosis. *Haematologica* 2007; 92(S3):41.
- 143.** Piccaluga PP, Rosti G, Rondoni M, Amabile M, Bosi C, Castagnetti F, Iacobucci I, Laterza C, Palandri F, Paolini S, **Soverini S**, Verlicchi L, Visani G, Bacarani M, Martinelli G. Dasatinib (Sprycel®) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or lymphoid blast phase chronic myeloid leukemia after imatinib failure: a single-center experience. *Haematologica* 2007;92(S3):180-181.
- 144.** Iacobucci I, Astolfi A, Ottaviani E, **Soverini S**, Paolini S, Piccaluga PP, Rondoni M, Papayannidis C, Formica S, Bacarani M, Pession A, Martinelli G. Genome-wide analysis of genetic alterations in Philadelphia-positive (Ph+) acute lymphoblastic leukaemia (all) patients resistant to tyrosin kinase inhibitors. *Haematologica* 2007;92(S3):169.
- 145.** Rondoni M, Paolini S, Colarossi S, Piccaluga PP, Papayannidis C, Palandri F, Giannoulia P, Laterza C, De Rosa F, Pregno P, Gatto S, Ottaviani E, Saglio G, Cilloni D, Pane F, Triggiani M, **Soverini S**, Zaccaria A, Bacarani M, Martinelli G. Response to dasatinib in



patients with aggressive systemic mastocytosis with D816V KIT mutation. *Haematologica* 2007;92(S3):120.

**146.** Esposito N, Izzo B, Quarantelli F, Colavita I, Buonomo T, Roberti V, **Soverini S**, Melo JV, Martinelli G, Martinelli R, Ruoppolo M, Rotoli B, Pane F. Multiple molecular mechanism may account for resistance to imatinib in resistant cell lines. *Haematologica* 2007;92(S3):44.

**147.** Breccia M, Palandri F, Iacobucci I, Martinelli G, Amabile M, **Soverini S**, Castagnetti F, Testoni N, Luatti S, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Russo D, Alimena G, Rosti G, Baccarani M. Imatinib 400 mg in philadelphia positive late chronic phase chronic myeloid leukemia. An analysis of the duration of complete cytogenetic response and of major molecular response in the long-term. *Haematologica* 2007;92(S3):43.

**148.** Castagnetti F, Palandri F, Marzocchi G, Luatti S, testoni N, Amabile M, **Soverini S**, Kerim S, Giugliano E, Specchia G, Cuneo A, Martinelli G, Alimena G, Baccarani M, Rosti G. Deletions Of The Derivative Chromosome 9 Do Not Influence Response to Imatinib In Early Chronic Phase Chronic Myeloid Leukemia Patients (A GIMEMA Working Party Analysis). *Haematologica* 92(S3):180-181, 2007.

**149.** Iacobucci I, Ottaviani E, Astolfi A, **Soverini S**, Testoni N, Paolini S, Piccaluga PP, Papayannidis C, Cilloni D, Pession A, Pane F, Vitale A, Chiaretti S, Foà R, Baccarani M, Martinelli G. High-Resolution Genomic Profiling of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukaemia (ALL) Identified Novel Recurrent Copy Number Variations Involved in Both Pathogenesis and Resistance to Tyrosine Kinase Inhibitors. *Blood* 110(11):75a, 2007.

**150.** Hughes T, Saglio G, Martinelli G, Kim DW, **Soverini S**, Mueller M, Haque A, Gallagher N, Shou Y, Radich J, Branford S, Hochhaus A. Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types. *Blood* 110(11):101a, 2007.

**151.** Iacobucci, A. Lonetti, E. Ottaviani, D. Cilloni, F. Messa, S. Paolini, C. Papayannidis, G. Panagiota, **S. Soverini**, M. Amabile, A. Poerio, M. Rondoni, G. Saglio, F. Pane, G. Berton, A. Baruzzi, A. Vitale, R. Foà, M. Baccarani, G. Martinelli. The Overexpression of Spliced Oncogenic Ikaros Isoforms in Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients Is a New Mechanism of Resistance to Tyrosine Kinase Inhibitors. *Blood* 110(11):221-222a, 2007.

**152.** Rondoni M, Paolini S, Colarossi S, Piccaluga PP, Papayannidis C, Palandri F, Laterza C, De Rosa F, Pregno P, Gatto S, Ottaviani E, Saglio G, Cilloni D, Pane F, Triggiani M, **Soverini S**, Zaccaria A, Baccarani M, Martinelli G. Response to Dasatinib in Patients with Aggressive Systemic Mastocytosis with D816V Kit Mutation. *Blood* 110(11): 1042a, 2007.

**153.** De Rosa F, Iacobucci I, Ottaviani E, Astolfi A, Lonetti A, Testoni N, Storlazzi T, Impera L, **Soverini S**, Paolini S, Piccaluga PP, Papayannidis C, Giannoulia P, Cilloni D, Pession A, Pane F, Vitale A, Foà R, Baccarani M, Martinelli G. Genome wide analysis of Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) reveals a recurring deletion of VPBEB1 gene which affects B-cell differentiation. *Cancer Res*, 2008; 68(S9):1462.

**154.** Iacobucci I, Ottaviani E, Astolfi A, De Rosa F, Lonetti A, Testoni N, Storlazzi T, Impera L, **Soverini S**, Paolini S, Piccaluga PP, Papayannidis C, Giannoulia P, Cilloni D, Pession A, Pane F, Vitale A, Foà R, Baccarani M, Martinelli G. High-resolution genomic profiling of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients identified novel recurrent copy number variations involved in both pathogenesis and resistance to tyrosine kinase inhibitors. *Cancer Res*, 2008; 68(S9):2213.

- 155.** Arruga F, Panuzzo C, Messa F, Nicoli P, Messa E, **Soverini S**, Iacobucci I, Martinelli G, Baccarani M, Rotolo A, Bracco E, Kalebic T, Saglio G, Cilloni D. FoxO transcription factor is delocalized in CML patients by Bcr-Abl induced PI3K/AKT activation and IKK pathway and can be reactivated by Imatinib treatment. *Cancer Res*, 2008; 68(S9): 4397.
- 156.** Iacobucci I, Lonetti A, Ottaviani E, Cilloni D, Messa F, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, **Soverini S** Amabile M, Saglio G, Pane F, Berton G, Baruzzi A, Vitale A, Foà R, Baccarani M, Martinelli G. The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors. *Cancer Res*, 2008; 68(S9):5515.
- 157.** Saglio G, Radich J, Kim D, Martinelli G, Branford S, Mueller M, **Soverini S**, Shou Y, Hochhaus Hughes AT. Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline. *J Clin Oncol* 26: (May 20 suppl; abstr 7060), 2008.
- 158.** Lonetti A, Iacobucci I, Zuntini R, Ferrari S, Cilloni D, Messa F, Ottaviani E, Arruga F, Salmi F, Paolini S, Papayannidis C, Piccaluga PP, Giannoulia P, **Soverini S**, Saglio G, Pane F, Vitale A, Chiaretti S, Foà R, Baccarani M and Martinelli G. Alternative splicing of Ikaros mRNA is responsible for the expression of different aberrant isoforms in Philadelphia chromosome-positive (Ph+) adult acute lymphoblastic leukaemia (ALL) patients. *Haematologica* 93(S1): 197, 2008.
- 159.** Iacobucci I, Ottaviani E, Astolfi A, Storlazzi T, Testoni N, Luciana I, Lonetti A, **Soverini S**, Paolini S, Piccaluga PP, Papayannidis C, Panagiota G, De Rosa F, Cilloni D, Messa F, Pession A, Pane F, Vitale A, Chiaretti S, Foà R, Baccarani M, Martinelli G. High-resolution genomic profiling of Ph-positive acute lymphoblastic leukaemia (ALL) identified recurrent copy number anomalies in genes regulating the cell cycle and the B-cell differentiation. *Haematologica* 93(S1): 184, 2008.
- 160.** Papayannidis C, Iacobucci I, **Soverini S**, Paolini S, De Rosa F, Cilloni D, Messa F, Pane F, Meneghini V, Giannoulia P, Ottaviani E, Testoni N, Lama B, Baccarani M and Martinelli G. Initial Report on 3 Patients In An Innovative Phase I Study Of Concomitant And Consecutive Treatment With Dasatinib And MK-0457 In Refractory Ph+ CML and ALL Patients. *Haematologica* 93(S1): 390, 2008.
- 161.** Colarossi S, Gnai A, **Soverini S**, Castagnetti F, Marzocchi G, Luatti S, Astolfi A, Formica S, Iacobucci I, Ottaviani E, Palandri F, Poerio A, Amabile M, Rosti G, Pession A, Testoni N, Baccarani M, Martinelli G. High-Resolution mapping of deletions of chromosome 9Q+ in patients with chronic myeloid leukemia by SNP-arrays: which genes matter? *Haematologica* 93(S1): 40, 2008.
- 162.** Palandri F, Iacobucci I, **Soverini S**, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Bruno B, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: introducing the concept of stable molecular response. *Haematologica* 93(S1): 53, 2008.
- 163.** Radich J, Kim DW, Martinelli G, **Soverini S**, Branford S, Mueller M, Haque A, Shou Y, Hochhaus A, Hughes T, Saglio G. Response to Nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline. *Haematologica* 93(S1): 55, 2008.
- 164.** Colarossi S, Gnani A, **Soverini S**, Castagnetti F, Marzocchi G, Luatti S, Astolfi A, Formica S, Iacobucci I, Ottaviani E, Palandri F, Poerio A, Amabile M, Rosti G, Pession A, Testoni N, Baccarani M, Martinelli G. high-resolution mapping of deletions of chromosome

9q in patients with chronic myeloid leukemia by SNP-Arrays: which genes matter? *Haematologica* 93(S2): S20, 2008.

**165.** Iacobucci I, Storlazzi T, Ottaviani E, Lonetti A, Salmi F, Ferrari A, Astolfi A, Testoni N, Impera L, Colarossi S, Baldazzi C, **Soverini S**, Gnani A, Paolini S, Piccaluga PP, Papayannidis C, Panagiota G, Cilloni D, Messa F, Pane F, Vitale A, Chiaretti S, Foà R, Baccarani M, Martinelli G. IKZF1 (IKAROS) deletions are a central event in the pathogenesis of BCR-ABL1 positive acute lymphoblastic leukemia. *Haematologica* 93(S2): S34, 2008.

**166.** Iacobucci I, Lonetti A, Ferrari A, **Soverini S**, Ottaviani E, Testoni N, Colarossi S, Salmi F, Gnani A, Paolini S, Piccaluga PP, Papayannidis C, Panagiota G, Cilloni D, Messa F, Pane F, Vitale A, Chiaretti S, Saglio G, Foà R, Baccarani M, Martinelli G. Activation-induced cytidine deaminase is aberrantly overexpressed in bcrabl1 positive acute lymphoblastic leukemia cells and promotes DNA-single strand breaks. *Haematologica* 93(S2): S35, 2008.

**167.** Papayannidis C, Iacobucci I, **Soverini S**, Paolini S, Santucci S, De Rosa F, Cilloni D, Messa F, Pane F, Meneghini V, Giannoulia P, Ottaviani E, Testoni N, Lama B, Baccarani M, Martinelli G. Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory PH+ CML and ALL patients. *Haematologica* 93(S2): S65, 2008.

**168.** Gnani A, **Soverini S**, Colarossi S, Castagnetti F, Paolini S, Poerio A, Amabile M, Iacobucci I, Palandri F, Ciccarese F, Rosti G, Baccarani M, Martinelli G. Long-term mutation follow-up of philadelphia-chromosome positive leukemia patients treated with dasatinib after imatinib failure: new bcr-abl kinase domain mutations associated with dasatinib resistance are mainly detected during the first year / follow-up. *Haematologica* 93(S2): 72-73, 2008.

**169.** Palandri F, Iacobucci I, **Soverini S**, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G, on behalf of the GIMEMA Working Party on CML. Treatment of philadelphia-positive chronic myeloid leukemia with imatinib: the importance of a stable molecular response. *Haematologica* 93(s2): 73-74, 2008.

**170.** Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Nielsen JL, Hjorth-Hansen H, Rege-Cambrin G, Specchia G, Amabile M, Testoni N, Palandri F, Iacobucci I, **Soverini S**, Pane F, Alimena G, Martinelli G, Russo D, Saglio G, Simonsson B, Baccarani M. A prospective randomized study of imatinib 400 mg vs 800 mg as a front-line therapy in High Sokal risk ph-positive chronic myeloid leukemia patients in chronic phase. *Haematologica* 93(S2):S60, 2008.

**171.** Peluso AL, Grammatico S, Elia L, Izzo B, Muccioli-Casadei G, Vitale D, Andreozzi MC, Esposito N, Picardi M, Martinelli G, **Soverini S**, Cimino G, Pane F. The dynamics of ABL mutations onset in PH+ acute lymphoblastic leukemia treated with imatinib mesylate. *Haematologica* 93(s2): 87, 2008.

**172.** Foà R, Vitale A, Guarini A, De Propriis MS, Elia L, Cimino G, Luppi M, Castagnola C, Sica S, Nieddu R, Piersantelli MN, Ferrara F, Nobile F, Fanin R, Fabbiano F, Vignetti M, Fazi P, **Soverini S**, Mandelli F, Martinelli G, Meloni G and Baccarani M. Line Treatment of Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Final Results of the GIMEMA LAL1205 Study. *Blood* 112(11):119, 2008.

**173.** Iacobucci I, Storlazzi CT, Ottaviani E, Lonetti A, Ferrari A, Chiaretti S, Messina M, Cilloni D, Testoni N, Papayannidis C, Messa F, Astolfi A, Impera L, Vitale A, Arruga F, Pane F, Piccaluga PP, D'Addabbo P, Colarossi S, **Soverini S**, Vignetti M, Paoloni F, Paolini S, Saglio G, Baccarani M, Foà R and Martinelli G. Identification and Molecular Characterization of Two Recurrent Genomic Deletions (Type A and Type B) on 7p12 in IKZF1 Gene in a Large Cohort

of BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL): on Behalf of the GIMEMA ALL Working Party Lymphoblastic Leukemia (ALL). *Blood* 112(11):163, 2008.

**174.** Esposito N, Quarantelli F, Luciano L, Izzo B, Peluso AL, Picardi M, Branford S, White DL, Hughes T, Radich J, **Soverini S**, Iacobucci I, Saglio G, Kalebic T, Thornquist M, Martinelli G, Pane F. The Expression of SHP -1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial. *Blood* 112(11):404, 2008.

**175.** Iacobucci I, Lonetti A, Ferrari A, **Soverini S**, Ottaviani E, Cilloni D, Chiaretti S, Testoni N, Papayannidis C, Messa F, Salmi F, Vitale A, Paoloni F, Arruga F, Giannoulia P, Vignetti M, Pane F, Piccaluga PP, Gnani A, Paolini S, Saglio G, Baccarani M, Foà R and Martinelli G. Different Isoforms of the B-Cell Mutator Activation-Induced Cytidine Deaminase (AID) Are Aberrantly Over-Expressed in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients and Promote Genetic Instability. *Blood* 112(11):532-3, 2008.

**176.** Esposito N, Colavita I, Quarantelli F, Izzo B, Luciano L, Del Vecchio L, Hughes T, Radich J, Russo D, **Soverini S**, Iacobucci I, Martinelli G, Saglio G, Melo J, Ruoppolo M, Kalebic T and Pane F. A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment. *Blood* 112(11):1093, 2008.

**177.** White DL, Saunders VA, Dang P, Frede A, Eadie L, **Soverini S**, Quarantelli F, Lin P, Thornquist M, Kim DW, Pane F, Martinelli G, Radich J, Kalebic T, Saglio G, and Hughes T. CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study. *Blood* 112(11):1093-4, 2008.

**178.** Terragna C, Durante S, Astolfi A, Palandri F, Castagnetti F, Testoni N, Luatti S, Rosti G, Amabile M, Poerio A, Iacobucci I, **Soverini S**, Kalebic T, Baccarani M. and Martinelli G. Gene Expression Profile (GEP) of Chronic Myeloid Leukemia (CML) Patients at Diagnosis: Two Distinguished Subgroups of CML Patients Identified, Based on a Molecular Signature, Irrespective of Their Sokal Risk Score. *Blood* 112(11):1095, 2008.

**179.** Iraci N, **Soverini S**, Gherardi S, Valli E, Castagnetti F, Bernardoni R, Rosti G, Della Valle G, Palandri F, Gugliotta G, Pane F, Saglio G, Esposito N, Cilloni D, Quarantelli F, Gottardi E, Baccarani M, Martinelli G and Perini G. Expression Profiling of ABC Transporter Genes in Chronic Myeloid Leukemia (CML) and Responsiveness to Imatinib. *Blood* 112(11):1096, 2008.

**180.** Hochhaus A, Kim DW, Martinelli G, Hughes TP, **Soverini S**, Branford S, Müller MC, Erben P, Haque A, Shou Y, Saglio G, and Radich JP. Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP). *Blood* 112(11):1103-4, 2008.

**181.** Iacobucci A, Lonetti A, Ferrari M, Vignetti M, Storlazzi CT, Paoloni F, Cilloni D, **Soverini S**, Vitale A, Chiaretti S, Cimino A, Astolfi N, Testoni N, Papayannidis S, Paolini PP, Piccaluga L, Elia F, Messa C, Dell'Agnola S, Cingarlini G, Meloni G, Leone S, Amadori D, Russo G, Saglio F, Pane M, Baccarani R, Foà G, Martinelli G. IKZF1 (IKAROS) deletions represent a poor prognostic marker in BCR-ABL1 positive acute lymphoblastic leukaemia patients: a GIMEMA ALL WP report. *Bone Marrow Transplant* 2009;43(1s): S6.

**182.** Iacobucci E, Ottaviani A, Lonetti A, Ferrari A, Astolfi CT, Storlazzi N, Testoni S, Paolini C, Papayannidis D, Cilloni F, Messa S, **Soverini S**, Arruga F, Pane A, Vitale M, Messina S, Chiaretti PP, Piccaluga C, Dell'Agnola S, Cingarlini R, Foà M, Baccarani G, Martinelli G. Ph-positive acute lymphoblastic leukaemia is characterised by recurrent copy

number anomalies in genes regulating the cell cycle and B-cell differentiation. *Bone Marrow Transplant* 2009;43(1s): S8.

**183.** Iacobucci I, Lonetti A, Ferrari A, Storlazzi CT, Ottaviani E, Chiaretti S, Messina M, Cilloni D, Baldazzi C, Papayannidis C, Messa F, Astolfi A, Impera L, Vitale A, Arruga F, Pane F, Piccaluga PP, Colarossi S, **Soverini S**, Vignetti M, Paolini S, Saglio G, Baccarani M, Foà R, Martinelli G. *IKZF1* (Ikaros) Deletions are a frequent event in *BCR-ABL1* Positive Acute Lymphoblastic Leukemia (ALL) and are associated with an impaired B-cell differentiation and poor outcome: A GIMEMA ALL Working Party Report. *Cancer Res* 2009;69(S9):1287.

**184.** Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, **Soverini S**, Chiaretti S, Ottaviani E, Testoni N, Papayannidis C, Messa F, Salmi F, Vitale A, Arruga F, Pane F, Piccaluga PP, Gnani A, Paolini S, De Giovanni C, Saglio G, Baccarani M, Foà R, Martinelli G. Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in *BCR-ABL1*-Positive Acute Lymphoblastic Leukemia (ALL) Patients. *Cancer Res* 2009;69(S9):5619.

**185.** Terragna C, Durante S, Astolfi A, Palandri F, Castagnetti F, Rosti G, Testoni N, Luatti S, Poerio A, Iacobucci I, Lemoli RM, Kalebic T, Amabile M, **Soverini S**, Biasco G, Baccarani M, Martinelli G. CD34+ obtained from high Sokal risk chronic myeloid leukemia (CML) patients (pts) expresses gene profiles (GEP) significantly different from CD34+ obtained from low and intermediate Sokal risk patients. *Cancer Res* 2009;69(S9):2600.

**186.** Papayannidis C, Iacobucci I, **Soverini S**, Paolini S, Santucci S, Cilloni D, Messa F, Pane F, Meneghini V, Giannoulia P, Ottaviani E, Testoni N, Lama B, Pantaleo M, Baccarani M, Martinelli G. Innovative phase I-II study of concomitant and consecutive treatment with Dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. *Cancer Res* 2009;69(S9):4814.

**187.** Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, **Soverini S**, Papayannidis C, Baccarani M, Foà R, Martinelli G.. Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in *BCR-ABL1*-positive acute lymphoblastic leukemia (ALL) patients. *J. Clin Oncol.* 27:15S, part 1, 367s, 2009.

**188.** Castagnetti F, Testoni N, Luatti S, Marzocchi G, Gugliotta G, Palandri F, Amabile M, **Soverini S**, Mancini M, Kerim S, Giuliano E, Specchia G, Cuneo A, Abruzzese E, Martinelli G, Pane F, Baccarani M, Rosti G. Deletions of the derivative chromosome 9 Do Not Influence The Outcome Of Chronic Myeloid Leukemia In Early Chronic Phase Treated With Imatinib Mesylate: A GIMEMA CML WP Analysis Of 521 Consecutive Patients. *Haematologica* 94[suppl.2]:125, 2009.

**189.** S. Durante, C. Terragna, A. Astolfi, F. Palandri, F. Castagnetti, G. Rosti, N. Testoni, S. Luatti, I. Iacobucci, T. Kalebic, **S. Soverini**, M. Amabile, A. Poerio, M. Baccarani, G. Martinelli. CD34+ obtained from High Sokal risk chronic myeloid leukemia patients expresses gene profiles significantly different from CD34+ obtained from Low and Intermediate Sokal risk patients. *Haematologica* 2009; 94[suppl.2]:124

**190.** Messina M, Chiaretti S, Iacobucci I, Tavoraro S, Vitale A, Della Starza I, Lonetti A, Papayannidis C, Negulici AD, **Soverini S**, Cilloni D, Guarini A, Martinelli G, Foà R. AID Expression In *BCR/ABL* Positive ALL Is Associated With A Peculiar Gene Expression Profile And Deregulation Of DNA Repair And Replication Genes. *Haematologica* 94[suppl.2]:249, 2009.

**191.** Gugliotta G, Castagnetti F, Amabile M, Testoni N, Palandri F, Iacobucci I, **Soverini S**, Luatti S, Breccia M, Specchia G, Intermesoli T, Radaelli F, Abruzzese E, Usala E, Saglio G, Martinelli G, Pane F, Baccarani M, Rosti G. Age Has No Impact On Outcome Of Early Chronic Phase, PH-POS CML, Imatinib Treated Patients: A Nationwide Analysis On 559 Cases Of The GIMEMA CML WP. *Haematologica* 94[suppl.2]:256, 2009.

- 192.** Martinelli G, Kim DW, Saglio G, Branford S, Erben P, Gottardi E, Beppu L, Haque A, Shou Y, Woodman R, **Soverini S**, H. Kantarjian, T. Hughes, A. Hochhaus, J. Radich. Response To Nilotinib Is Similar In Imatinib-Resistant Chronic Myeloid Leukemia Patients In Accelerated Phase (CML-AP) With And Without BCR-ABL Mutations Except E255K/V, Y253H, AND F359C/V. *Haematologica* 94[suppl.2]:258, 2009.
- 193.** Saglio G, Hochhaus A, Martinelli G, Gottardi E, **Soverini S**, Branford S, Müller M, Beppu L, Haque A, Shou Y, Woodman R, Kantarjian H, J. Radich, T. Hughes, D.W. Kim. Dynamics Of Cytogenetic And Molecular Response To Nilotinib Is Similar In Imatinib-Resistant Chronic Myeloid Leukemia Patients In Chronic Phase (CML-CP) With And Without Bcr-Abl Mutations Except E255K/V, Y253H, And F359C/V. *Haematologica* 94[suppl.2]:261, 2009.
- 194.** Iacobucci I, Lonetti A, Ferrari A, Cilloni D, Messa F, Guadagnolo V, Storlazzi CT, Chiaretti S, Papayannidis C, Messina M, Vitale A, Ottaviani E, **Soverini S**, Arruga F, Piccaluga PP, Paolini S, Saglio G, Pane F, Foà R, Baccarani M, Martinelli G. PAX5 gene is frequently the target of genetic alterations in BCR-ABL1-positive acute lymphoblastic leukemia patients. *Haematologica* 94(s4): 2, 2009.
- 195.** Gugliotta G, Castagnetti F, Amabile M, Testoni N, Palandri F, Iacobucci I, **Soverini S**, Luatti S, Breccia M, Specchia G, Intermesoli T, Radaelli F, Abbruzzese E, Usala E, Bocchia M, Russo S, Meneghini V, Trentin L, Saglio G, Martinelli G, Pane F, Baccarnai M, Rosti G. No impact of age in out come in early chronic phase, PH-POS CML, imatinib treated patients: a nationwide analysis on 559 cases of the GIMEMA CML WP. *Haematologica* 94(s4): 18, 2009.
- 196.** Colarossi S, Gnani A, **Soverini S**, Castagnetti F, Marzocchi G, Luatti S, Astolfi A, Formica S, Iacobucci I, Lonetti A, Palandri F, Poerio A, Amabile M, Rosti G, Pession A, Testoni N, Baccarani M, Martinelli G. Genome wide screening of chronic myeloid leukemia patients by SNP arrays: alterations associated with disease progression. *Haematologica* 94(s4): 19, 2009.
- 197.** Durante S, Terragna C, Astolfi A, Palandri F, Castagnetti F, Rosti G, Testoni N, Luatti S, Iacobucci I, Kalebic T, **Soverini S**, Amabile M, Poerio A, Baccarani M, Martinelli G. CD34+ obtained from high sokal risk chronic myeloid leukemia (CML) patients (PTS) espresse gene profiles (GEP) significantly different from CD34+ obtained from low and intermediate sokal risk patients. *Haematologica* 94(s4): 19, 2009.
- 198.** Iacobucci I, Lonetti A, Ferrari A, Storlazzi CT, Chiaretti S, Messina M, Ottaviani E, Guadagnuolo V, Cilloni D, Baldazzi C, Papayannidis C, Messa F, Vitale A, Arruga F, Pane F, Piccaluga PP, **Soverini S**, Vignetti M, Paolini S, Saglio G, Baccarani M, Foà R, Martinelli G. IKZF1 (IKAROS) deletions are independent on the philadelphia chromosome and are associated with an impaired b-cell differentiation and poor outcome in acute lymphoblastic leukemia (ALL) patients. *Haematologica* 94(s4): 50, 2009.
- 199.** Papayannidis C, Iacobucci I, **Soverini S**, Colarossi S, Gnani A, Lonetti A, teston N, Amabile M, Ottaviani E, Abbenante M, Curti A, Paolini S, Lama B, Castagnetti F, Poerio A, Clissa C, Parisi S, Guadagnuolo V, Piccaluga PP, Rosti G, Baccarani M, Martinelli G. Efficacy and clinical outcome of philadelphia positive acute lymphoblastic leukemia patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience. *Haematologica* 94(s4): 51, 2009.
- 200.** Rondoni M, Paolini S, Colarossi S, Fabbri A, Pregno P, Piccaluga PP, Galimberti S, Baratè C, Papayannidis C, De Fina M, **Soverini S**, Lauria F, Baccarani M, Martinelli G. Response to Dasatinib in patients with systemic mastocytosis with D816V kit mutation: 9 Italian cases. *Haematologica* 94(s4): 54, 2009.

- 201.** Lonetti A, Iacobucci I, Ferrari A, Messina M, Cilloni D, **Soverini S**, Chiaretti S, Ottaviani E, Papayannidis C, Messa F, Guadagnuolo V, Salmi F, Vitale A, Arruga F, Pane F, Piccaluga PP, Gnani A, Paolini S, Saglio G, Baccarani M, Foà R, Martinelli G. The B-Cell mutator activation-induced cytidine deaminase (AID) is alternatively spliced in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients. *Haematologica* 94(s4): 68, 2009.
- 202.** Ferrari A, Iacobucci I, Lonetti A, Guadagnuolo V, Cilloni D, Storlazzi CT, Ottaviani E, Messina M, Chiaretti S, Papayannidis C, Messa F, Salmi F, **Soverini S**, Vitale A, Arruga F, Pane F, Piccaluga PP, Testoni N, Paolini S, Saglio G, Foà R, Baccarani M, Martinelli G. Genomic deletions of the CDKN2A locus in BCR-ABL1-positive acute lymphoblastic leukemia (ALL) deregulate G1/S control and contribute to progression of disease. *Haematologica* 94(s4): 76, 2009.
- 203.** Gnani A, **Soverini S**, Colarossi S, Castagnetti F, Merante S, Breccia M, Capucci A, Abruzzese E, Specchia G, Radaelli F, Poerio A, Iacobucci I, Amabile M, Rosti G, Palandri F, Pane F, Izzo B, Saglio G, Cilloni D, Baccarani M, Martinelli G. Contribution of ABL kinase domain mutations to failures and suboptimal responses to imatinib in newly diagnosed chronic phase myeloid leukemia patients. *Haematologica* 94(s4): 167, 2009.
- 204.** Esposito N, Quarantelli F, Luciano I, Izzo B, Ficardi M, Brandford S, White DL, Hughes T, Radich J, **Soverini S**, Iacobucci I, Saglio G, Kalebic T, Thornquist M, Martinelli G, Pane F. The expression of SHP1 and SIT: novel powerful predictor of major molecular response (MMR) achievement in chronic myeloid leukemia Gleevec-treated patients enrolled into the tops clinical trial. *Haematologica* 94(s4): 168, 2009.
- 205.** Esposito N, Colavita I, Quarantelli F, Izzo B, Luciano I, Del Vecchio L, Hughes T, Radich J, Russo D, **Soverini S**, Iacobucci I, Saglio G, Melo JV, Ruoppolo M, Kalebic T, Martinelli G, Pane F. A decreased level of SHP1 provides an additive survival advantage to the Ph+ cells of chronic myeloid leukemia (CML) patients and may account for resistance to imatinib treatment. *Haematologica* 94(s4): 168, 2009.
- 206.** Iacobucci I, Papayannidis C, Paoloni F, Lonetti A, Muschen M, Vignetti M, Cilloni D, **Soverini S**, Messa F, Paolini S, Chiaretti S, Guadagnuolo V, Fazi P, Vitale A, Meloni G, Gobbi M, Malagola M, Saglio G, Pane F, Baccarani M, Foà R, Martinelli G. *PAX5* Wild-Type without *IKZF1* (Ikaros) Deletion Is Associated with Prolonged Disease-Free Survival and Low Rate of Cumulative Incidence of Relapse in Adult *BCR-ABL1*-Positive Acute Lymphoblastic Leukemia (ALL): On Behalf of GIMEMA AL Working Party. *Blood* 114(22): 12, 2009.
- 207.** Iraci N, Valli E, Gherardi S, **Soverini S**, Kalebic T, Baccarani M, Martinelli G, and Perini G. Suppression of Bcr-Abl Expression in CML by A Panel of miRNAs. *Blood* 114(22): 854, 2009.
- 208.** Iacobucci I, Messina M, Iraci N, Lonetti A, Chiaretti S, Ferrari A, Papayannidis C, Messa F, Vitale A, Paoloni F, Cilloni D, Storlazzi CT, Ottaviani E, Paolini S, Durante S, **Soverini S**, Guarini R, Vignetti M, Pane F, Saglio G, Foà R, Muschen M, Pfifer H, Ottmann O, Perini G, Baccarani M, Martinelli G. *IKZF1* (IKAROS) Deletions Are Independent On *BCR-ABL1* Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. *Blood* 114(22): 912, 2009.
- 209.** Gugliotta G, Castagnetti F, Palandri F, Breccia M, Amabile M, **Soverini S**, Testoni N, Marzocchi G, Baldazzi C, Annunziata M, Usala E, Sica S, Tiribelli M, Bocchia M, Gozzini A, Russo S, Palmieri F, Meneghini V, D'Emilio A, Alimena G, Martinelli G, Pane F, Saglio G, Baccarani M, and Rosti G. Old Age Affects Survival but Not Response in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib (IM): A Study of the GIMEMA CML WORKING PARTY. *Blood* 114(22): 1118, 2009.

- 210.** Radich JP, Martinelli G, Hochhaus A, Gottardi E, **Soverini S**, Branford S, Müller M, Beppu L, Shou Y, Haque A, Woodman RC, Kantarjian HM, Hughes TP, Kim DW, and Saglio G. Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations. *Blood* 114(22): 1130, 2009.
- 211.** Papayannidis C, Iacobucci I, **Soverini S**, Colarossi S, Gnani A, Lonetti A, Baldazzi C, Testoni N, Amabile M, Ottaviani E, Abbenante MC, Curti A Paolini S, Lama B, Castagnetti F, Poerio A, Clissa C, Parisi S, Polverelli N, Guadagnuolo V, Piccaluga PP, Rosti G, Baccarani M, Martinelli G. Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience. *Blood* 114(22): 2027, 2009.
- 212.** Terragna C, Durante S, Astolfi A, Palandri F, Castagnetti F, Rosti G, Testoni N, Luatti S, Iacobucci I, Kalebic T, **Soverini S**, Amabile M, Poerio A, Baccarani M, Martinelli G. CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients. *Blood* 114(22): 2174, 2009.
- 213.** Rosti G, Castagnetti F, Palandri F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Rege Cambrin G, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, **Soverini S**, Testoni N, Alimena G, Pane F, Saglio G, Baccarani M, Martinelli G. Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. *Blood* 114(22): 2205, 2009.
- 214.** Iacobucci I, Ferrarini A, Sazzini M, Giacomelli E, Lonetti E, Muschen M, Sumerle L, Papayannidis C, **Soverini S**, Ottaviani E, Paolini S, Ferrari A, Messa F, Cilloni D, Vitale A, Pane F, Saglio G, Foà R, Baccarani M, Delledonne M, Martinelli G. Whole Transcriptome Sequencing of a Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL) with "Next Generation Sequencing" Technology Revealed Novel Point Mutations Associated with Disease-Progression. *Blood* 114(22): 3074, 2009.
- 215.** Gherardi S, **Soverini S**, Iraci N, Terragna C, Valli E, Durante S, Astolfi A, Bernardoni R, Kalebic T, Pane F, Saglio G, Martinelli G, Baccarani M, and Perini G. C-Myc Mediated Regulation of Multidrug Resistance Genes in Chronic Myeloid Leukaemia Cd34+ Cell Progenitors. *Blood* 114(22): 3252, 2009.
- 216.** Rondoni M, Ottaviani E, Cilloni D, Piccaluga PP, Paolini S, Iacobucci I, **Soverini S**, Merante S, Messa F, Buccisano F, Tiribelli M, Pane F, Saglio G, Lauria F, Baccarani M, Martinelli G. Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow –up of 30 to 92 Months. *Blood* 114(22): 3894, 2009.
- 217.** Martinelli G, Papayannidis C, Iacobucci I, **Soverini S**, Paolini S, Santucci S, De Rosa F, Cilloni D, Messa F, Pane F, Meneghini V, Giannoulia P, Ottaviani E, Testoni N, Lama B, Baccarani M. Innovative Phase I Study of Concomitant and Consecutive Treatment with Dasatinib and MK-0457 in Refractory Ph+ CML and ALL Patients. *Blood* 114(22): 4277, 2009
- 218.** Angelini, S.; Turrini, E.; Ravegnini, G.; **Soverini, S.**; Martinelli, G.; Kalebic, T.; Barnett, M.; Hrelia, P. A pharmacogenetic approach towards personalised anti-cancer drug use. *Journal of Biotechnology* 2010;150(S1):S106
- 219.** Gnani A, **Soverini S**, Colarossi S, Castagnetti F, Astolfi A, Formica S, Palandri F, Iacobucci, Gugliotta G, Poerio, Amabile M, MARzocchi G, Testoni N, Abruzzese E, Rosti G, Baccarani M, Martinelli. High-Resolution Molecular Karyotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Identifies Focal Copy Number



Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes. *Cancer Res* 2010;70(S8):2143

**220.** Giovanni Martinelli, Angela Poerio, **Simona Soverini**, Giuseppe Saglio, Fabrizio Pane, Fausto Castagnetti, Adele Capucci, Mario Tiribelli, Fabio Stagno, Francesca Palandri, Gabriele Gugliotta, Alfonso Zaccaria, Tamara Intermesoli, Bruno Martino, Guido Biasco, Monica Bocchia, Michele Cedrone, Nicoletta Testoni, Marilina Amabile, Ilaria Iacobucci, Massimo Breccia, Giuliana Alimena, Luciano Levato, Michele Bacarani and Gianantonio Rosti. Improving on Imatinib for targeted therapy of chronic myeloid leukemia: First line treatment with Nilotinib 800 mg daily results in unprecedentedly high rate of rapid, “deep” and stable molecular responses - Results of a phase 2 trial of the GIMEMA CML working party. *Cancer Res* 2010;70(8S):1805

**221.** Cristina Papayannidis, Ilaria Iacobucci, **Simona Soverini**, Sabrina Colarossi, Alessandra Gnani, Annalisa Lonetti, Anna Ferrari, Nicoletta Testoni, Marilina Amabile, Emanuela Ottaviani, Maria Chiara Abbenante, Antonio Curti, Stefania Paolini, Barbara Lama, Cristina Clissa, Sarah Parisi, Viviana Guadagnuolo, Michele Bacarani and Giovanni Martinelli. Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience. *Cancer Res* 2010;70(8S):1804

**222.** Ilaria Iacobucci, Alberto Ferrarini, Marco Sazzini, Annalisa Lonetti, Enrico Giacomelli, Luciano Xumerle, Anna Ferrari, Cristina Papayannidis, Emanuela Ottaviani, Stefania Paolini, Francesca Messa, Daniela Cilloni, Antonella Vitale, Fabrizio Pane, **Simona Soverini**, Giuseppe Saglio, Robin Foà, Michele Bacarani, Massimo Delledonne and Giovanni Martinelli. Whole transcriptome sequencing of Philadelphia positive acute lymphoblastic leukemia (ALL) by RNA-seq: an exhaustive overview of novel point mutations, gene expression and alternative splicing profiles. *Cancer Res* 2010;70(8S):651

**223.** Annalisa Lonetti, Ilaria Iacobucci, Cristina Papayannidis, Anna Ferrari, Viviana Guadagnuolo, Daniela Cilloni, Francesca Messa, Stefania Paolini, Sabina Chiaretti, **Simona Soverini**, Giuseppe Saglio, Fabrizio Pane, Michele Bacarani, Robin Foà and Giovanni Martinelli. Molecular Characterization of PAX5 alterations in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL). *Cancer Res* 2010;70(8S):1600

**224.** G. Rosti, F. Castagnetti, F. Palandri, A. Poerio, **S. Soverini**, M. Breccia, F. Pane, G. Martinelli, M. Bacarani, G. Saglio. Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. *J Clin Oncol* 28(15s):490s, 2010.

**225.** I Iacobucci, A Lonetti, M Sazzini, S Formica, A Ferrari, C Papayannidis, P Garagnani, A Boattini, A Astolfi, S Paolini, D Cilloni, MC Abbenante, V Guadagnuolo, A Vitale, F Pane, **S Soverini**, M Vignetti, R Foà, M Bacarani, G Martinelli. High-resolution pharmacogenetic profiles of genes involved in drug absorption, distribution, metabolism and elimination in adult philadelphia-positive acute lymphoblastic leukemia patients. *Haematologica* 95[suppl.2]:1, 2010.

**226.** F Castagnetti, F Palandri, G Gugliotta, M Breccia, G Specchia, E Abruzzese, L Levato, T Intermesoli, B Martino, P Pregno, E Orlandi, I Iacobucci, **S Soverini**, N Testoni, G Alimena, G Martinelli, F Pane, G Saglio, M Bacarani, G Rosti. Long term outcome of 559 ph+ chronic myeloid leukemia patients treated front-line with imatinib: 5-year results of 3 independent studies of the GIMEMA CML working party. *Haematologica* 95[suppl.2]:54, 2010.

**227.** T Hughes, D Kim, G Martinelli, S Branford, M Müller, L Beppu, H Goh, **S Soverini**, Y Shou, J Reynolds, R Woodman, H Kantarjian, G Saglio, J Radich, A Hochhaus. Early molecular response to nilotinib in patients who failed imatinib is associated with a higher

probability of cytogenetic response in chronic myeloid leukemia (CML). *Haematologica* 95[suppl.2]:54, 2010.

**228.** A Stein, Y Shou, D Bottino, YL Chia, R Woodman, G Martinelli, T Hughes, M Müller, L Beppu, E Gottardi, S Branford, **S Soverini**, H Goh, A Hochhaus, D Kim, G Saglio, J Radich. Rapid initial decline in Bcr-Abl levels is associated with superior responses in imatinib-resistant or -intolerant chronic myeloid leukemia patients in chronic phase (CML-CP) treated with nilotinib. *Haematologica* 95[suppl.2]:56, 2010.

**229.** G Martinelli, A Hochhaus, J Radich, **S Soverini**, S Branford, P Erben, E Gottardi, L Beppu, H Goh, H Kantarjian, A Haque, Y Shou, R Woodman, T Hughes, G Saglio, DW Kim. Detection of new mutations in nilotinib-treated patients with imatinib-resistant chronic myeloid leukemia in chronic phase. *Haematologica* 95[suppl.2]:62, 2010.

**230.** I Iacobucci, A Ferrari, A Lonetti, C Papayannidis, V Guadagnuolo, C Storlazzi, E Ottaviani, MC Abbenante, S Paolini, S Parisi, D Cilloni, **S Soverini**, F Pane, A Vitale, B Lama, R Foà, M Baccarani, G Martinelli. Loss of the tumor suppressor gene CDKN2A/ARF by genomic deletions is a frequent event in adult Bcr-Abl1 positive acute lymphoblastic leukemia (ALL) patients and contributes to disease progression. *Haematologica* 95[suppl.2]:227, 2010.

**231.** C Papayannidis, I Iacobucci, **S Soverini**, S Paolini, C Clissa, S Parisi, MC Abbenante, S Colarossi, A Gnani, A Lonetti, A Ferrari, N Testoni, M Amabile, E Ottaviani, A Curti, V Guadagnuolo, M Baccarani, G Martinelli. Efficacy and clinical outcome of philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): the Bologna experience. *Haematologica* 95[suppl.2]:257, 2010.

**232.** G Saglio, T Hughes, DW Kim, B Hanfstein, E Gottardi, S Branford, H Goh, L Beppu, **S Soverini**, Y Shou, A Stein, R Woodman, H Kantarjian, J Radich, A Hochhaus, G Martinelli. Response to nilotinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) with different Bcr-Abl transcript types. *Haematologica* 95[suppl.2]:342, 2010.

**233.** SH Kim, HG Goh, F Pane, T Hughes, J Radich, P Lin, G Saglio, S Branford, G Martinelli, **S Soverini**, A Hochhaus, DW Kim. Bcr-Abl mutation analysis using both ASO-PCR and direct sequencing in new chronic phase chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment. *Haematologica* 95[suppl.2]:344, 2010.

**234.** Iacobucci I, Ferrarini A, Sazzini M, Lonetti A, Ferrari A, Papayannidis C, Giacomelli E, Xumerle L, Paolini S, Abbenante M, Guadagnuolo V, Vitale A, Pane F, **Soverini S**, Baccarani M, Delledonne M, Martinelli G. Whole Transcriptome Deep-Sequencing Identifies Novel Point Mutations, Gene Expression And Alternative Splicing Profiles In Bcr-Abl1 Positive Acute Lymphoblastic Leukemia. *Haematologica* 2010; 95(S3) : S28

**235.** Iacobucci I, Lonetti A, Ferrari A, Papayannidis C, Abbenante M, Ottaviani E, Paolini S, Guadagnuolo V, Parisi S, Vitale A, Vignetti M, Cilloni D, Pane F, **Soverini S**, Foà R, Baccarani M, Martinelli G. From Diagnosis To Relapse: An High-Resolution Molecular Allelokaryotyping Analysis Of Paired Diagnosis-Relapse Samples In Bcr-Abl1-Positive ALL Indicates Involvement Of Alterations Targeting Key Regulators Of Tumor Suppression, Cell Cycle Control, And Lymphoid/B Cell Development. *Haematologica* 2010; 95(S3) : S29

**236.** Martinelli G, Poerio A, **Soverini S**, Saglio G, Pane F, Castagnetti F, Capucci A, Tiribelli M, Stagno F, Palandri F, Gugliotta G, Zaccaria A, Intermesoli T, Martino B, Bocchia M, Cedrone M, Testoni N, Amabile M, Iacobucci I, Breccia M, Alimena G, Levato L, Baccarani M, Rosti G. Improving On Imatinib For Targeted Therapy Of Chronic Myeloid Leukemia: First Line Treatment With Nilotinib 800 Mg Daily Results In Unprecedentedly

High Rate Of Rapid, “Deep” And Stable Molecular Responses - Results Of A Phase 2 Trial Of The GIMEMA CML Working Party. *Haematologica* 2010; 95(S3) : S56

**237.** Russo D, Martinelli G, Malagola M, Colombi C, Rosti G, Amabile M, Fogli M, Mirto S, Turri D, Gobbi M, Pierri I, Vitolo U, Pregno P, Morra E, Pungolino E, Di Raimondo F, Stagno F, Foà R, Alimena G, Breccia M, Nobile F, Martino B, Rambaldi R, Intermesoli T, Saglio G, Rege Cambrin G, Visani G, Nicolini G, De Fabritiis P, Abruzzese E, Fanin R, Tiribelli M, Galieni P, Bigazzi C, Liso V, Specchia G, Angelucci E, Usala E, Musolino C, Russo S, Gaidano G, Lunghi M, Lauria F, Bocchia M, Rodeghiero F, D’emilio A, Bosi A, Santini V, Quarta G, Girasoli M, Fioritoni G, Di Lorenzo R, Testoni N, De Vivo A, **Soverini S**, Iacobucci I, Baccarani M. Pre-Final Analysis Of The Phase Ii Explorative Study Of Intermittent Imatinib (IM) Treatment (INTERIM) In Elderly Ph+ CML Patients With Stable Complete Cytogenetic Response (CCgR) – Eudract Number 2007-005102-42, Clinicaltrials.Gov Nct 00858806. *Haematologica* 2010; 95(S3) : S57

**238.** Iacobucci I, Sazzini M, Ferrari A, Lonetti A, Boattini A, Papayannidis C, Garagnani P, Abbenante M, Mantovani V, Marasco E, Ottaviani E, Paolini S, Guadagnuolo V, Girelli D, Vignetti M, Pane F, **Soverini S**, Baccarani M, Martinelli G. Polymorphism In The Chromosome 9p21 ANRIL Locus Is Associated To Philadelphia Positive Acute Lymphoblastic Leukemia Susceptibility. *Haematologica* 2010; 95(S3) : S61-S62

**239.** Russo D, Malagola M, Testoni N, Martinelli G, Colombi C, Skert C, Rosti G, Amabile M, Fogli M, Mirto S, Turri D, Gobbi M, Pierri I, Vitolo U, Pregno P, Morra E, Pungolino E, Di Raimondo F, Stagno F, Foà R, Alimena G, Breccia M, Nobile F, Martino B, Rambaldi R, Intermesoli T, Saglio G, Rege Cambrin G, Visani G, Nicolini G, De Fabritiis P, Abruzzese E, Fanin R, Tiribelli M, Galieni P, Bigazzi C, Liso V, Specchia G, Angelucci E, Usala E, Musolino C, Russo S, Gaidano G, Lunghi M, Lauria F, Bocchia M, Rodeghiero F, D’Emilio A, Bosi A, Santini V, Quarta G, Girasoli M, Fioritoni G, Di Lorenzo R, De Vivo A, **Soverini S**, Iacobucci I, Baccarani M. Monitoring Of Complete Cytogenetic Response (Ccgr) By Interphase Fluorescence In Situ Hybridization (I-FISH) On Peripheral Blood In Elderly Ph+ CML Patients With Stable Ccgr Treated With Intermittent Imatinib (IM) Eudract Number 2007-005102-42, Clinicaltrials.Gov Nct 00858806. *Haematologica* 2010; 95(S3) : S121-S122

**240.** Castagnetti F, Palandri F, Poerio A, Breccia M, Levato L, Capucci A, Tiribelli M, Zaccaria A, Intermesoli T, Martino B, Cedrone M, Bocchia M, Cavazzini F, Stagno F, Specchia G, Musso M, **Soverini S**, Gugliotta G, Testoni N, Alimena G, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G. Nilotinib 400 Mg Bid In Early Chronic Phase Ph+ Chronic Myeloid Leukemia: Results At 2 Years Of A Phase II Trial Of The GIMEMA CML Working Party. *Haematologica* 2010; 95(S3) : S132

**241.** Gugliotta G, Castagnetti F, Palandri F, Breccia M, **Soverini S**, Girasoli M, Levato L, Cavazzini F, Pregno P, Bigazzi C, Sica S, Abruzzese E, Di Lorenzo R, Ciccone F, Capucci A, Alimena G, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G. Incidence Of Second Malignancies In 559 Patients With Chronic Myeloid Leukemia Treated With Imatinib Frontline: Data From The GIMEMA CML Working Party. *Haematologica* 2010; 95(S3) : S133-S134

**242.** Ferrari A, Iacobucci I, Lonetti A, Papayannidis C, Paolini S, Parisi S, Abbenante M, Guadagnuolo V, **Soverini S**, Cilloni D, Pane F, Baccarani M, Martinelli G. Loss Of The Tumor Suppressor Gene CDKN2A/ARF Is Frequently Deleted But Not Mutated In Bcr-Abl1-Positive Acute Lymphoblastic Leukemia Patients. *Haematologica* 2010; 95(S3) : S140-S141

**243.** Iacobucci A, Lonetti A, Ferrarini M, Sazzini A, Ferrari C, Papayannidis S, **Soverini S**, E Giacomelli, L Xumerle, V Guadagnuolo, A Vitale, F Pane, M Baccarani, M Delledonne, and G Martinelli. Whole Transcriptome Resequencing of Paired Diagnosis-

Relapse BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Samples Reveals the Loss of Cell Cycle Regulation as the Main Mechanism Responsible for Leukemia Progression. *Blood* 2010; 116(21): 1024.

**244.** C Terragna, S Durante, A Astolfi, F Palandri, F Castagnetti, N Testoni, M Amabile, I Iacobucci, **S Soverini**, G Alimena, M Breccia, F Pane, G Saglio, G Rosti, M Baccarani, G Martinelli. The Elevated Expression of FBP1, a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients. *Blood* 2010; 116(21): 3399.

**245.** FE Nicolini, S Morisset, A Hochhaus, G Martinelli, D-W Kim, I Dufva, M Mauro, JE Cortes, C Chuah, J Apperley, F Guilhot, G Saglio, MC Müller, **S Soverini**, S Corm, I Tigaud, M Etienne, C Roche-Lestienne, S Hayette, S Peter, W Zhou, and M Michallet. The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis. *Blood* 2010; 116(21): 3410.

**246.** D Russo, G Martinelli, M Malagola, C Colombi, G Rosti, M Amabile, M Fogli, D Turri, S Mirto, M Gobbi, I Pierri, U Vitolo, P Pregno, E Morra, E Pungolino, F Di Raimondo, F Stagno, R Foà, G Alimena, M Breccia, F Nobile, B Martino, A Rambaldi, T Intermesoli, G Saglio, G Rege Cambrin, G Visani, G Nicolini, P de Fabritiis, E Abruzzese, R Fanin, M T, P Galieni, C Bigazzi, G Specchia, V Liso, E Angelucci, E Usala, C Musolino, S Russo, G Gaidano, M Lunghi, F Lauria, M Bocchia, F Rodeghiero, A D'Emilio, A Bosi, V Santini, G Quarta, M Girasoli, G Fioritoni, R Di Lorenzo, N Testoni, Antonio De Vivo, **S Soverini**, I Iacobucci, M Baccarani. One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806. *Blood* 2010; 116(21): 3412.

**247.** D-W Kim, D Kim, S-H Kim, H-G Goh, F Pane, T Hughes, JP Radich, P Lin, G Saglio, S Branford, G Martinelli, **S Soverini**, A Hochhaus. Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment. *Blood* 2010; 116(21): 3441.

**248.** T Ernst, F Lin, HE White, P La Rosée, T Lion, G Mitterbauer-Hohendanner, P Vandenberghe, R Zadro, K Machova Polakova, R Plachy, C Guldborg Nyvold, T Lundán, JM Cayuela, T Lange, MC Müller, K Zoi, H Andrikovics, T Tohami, F Pane, **S Soverini**, F Arruga, L Eggen, T Sacha, J Diamond, R Talmaci, T Pajic, D Colomer, M Hermanson, E Oppliger Leibundgut, PJM Valk, U Ozbek, G Gerrard, G Saglio, A Hochhaus, NCP Cross. Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. *Blood* 2010; 116(21): 894.

**249.** M Suriano, G Martinelli, A Poerio, M Amabile, G Rosti, F Castagnetti, I Iacobucci, **S Soverini**, A Lonetti, C Papayannidis, M Abbenante, Sarah Parisi, F Palandri, and M Baccarani. Evaluation of the GeneXpert Assay for the Monitoring of BCR-ABL Transcript Levels In Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of a Comparison with the Manual and Traditional Manual TaqMan RQ-PCR Assay. *Blood* 2010; 116(21): 4831.

**250.** F Castagnetti, G Gugliotta, F Palandri, M Breccia, G Specchia, E Abruzzese, T Intermesoli, A Capucci, B Martino, F Stagno, P Pregno, M Amabile, **S Soverini**, N Testoni, G Alimena, G Martinelli, F Pane, G Saglio, M Baccarani, and G Rosti. BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis. *Blood* 2010; 116(21): 1230.

- 251.** G Martinelli, A Poerio, M Amabile, I Iacobucci, **S Soverini**, F Castagnetti, F Palandri, G Gugliotta, A Capucci, M Tiribelli, F Stagno, A Zaccaria, T Intermesoli, B Martino, M Bocchia, M Cedrone, N Testoni, M Breccia, G Alimena, L Levato, C Papayannidis, A Lonetti, C Terragna, D Russo, F Pane, G Saglio, G Rosti, M Baccarani. First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, "Deep" and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. *Blood* 2010; 116(21): 2720.
- 252.** G Rosti, F Castagnetti, G Gugliotta, M Breccia, L Levato, A Capucci, M Tiribelli, A Zaccaria, M Bocchia, A Cuneo, F Stagno, G Specchia, F Porretto, B Martino, M Cedrone, T Intermesoli, F Palandri, M Amabile, **S Soverini**, N Testoni, G Alimena, F Pane, G Saglio, G Martinelli, M Baccarani. Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. *Blood* 2010; 116(21): 359.
- 253.** I Iacobucci, M Sazzini, A Ferrari, A Lonetti, A Boattini, C Papayannidis, P Garagnani, M Abbenante, V Mantovani, E Marasco, E Ottaviani, S Paolini, D Girelli, M Vignetti, F Pane, **S Soverini**, M Baccarani, and G Martinelli. Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. *Blood* 2010; 116(21): 1670.
- 254.** I Iacobucci, A Lonetti, A Ferrari, C Papayannidis, **S Soverini**, S Paolini, M Abbenante, V Guadagnuolo, S Parisi, L Potenza, M Luppi, F Cattina, D Russo, F Pane, M Baccarani, G Martinelli. Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). *Blood* 2010; 116(21): 1677.
- 255.** I Iacobucci, A Ferrari, A Lonetti, C Papayannidis, V Guadagnuolo, E Ottaviani, M Abbenante, F Cattina, A Vitale, S Paolini, **S Soverini**, S Parisi, F Paoloni, F Castagnetti, M Vignetti, R Foà, M Baccarani, G Martinelli. The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients. *Blood* 2010; 116(21): 3136.
- 256.** I Iacobucci, A Ferrari, C Papayannidis, F Paoloni, M Abbenante, V Guadagnuolo, E Ottaviani, F Cattina, A Vitale, S Paolini, **S Soverini**, S Parisi, M Vignetti, M Baccarani, G Martinelli. Loss of the tumor suppressor genes *CDKN2A/ARF* impairs prognosis in adult *BCR-ABL1* positive acute lymphoblastic leukemia (ALL). *Cancer Res* 2011;71(S8):311
- 257.** A Ferrari, I Iacobucci, M Sazzini, A Lonetti, A Boattini, C Papayannidis, M Abbenante, V Mantovani, V Guadagnuolo, F Cattina, E Marasco, E Ottaviani, S Paolini, D Girelli, **S Soverini**, M Baccarani, G Martinelli. A germline polymorphism in the *ANRIL* (*CDKN2BAS*) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL). *Cancer Res* 2011;71(S8):3811
- 258.** A Ferrari, I Iacobucci, M Sazzini, A Lonetti, A Boattini, C Papayannidis, P Garagnani, M Abbenante, V Mantovani, F Cattina, E Marasco, E Ottaviani, S Paolini, D Girelli, M Vignetti, F Pane, **S Soverini**, M Baccarani, G Martinelli. The Rs564398, A Polymorphism In The Antisense Non-Coding RNA In The *INK4* Locus, *ANRIL*, Is Associated To Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Susceptibility. *Haematologica* 2011; 96(S2): 2-3S
- 259.** S Durante, C Terragna, A Astolfi, F Palandri, F Castagnetti, N Testoni, M Amabile, I Iacobucci, **S Soverini**, G Alimena, M Breccia, F Pane, G Saglio, G Rosti, M Baccarani, G Martinelli. Overexpression Of *FBP1* Is Associated To High Sokal Risk In Chronic Myeloid Leukemia Patients. *Haematologica* 2011; 96(S2): 51-52

- 260.** T Ernst, F Lin, H White, P La Rosée, T Lion, G Mitterbauer-Hohendanner, P Vandenberghe, R Zadro, K Machova Polakova, C Guldborg Nyvold, T Lundán, O Jm Cayuela, T Lange, M Müller, K Zoi, H Andrikovics, T Tohami, F Pane, **S Soverini**, F Arruga, L Eggen, T Sacha, R Talmaci, M Hermanson, E Oppliger Leibundgut, P Valk, U Ozbek, G Gerrard, P Schuld, G Saglio, A Hochhaus. Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Final Results Of A Survey And First Control Round Within 24 National Reference Laboratories In Europe. *Haematologica* 2011; 96(S2): 53-54
- 261.** G Rosti, F Castagnetti, M Breccia, G Gugliotta, L Levato, A Capucci, F Cavazzini, M Tiribelli, M Bocchia, M Salvucci, F Stagno, A Russo Rossi, F Porretto, B Martino, M Cedrone, T Intermesoli, F Palandri, M Amabile, **S Soverini**, N Testoni, G Alimena, F Pane, G Saglio, G Martinelli, M Baccharani. Nilotinib 400 Mg Bid Frontline: With A Follow-Up Of 3 Years, Results Remain Excellent And Stable. (A GIMEMA CML WP Phase 2 Trial). *Haematologica* 2011; 96(S2): 54-55
- 262.** F Castagnetti, G Gugliotta, F Palandri, M Breccia, G Specchia, E. Abruzzese, L Levato, F Cavazzini, E Orlandi, F Stagno, R Di Lorenzo, M Annunziata, E Usala, S Sica, P Galieni, G Rege-Cambrin, M Amabile, **S Soverini**, N Testoni, G Alimena, G Martinelli, F Pane, G Saglio, M Baccharani, G Rosti. Bcr-Abl Fusion Transcript And Outcome Of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated With Imatinib: A GIMEMA CML WP Analysis. *Haematologica* 2011; 96(S2): 205-206
- 263.** Castagnetti F, Gugliotta G, Palandri F, Breccia M, Specchia G, Abruzzese E, Levato L, Cavazzini F, Orlandi E, Stagno F, Di Lorenzo R, Annunziata M, Usala E, Sica S, Galieni P, Rege-Cambrin G, Amabile M, **Soverini S**, Testoni N, Alimena G, Martinelli G, Pane F, Saglio G, Baccharani M, Rosti G For The GIMEMA CML Working Party. The Bcr-Abl Fusion Transcript Has A Prognostic Impact In Chronic Myeloid Leukemia Patients Treated With Imatinib In Early Chronic Phase: A GIMEMA CML WP Analysis. *Haematologica* 2011; 97(S2) : S38
- 264.** Iacobucci I, Ferrari A, Papayannidis C, Lonetti A, Paoloni F, Trino S, Abbenante Mc, Guadagnuolo V, Ottaviani, Cattina F, Vitale A, Paolini S, **Soverini S**, Parisi S, Vignetti M, Baccharani M, Martinelli G. Loss Of CDKN2A Gene Is A Poor Prognostic Marker In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients. *Haematologica* 2011; 97(S2) : S43
- 265.** Castagnetti F, Gugliotta G, Breccia M, Levato L, Capucci A, Tiribelli M, Zaccaria A, Bocchia M, Cuneo A, Stagno F, Specchia G, Porretto F, Martino B, Cedrone M, Intermesoli T, Palandri F, Amabile M, **Soverini S**, Testoni N, Alimena G, Pane F, Saglio G, Martinelli G, Baccharani M, Rosti G. Very Deep Molecular Responses In Chronic Myeloid Leukemia Patients Treated Frontline With Nilotinib 800 Mg Daily: 3-Years Results Of A GIMEMA CML WP Study. *Haematologica* 2011; 97(S2) : S147
- 266.** Iacobucci I, Ferrarini A, Sazzini M, Lonetti A, Ferrari A, Papayannidis C, **Soverini S**, Xumerle L, Guadagnuolo V, Trino S, Cattina F, Pane F, Baccharani M, Russo D, Delledonne M, martinelli G. Next Generation Paired End Transcriptomic Re-Sequencing Technology Reveals Novel Common Genetic Alterations In The Hedgehog Pathway In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL). *Haematologica* 2011; 97(S2) : S166-S167
- 267.** Iacobucci A, Ferrari S, Trino A, Lonetti C, Papayannidis A, Ferrarini, L Venturini, MC Abbenante, S Parisi, F Cattina, **S Soverini**, S Paolini, D Russo, M Vignetti, F Pane, P Musto, M Delledonne, M Baccharani, G Martinelli. TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukaemia. *Blood* 2011; 118(21): 1484.

- 268.** V Guadagnuolo, C Papayannidis, I Iacobucci, S Durante, C Terragna, E Ottaviani, MC Abbenante, F Cattina, **S Soverini**, B Lama, L Toni, W J. Levin, R Courtney, C Baldazzi, A Curti, M Baccarani, C Jamieson, JE Cortes, V Oehler, K McLachlan, T Van Arsdale, G Martinelli. GAS1 and KIF27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. *Blood* 2011; 118(21): 1535.
- 269.** F Castagnetti, G Rosti, M Breccia, A Gozzini, F Stagno, Giovanna Rege Cambrin, I Pierri, Luigia Luciano, G Specchia, E Abruzzese, B Martino, A Capucci, M Bocchia, F Cavazzini, M Tiribelli, G Gugliotta, F Palandri, S Durante, **S Soverini**, N Testoni, F Pane, G Saglio, G Alimena, G Martinelli, M Baccarani. Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. *Blood* 2011; 118(21): 453.
- 270.** I Iacobucci, H Pfeifer, A Lonetti, C Papayannidis, A Ferrari, S Trino, MC Abbenante, Sarah Parisi, **S Soverini**, A Vitale, S Paolini, E Ottaviani, C Baldazzi, F Pane, M Baccarani, O G. Ottmann, and G Martinelli. BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development. *Blood* 2011; 118(21): 3580.
- 271.** G Gugliotta, F Castagnetti, M Breccia, L Levato, A Capucci, M Tiribelli, A Zaccaria, M Bocchia, A Cuneo, F Stagno, G Specchia, Maurizio Musso, B Martino, M Cedrone, T Intermesoli, F Palandri, **S Soverini**, C Baldazzi, S Durante, N Testoni, G Alimena, F Pane, G Saglio, M Baccarani, G Martinelli, G Rosti. Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). *Blood* 2011; 118(21): 2756.
- 272.** D Russo, G Alimena, C Colombi, M Breccia, **S Soverini**, I Iacobucci, F Cattina, G Martinelli, N Testoni, AM Liberati, V Appolloni, M Tiribelli, R Fanin, F Ferrara, M Annunziata, E Trabacchi, D Vallisa, A De Vivo, F Castagnetti, M Fogli, S Durante, F Di Raimondo, F Stagno, A. M. Carella, G. Pica, A Iurlo, T Radice, P Pregno, U Vitolo, E Abruzzese, P de Fabritiis, M Longinotti, S Pardini, C Musolino, S Russo, M Gobbi, I Pierri, G Gaidano, M Lunghi, G Visani, S Barulli, M Cazzola, S Merante, C Skert, M Malagola, G Rosti, M Baccarani. Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. *Blood* 2011; 118(21): 786.
- 273.** I Iacobucci, F Cattina, S Pomella, A Lonetti, A Ferrari, C Papayannidis, S Trino, D Erriquez, V Guadagnuolo, E Ottaviani, S Formica, **S Soverini**, F Paoloni, M Vignetti, D Russo, G Perini, M Baccarani, G Martinelli. ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112. *Blood* 2011; 118(21): 2574.
- 274.** C Papayannidis, V Guadagnuolo, I Iacobucci, S Durante, C Terragna, E Ottaviani, MC Abbenante, F Cattina, **S Soverini**, B Lama, L Toni, W J. Levin, R Courtney, C Baldazzi, A Curti, M Baccarani, C Jamieson, JE Cortes, V Oehler, K McLachlan, T Van Arsdale, G Martinelli. PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients. *Blood* 2011; 118(21): 1429.
- 275.** D Russo, M Baccarani, G Martinelli, C Colombi, M Malagola, C Skert, **S Soverini**, I Iacobucci, D Turri, S Mirto, M Gobbi, I Pierri, U Vitolo, P Pregno, M Fogli, N Testoni, A De Vivo, F Castagnetti, E Morra, E Pungolino, F Di Raimondo, F Stagno, G Alimena, M Breccia, F Nobile, B Martino, A Rambaldi, T Intermesoli, G Saglio, G Rege Cambrin, G Visani, G Nicolini, P de Fabritiis, E Abruzzese, R Fanin, M Tiribelli, P Galieni, C Bigazzi, G Specchia, E

Angelucci, E Usala, C Musolino, S Russo, G Gaidano, M Lunghi, F Lauria, M Bocchia, F Rodeghiero, A D'Emilio, A Bosi, V Santini, G Quarta, M Girasoli, G Fioritoni, R Di Lorenzo, B Cesana, and G Rosti. Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. *Blood* 2011; 118(21): 1682.

**276.** M Bonifacio, G De Matteis, C De Benedittis, O Perbellini, A Zamò, P Bonadonna, E Paviati, A Artuso, **S Soverini**, G Pizzolo, G Martinelli, R Zanotti. Improved Detection of the KIT D816V Mutation Using a Real-Time PCR Assay Allows a Finer Recognition of Patients with Indolent Systemic Mastocytosis. *Blood* 2011; 118(21): 5163.

**277.** I Iacobucci, F Cattina, S Pomella, A Lonetti, E Derenzini, E Brighenti, A Ferrari, C Papayannidis, MV Verga Falzacappa, V Guadagnuolo, M Aluigi, E Ottaviani, S Formica, MC Abbenante, **S Soverini**, D Russo, F Pane, PG Pellicci, M Baccarani, and G Martinelli. The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). *Blood* 2011; 118(21): 76.

**278.** V Guadagnuolo, C Papayannidis, I Iacobucci, S Durante, C Terragna, E Ottaviani, MC Abbenante, F Cattina, **S Soverini**, B Lama, L Toni, W Levin, R Courtney, C Baldazzi, A Curti, M Baccarani, C Jamieson, J Cortes, V Oehler, K McLachlan, T Van Arsdale, G Martinelli. *Gas1* and *Kif27* genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients. *Cancer Res* 2012;72(S8):906

**279.** I Iacobucci, F Cattina, S Pomella, E Brighenti, C Papayannidis, Enrico Derenzini, A Lonetti, A Ferrari, MV Verga Falzacappa, V Guadagnuolo, M Aluigi, E Ottaviani, MC Abbenante, **S Soverini**, D Russo, PG Pellicci, M Baccarani, G Martinelli. Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL). *Cancer Res* 2012;72(S8):1772

**280.** C Papayannidis, V Guadagnuolo, I Iacobucci, S Durante, C Terragna, E Ottaviani, MC Abbenante, F Cattina, **S Soverini**, B Lama, L Toni, W Levin, Rachel Courtney, C Baldazzi, A Curti, M Baccarani, C Jamieson, J Cortes, V Oehler, K McLachlan, Todd VanArsdale, G Martinelli. PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of *ABCA2* and *BCL2* on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients. *Cancer Res* 2012;72(S8):4619

**281.** I Iacobucci, A Ferrari, A Lonetti, C Papayannidis, S Trino, C Venturi, A Ferrarini, L Venturini, M Abbenante, S Parisi, F Cattina, **S Soverini**, DRusso, M Vignetti, F Pane, M Delledonne, M Baccarani, G Martinelli. Molecular Characterization Of TP53 Mutations In B-Acute Lymphoblastic Leukemia (B-ALL) Reveals Missense Substitutions, Aberrant Exon-Junctions And Intron Retention Events. *Haematologica* 2012; 97(S1): 2-3

**282.** Russo, G Martinelli, M Malagola, V Cancelli, S Zedda, C Skert, **S Soverini**, I Iacobucci, D Turri, S Mirto, M Gobbi, I Pierri, U Vitolo, P Pregno, M Fogli, N Testoni, A De Vivo, F Castagnetti, E Morra, E Pungolino, F Di Raimondo, F Stagno, G Alimena, M Breccia, F Nobile, B Martino, A Rambaldi, T Intermesoli, G Saglio, G Rege Cambrin, G Visani, G Nicolini, P De Fabritiis, E Abruzzese, R Fanin, M Tiribelli, P Galieni, C Bigazzi, G Specchia, E Angelucci, E Usala, C Musolino, S Ruso, L Gaidano, M Lunghi, F Lauria, M Bocchia, F Rodeghiero, A D'Emilio, A Bosi, V Santini, G Quarta, M Girasoli, G Fioritoni, R Di Lorenzo, B Cesana, G Rosti, M Baccarani. Intermittent Imatinib (INTERIM) Treatment In Ph+-CML Elderly Patients In Stable Complete Cytogenetic Response. *Haematologica* 2012; 97(S1): 73-74

**283.** F Castagnetti, G Gugliotta, F Palandri, M Breccia, L Levato, F Stagno, G Specchia, G Rege Cambrin, L Luciano, A Gozzini, B Martino, A Capucci, T Intermesoli, M Tiribelli, M



Cedrone, F Cavazzini, E Usala, **S Soverini**, N Testoni, F Pane, G Saglio, G Alimena, G Martinelli, G Rosti, M Baccarani. EUTOS Score Is Predictive For Survival And Outcome In Patients With Early Chronic Phase Chronic Myeloid Leukemia Treated With Nilotinib-Based Regimens. *Haematologica* 2012; 97(S1): 76-77

**284.** G Gugliotta, F Castagnetti, F Palandri, M Breccia, L Levato, F Stagno, G Rege Cambrin, A Zaccaria, G Specchia, E Usala, A Gozzini, B Martino, A Capucci, I Pierri, M Tiribelli, M Bocchia, E Abruzzese, **S Soverini**, N Testoni, G Saglio, G Martinelli, F Pane, G Alimena, G Rosti, M Baccarani. Early Predictors Of Progression To Accelerated-Blastic Phase In Early Chronic Phase Chronic Myeloid Leukemia Patients Treated Frontline With Nilotinib-Based Regimens. *Haematologica* 2012; 97(S1): 77-78

**285.** G Rosti, G Gugliotta, M Breccia, F Castagnetti, L Levato, A Capucci, M Tiribelli, A Zaccaria, M Bocchia, A Cuneo, F Stagno, G Specchia, M Musso, B Martino, M Cedrone, T Intermesoli, F Palandri, **S Soverini**, C Baldazzi, S Durante, N Testoni, G Alimena, F Pane, G Saglio, G Martinelli, M Baccarani. Nilotinib 400 Mg Bid In Early Chronic Phase Chronic Myeloid Leukemia: Beyond 4 Years Results Remain Stable - The GIMEMA CML WP Trial CML0307. *Haematologica* 2012; 97(S1): 79

**286.** F Castagnetti, G Rosti, M Breccia, F Stagno, A Gozzini, G Specchia, A Capucci, B Martino, G Rege Cambrin, L Luciano, E Abruzzese, M Bocchia, F Cavazzini, M Tiribelli, I Pierri, G Gugliotta, F Palandri, S Durante, **S Soverini**, N Testoni, F Pane, G Saglio, G Alimena, G Martinelli, M Baccarani. Frontline Treatment Of Philadelphia Positive Chronic Myeloid Leukemia With Sequential Administration Of Nilotinib 400 Mg Twice Daily And Imatinib 400 Mg Once Daily: A Phase 2 Multicentric Study. *Haematologica* 2012; 97(S1): 97

**287.** A Ferrari, I Iacobucci, C Papayannidis, M Abbenante, C Venturi, F Cattina, V Guadagnuolo, **S Soverini**, M Vignetti, S Parisi, M Baccarani, G Martinelli. Set-Up Of A Multiplex Pcr To Rapidly Detect IKZF1 (Ikaros) Gene Breakpoint Deletion In Acute Lymphoblastic Leukemia (ALL). *Haematologica* 2012; 97(S1): 253

**288.** V Guadagnuolo, C Papayannidis, I Iacobucci, S Durante, C Terragna, E Ottaviani, F Cattina, M Abbenante, **S Soverini**, L Toni, W Levin, R Courtney, C Baldazzi, A Curti, M Baccarani, C Jamieson, J Cortes, V Oehler, K Mclachlan, T Van Arsdale, G Martinelli. Gas1 And Kif27 Genes Are Strongly Up-Regulated Biomarkers Of Hedgehog Inhibition (PF-04449913) On Leukemia Stem Cells In Phase I Acute Myeloid Leukemia And Chronic Myeloid Leukemia Treated Patients. *Haematologica* 2012; 97(S1): 438

**289.** Guadagnuolo V, Papayannidis C, Iacobucci I, Durante S, Terragna C, Ottaviani E, Cattina F, **Soverini S**, Levin W, Courtney R, Baccarani M, Jamieson C, Cortes J, Oehler V, Mclachlan K, Van Arsdale T, Martinelli G. PF-04449913 Specifically Targets The Hh Pathway In CD34+ Cells And Reverts The Multi Drug Resistance Mechanism. *Haematologica* 2012; 97(S2) : S19-S20

**290.** Castagnetti F, Gugliotta G, Palandri F, Breccia M, Levato L, Stagno F, Rege Cambrin G, Luciano L, Specchia G, Abruzzese E, Gozzini A, Martino B, Capucci A, Intermesoli T, Tiribelli M, Cedrone M, Cavazzini F, **Soverini S**, Testoni N, Saglio G, Martinelli G, Pane F, Alimena G, Rosti G, Baccarani M. High Eutos Score Is Predictive For Adverse Outcome In Early Chronic Phase CML Patients Treated With Nilotinib-Based Regimens. *Haematologica* 2012; 97(S2) : S39

**291.** Gugliotta G, Castagnetti F, Breccia M, Levato L, Capucci A, Tiribelli M, Zaccaria A, Bocchia M, Cuneo A, Stagno F, Specchia G, Musso M, Martino B, Cedrone M, Intermesoli T, Palandri F, **Soverini S**, Baldazzi C, Durante S, Testoni N, Alimena G, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Frontline Nilotinib 400 Mg Bid In Early Chronic Phase Chronic Myeloid Leukemia: Stable Results Beyond 4 Years - The GIMEMA CML WP Trial CML0307. *Haematologica* 2012; 97(S2) : S40

- 292.** Terragna C, Durante S, Astolfi A, Palandri F, Castagnetti F, Testoni N, Iacobucci I, **Soverini S**, Alimena G, Breccia M, Pane F, Saglio G, Rosti G, Baccarani M, Martinelli G. High Sokal Risk In Chronic Myeloid Leukemia Patients At Diagnosis Showed The Elevated Expression Of FBP, A Key-Enzyme Of Gluconeogenesis. *Haematologica* 2012; 97(S2) : S42
- 293.** Ferrari A, Iacobucci I, Papayannidis C, Trino S, Venturi C, Abbenante MC, Parisi S, Cattina F, **Soverini S**, Russo D, Pane F, Baccarani M, Martinelli G. Screening Of Tp53 (Tumor Protein 53) Mutations In B-Acute Lymphoblastic Leukemia (B-ALL) Reveals Missense Substitutions, Aberrant Exon-Junctions And Intron Retention Events. *Haematologica* 2012; 97(S2) : S54-S55
- 294.** Papayannidis C, Abbenante MC, Parisi S, Paolini S, Iacobucci I, Ottaviani E, Ferrari A, Guadagnuolo V, Sartor C, Curti A, **Soverini S**, De Benedittis C, Baldazzi C, Testoni N, Baccarani M, Martinelli G. PKC412 (Midostaurin) Is Safe And Highly Effective In Systemic Mastocytosis Patients: The Bologna Experience. *Haematologica* 2012; 97(S2) : S58-S59
- 295.** Castagnetti F, Rosti G, Breccia M, Gozzini A, Stagno F, Rege Cambrin G, Pierri I, Luciano L, Abruzzese E, Martino B, Capucci A, Bocchia M, Cavazzini F, Tiribelli M, Gugliotta G, Palandri F, Durante S, **Soverini S**, Testoni N, Saglio G, Alimena G, Specchia G, Pane F, Martinelli G, Baccarani M. Treatment Of Ph+ CML In Early Chronic Phase With Sequential Administration Of Nilotinib 400 Mg Twice Daily And Imatinib 400 Mg Once Daily: A GIMEMA Phase 2 Multicentric Study. *Haematologica* 2012; 97(S2) : S66-S67
- 296.** Gugliotta G, Castagnetti F, Palandri F, Breccia M, Levato L, Stagno F, Rege Cambrin G, Zaccaria A, Specchia G, Usala E, Gozzini A, Martino B, Capucci A, Pierri I, Tiribelli M, Bocchia M, Abruzzese E, **Soverini S**, Testoni N, Saglio G, Martinelli G, Pane F, Alimena G, Rosti G, Baccarani M. Early Evaluation Of The Risk Of Progression To Accelerated-Blastic Phase In Chronic Myeloid Leukemia Patients Treated Frontline With Nilotinib. *Haematologica* 2012; 97(S2) : S68-S69
- 297.** Russo D, Alimena G, Colombi C, Breccia M, **Soverini S**, Iacobucci I, Cattina F, Martinelli G, Testoni N, Liberati AM, Appolloni V, Tiribelli M, Fanin R, Ferrara F, Annunziata M, Trabacchi E, Vallisa D, De Vivo A, Castagnetti F, Fogli M, Durante S, Di Raimondo F, Stagno F, Carella AM, Pica G, Cortelezzi A, Iurlo A, Pregnò P, Vitolo U, Abruzzese E, De Fabritiis P, Longinotti M, Pardini S, Musolino C, Russo S, Gobbi M, Pierri I, Gaidano G, Lunghi M, Visani G, Barulli S, Cazzola M, Merante S, Skert C, Malagola M, Rosti G, Mandelli F, Baccarani M. Long-term Follow Up of Ph+ CML patients in complete cytogenetic response after interferon-based therapies in the imatinib era - GIMEMA CML0509 protocol. *Haematologica* 2012; 97(S2) : S71-S72
- 298.** Cattina F, Iacobucci I, Ottaviani E, **Soverini S**, Carella G, Malagoli A, Malagola M, Skert C, Bergonzi C, Filì C, Turra A, Bernardi S, De Benedittis C, Bochicchio MT, Guadagnuolo V, Martinelli G, Russo D. HLA-Typing By Pyrosequencing Technology: A New Promising Quickly And Accurate Approach Without Phase Ambiguities. *Haematologica* 2012; 97(S2) : S75-S76
- 299.** Castagnetti F, Gugliotta G, Palandri F, Breccia M, Stagno F, Levato L, Fava F, Luciano L, Intermesoli M, Cedrone AM, Carella F, Cavazzini D, Turri P, Avanzini I, Pierri M, Lunghi C, Venturi C, **Soverini S**, Testoni N, Alimena G, Saglio G, Martinelli G, Pane F, Baccarani M, Rosti G. The BCR-ABL1 Transcript Type Does Not Influence the Response and the Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. *Blood* 2012; 120(21): 1680.
- 300.** Castagnetti F, Gugliotta G, Breccia M, Specchia G, Abruzzese E, Levato L, Cavazzini A, Iurlo F, Stagno D, Ferrero F, Porretto B, Martino S, Rupoli T, Intermesoli C, Fava F, Palandri C, Venturi C, **Soverini S**, Testoni N, Alimena G, Pane F, Saglio G, Martinelli M, Baccarani M, Rosti G. The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-

Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. *Blood* 2012; 120(21): 1678.

**301.** G Rosti, G Gugliotta, F Castagnetti, M Breccia, L Levato, G Rege-Cambrin, A Capucci, M Tiribelli, A Zaccaria, M Bocchia, F Stagno, F Cavazzini, G Specchia, B Martino, M Cedrone, T Intermesoli, F Palandri, **S Soverini**, MT Bochicchio, N Testoni, G Alimena, F Pane, G Saglio, G Martinelli, M Bacarani. Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. *Blood* 2012; 120(21): 3784.

**302.** G Gugliotta, F Castagnetti, F Palandri, M Breccia, L Levato, F Stagno, G Rege-Cambrin, A Zaccaria, G Specchia, E Usala, A Gozzini, B Martino, A Capucci, P Musto, M Tiribelli, E Abruzzese, **S Soverini**, MT Bochicchio, N Testoni, G Saglio, G Martinelli, F Pane, G Alimena, M Bacarani, G Rosti. Cytogenetic and Molecular Responses At 3 Months Are Associated with a Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib. *Blood* 2012; 120(21): 2797.

**303.** I Iacobucci, D Erriquez, A Ferrari, C Papayannidis, C Venturi, S Trino, V Guadagnuolo, A Lonetti, F Cattina, E Ottaviani, MC Abbenante, S Parisi, **S Soverini**, D Russo, F Pane, M Bacarani, G Perini, G Martinelli. Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. *Blood* 2012; 120(21) 2522.

**304.** A Brouckova, **S Soverini**, C De Benedittis, H Klamova, C Salek, M Trneny, M Bacarani, G Martinelli, and K Machova Polakova. Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation. *Blood* 2012; 120(21): 1396.

**305.** C Papayannidis, M Abbenante, S Parisi, S Paolini, I Iacobucci, F Frabetti, E Ottaviani, A Ferrari, V Guadagnuolo, C Sartor, **S Soverini**, C De Benedittis, C Baldazzi, N Testoni, M Bacarani, and G Martinelli. PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience. *Blood* 2012; 120: 1749.

**306.** I Iacobucci, A Ferrari, A Kohlmann, C Papayannidis, C Venturi, M Perricone, MC Fontana, P Bresciani, S Chiaretti, M Abbenante, S Paolini, Sarah Parisi, F Cattina, **S Soverini**, D Russo, F Pane, R Foà, M Luppi, T Haferlach, M Bacarani, and G Martinelli. Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL). *Blood* 2012; 120(21): 2497.

**307.** C Papayannidis, P Fazi, A Piciocchi, F Di Raimondo, G Pizzolo, AM Carella, M Cazzola, A Cuneo, P Leoni, M Luppi, E Morra, G Specchia, E Angelucci, M Bocchia, R Fanin, G Saglio, D Vallisa, S De Simone, A Vitale, I Iacobucci, **S Soverini**, A Ferrari, C Venturi, C De Benedittis, N Testoni, A Curti, S Paolini, M Fogli, G Martinelli, M Bacarani. Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. *Blood* 2012; 120(21): 2601.

**308.** C Quintarelli, B De Angelis, S Errichiello, S Caruso, N Esposito, L Luciano, S Paratore, C Galimberti, **S Soverini**, C Terragna, D Cilloni, G Saglio, G Martinelli, F Giles, A Hochhaus, F Pane. Analysis of Bone Marrow Microenvironment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib. *Blood* 2012; 120(21): 2795.

**309.** C Quintarelli, B De Angelis, S Errichiello, S Caruso, N Esposito, M Raia, S Pagliuca, M Picardi, A Risitano, L Luciano, **S Soverini**, G Martinelli, G Saglio, F Pane. Synergy between JAK inhibitor ruxolitinib and tyrosine kinase inhibitors (TKIs) to overcome drug resistance-

related bone marrow (BM) stroma microenvironment in chronic myeloid leukemia (CML). *Haematologica* 2013; 98(S1):S49

**310.** E Leo, M Mancini, S Luatti, F Castagnetti, E Borsi, I Iacobucci, **S Soverini**, C De Benedittis, M Santucci, G Martinelli. Reduced expression of Chibby is a component of beta-Catenin activation in chronic myeloid leukemia stem cells. *Haematologica* 2013; 98(S1):S50

**311.** C De Benedittis, **S Soverini**, K Polakova, A Brouckova, F Castagnetti, G Gugliotta, F Palandri, C Papayannidis, H Klamova, P Bresciani, V Coluccio, M Salvucci, M Tiribelli, T Interimesoli, G Binotto, I Iacobucci, C Venturi, M Luppi, E Ottaviani, M Bochicchio, F Cattina, M Manuela, E Leo, T Haferlach, A Kohlmann, D Russo, G Rosti, M Baccarani, M Cavo, G Martinelli. Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35ins insertion/truncation higher than expected. *Haematologica* 2013; 98(S1):S52

**312.** G Gugliotta, F Castagnetti, F Palandri, M Breccia, L Levato, F Stagno, L Luciano, A Zaccaria, A Rossi, E Usala, A Gozzini, A Carella, A Capucci, P Musto, M Tiribelli, E Abruzzese, P Avanzini, **S Soverini**, MT Bochicchio, N Testoni, G Alimena, F Pane, G Martinelli, M Cavo, G Saglio, M Baccarani, G Rosti. Early cytogenetic and molecular responses and long-term outcome in early chronic phase chronic myeloid leukemia (cml) patients treated with nilotinib. *Haematologica* 2013; 98(S1):S58

**313.** F Castagnetti, G Gugliotta, M Breccia, F Albano, E Abruzzese, L Levato, F Cavazzini, A Iurlo, F Stagno, D Ferrero, F Porretto, B Martino, S Rupoli, T Interimesoli, C Fava, I Pierri, F Palandri, C Venturi, **S Soverini**, S Luatti, G Alimena, F Pane, G Martinelli, G Saglio, M Cavo, M Baccarani, G Rosti. Clinical significance of early molecular response in chronic myeloid leukemia patients treated frontline with imatinib mesylate. *Haematologica* 2013; 98(S1):S59

**314.** G Gugliotta, F Castagnetti, M Breccia, L Levato, G Rege-Cambrin, A Capucci, M Tiribelli, A Zaccaria, M Bocchia, F Stagno, F Cavazzini, G Specchia, B Martino, M Cedrone, T Interimesoli, D Turri, F Palandri, **S Soverini**, M Bochicchio, N Testoni, G Alimena, F Pane, G Martinelli, M Cavo, G Saglio, M Baccarani, G Rosti. High rate of deep molecular response after 5 years of nilotinib 400 mg bid in early chronic phase chronic myeloid leukemia - update of the GIMEMA CML WP trial CML0307. *Haematologica* 2013; 98(S1):S61

**315.** F Cattina, S Bernardi, I Iacobucci, **S Soverini**, E Ottaviani, G Carella, A Malagoli, M Malagola, C Skert, C Bergonzi, C Fili, E Alghisi, S Perucca, A Di Palma, C De Benedittis, M Teresa Bochicchio, V Guadagnuolo, G Martinelli, D Russo. Pyrosequencing is a new promising approach to perform HLA typing in a quickly, simple and accurate way. *Haematologica* 2013; 98(S1):S366

**316.** A Brouckova, **S Soverini**, V Kulvait, A Kohlmann, M Jaruskova, C de Benedittis, H Klamova, M Trneny, T Haferlach, M Baccarani, G Martinelli, K Polakova. Ultra-deep sequencing with computed thresholds for sensitive mutation analysis in the kinase domain of BCR-ABL: focused on deep mutation detection in chronic myeloid leukemia in chronic phase. *Haematologica* 2013; 98(S1):S452

**317.** F Cattina, C Skert, S Bernardi, E Ottaviani, M Bochicchio, I Iacobucci, **S Soverini**, F Bonifazi, M Arpinati, M Motta, E Toffoletti, D Damiani, A Santoro, F Fabbiano, D Pastore, G Specchia, G Console, B Martino, V Guadagnuolo, C De Benedittis, M Malagola, C Bergonzi, C Fili, A Turra, R Ribolla, V Cancelli, E Alghisi, S Perucca, A Di Palma, G Martinelli, D Russo. Multi-genotype of minor histocompatibility antigens (MHAGS) to study graft versus host disease (GVHD) and graft versus leukemia (GVL) effects in allogeneic stem cell transplantation. *Haematologica* 2013; 98(S1):S491

**318.** A Ferrari, I Iacobucci, C Papayannidis, C Venturi, M Abbenante, S Parisi, S Paolini, C Sartor, A Di Rora', E Ottaviani, V Guadagnuolo, **S Soverini**, F Cattina, D Russo, M

Baccarani, M Cavo, G Martinelli. Characterization of MDM2/P53 axis in adult acute lymphoblastic leukemia (ALL). *Haematologica* 2013; 98(S1):S497

**319.** P Couceiro, **S Soverini**, M Ferreira-Teixeira, P Freitas-Tavares, P Santos. Screening of ABL kinase domain mutations using next generation sequencing in chronic myeloid leukaemia: impact in the response to treatment with tyrosine kinase inhibitors. *Haematologica* 2013; 98(S1):S556

**320.** C Papayannidis, A Piciocchi, A Vitale, I Iacobucci, **S Soverini**, F Di Raimondo, S Paolini, G Pizzolo, AM Carella, M Cazzola, A Cuneo, P Leoni, M Luppi, E Morra, G Specchia, L Elia, R Foa, M Baccarani, G Martinelli. Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408. *J Clin Oncol* 31, 2013 (suppl; abstr 7025).

**321.** C Papayannidis, M Abbenante, S Parisi, S Paolini, I Iacobucci, E Ottaviani, A Ferrari, V Guadagnuolo, C Sartor, **S Soverini**, C De Benedittis, C Baldazzi, M Baccarani, M Cavo, G Martinelli. PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience. *Cancer Res* 2013;73(S8):2082

**322.** Papayannidis C, Sartor C, Iacobucci I, Abbenante MC, **Soverini S**, De Benedittis C, Conficoni A, Bochicchio MT, Ferrari A, Guadagnuolo V, Ottaviani E, Testoni N, Baldazzi C, Luatti S, Parisi S, Paolini S, Clissa C, Di Bartolomeo P, Di Lorenzo R, Fanin R, Cimino G, Martinelli G. Ponatinib is safe and active in patients with relapsed/refractory philadelphia positive acute lymphoblastic leukemia (PH+ ALL) harbouring T315I mutation: the Bologna experience. *Haematologica* 2013; 98(S3):S21

**323.** Castagnetti F, Gugliotta G, Breccia M, Abruzzese E, Intermesoli T, Capucci A, Iurlo A, Martino B, Pregno P, Stagno F, Cavazzini F, Annunziata M, Ferrero D, Palandri F, Venturi C, **Soverini S**, Testoni N, Specchia G, Alimena G, Saglio G, Pane F, Martinelli G, Cavo M, Baccarani M, Rosti G. Imatinib mesylate for newly diagnosed patients with chronic myeloid leukemia in chronic phase: a long-term analysis by the GIMEMA CML WORKING party. *Haematologica* 2013; 98(S3):S43.

**324.** Bernardi S, Cattina F, Iacobucci I, **Soverini S**, Ottaviani E, Carella G, Malagoli A, Malagola M, Skert C, Bergonzi C, Fili C, Alghisi E, Perucca S, Di Palma A, De Benedittis C, Bochicchio MT, Guadagnuolo V, Martinelli G, Russo D. A new promising approach to perform HLA typing in a quickly, simple and accurate way: the pyrosequencing. *Haematologica* 2013; 98(S3):S89.

**325.** De Matteis G, Zanotti R, Colarossi S, De Benedittis C, Benati M, Paviati E, Bonifacio M, Perbellini O, Bonadonna P, Martinelli G, Pizzolo G, **Soverini S**. Improved detection of the C-KIT D816V mutation using allele-specific ARMS real time PCR assay allows a finer recognition of patients with indolent systemic mastocytosis. *Haematologica* 2013; 98(S3):S90.

**326.** Cattina F, Skert C, Bernardi S, Malagola M, Ottaviani E, Bochicchio MT, Iacobucci I, **Soverini S**, Bonifazi F, Bandini G, Arpinati M, Motta MR, Toffoletti E, Damiani D, Santoro A, Fabbiano F, Pastore D, Specchia G, Console G, Martino B, Carella G, Malagoli A, Guadagnuolo V, De Benedittis C, Bergonzi C, Fili C, Turra A, Ribolla R, Cancelli V, Alghisi E, Perucca A, Di Palma A, Martinelli G, Russo D. multi-genotyping of minor histocompatibility antigens (MHAGS) to evaluate their role in determining graft versus host disease (GVHD) and graft versus leukemia (GVL) effects in allogeneic stem cell transplantation. *Haematologica* 2013; 98(S3):S98.

**327.** Russo D, Malagola M, Martinelli G, Skert C, **Soverini S**, Iacobucci I, De Vivo A, Testoni N, Castagnetti F, Gugliotta G, Turri D, Bergamaschi M, Pregno P, Pungolino E, Stagno F, Breccia M, Martino B, Intermesoli T, Fava C, Abruzzese E, Tiribelli M, Bigazzi C, Cesana BM, Rosti G, Baccarani M. Cytogenetic response, molecular response and outcome

of elderly Ph+ CML patients with stable complete cytogenetic response after 4-years of intermittent treatment with imatinib (INTERIM). *Haematologica* 2013; 98(S3):S125.

**328.** De Benedittis C, **Soverini S**, Machova Polakova K, Brouckova A, Castagnetti F, Gugliotta G, Palandri F, Papayannidis C, Klamova H, Bresciani P, Coluccio V, Salvucci M, Tiribelli M, Binotto G, Intermesoli T, Iacobucci I, Venturi C, Luppi M, Ottaviani E, Bochicchio MT, Cattina F, Mancini M, Leo E, Haferlach T, Kohlmann A, Russo D, Rosti G, Baccarani M, Cavo M, Martinelli G. High frequency of small insertions and deletions in the BCR-ABL kinase domain revealed by ultra-deep sequencing. *Haematologica* 2013; 98(S3):S128.

**329.** Peluso AL, Quintarelli C, Seneca E, Cosenza MR, Musella F, Cacciapuoti V, Esposito N, Izzo B, Muccioli-Casadei G, Pisano I, De Angelis B, Annunziata M, Sessa U, Nunziata G, Palmieri F, Palmieri R, Danise P, Pezzullo L, Serio B, Esposito MR, Villa MR, Spiezia M, Vallone R, De Falco G, Sica A, Camera A, Iovine M, Svanera L, **Soverini S**, Martinelli G, Luciano L, Pane F. Clinical outcome of chronic myeloid leukemia (CML) patients with deletion and insertion events (DI) in the tyrosine kinase domain of BCR-ABL. *Haematologica* 2013; 98(S3):S176.

**330.** Leo E, Mancini M, Luatti S, Castagnetti F, Gugliotta G, Borsi E, **Soverini S**, De Benedittis C, Santucci MA, Martinelli G. Reduced expression of Chibby is a component of beta-Catenin activation in chronic myeloid leukemia stem cells. *Haematologica* 2013; 98(S3):S178.

**331.** Gugliotta G, Castagnetti F, Palandri F, Breccia M, Levato L, Rege-Cambrin G, Luciano L, Zaccaria A, Bocchia M, Russo Rossi A, Usala E, Gozzini A, Cedrone M, Tiribelli M, Abruzzese E, Avanzini P, **Soverini S**, Bochicchio MT, Testoni N, Pane F, Saglio G, Alimena G, Martinelli G, Cavo M, Baccarani M, Rosti G. The chronic myeloid leukemia italian registry of nilotinib: a GIMEMA CML WP analysis of the outcome of patients treated frontline with nilotinib-based regimens. *Haematologica* 2013; 98(S3):S180.

**332.** Mancini M, Leo E, Castagnetti F, Gugliotta G, Luatti S, Borsi E, **Soverini S**, De Benedittis C, Santucci MA, Martinelli G. Reduced expression of chibby in chronic myeloid leukemia arises from the BCR-ABL effects on its stability. *Haematologica* 2013; 98(S3):S181.

**333.** MW Deininger, NP Shah, JE Cortes, D-W Kim, FE Nicolini, M Talpaz, M Baccarani, MC Muller, J Li, S Lustgarten, T Clackson, CD Turner, FG Haluska, G Hodgson, VM Rivera, F Guilhot, JM Goldman, HM Kantarjian, **S Soverini**, A Hochhaus, TP Hughes, and S Branford. Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML). *Blood* 2013; 122(21):652

**334.** K Machova Polakova, V Kulvait, J Linhartova, A Brouckova, **S Soverini**, M Jaruskova, C De Benedittis, T Haferlach, M Baccarani, G Martinelli, A Kohlmann, and H Klamova. Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia. *Blood* 2013; 122(21):3987

**335.** A Kohlmann, G Martinelli, M Alikian, V Artusi, B Auber, M Belickova, I Bronzini, G Cazzaniga, S Chiaretti, T Ernst, M Fuellgrabe, C Gabriel, JM Hernandez, JH Jansen, I Iacobucci, T Lion, L Lode, J Martinez-Lopez, KI Mills, M Mossner, K Machova Polakova, NA Porret, S Pospisilova, C Preudhomme, M Sayitoglu, **S Soverini**, O Spinelli, C Thiede, P Vandenberghe, JE Yeoh, A Hochhaus, T Haferlach. The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories. *Blood* 2013; 122(21):743

- 336.** F Castagnetti, G Gugliotta, M Breccia, A Iurlo, E Abruzzese, F Albano, PG Vigneri, F Cavazzini, E Orlandi, P Pregno, M Annunziata, P Galieni, E Montefusco, C Fava, F Palandri, C Venturi, **S Soverini**, N Testoni, G Alimena, G Saglio, F Pane, G Martinelli, M Cavo, M Bacarani, G Rosti. The e13a2 BCR-ABL1 Fusion Transcript Is a Candidate Adverse Prognostic Factor In Chronic Myeloid Leukemia Patients Treated Frontline With Imatinib Mesylate. *Blood* 2013; 122(21):1486
- 337.** G Gugliotta, F Castagnetti, M Breccia, L Levato, G Rege-Cambrin, L Luciano, F Palandri, A Zaccaria, M Bocchia, A Russo Rossi, E Usala, A Gozzini, M Cedrone, M Tiribelli, E Abruzzese, P Avanzini, **S Soverini**, MT Bochicchio, N Testoni, G Alimena, F Pane, G Saglio, G Martinelli, M Cavo, M Bacarani, and G Rosti. 4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. *Blood* 2013; 122(21):4000
- 338.** C De Benedittis, **S Soverini**, K Machova Polakova, A Brouckova, F Castagnetti, G Gugliotta, F Palandri, C Papayannidis, H Klamova, P Bresciani, M Salvucci, G Binotto, T Intermesoli, I Iacobucci, C Venturi, M Luppi, E Ottaviani, MT Bochicchio, Manuela Mancini, Elisa Leo, T Haferlach, A Kohlmann, D Russo, G Rosti, M Bacarani, M Cavo, G Martinelli. Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain. *Blood* 2013 122(21):3986
- 339.** F Castagnetti, G Gugliotta, M Breccia, G Specchia, T Intermesoli, A Capucci, B Martino, M Tiribelli, G Binotto, E Abruzzese, F Stagno, Pietro Leoni, D Ferrero, Filippo Gherlinzoni, F Palandri, C Venturi, MT Bochicchio, **S Soverini**, G Alimena, G Martinelli, F Pane, G Saglio, M Cavo, M Bacarani, G Rosti. Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. *Blood* 2013; 122(21):258
- 340.** C Papayannidis, C De Benedittis, **S Soverini**, I Iacobucci, MC Abbenante, C Sartor, MT Bochicchio, A Ferrari, C Venturi, V Robustelli, A Ghelli Luserna Di Rorà, V Guadagnuolo, E Ottaviani, N Testoni, C Baldazzi, S Luatti, S Parisi, S Paolini, Cristina Clissa, Alberto Conficoni, F Frabetti, E Lani, S Piccari, P Di Bartolomeo, R Di Lorenzo, R Fanin, G Cimino, G Martinelli. Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harboring T315I Mutation: The Bologna Experience. *Blood* 2013; 122(21):3911
- 341.** F Cattina, C Skert, S Bernardi, M Malagola, E Ottaviani, MT Bochicchio, I Iacobucci, **S Soverini**, F Bonifazi, G Bandini, M Arpinati, M R Motta, E Toffoletti, D Damiani, A Santoro, F Fabbiano, D Pastore, G Specchia, G Console, M Bruno, G Carella, A Malagoli, V Guadagnuolo, C De Benedittis, C Bergonzi, C Filì, A Turra, R Ribolla, V Cancelli, E Alghisi, S Perucca, A Di Palma, G Martinelli, D Russo. Multi-genotyping of Minor Histocompatibility Antigens (MHAGS) in allogeneic stem cell transplantation and their role in determining Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) effect. *Bone Marrow Transplant* 2014;49(1s): S151.
- 342.** S Bernardi, F Cattina, **S Soverini**, E Ottaviani, G Carella, A Malagoli, M Malagola, C Skert, C Filì, E Alghisi, S Perucca, A Di Palma, C De Benedittis, M T Bochicchio, C Bergonzi, G Martinelli, D Russo. The pyrosequencing: a new promising approach to perform HLA typing and select the stem cell donor in a quickly, simple and accurate way. *Bone Marrow Transplant* 2014;49(1s): S210.
- 343.** C Papayannidis, **S Soverini**, C De Benedittis, MC Abbenante, C Sartor, I Iacobucci, C Baldazzi, E Ottaviani, A Ferrari, V Guadagnuolo, A Conficoni, S Paolini, S Parisi,

F Frabetti, S Piccari, S Grilli, E Lani, G Martinelli. PKC412 (Midostaurin) is safe and highly effective in systemic mastocytosis patients: Follow up of a single-center Italian compassionate use. *Cancer Res* 2014;74(19S):746

**344.** C Papayannidis, C De Benedittis, **S Soverini**, I Iacobucci, MC Abbenante, C Sartor, MT Bochicchio, A Ferrari, C Venturi, V Robustelli, A Ghelli Luserna di Rorà, V Guadagnuolo, E Ottaviani, N Testoni, C Baldazzi, S Luatti, S Parisi, S Paolini, A Conficoni, F Frabetti, E Lani, S Piccari, P Di Bartolomeo, R Di Lorenzo, R Fanin, G Cimino, Ciceri, G Martinelli. Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience. *Cancer Res* 2014;74(19S):CT312

**345.** G Martinelli, C Papayannidis, A Piciocchi, A Vitale, I Iacobucci, **S Soverini**, F Di Raimondo, S Paolini, M Bonifacio, AM Carella, M Cazzola, A Cuneo, P Leoni, M Luppi, E Morra, G Specchia, L Elia, R Foà, M Baccarani. Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408. *Cancer Res* 2014;74(19S):5552

**346.** V Guadagnuolo, E Imbrogno, A Ghelli Luserna di Rorà, A Padella, G Simonetti, E Ottaviani, C Papayannidis, I Iacobucci, A Ferrari, **S Soverini**, G Martinelli. Clec12a: A new AML stem cell-associated antigen. *Cancer Res* 2014;74(19S):3886

**347.** C Papayannidis, **S Soverini**, C De Benedittis, M Rondoni, M Abbenante, C Sartor, I Iacobucci, F Volpato, C Baldazzi, E Ottaviani, A Ferrari, V Guadagnuolo, A Conficoni, S Paolini, S Parisi, F Frabetti, S Piccari, E Lani, G Martinelli. PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use. *J Clin Oncol* 32:5s, 2014 (suppl; abstr 7113).

**348.** C Quintarelli, B De Angelis, S Errichiello, S Caruso, N Esposito, L Luciano, **S Soverini**, C Terragna, D Cilloni, G Saglio, G Martinelli, F Giles, A Hochhaus, F Pane. Bone marrow (BM) microenvironment factors as early markers of response in patients with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) treated with Nilotinib. *Haematologica* 2014;99(S1):66

**349.** G Gugliotta, F Castagnetti, M Breccia, L Levato, C Fava, L Luciano, A Zaccaria, A Russo Rossi, E Usala, A Gozzini, P Vigneri, M Cedrone, M Tiribelli, E Abruzzese, P Avanzini, F Palandri, **S Soverini**, G Alimena, F Pane, G Martinelli, M Cavo, G Saglio, M Baccarani, G Rosti. Four-year outcome of 215 newly diagnosed chronic myeloid leukemia patients treated with nilotinib frontline: a GIMEMA CML working party analysis. *Haematologica* 2014;99(S1):333

**350.** I Iacobucci, A Ferrari, M Perricone, V Robustelli, C Papayannidis, R Zuntini, MC Abbenante, C Venturi, C Baldazzi, E Ottaviani, B Giannini, A Ghelli Luserna Di Rorà, A Lonetti, A Vitale, L Elia, V Guadagnuolo, N Testoni, **S Soverini**, S Paolini, S Parisi, C Sartor, F Cattina, D Russo, R Foà, S Chiaretti, A Kohlmann, G Martinelli. Complex genetic heterogeneity influences prognosis in adult b-cell precursor acute lymphoblastic leukemia negative for recurrent fusion genes. *Haematologica* 2014;99(S1):271

**351.** J Linhartova, L Hovorkova, **S Soverini**, A Benesova, M Jaruskova, H Klamova, J Zuna, K Machova Polakova. Genomic BCR-ABL1 fusion characterisation and SNPs identification upstream and downstream of the breakpoints in BCR and ABL1 genes of CML patients using next generation sequencing. *Haematologica* 2014;99(S1):342

**352.** G Martinelli, C Papayannidis, A Piciocchi, A Vitale, I Iacobucci, **S Soverini**, F Di Raimondo, S Paolini, G Pizzolo, A M Carella, M Cazzola, A Cuneo, P Leoni, M Luppi, E Morra, G Specchia, L Elia, R Foà, M Baccarani. Extremely high rate of complete haematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of nilotinib and imatinib. *Haematologica* 2014;99(S1):277



- 353.** C Papayannidis, **S Soverini**, C De Benedittis, M C Abbenante, C Sartor, I Iacobucci, C Baldazzi, E Ottaviani, A Ferrari, V Guadagnuolo, G Simonetti, A Conficoni, S Paolini, S Parisi, F Frabetti, S Piccari, E Lani, G Martinelli. PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis patients: follow up of a single-center italian compassionate use. *Haematologica* 2014;99(S1):391
- 354.** F Castagnetti, G Gugliotta, M Breccia, G Specchia, T Intermesoli, A Iurlo, B Martino, G Binotto, F Cavazzini, E Abruzzese, F Stagno, P Leoni, D Ferrero, G Rege-Cambrin, M Bocchia, F Gherlinzoni, F Palandri, **S Soverini**, G Alimena, F Pane, G Martinelli, M Cavo, G Saglio, M Baccarani, G Rosti. Declining role of disease transformation as a cause of death in chronic myeloid leukemia treated with imatinib in early chronic phase: a long-term analysis by the GIMEMA CML WP. *Haematologica* 2014;99(S1):73
- 355.** M W Deininger, N P Shah, J E Cortes, DW Kim, F E Nicolini, M Talpaz, M Baccarani, M C Müller, J Li, S Lustgarten, T Clackson, C D Turner, F G Haluska, G Hodgson, V M Rivera, F Guilhot, H M Kantarjian, **S Soverini**, A Hochhaus, T P Hughes, S Branford. Longer-term follow-up of the impact of baseline (BL) mutations on ponatinib response and end of treatment (EOT) mutation analysis in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML). *Haematologica* 2014;99(S1):533
- 356.** Caruso S, Quintarelli C, De Angelis B, Errichiello S, Esposito N, Luciano L, **Soverini S**, Terragna C, Cilloni D, Saglio G, Martinelli G, Giles F, Hochhaus A, Pane F. Bone marrow (BM) microenvironment factors as early markers of response in patients with newly diagnosed chronic phase chronic myelogenous leukemia (CML-CP) treated with nilotinib. *Haematologica* 2014;99(S2):S54
- 357.** Castagnetti F, Gugliotta G, Breccia M, Specchia G, Intermesoli T, Iurlo A, Martino B, Binotto G, Cavazzini F, Abruzzese E, Stagno F, Leoni P, Ferrero D, Rege-Cambrin G, Bocchia M, Gherlinzoni F, Bochicchio MT, **Soverini S**, Alimena G, Pane F, Saglio G, Cavo M, Martinelli G, Baccarani M, Rosti G. Predictors of deep molecular response in chronic myeloid leukemia patients treated frontline with imatinib mesylate: an analysis by the GIMEMA CML WP. *Haematologica* 2014;99(S2):S54
- 358.** De Benedittis C, **Soverini S**, Papayannidis C, Dal Pero F, Zazzeroni L, Rondoni M, Zanotti R, De Matteis G, Merante S, Elena C, Cavo M, Martinelli G. Ultra-deep sequencing allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis. *Haematologica* 2014;99(S2):S92
- 359.** D Russo, G Martinelli, M Malagola, V Cancelli, C Skert, **S Soverini**, I Iacobucci, D Turri, S Mirto, M Gobbi, I Pierri, U Vitolo, P Pregno, M Fogli, N Testoni, A De Vivo, F Castagnetti, E Morra, E Pungolino, F Di Raimondo, F Stagno, G Alimena, M Breccia, F Nobile, B Martino, A Rambaldi, T Intermesoli, G Saglio, G Rege Cambrin, G Visani, G Nicolini, P de Fabritiis, E Abruzzese, R Fanin, M Tiribelli, P Galieni, C Bigazzi, G Specchia, E Angelucci, E Usala, C Musolino, S Russo, G Gaidano, M Lunghi, F Lauria, M Bocchia, F Rodeghiero, A D'Emilio, A Bosi, V Santini, G Quarta, M Girasoli, G Fioritoni, R Di Lorenzo, BM Cesana, G Rosti. Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML. *Blood* 2014;124(21):1794
- 360.** F Castagnetti, G Gugliotta, M Breccia, B Martino, G Rossi, F Stagno, D Turri, M Tiribelli, E Trabacchi, A Isidori, I Pierri, G Leonardi, P Pregno, AM Carella, MT Bochicchio, N Testoni, **S Soverini**, G Specchia, G Alimena, M Cavo, G Martinelli, F Pane, G Saglio, M Baccarani, G Rosti. Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. *Blood* 2014;124(21):4532
- 361.** L Pieri, P Bonadonna, C Elena, C Papayannidis, FI Grifoni, M Rondoni, S Girlanda, M Mauro, D Magliacane, EM Elli, ML Iorno, M Severino, F Almerigogna, F Scarfi, M

- Bonifacio, O Perbellini, A Artuso, **S Soverini**, C De Benedittis, S Muratori, L Lunardon, V Cova, G Cortellini, A Bosi, A Cortelezzi, G Martinelli, M Triggiani, S Merante, AM Vannucchi, R Zanotti. A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. *Blood* 2014;124(21):3188
- 362.** C De Benedittis, **S Soverini**, C Papayannidis, M Rondoni, S Colarossi, F Dal Pero, L Zazzeroni, R Zanotti, G De Matteis, S Merante, C Elena, FI Grifoni, M Bonifacio, O Perbellini, G Specchia, L Pagano, D Gangemi, P Bonadonna, L Pieri, M Cavo, G Martinelli. Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis. *Blood* 2014;124(21):1856
- 363.** G Gugliotta, F Castagnetti, M Breccia, L Levato, G Rege-Cambrin, L Luciano, M Bocchia, A Russo Rossi, E Usala, M Salvucci, A Gozzini, G Binotto, M Cedrone, E Abruzzese, P Avanzini, C Venturi, N Testoni, **S Soverini**, G Alimena, M Cavo, G Martinelli, F Pane, G Saglio, M Baccarani, G Rosti. Five-Year Outcome of 215 Newly Diagnosed Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib-Based Regimens: A Gimema CML Working Party Analysis. *Blood* 2014;124(21):3141
- 364.** M Mancini, **S Soverini**, E Leo, F Castagnetti, C De Benedittis, G Gugliotta, G Rosti, M A Santucci, M Cavo, G Martinelli. Aurora Kinase a: A New Component of Imatinib Resistance in Chronic Myeloid Leukemia. *Blood* 2015; 126(23):1573.
- 365.** G Simonetti, A Padella, Í Faria do Valle, G Fontanarosa, E Zago, Marianna Garonzi, C Papayannidis, MC Abbenante, G Marconi, V Guadagnuolo, MC Fontana, S Bruno, A Ferrari, E Zuffa, E Franchini, A Astolfi, E Dan, B Sinigaglia, I Iacobucci, **S Soverini**, M Cavo, E Ottaviani, A Ferrarini, M Delledonne, D Remondini, G Martinelli. Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia. *Blood* 2015; 126(23):3837.
- 366.** MC Fontana, V Guadagnuolo, C Papayannidis, G Simonetti, A Padella, A Ferrari, M Manfrini, I Faria do Valle, B Santacroce, M Perricone, G Marconi, E Ottaviani, J D. Milosevic Feenstra, D Chen, N C.C. Them, **S Soverini**, D Remondini, G Musuraca, M Cavo, R Kralovics, Giovanni Martinelli. Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia. *Blood* 2015; 126(23):2600.
- 367.** F Castagnetti, G Gugliotta, M Breccia, F Stagno, A Iurlo, F Albano, E Abruzzese, B Martino, L Levato, T Intermesoli, P Pregno, G Rossi, F Gherlinzoni, P Leoni, F Cavazzini, D Ferrero, E Usala, M Bocchia, M Tiribelli, E Montefusco, S Sica, C Venturi, **S Soverini**, M Cavo, G Alimena, G Martinelli, F Pane, G Saglio, M Baccarani, G Rosti. Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. *Blood* 2015; 126(23):2792.
- 368.** S Errichiello, S Caruso, C Quintarelli, B De Angelis, N Pugliese, R Della Pepa, B Izzo, L Luciano, **S Soverini**, C Terragna, G Martinelli, D Cilloni, G Saglio, M Annunziata, G Caocci, L Levato, E Usala, M Breccia, AM Carella, N Cascavilla, M D'Adda, C Galimberti, F Giles, A Hochhaus, F Pane. Bone Marrow (BM) Microenvironment Factors As Early Markers of Response in Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated with Nilotinib. *Blood* 2015; 126(23):1570.
- 369.** A Ghelli Luserna Di Rorà, I Iacobucci, E Imbrogno, E Derenzini, A Ferrari, V Guadagnuolo, V Robustelli, **S Soverini**, C Papayannidis, MC Abbenante, M Cavo, Giovanni Martinelli. The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia. *Blood* 2015; 126(23):2478.
- 370.** VM Rivera, S Branford, F E. Nicolini, JR Pritchard, JM Gozgit, W Kern, D Milojkovic, S Claudiani, MC Muller, SK Tantravahi, MW Deininger, M Heinrich, **S Soverini**,

M Baccarani, JP Radich, E Jabbour, JE Cortes, G Etienne, Torsten Haferlach. A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients. *Blood* 2015; 126(23):2790.

**371.** A Padella, G Simonetti, G Paciello, A Ferrari, E Zago, C Baldazzi, V Guadagnuolo, C Papayannidis, V Robustelli, E Imbrogno, N Testoni, G Musuraca, **S Soverini**, M Delledonne, I Iacobucci, CT Storlazzi, E Ficarra, Giovanni Martinelli. RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia. *Blood* 2015; 126(23):3627.

**372.** A Ghelli Luserna Di Rora, I Iacobucci, N Beeharry, **S Soverini**, C Papayannidis, G Martinelli, TJ Yen. The Wee1 inhibitor, MK-1775, sensitizes leukemia cells to different antineoplastic drugs interfering with DNA-damage response pathway. *Blood* 2015; 126(23):1276.

**373.** G Marconi, C Papayannidis, F Mosna, M Gottardi, G Simonetti, **S Soverini**, A Curti, E Zuffa, MC Abbenante, S Parisi, S Paolini, C Sartor, E Franchini, E Ottaviani, C Venturi, MC Fontana, A Padella, V Guadagnuolo, MT Bochicchio, A Ferrari, N Testoni, C Baldazzi, M Manfrini, D Capelli, P Galieni, A Piccin, Giuseppe Visani, F Rodeghiero, C Tecchio, F Gherlinzoni, M Cavo, G Martinelli. Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients. *Blood* 2015; 126(23):3198

**374.** C Papayannidis, A Candoni, M Malagola, G Marconi, M Manfrini, G Simonetti, E Zuffa, MC Abbenante, S Parisi, S Paolini, C Sartor, E Franchini, E Ottaviani, C Venturi, MC Fontana, A Padella, V Guadagnuolo, MT Bochicchio, A Ferrari, **S Soverini**, N Testoni, C Baldazzi, R Fanin, D Russo, M Cavo, G Martinelli. Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia. *Blood* 2015; 126(23):2513.

**375.** G Simonetti, A Padella, Í Faria do Valle, M Manfrini, C Papayannidis, C Baldazzi, MC Fontana, V Guadagnuolo, A Ferrari, E Zago, M Garonzi, S Bernardi, E Ottaviani, A Astolfi, MC Abbenante, G Marconi, **S Soverini**, Michele Cavo, N Testoni, A Ferrarini, M Delledonne, T Haferlach, D Remondini, Ilaria Iacobucci, G Martinelli. A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium. *Blood* 2015; 126(23):3840.

**376.** Sartor, Chiara ; Papayannidis, Cristina ; Piciocchi, Alfonso ; Vitale, Antonella ; Iacobucci, Ilaria ; **Soverini, Simona** ; Lollini, Pier Luigi ; Di Raimondo, Francesco ; Paolini, Stefania ; Bonifacio, Massimiliano ; Carella, Angelo Michele ; Cazzola, Mario ; Cuneo, Antonio ; Leoni, Pietro ; Luppi, Mario ; Morra, Enrica ; Specchia, Giorgina ; Elia, Loredana ; Foà, Robin ; Baccarani, Michele ; Martinelli, Giovanni. Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph plus acute lymphoblastic leukemia: the GIMEMA experience. *Cancer Res* 2015;75(S15):5491

**377.** F Castagnetti , G Gugliotta , M Breccia , G Specchia , G Binotto , E Abruzzese , A Iurlo , P Vigneri , F Cavazzini , TIntermesoli , Dario Ferrero , B Martino , P Leoni , M Bocchia , G Rege-Cambrin , F Gherlinzoni , MT Bochicchio , **S Soverini** , G Alimena , F Pane , G Saglio , M Cavo , G Martinelli , M Baccarani , G Rosti. Predictors of deep molecular response in chronic myeloid leukemia patients treated frontline with imatinib mesylate: an analysis by the GIMEMA CML WP. *Haematologica* 2015; 100(S1):324.

**378.** F Castagnetti , G Gugliotta , M Breccia , G Rossi , F Stagno , D Turri , P Pregno , M Tiribelli , E Trabacchi , AM Carella , A Isidori , I Pierri , M Salvucci , Giorgina Specchia ,

Luciano Levato , Paolo Avanzini , MT Bochicchio , **S. Soverini** , G Alimena , M Cavo , G Martinelli , F Pane , G Saglio , Michele Baccarani , G Rosti. Deep molecular response to nilotinib as first-line treatment of BCR-ABL+ CML. *Haematologica* 2015; 100(S1):62.

**379.** G Gugliotta, F Castagnetti , M Breccia , A Gozzini , F Stagno , G Rege-Cambrin , AM Carella , L Luciano , G Specchia , E Abruzzese , B Martino , E Usala , G Rossi , M Bocchia , F Cavazzini , M Tiribelli , C Venturi , **S. Soverini** , Giuliana Alimena , Michele Cavo , F Pane , G Martinelli , G Saglio , G Rosti , M Baccarani. Long-term outcome of alternating nilotinib 400 mg twice daily and imatinib 400 mg once daily as first-line treatment of chronic myeloid leukemia: a phase 2 study of the GIMEMA CML Working Party. *Haematologica* 2015; 100(S1):181.

**380.** C. Papayannidis, A. Piciocchi, A. Vitale, **S. Soverini**, C. De Benedittis<sup>1</sup>, I. Iacobucci<sup>1</sup>, S. Paolini, C. Sartor, M. Abbenante, F. Di Raimondo, M. Bonifacio, A. M. Carella, M. Cazzola, A. Cuneo, P. Leoni, M. Luppi, E. Morra, G. Specchia, D. Vallisa, M. Bocchia, R. Fanin, G. Saglio, L. Elia, R. Foà, M. Cavo, M. Baccarani, G. Martinelli. High rate of complete hematological response in elderly Ph<sup>+</sup> acute lymphoblastic leukemia (ALL) patients by innovative sequential use of nilotinib and imatinib: a gimema clinical trial LAL 1408. *Haematologica* 2015;100(S1):30.

**381.** V. Polivkova, P. Rohon, N. Curik, H. Klamova, O. Cerna, M. Divoka, J. Zach, M. Novak, I. Marinov, **S. Soverini**, E. Faber, K. Machova Polakova. Interferon-alpha revisited: individualized immune-modulation eased up selection pressure of TKI on BCR\_ABL mutated clones and improves molecular response in high-risk CML patients. *Haematologica* 2015;100(S1):233.

**382.** T. Ernst, J. Rinke, M. Stiens, **S. Soverini**, C. De Benedittis, K. Machova Polakova, V. Polivkova, S. Schnittger, C. Bär, M. Müller, C. Dietz, M. Füllgrabe, M. Brüggemann, B. Auber, N. von Neuhoff<sup>8</sup>, J.M. Hernandez Rivas, C. Robledo, S. Akiki, U. Ozbek, P. Valk, F. Kavelaars, G. Martinelli, T. Haferlach, A. Hochhaus. International control round for deep sequencing analysis of BCR-ABL kinase domain mutations in 11 laboratories from 7 European countries. *Haematologica* 2015;100(S1):326.

**383.** C. De Benedittis, **S. Soverini**, C. Papayannidis, M. Rondoni, S. Colarossi, F. Dal Pero, R. Zanotti, G. De Matteis, M. Mancini, L. Zazzeroni, C. Elena, S. Merante, F.I. Grifoni, M. Bonifacio, O. Perbellini, G. Specchia, L. Pagano, D. Gangemi, P. Bonadonna, L. Pieri, M. Cavo, G. Martinelli. Ultra-deep sequencing (UDS) allows more sensitive detection of the D816V and other KIT gene mutations in systemic mastocytosis. *Haematologica* 2015;100(S1):533.

**384.** M. Baccarani, F. Castagnetti, G. Gugliotta, M. Breccia, A. Iurlo, L. Levato, E. Abruzzese, F. Stagno, M. Bonifacio, A. Gozzini, P. Pregno, G. Binotto, M. Annunziata, P. Galieni, C. Fava, M. Bocchia, M. Gobbi, D. Russo, G. Specchia, **S. Soverini**, G. Alimena, G. Martinelli, F. Pane, G. Saglio, G. Rosti. A critical comparison of Sokal, Euro, and EUTOS risk scores in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. *Haematologica* 2015;100(S1):435.

**385.** D. Russo, M. Malagola, C. Skert, V. Cancelli, D. Turri, P. Pregno, I. Pierri, M. Fogli, N. Testoni, A. De Vivo, F. Castagnetti, E. Pungolino, F. Stagno M. Breccia, B. Martino, T. Intermesoli, G. Rege Cambrin, G. Nicolini, E. Abruzzese, M. Tiribelli, C. Bigazzi, E. Usala, S. Russo, A. Russo-Rossi, M. Lunghi, M. Bocchia, A. D'Emilio, V. Santini, M. Girasoli, R. Di Lorenzo, B.M. Cesana, **S. Soverini**, G. Martinelli, G. Rosti, M. Baccarani. Long term outcome of intermittent imatinib treatment policy for managing chronic myeloid leukemia in the elderly. *Haematologica* 2015; 100(S3):5-6

**386.** F Castagnetti , G Gugliotta , M Breccia , G Rossi , F Stagno , D Turri , P Pregno , M Tiribelli , E Trabacchi , AM Carella , A Isidori , I Pierri , M Salvucci , Giorgina Specchia ,

- Luciano Levato , Paolo Avanzini , MT Bochicchio , **S Soverini** , G Alimena , M Cavo , G Martinelli , F Pane , G Saglio , Michele Baccarani , G Rosti. Deep molecular response to nilotinib as first-line treatment of BCR-ABL+ CML. *Haematologica* 2015; 100(S3):55
- 387.** M. Mancini, E. Leo, **S. Soverini**, F. Castagnetti, C. De Benedittis, G. Rosti, G. Gugliotta, M.A. Santucci, M. Cavo, G. Martinelli. FOXM1 post-translational modifications associated with the BCR-ABL1 fusion gene of chronic myeloid leukemia. *Haematologica* 2015; 100(S3):55
- 388.** G. Gugliotta, F. Castagnetti, M. Breccia, F. Stagno, B. Martino, C. Fava, L. Luciano, A. Gozzini, A.M. Carella, E. Abruzzese, L. Levato, E. Usala, G. Rossi, M. Bocchia, M. Tiribelli, F. Cavazzini, M. Salvucci, M. Cedrone, E. Trabacchi, G. Binotto, C. Venturi, **S. Soverini**, M. Cavo, G. Specchia, G. Alimena, F. Pane, G. Martinelli, G. Saglio, M. Baccarani, G. Rosti. Cardiovascular events in chronic myeloid leukemia patients treated with Nilotinib first-line: an analysis of the GIMEMA CML WP. *Haematologica* 2015; 100(S3):56
- 389.** M. Salvucci, R. Zanchini, M. Tonelli, B. Giannini, C. De Benedittis, A.M. Valenti, A. D'Addio, B. Vertogen, L. Bagli, A. Sensi, **S. Soverini**, E. Zuffa, on behalf MPDs-CML group of Romagna Case report of a patient with high Sokal risk Ph+ CML with additional chromosome aberrations [+8, del(7q)] in Ph- cells and late response to nilotinib. *Haematologica* 2015; 100(S3):127
- 390.** F. Castagnetti, G. Gugliotta, M. Breccia, F. Stagno, A. Iurlo, F. Albano, E. Abruzzese, B. Martino, L. Levato, T. Intermesoli, P. Pregno, G. Rossi, F. Gherlinzoni, P. Leoni, F. Cavazzini, D. Ferrero, E. Usala, M. Bocchia, M. Tiribelli, E. Montefusco, S. Sica, C. Venturi, **S. Soverini**, M. Cavo, G. Alimena, G. Martinelli, F. Pane, G. Saglio, M. Baccarani, G. Rosti, on behalf of the GIMEMA CML Working Party long-term outcome to first-line imatinib according to 2013 European LeukemiaNet response criteria: a GIMEMA CML WP analysis. *Haematologica* 2015; 100(S3):128
- 391.** G. Gugliotta, F. Castagnetti, M. Breccia, A. Gozzini, F. Stagno, G. Rege-Cambrin, A.M. Carella, L. Luciano, E. Abruzzese, B. Martino, E. Usala, G. Rossi, M. Bocchia, F. Cavazzini, M. Tiribelli, S. Luatti, C. Venturi, **S. Soverini**, M. Cavo, G. Specchia, G. Alimena, F. Pane, G. Martinelli, G. Saglio, G. Rosti, M. Baccarani. Long-term outcome of alternating nilotinib 400 mg twice daily and imatinib 400 mg once daily as frontline treatment of chronic myeloid leukemia: a phase 2 study of the GIMEMA CML Working Party. *Haematologica* 2015; 100(S3):131
- 392.** Papayannidis C, Fontana MC, Marconi G, Guadagnuolo V, Simonetti G, Padella A, **Soverini S**, Paolini S, Abbenante MC, Parisi S, Sartor C, Lo Monaco S, Manfrini M, Zuffa E, Franchini E, Venturi C, Bochicchio MT, Ghelli Luserna di Rorà A, Ottaviani E, Martinelli G. Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy. *Cancer Res* 2016;76(14S):368
- 393.** Fontana MC, Guadagnuolo V, Papayannidis C, Marconi G, Simonetti G, Padella A, Manfrini M, Santacroce B, Perricone M, Lo Monaco S, Ottaviani E, **Soverini S**, Cavo M, Martinelli G. Chromothripsis in AML patients: A new mechanism of cancer initiation and progression. *Cancer Res* 2016;76(14S):3582
- 394.** Fontana, Maria Chiara; Marconi, Giovanni; Papayannidis, Cristina; Guadagnuolo, Viviana; Lo Monaco, Silvia; Ferrari, Anna; Tenti, Elena; di Rorà, Andrea Ghelli Luserna; Simonetti, Giorgia; Abbenante, Maria Chiara; Parisi, Sarah; Paolini, Stefania; Sartor, Chiara; Padella, Antonella; **Soverini, Simona**; Manfrini, Marco; Testoni, Nicoletta; Baldazzi, Carmen; Martinelli, Giovanni. Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis. *J Clin Oncol* 2016;34(15S):7044

- 395.** MC Fontana, G Marconi, JD Milosevic Feenstra, L Semerad, V Guadagnuolo, C Papayannidis, G Simonetti, A Padella, A Ferrari, E Franchini, **S Soverini**, S Paolini, S Parisi, MC Abbenante, C Sartor, M Manfrini, F Volpato, M Doubek, M Steurer, Z Racil, R Kralovics, G Martinelli. Chromothripsis: a new mechanism of cancer initiation and progression in adult acute myeloid leukemia. *Haematologica* 2016;101(S1);39
- 396.** G Gugliotta, F Castagnetti, M Breccia, M D'Adda, F Stagno, L Levato, AM Carella, B Martino, M Tiribelli, G Rege-Cambrin, A Gozzini, M Salvucci, M Cedrone, E Trabacchi, E Usala, AR Scortechini, L Luciano, **S Soverini**, G Alimena, M Cavo, G Martinelli, F Pane, G Saglio, M Baccarani, G Rosti. Efficacy and safety of first-line treatment with nilotinib in elderly chronic myeloid leukemia patients. *Haematologica* 2016;101(S1);62
- 397.** F Castagnetti, G Gugliotta, M Breccia, F Stagno, M D'Adda, L Levato, AM Carella, B Martino, M Tiribelli, C Fava, G Binotto, P Avanzini, M Bocchia, M Bergamaschi, A Russo-Rossi, F Cavazzini, E Abruzzese, **S Soverini**, G Alimena, M Cavo, G Martinelli, F Pane, G Saglio, M Baccarani, G Rosti. The EUTOS long-term survival score is predictive for response and outcome in CML patients treated frontline with nilotinib-based regimens. *Haematologica* 2016;101(S1);152
- 398.** M Mancini, **S Soverini**, F Castagnetti, C De Benedittis, G Gugliotta, G Rosti, MA Santucci, M Cavo, G Martinelli. Role of the aurora kinase A axis in imatinib resistance of chronic myeloid leukemia CD34+ progenitors. *Haematologica* 2016;101 (S1);235
- 399.** S Bernardi, A Di Palma, F Cattina, M Malagola, M Tiribelli, E Codarin, MT Bochicchio, G Ruggeri, L Franceschini, V Cancelli, F Castagnetti, **S Soverini**, M Fogli, C Venturi, S Lavorgna, C Pagani, S Perucca, C Skert, C Zanaglio, L Caimi, G Rossi, MT Voso, G Rosti, G Martinelli, M Baccarani, D Russo. Assessment of BCR-ABL1 transcript levels by digital PCR (dPCR) in 116 Ph+ CML patients treated with tyrosine kinase inhibitors (TKIs): a comparative analysis between dPCR and qPCR. *Haematologica* 2016;101(S1);236
- 400.** F Castagnetti, F Stagno, A de Vivo, A Spitalieri, G Gugliotta, F Fabbiano I Capodanno, D Mannina, M Salvucci, A Antolino, R Marasca, M Musso, M Crugnola, U Consoli, E Trabacchi, C Musolino, F Cavazzini, G Longo, P Tosi, G Cardinale, **S Soverini**, M Rizzo, G Martinelli, M Cavo, P Vigneri, G Rosti, F Di Raimondo, M Baccarani. Imatinib first-line with switch to 2nd generation tyrosine kinase inhibitors in case of failure or toxicity: real-life data from a population-based registry of BCR-ABL1+ CML patients. *Haematologica* 2016;101(S1);456
- 401.** G Gugliotta, F Stagno, A De Vivo, A Spitalieri, F Castagnetti, F Fabbiano, I Capodanno, D Mannina, M Salvucci, A Antolino, R Marasca, M Musso, M Crugnola, U Consoli, E Trabacchi, C Musolino, F Cavazzini, G Longo, P Tosi, G Cardinale, M Rizzo, **S Soverini**, G Martinelli, M Cavo, P Vigneri, G Rosti, F Di Raimondo, M Baccarani. Treatment, response, and outcome in unselected elderly patients with newly diagnosed, chronic phase (CP), Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia. *Haematologica* 2016;101(S1);739
- 402.** Fontana, M. C. ; Marconi, G. ; Feenstra, J. D. Milosevic ; Semerad, L. ; Guadagnuolo, V. ; Papayannidis, C. ; Simonetti, G. ; Padella, A. ; Ferrari, A. ; Franchini, E. ; **Soverini, S.** ; Paolini, S. ; Parisi, S. ; Abbenante, M. C. ; Sartor, C. ; Lo Monaco, S. ; Manfrini, M. ; Volpato, F. ; Ottaviani, E. ; Testoni, N. ; Baldazzi, C. ; Doubek, M. ; Steurer, M. ; Racil, Z. ; Kralovics, R. ; Martinelli, G. Multi-center observational study of prevalence, impact on survival of chromothripsis, and recurrently associated alterations in a consecutive cohort of 303 adult patients with non M3 acute myeloid leukemia. *Haematologica* 2016;101(S3):S68-S69
- 403.** Bernardi, S. ; Di Palma, A. ; Cattina, F. ; Perucca, S. ; Malagola, M. ; Tiribelli, M. ; Codarin, E. ; Bochicchio, M. T. ; Ruggeri, G. ; Franceschini, L. ; Cancelli, V. ; Castagnetti, F. ;

**Soverini, S.** ; Fogli, M. ; Venturi, C. ; Lavorgna, S. ; Pagani, C. ; Skert, C. ; Zanaglio, C. ; Caimi, L. ; Rossi, G. ; Voso, M. T. ; Rosti, G. ; Martinelli, G. ; Baccarani, M. ; Russo, D. Assessment of BCR-ABL1 transcript levels by digital PCR (dPCR) in CML patients who achieved a DMR (MR4.0, MR4.5 and MR5.0) with TKIs (imatinib or nilotinib) and maintained their DMR after the discontinuation of the treatment. *Haematologica* 2016;101(S3):S72

**404.** Gugliotta, G. ; Castagnetti, F. ; Breccia, M. ; D'Adda, M. ; Stagno, F. ; Levato, L. ; Carella, A. M. ; Martino, B. ; Tiribelli, M. ; Rege-Cambrin, G. ; Gozzini, A. ; Salvucci, M. ; Cedrone, M. ; Trabacchi, E. ; Usala, E. ; Scortechini, A. R. ; Luciano, L. ; **Soverini, S.** ; Alimena, G. ; Cavo, M. ; Martinelli, G. ; Pane, F. ; Saglio, G. ; Baccarani, M. ; Rosti, G. Efficacy and safety of first-line treatment with nilotinib in elderly chronic myeloid leukemia patients. *Haematologica* 2016;101(S3):S102

**405.** Giovanni Marconi, Cristina Papayannidis, Maria Chiara Fontana, Antonella Padella, Giorgia Simonetti, Marco Manfrini, Anna Ferrari, Eugenia Franchini<sup>1</sup>, Stefania Paolini, Sarah Parisi, Chiara Sartor, Maria Chiara Abbenante, Silvia Lo Monaco, Francesca Volpato, Elena Tenti<sup>1</sup>, Viviana Guadagnuolo, Margherita Perricone, Maria Teresa Bochicchio, Andrea Ghelli Luserna Di Rora, Carmen Baldazzi, Valentina Robustelli, Nicoletta Testoni, **Simona Soverini**, Emanuela Ottaviani and Giovanni Martinelli. Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML). *Blood* 2016; 128(22):1679

**406.** F Castagnetti, G Gugliotta, M Breccia, F Stagno, M D'Adda, L Levato, AM Carella, B Martino, M Tiribelli, C Fava, G Binotto, P Avanzini, M Bocchia, M Bergamaschi, A Russo Rossi, F Cavazzini, E Abruzzese, **S Soverini**, G Alimena, M Cavo, G Martinelli, F Pane, G Saglio, M Baccarani, G Rosti. Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. *Blood* 2016; 128(22):3070

**407.** G Gugliotta, F Castagnetti, M Breccia, M D'Adda, F Stagno, L Levato, AM Carella, B Martino, M Tiribelli, G Rege Cambrin, A Gozzini, M Salvucci, M Cedrone, E Trabacchi, E Usala, AR Scortechini, L Luciano, **S Soverini**, G Alimena, M Cavo, G Martinelli, F Pane, G Saglio, M Baccarani, G Rosti. Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. *Blood* 2016; 128(22):3068

**408.** F Castagnetti, F Di Raimondo, A de Vivo, A Spitaleri, G Gugliotta, F Fabbiano, I Capodanno, D Mannina, M Salvucci, A Antolino, R Marasca, M Musso, M Crugnola, S Impera, Elena Trabacchi, C Musolino, F Cavazzini, G Mineo, P Tosi, CAM Tomaselli, M Rizzo, S Siragusa, M Fogli, R Ragionieri, A Zironi, **S Soverini**, G Martinelli, M Cavo, P Vigneri, F Stagno, G Rosti, M Baccarani. A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line. *Blood* 2016; 128(22):3076

**409.** S Bernardi, A Di Palma, F Cattina, S Perucca, M Malagola, M Tiribelli, E Codarin, MT Bochicchio, G Ruggeri, L Franceschini, V Cancelli, F Castagnetti, **S Soverini**, M Fogli, C Venturi, S Lavorgna, C Pagani, C Skert, C Zanaglio, A Turra, N Polverelli, L Caimi, G Rossi, MT Voso, G Rosti, G Martinelli, M Baccarani, D Russo. Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with TKIs May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR). *Blood* 2016; 128(22):3096

**410.** MC Fontana, G Marconi, J D. Milosevic Feenstra, C Papayannidis, M Manfrini, V Guadagnuolo, G Simonetti, A Padella, A Ferrari, E Franchini, A Ghelli Luserna di Rorà, E Ottaviani, R De Tommaso, S Bruno, **S Soverini**, N Testoni, S Paolini, C Sartor, S Parisi, E

Tenti, R Kralovics, G Martinelli. Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations. *Blood* 2016; 128(22):1678

**411.** C Papayannidis, S Paolini, A Santoro, V Robustelli, **S Soverini**, C De Benedittis, E Imbrogno, C Terragna, A Ghelli Luserna Di Rora, S Parisi, C Sartor, G Marconi, S Lo Monaco, MC Abbenante, MC Fontana, A Padella, A Ferrari, G Simonetti, E Tenti, F Frabetti, F Volpato, C Baldazzi, G Martinelli. Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience. *Blood* 2016; 128(22):5191

**412.** MC Fontana, G Marconi, C Papayannidis, E Fonzi, G Simonetti, A Padella, A Ferrari, E Ottaviani, S Lo Monaco, S Paolini, **S Soverini**, G Martinelli. Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia. *Cancer Res* 2017;77(13S):2451

**413.** G Gugliotta, F Castagnetti, M Breccia, M D'Adda, F Stagno, L Levato, AM Carella, B Martino, M Tiribelli, Giovanna Rege-Cambrin, A Gozzini, M Salvucci, M Cedrone, E Trabacchi, Emilio Usala, AR Scortechini, L Luciano, **S Soverini**, M Cavo, G Martinelli, F Pane, G Saglio, M Baccarani, G Rosti. Impact of arterial thrombotic events on the long-term outcome of chronic myeloid leukemia (CML) patients treated in first-line with nilotinib: an analysis of the GIMEMA CML working party. *Haematologica* 2017;102(S2):237

**414.** M. Mancini, **S. Soverini**, S. De Santis, C. Monaldi, F. Castagnetti, L. Bavaro, M. Martelli, G. Gugliotta, G. Rosti, M.A. Santucci, M. Cavo, G. Martinelli. Role of the Aurora kinase A/PLK 1 axis inhibition in restoration of cell growth control of chronic myeloid leukemia progenitors. *Haematologica* 2017;102(S2):238

**415.** S. Bernardi, M. Malagola, N. Polverelli, C. Zanaglio, F. Cattina, V. Cancelli, M. Tiribelli, E. Codarin, M.T. Bochicchio, G. Ruggeri, L. Franceschini, S. Perucca, F. Castagnetti, **S. Soverini**, M. Fogli, C. Venturi, S. Lavorgna, C. Pagani, B. Rambaldi, L. Caimi, G. Rossi, M.T. Voso, G. Rosti, G. Martinelli, M. Baccarani, D. Russo. Comparative monitoring of minimal residual disease (MRD) by QPCR and Digital-PCR (DPCR) in chronic myeloid leukemia patients achieving major or deep molecular response with tirosin-kinase inhibitors. *Haematologica* 2017;102(S2):238

**416.** F. Castagnetti, G. Gugliotta, M. Breccia, F. Stagno, M. D'Adda, L. Levato, E. Angelucci, B. Martino, M. Tiribelli, C. Fava, G. Binotto, I. Capodanno, M. Bocchia, M. Bergamaschi, A. Russo-Rossi, F. Cavazzini, E. Abruzzese, **S. Soverini**, R. Foà, M. Cavo, G. Martinelli, G. Saglio, F. Pane, M. Baccarani, G. Rosti. Impact of BCR-ABL1 transcript type in chronic myeloid leukemia treated frontline with nilotinib. *Haematologica* 2017;102(S2):729

**417.** S. Bernardi, M. Malagola, N. Polverelli, C. Zanaglio, F. Cattina, V. Cancelli, M. Tiribelli, E. Codarin, M.T. Bochicchio, G. Ruggeri, L. Franceschini, S. Perucca, F. Castagnetti, **S. Soverini**, M. Fogli, C. Venturi, S. Lavorgna, C. Pagani, B. Rambaldi, A. Montanelli, G. Rossi, M.T. Voso, G. Rosti, G. Martinelli, M. Baccarani, D. Russo. Comparative monitoring of minimal residual disease by QPCR and Digital-PCR in chronic myeloid leukemia patients achieving major or deep molecular response with tirosin-kinase inhibitors. *Haematologica* 2017;102(S3):20

**418.** G. Gugliotta, F. Castagnetti, M. Breccia, M. D'Adda, F. Stagno, L. Levato, A.M. Carella, B. Martino, M. Tiribelli, G. Rege-Cambrin, A. Gozzini, M. Salvucci, M. Cedrone, E. Trabacchi, E. Usala, A.R. Scortechini, L. Luciano, **S. Soverini**, R. Foà, M. Cavo, G. Martinelli, F. Pane, G. Saglio, M. Baccarani, G. Rosti. Impact of age on efficacy, safety, and long-term outcome of chronic myeloid leukemia (CML) patients treated in first-line with nilotinib: a GIMEMA CML working party analysis. *Haematologica* 2017;102(S3):85



- 419.** G. Gugliotta, F. Castagnetti, F. Lunghi, S. Rupoli, E. Abruzzese, M. Breccia, A. Iurlo, B. Martino, P. Pregno, M. Tiribelli, C. Fava, G. Tagariello, L. Nocilli, A.P. Falcone, D. Luzi, M. Crugnola, S. Barulli, M. Bonifacio, S. Russo, D. Noli, **S. Soverini**, R. Foà, M. Cavo, G. Martinelli, F. Pane, G. Saglio, M. Baccharani, G. Rosti. First-line treatment with nilotinib in chronic myeloid leukemia patients: results of the observational study GIMEMA CML0912. *Haematologica* 2017;102(S3):86
- 420.** F. Castagnetti, G. Gugliotta, M. Breccia, F. Stagno, M. D'Adda, L. Levato, E. Angelucci, B. Martino, M. Tiribelli, C. Fava, G. Binotto, P. Avanzini, M. Bocchia, M. Bergamaschi, A. Russo-Rossi, F. Cavazzini, E. Abruzzese, **S. Soverini**, R. Foà, M. Cavo, G. Martinelli, G. Saglio, F. Pane, M. Baccharani, G. Rosti. The EUTOS long-term survival scoring system is predictive for response and outcome in chronic myeloid leukemia patients treated frontline with nilotinib. *Haematologica* 2017;102(S3):86-87
- 421.** M. Mancini, **S. Soverini**, S. De Santis, C. Monaldi, F. Castagnetti, L. Bavaro, M. Martelli, G. Gugliotta, G. Rosti, M.A. Santucci, M. Cavo, G. Martinelli. Role of the Aurora kinase A/PLK 1 axis inhibition in restoration of cell growth control of chronic myeloid leukemia progenitors. *Haematologica* 2017;102(S3):91
- 422.** F. Castagnetti, G. Gugliotta, M. Breccia, F. Sorà, A. Iurlo, A. Gozzini, A.R. Scortechini, L. Luciano, F. Stagno, A. Malato, E. Abruzzese, M. Crugnola, P. Pregno, G. Specchia, P. Musto, N. Cascavilla, M. Tiribelli, M. Bonifacio, P. Galieni, F. Palmieri, **S. Soverini**, M.T. Bochicchio, S. Sica, R. Foà, M. Cavo, G. Martinelli, G. Saglio, F. Pane, M. Baccharani, G. Rosti. Front-line treatment of BCR-ABL+ chronic myeloid leukemia with dasatinib: a prospective multicentric observational study. *Haematologica* 2017;102(S3):92
- 423.** Gugliotta, G, Castagnetti, F, Breccia, M, D'Adda, M, Stagno, F, Levato, L, Carella, AM, Martino, B, Tiribelli, M, Rege-Cambrin, G, Gozzini, A, Salvucci, M, Cedrone, M, Trabacchi, E, Usala, E, Scortechini, AR, Luciano, L, **Soverini, S**, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Baccharani, M, Rosti, G. Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis. *Clin Lymphoma Myeloma Leuk* 2017;17(S2):S313-S314.
- 424.** G Martinelli, A Piciocchi, C Papayannidis, Stefania Paolini, Valentina Robustelli, **Simona Soverini**, Carolina Terragna, Roberto M Lemoli, Fabio Guolo, Paolo Di Bartolomeo, Monia Lunghi, Paolo de Fabritiis, Anna Candoni, Carmine Selleri, Federico Simonetti, Monica Bocchia, Antonella Vitale, Luca Frison, Alessandra Tedeschi, Antonio Cuneo, Massimiliano Bonifacio, Brunangelo Falini, Stefano D'Ardia, Silvia Trappolini, Patrizia Tosi, Piero Galieni, Francesco Fabbiano, Maria Chiara Abbenante, Giovanni Marconi, Chiara Sartor, Michele Cavo, Robin Foà, Paola Fazi, Marco Vignetti, Michele Baccharani. First Report of the GIMEMA LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. *Blood* 2017;130(S1):199
- 425.** Gabriele Gugliotta, Fausto Castagnetti, Francesca Lunghi, Serena Rupoli, Elisabetta Abruzzese, Massimo Breccia, Alessandra Iurlo, Bruno Martino, Patrizia Pregno, Mario Tiribelli, Giovanna Rege Cambrin, Giuseppe Tagariello, Laura Nocilli, Antonietta Pia Falcone, Debora Luzi, Monica Crugnola, MD, Sara Barulli, Massimiliano Bonifacio, Sabina Russo, Delia Noli, **Simona Soverini**, Robin Foà, Michele Cavo, Giovanni Martinelli, Fabrizio Pane, Giuseppe Saglio, Michele Baccharani, Gianantonio Rosti. First-Line Treatment with Nilotinib in Chronic Myeloid Leukemia Patients in Real-Life: Results of the Observational Study Gimema CML0912. *Blood* 2017;130(S1):15253
- 426.** Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Mariella D'adda, Fabio Stagno, Luciano Levato, Angelo Michele Carella, Bruno Martino, Mario Tiribelli, Carmen Fava, Antonella Gozzini, Marzia Salvucci, Michele Cedrone, Elena Trabacchi, Emilio

Usala, Anna Rita Scortechini, Luigia Luciano, **Simona Soverini**, Michele Cavo, Giovanni Martinelli, Fabrizio Pane, Giuseppe Saglio, Michele Bacarani, Gianantonio Rosti. Arterial Thrombotic Events in CML Patients Treated with First-Line Nilotinib: Incidence, Management and Impact on the Long Term Outcome — a GIMEMA CML WP Analysis. *Blood* 2017;130(S1):11625

**427.** Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, Federica Sorà, Alessandra Iurlo, Antonella Gozzini, Anna Rita Scortechini, Luigia Luciano, Fabio Stagno, Alessandra Malato, Elisabetta Abruzzese, Monica Crugnola, Patrizia Pregno, Giorgina Specchia, Pellegrino Musto, Nicola Cascavilla, Mario Tiribelli, Massimiliano Bonifacio, Piero Galieni, Fausto Palmieri, **Simona Soverini**, Maria Teresa Bochicchio, Simona Sica, Robin Foà, Michele Cavo, Giovanni Martinelli, Giuseppe Saglio, Fabrizio Pane, Michele Bacarani, Gianantonio Rosti. First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study. *Blood* 2017;130(S1):11604

**428.** F. Castagnetti, G. Gugliotta, M. Breccia, F. Stagno, G. Specchia, L. Levato, B. Martino, M. D'Adda, E. Abruzzese, P. Pregno, M. Tiribelli, A. Iurlo, T. Intermesoli, F. Cavazzini, A. R. Scortechini, C. Fava, M. Bonifacio, M. Salvucci, M. Bocchia, E. Usala, A. Gozzini, M. Bergamaschi, **S. Soverini**, R. Foà, G. Martinelli, M. Cavo, G. Saglio, F. Pane, M. Bacarani, G. Rosti. The EUTOS long-term survival score predicts response and survival of elderly chronic myeloid leukemia patients better than Sokal score. *HemaSphere* 2018;2(S1):508

**429.** M.C. Fontana, J. Nanni, A. Ghelli Luserna di Rorà, A. Padella, S. Bruno, G. Marconi, C. Papayannidis, M. Abbenante, **S. Soverini**, M. Cavo, G. Simonetti, G. Martinelli. Pharmacological inhibition of Wip1 sensitizes acute myeloid leukemia cells to Mdm2 inhibitors. *HemaSphere* 2018;2(S1):768

**430.** A Padella, G. Simonetti, M.C. Fontana, G. Marconi, A. Ferrari, C. Papayannidis, S. Bruno, E. Fonzi, M. Pazzaglia, E. Ottaviani, M. Cavo, **S. Soverini**, G. Martinelli. The DNA damage repair pathway is altered in poor prognosis acute myeloid leukemia patients and identifies potential targets for synthetic lethal therapies. *HemaSphere* 2018;2(S1):773

**431.** M. Rondoni, G. Poletti, V. Cova, A. Pezzi, G. Cortellini, E. Massari, C. Zingaretti, M. Rosetti, F. Monti, C. Conti, **S. Soverini**, M. Mancini, L. Riccioni, L. Cardinale, G. Martinelli, F. Lanza. Bone marrow tryptase level evaluation in systemic mastocytosis: role in diagnosis and classification of disease. *HemaSphere* 2018;2(S1):1004

**432.** A. Padella, G. Simonetti, M.C. Fontana, G. Marconi, A. Ferrari, C. Papayannidis, S. Bruno, M. Pazzaglia, E. Fonzi, E. Ottaviani, M. Cavo, **S. Soverini**, G. Martinelli. Identification of genomic and transcriptomic alterations in the DNA damage response pathway of Acute Myeloid Leukemia patients: potential targets of synthetic lethality approaches. *Haematologica* 2018;103(S3):S73

**433.** F Pane, L Luciano, N Pugliese, JL Steegman, PE Westerweel, E Abruzzese, M Breccia, M Bocchia, **S Soverini**, F Castagnetti, M Monteverde, G Rosti, Ge Saglio, JJ Janssen. International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. A GIMEMA and HOVON Study. *Blood* 2018;132(S1):11750

**434.** Fausto Castagnetti, MD PhD, Gabriele Gugliotta, MD PhD, Massimo Breccia, MD, Fabio Stagno, Giorgina Specchia, MD, Luciano Levato, Bruno Martino, MD, Mariella D'Adda, Elisabetta Abruzzese, Patrizia Pregno, Mario Tiribelli, Alessandra Iurlo, Tamara Intermesoli, Anna Rita Scortechini, Francesco Cavazzini, Carmen Fava, Massimiliano Bonifacio, Marzia Salvucci, Monica Bocchia, Giovanni Caocci, Antonella Gozzini, Micaela Bergamaschi, **Simona Soverini**, Robin Foà, Giovanni Martinelli, Michele Cavo, Giuseppe

Saglio, Fabrizio Pane, Michele Baccarani, Gianantonio Rosti. The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. *Blood* 2018;132(S1):144

**435.** Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Alessandra Iurlo, Mariella D'Adda, Fabio Stagno, Luciano Levato, Bruno Martino, Francesca Lunghi, Mario Tiribelli, Giovanna Rege Cambrin, Elisabetta Abruzzese, Serena Rupoli, Antonella Gozzini, Patrizia Pregno, Marzia Salvucci, Elena Trabacchi, Giovanni Caocci, Anna Rita Scortechini, Luigia Luciano, Giuseppe Tagariello, Massimiliano Bonifacio, **Simona Soverini**, Robin Foà, Giovanni Martinelli, Michele Cavo, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Gianantonio Rosti. Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. *Blood* 2018;132(S1):1458

**436.** Antonella Padella, Giovanni Marconi, Giorgia Simonetti, Andrea Ghelli Luserna Di Rora, Maria Chiara Fontana, Cristina Papayannidis, Emanuela Ottaviani, Michele Cavo, **Simona Soverini**, Giovanni Martinelli. Higher Expression of PALB2 Predict Poor Prognosis in AML Patients and Identifies Potential Targets of Synthetic Lethal Therapies. *Blood* 2018;132(S1):11507

**437.** Vaclava Polivkova, Nikola Curik, Hana Zizkova, Adela Benesova, Pavel Burda, Pavla Pecherkova, Eliska Motlova, Jana Brezinova, Sarka Ransdorfova, Hana Klamova, Lenka Hovorkova, Jan Zuna, Thomas Ernst, **Simona Soverini**, Katerina Machova. DNA Analysis of Mutations in the Kinase Domain of BCR-ABL1 By Allele-Specific Digital PCR Is Highly Sensitive and Refines Prediction of Kinetics of Resistant CML Clones. *Blood* 2018;132(S1):11743

**438.** Maria Chiara Fontana, Matteo Olivi, Giovanni Marconi, Mariachiara Abbenante, Eugenio Fonzi, Stefania Paolini, Chiara Sartor, Sarah Parisi, Samantha Bruno, Martina Pazzaglia, Stefano De Polo, Jacopo Nanni, Luca Bertamini, Simone Ragaini, Annalisa Talami, Maria Teresa Bochicchio, Emanuela Ottaviani, Anna Ferrari, Carmen Baldazzi, Nicoletta Testoni, Torsten Haferlach, Robert Kralovics, Jelena D. Milosevic Feenstra, **Simona Soverini**, Giovanni Martinelli, Antonio Curti, Michele Cavo, Cristina Papayannidis, Giorgia Simonetti. Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics. *Blood* 2018;132(S1):12748.

**439.** Bruno S, Pazzaglia M, Cerchione C, **Soverini S**, Cavo M, Montanaro L, Simonetti G, Martinelli G. Deep hypoxia and the genomic background cooperate to shape the metabolic profile of acute myeloid leukemia cells. *Cancer Res* 2019;79(13);2651

**440.** Fontana MC, Nanni J, Marconi G, Pazzaglia M, Bocconcelli M, Padella A, **Soverini S**, Iacobucci I, Papayannidis C, Ferrari A, Bochicchio MT, Imbrogno E, Cavo M, di Rora AGL, Simonetti G, Martinelli G. Pharmacological inhibition of WIP1 by GSK2830371 sensitizes AML cells to MDM2 inhibitor Nutlin-3a. *Cancer Res* 2019;79(13);2964

**441.** Martinelli G, Paolini S, Cerchione C, Santoro A. Robustelli V, **Soverini S**, De Benedittis C, Imbrogno E, Di Rora AGL, Parisi S, Sartor C, Marconi G, Lo Monaco S, Abbenante MC, Fontana MC, Padella A, Ferrari A, Simonetti G, Tenti E, Frabetti F, Volpato F, Bruno S, Mammoli F, Bochicchio MT, Baldazzi C. Papayannidis C. Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+patients: The Bologna compassionate program experience. *Cancer Res* 2019;79(13);3100

**442.** Bruno S., Ghelli Luserna di Rorà A., **Soverini S.**, Martinelli G., Simonetti G. CDC20 is a novel potential therapeutic target in acute myeloid leukemia. *HemaSphere* 2019;3(S1):779.

**443.** Martinelli G, Paolini S, Cerchione C, Santoro A. Robustelli V, **Soverini S**, De Benedittis C, Imbrogno E, Di Rora AGL, Parisi S, Sartor C, Marconi G, Lo Monaco S,

- Abbenante MC, Fontana MC, Padella A, Ferrari A, Simonetti G, Tenti E, Frabetti F, Volpato F, Bruno S, Mammoli F, Bochicchio MT, Baldazzi C. Papayannidis C. Blinatumomab is safe and effective in relapsed and MRD positive B-ALL CD19+patients: The Bologna compassionate program experience. *J Clin Oncol* 2019;37(15S):e18522
- 444.** F. Castagnetti, G. Gugliotta, M. Breccia, F. Stagno, A. Iurlo, F. Albano, E. Abruzzese, B. Martino, L. Levato, T. Intermesoli, P. Pregno, M. D'Adda, E. Calistri, S. Rupoli, F. Cavazzini, D. Ferrero, G. Caocci, M. Bocchia, M. Tiribelli, E. Montefusco, F. Sorà, M. Bonifacio, C. Elena, **S. Soverini**, R. Foà, M. Cavo, F. Pane, G. Saglio, M. Baccharani, G. Rosti. Clinical significance of MR2 at one year and beyond: a GIMEMA CML WP analysis on 559 CML patients treated frontline with imatinib mesylate. *Haematologica* 2019;104(S2);141.
- 445.** G. Gugliotta, F. Castagnetti, M. Breccia, L. Levato, T. Intermesoli, M. D'Adda, M. Salvucci, F. Stagno, G. Rege Cambrin, M. Tiribelli, B. Martino, M. Bocchia, M. Cedrone, E. Trabacchi, F. Cavazzini, F. Porretto, F. Sorà, E. Usala, F. Albano, G. Martinelli, **S. Soverini**, R. Foà, F. Pane, M. Cavo, G. Saglio, M. Baccharani, G. Rosti. Long-term (10-year) outcome of patients with chronic myeloid leukemia treated with nilotinib 400 bid in first-line: final results of the GIMEMA CML 0307 study. *Haematologica* 2019;104(S2);146.
- 446.** Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Luciano Levato, Tamara Intermesoli, Mariella D'adda, Marzia Salvucci, Fabio Stagno, Giovanna Rege Cambrin, Mario Tiribelli, Bruno Martino, Monica Bocchia, Elena Trabacchi, Francesco Cavazzini, Ferdinando Porretto, Federica Sorà, Giovanni Caocci, Francesco Albano, Giovanni Martinelli, **Simona Soverini**, Robin Foà, Fabrizio Pane, Michele Cavo, Giuseppe Saglio, Michele Baccharani, Gianantonio Rosti. Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the GIMEMA CML 0307 Trial. *Blood* 2019;134(S1):4145.
- 447.** Franke, Georg-Nikolaus; Pallisgaard, Niels; Maier, Jacqueline; Wildenberger, Kathrin; Polakova, Katerina Machova; Salmon, Matthew; Cross, Nicholas C. P.; White, Helen E.; Saglio, Giuseppe; Gottardi, Enrico; **Soverini, Simona**; Hochhaus, Andreas; Niederwieser, Dietger; Lange, Thoralf; Ernst, Thomas. Accurate and Reproducible Measurement of BCR-ABL1 (IS) Using Digital PCR: Results from a EUTOS Ring Trial. *Oncology Research and Treatment* 2020;43(S1):108
- 448.** C. Sartor, G. Marconi, M. C. Abbenante, V. Robustelli, C. Baldazzi, G. Cristiano, J. Nanni, S. Parisi, C. Terragna, N. Testoni, **S. Soverini**, G. Martinelli, S. Paolini, A. Curti, M. Cavo, C. Papayannidis. Inotuzumab ozagamicin is safe and effective in relapsed/refractory acute lymphoblastic leukemia: a single Italian center experience. *HemaSphere* 2020;4(S1):162.
- 449.** C Papayannidis, C Sartor, A Dominietto, E Zappone, G Marconi, MC Abbenante, S Parisi, V Robustelli, C Terragna, J Nanni, **S Soverini**, G Cristiano, M Arpinati, S Paolini, G Martinelli, A Curti, M Cavo, F Bonifazi. Inotuzumab Ozogamicin (IO) and Donor Lymphocyte Infusion (DLI) are a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT). *Clin Lymphoma Myeloma Leuk* 2020;20(S1):S161.
- 450.** C. Sartor, G. Marconi, M.C. Abbenante, V. Robustelli, C. Baldazzi, G. Cristiano, J. Nanni, S. Parisi, C. Terragna, N. Testoni, **S. Soverini**, S. Paolini, G. Martinelli, A. Curti, M. Cavo, C. Papayannidis. Inotuzumab ozagamicin is safe and effective in relapsed/refractory acute lymphoblastic leukemia: a single italian center experience. *Haematologica* 2020;105(S2):S95.
- 451.** C. Salvadori, G. Rotunno, E. Fabiani, L. Bandini, E. Ottaviani, V. Randazzo, C. Agueli, R. Cucci, P. Fazi, A. Santoro, **S. Soverini**, M.T. Voso, A.M. Vannucchi, P. Guglielmelli. Standardization of next generation sequencing (NGS) for advanced molecular diagnosis of

Myeloid neoplasms, a GIMEMA LabNet (Gruppo Italiano Malattie Ematologiche dell'Adulto) project. *Haematologica* 2021;106(S3);6.

**452.** J Nanni, J Vadakekolathu, L Bandini, Sa Bruno, L Zannoni, C Sartor, G Cristiano, S Parisi, F Zingarelli, R Ciruolo, G Marconi, C Venturi, M Ciciarello, A Kanapari, G Mazzocchetti, G Simonetti, M Ghetti, N Testoni, S Paolini, **S Soverini**, E Ottaviani, C Papayannidis, M Cavo, S Rutella, A Curti. T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3 -Mutated Acute Myeloid Leukemia. *Blood* 2023;142(Supplement 1):2947.

**453.** D Forte, F Maltoni, S Bruno, P Garcia-Gonzalez, G Cristiano, C Sartor, **S Soverini**, L Catani, RJ Argüello, M Cavo, A Curti. Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia. *Blood* 2023;142 (Supplement 1):1598.

**454.** D Forte, P Garcia Gonzales, F Maltoni, S Bruno, G Narimanfar, M Barone, **S Soverini**, R Argüello, M Cavo, A Curti. Single-cell metabolic analysis and extracellular vesicle profiling improve risk stratification and reveal novel metabolic vulnerabilities in acute myeloid leukemia. *HemaSphere* 2024;8(S1):733.

**455.** C Sartor, C Azzimondi, A D Romagnoli, F Ardizzoia, A S Sartor, J Nanni, G Cristiano, L Zannoni, F Zingarelli, **S Soverini**, C Monaldi, S De Santis, E Sabattini, C Bertuzzi, M Arpinati, E Boni, G De Leonardi, A Buffa, I Neri, A Curti, M Cavo, C Papayannidis. Relationship between the KIT D816V allele burden and mediator-related symptoms evaluated with the indolent systemic mastocytosis symptom assessment form (ISM-SAF). *HemaSphere* 2024;8(S1):3807.

**456.** M Breccia, R Cucci, G Marsili, F Castagnetti, S Galimberti, B Izzo, F Sorà, **S Soverini**, M Messina, A Picicchi, M Bonifacio, D Cilloni, A Iurlo, G Martinelli, G Rosti, F Stagno, P Fazi, M Vignetti, F Pane. Deep molecular response rate in chronic phase chronic myeloid leukemia. Eligibility to discontinuation related to time to response and different frontline TKI: the LabNet CML national network. *HemaSphere* 2024;8(S1):1238.

## Allegato 4

### PARTECIPAZIONE A CONGRESSI NAZIONALI E INTERNAZIONALI IN QUALITA' DI RELATRICE SU INVITO

---

1. VIII Workshop su "La terapia convenzionale e sovramassimale del mieloma multiplo: moderne strategie terapeutiche del mieloma multiplo e dei linfomi"; Scicli (RG), 12-15 settembre 2000
2. IX Workshop su "La terapia convenzionale e sovramassimale del mieloma multiplo: moderne strategie terapeutiche del mieloma multiplo e dei linfomi"; Napoli, 4-8 settembre 2001
3. Stage in Ematologia "La malattia minima residua: diagnostica e terapia"; Bologna, 25 ottobre 2001
4. Aggiornamento teorico-pratico in Ematologia "Mieloma multiplo: come si cura oggi"; Bologna, 13-15 maggio 2002
5. "Conferenza nazionale sul Mieloma"; Pesaro, 29-31 maggio 2002
6. X Workshop su "La terapia convenzionale e sovramassimale del mieloma multiplo: moderne strategie terapeutiche del mieloma multiplo e dei linfomi"; Sassari, 3-7 settembre 2002
7. Stage in Ematologia "Nuove strategie terapeutiche: dal debulky alla malattia minima residua"; Bologna, 22 novembre 2002
8. XI Workshop su "La terapia convenzionale e sovramassimale del mieloma multiplo: moderne strategie terapeutiche del mieloma multiplo e dei linfomi"; Cagliari, 2-4 settembre 2003
9. "Discutiamone Insieme"; 20 novembre 2003
10. Workshop "Le malattie immunoproliferative e sindromi correlate"; Taranto il 21-22 novembre 2003
11. Aggiornamento teorico-pratico in Ematologia "Mieloma multiplo: prognosi e terapia"; Bologna, 24-26 novembre 2003
12. "EICML Meeting"; Poitiers, Francia, 29 aprile-1° maggio 2004
13. Aggiornamento teorico-pratico in ematologia "Le gammopatie monoclonali: biologia e clinica"; Bologna, 15-17 novembre 2004
14. "EICML Meeting"; Oxford, Inghilterra, 7-9 aprile 2005
15. "3rd ESH International Conference on Chronic Myeloid Leukemia in the 21st Century"; Genova, 11-13 novembre 2005
16. "2° giornata della Medicina Genetica a Bologna"; Bologna, 29 novembre 2005
17. "EICML meeting"; Barcellona, Spagna, 30 marzo-1° aprile 2006
18. "X-Phile: monitoring the CML from bench to bedside"; Bologna, 10-12 aprile 2006
19. "Workshop on RQ PCR for monitoring CML patients treated with imatinib"; Orbassano (TO), 4-5 maggio 2006
20. ELN meeting "Evolving Concepts in the Management of CML"; Venezia, 8-9 maggio 2006
21. "X-Phile: monitoring the CML from bench to bedside"; Orbassano (TO), 9-11 ottobre 2006
22. "1st Annual global CML workshop"; Hamilton, Bermuda, 15-16 dicembre 2006
23. "Leucemie PH+: nuove prospettive terapeutiche nell'era post imatinib"; Firenze, 16 febbraio 2007
24. "Il punto sull'imatinib: passato, presente e futuro"; Bologna, 3-4 aprile 2007
25. "EICML Meeting"; Stoccolma, Svezia, 10-12 maggio 2007
26. "Next steps in targeted therapy for CML" Novartis Satellite Symposium, 12th Congress of the EHA, Vienna, Austria, 7 giugno 2007
27. "Jubilee Symposium – 25 years German CML Study Group & 16<sup>th</sup> International CML-Workshop"; Mannheim, Germania, 29-30 giugno 2007

28. Workshop "Nuove frontiere biologico-terapeutiche nelle leucemie Ph<sup>+</sup>"; Napoli, 17 settembre 2007
29. "X-Phile: monitoring the CML from bench to bedside"; Orbassano (TO), 24-26 settembre 2007
30. ESH meeting "CML - Prospects for the 21st century"; Mandelieu, Francia, 28-30 settembre 2007
31. ELN meeting "Next steps in the evolution of targeted terapie in CML – implementing the ELN recommendations"; Budapest, Ungheria, 20-21 ottobre 2007
32. "2nd Global Meeting on the Biology and Novel Therapy of the Myeloproliferative Diseases." San Juan, Puerto Rico, 12-13 dicembre 2007
33. "CRBA (Centro Unificato di Ricerca Biomedica Applicata) - 6° seminario annuale dei ricercatori"; Bologna, 9 aprile 2008
34. "EICML meeting"; Heraklion, Creta, 8-11 maggio 2008
35. "X-Phile: monitoring the CML from bench to bedside"; Orbassano (TO), 19-21 maggio 2008
36. "Nuove prospettive analitiche e protocolli per la DHPLC"; Roma, 10 giugno 2008
37. Convegno "Ph<sup>+</sup> leukemias in 2008 and beyond"; Torino, 27-28 giugno 2008
38. "10<sup>th</sup> ESH International Conference on CHRONIC MYELOID LEUKEMIA – Biological Approaches to Cure"; Boston, Massachusetts (USA) 5-7 settembre 2008
39. ELN Frontiers Meeting "Targeted CML Therapy: Innovating today for a better tomorrow"; Cannes, Francia, 17-19 ottobre 2008
40. "4th Nilotinib Global Investigator Meeting"; Dublino, Irlanda, 24-25 ottobre 2008
41. "Sabati Ematologici della Romagna"; Meldola (FC), 15 novembre 2008
42. "Chronic Myeloproliferative Disorders: Topical Issues for 2009"; Sonoma, California (USA), 10-11 dicembre 2008
43. "Current Trends in the Treatment of Haematologic Malignancies", Istanbul, Turchia, 17 gennaio 2009
44. "Targeted therapy: il futuro in Ematologia"; Roma, 6-7 febbraio 2009
45. "24th Nagoya International Cancer Treatment Symposium"; Nagoya, Japan, 14-15 febbraio 2009
46. "Ph<sup>+</sup> leukemias in 2009 and beyond" Torino, 27-29 marzo 2009
47. EICML meeting; Salisburgo, Austria, 7-10 maggio 2009
48. "2° Workshop Nazionale in Ematologia Traslazionale"; Verona, 21-22 maggio 2009
49. Corso di Aggiornamento "Update – Ultimi Progressi delle Metodiche BioMolecolari: Applicazioni Teorico-Pratiche in Onco-Ematologia" Corso di Aggiornamento sull'Impiego Clinico delle Nuove Tecniche Biomolecolari in Onco-Ematologia; Reggio Calabria, 22 maggio 2009
50. "Improving Clinical Outcomes in CML: A Changing Therapeutic Landscape" Novartis Satellite Symposium, 14th Congress of the EHA; Berlino, Germania, 4 giugno 2009
51. "Discutiamone Insieme"; Firenze, 11 giugno 2009
52. "X-Phile: monitoring the CML from bench to bedside"; Roma, 15 giugno 2009
53. Preceptorship "CML treatment and monitoring: an interactive journey, from bench to bedside and back, led by the GIMEMA CML Working Party"; Bologna, 2-3 luglio 2009
54. "11th International Conference on Chronic Myeloid Leukemia – Biological Basis of Therapy"; Bordeaux, Francia, 11-13 settembre 2009
55. "Latest Update on CML"; Orbassano, 17-18 settembre 2009
56. ELN Frontiers Meeting "Continuing the CML revolution: expanding options in targeted therapy"; Barcellona, Spagna, 18-20 settembre 2009

57. Corso residenziale "Avanzamenti diagnostici e terapeutici in ematologia"; Firenze, 22-24 settembre 2009
58. "Lunch Meeting Novartis: Progressi nella Leucemia mieloide Cronica Ph+" durante il "42° Congresso Nazionale della Società Italiana di Ematologia", Milano, 20 ottobre 2009
59. "5th Nilotinib Global Investigators' Meeting"; Istanbul, Turchia, 30-31 ottobre 2009
60. "Presidential Symposium of the 50<sup>th</sup> Fall Meeting of the Korean Society of Hematology"; Jeonbuk, Korea, 6 novembre 2009
61. "Meeting of the Brazilian Hematology and Hemotherapy HEMO 2009"; Florianopolis, Brasile, 11-14 novembre 2009
62. "Fourth International Workshop on CML and MPN"; Natchez, Mississippi (USA), 9-10 dicembre 2009
63. "Oncoematologia Molecolare: risvolti clinici e terapeutici"; Torino, 26-27 marzo 2010
64. Workshop sulla Leucemia Mieloide Cronica; Spineto (SI), 9-10 aprile 2010
65. "Philadelphia-positive leukemias 2010: biology and treatment"; Genova, 12-13 aprile 2010
66. "Nuovi orizzonti nella Terapia della LMC con gli inibitori delle tirosino chinasi di II generazione"; Pesaro, 16 aprile 2010
67. LAB NEXUS Meeting "State-of-the-art CML management – Evolving concepts in clinical practice and molecular monitoring"; Tunisi, Tunisia, 26-27 aprile 2010
68. EICML meeting; Sarteano (SI), 13-16 maggio 2010
69. "La leucemia mieloide cronica: verso la guarigione?"; Pezze di Greco (BR), 28 maggio 2010
70. LAB NEXUS Meeting "State-of-the-art CML management – Evolving concepts in clinical practice and molecular monitoring"; Istanbul, Turchia, 15-16 settembre 2010
71. "12th International Conference on Chronic Myeloid Leukemia: Biological Basis of Therapy"; Washington, DC (USA), 24-26 settembre 2010
72. Excel Preceptorship "Treatment and monitoring of CML at the University of Bologna: an interactive clinical journey", Bologna, 14-15 ottobre 2010
73. "CML Workshop"; Mosca, Russia, 16 ottobre 2010
74. ELN Frontiers Meeting 2010 "New benchmarks in leukemia – Focus on CML, AML and MDS"; Vienna, Austria, 22-24 ottobre 2010
75. "Le Leucemie Ph+ nell'era dei TKI (second edition)"; Bologna, 19 ottobre 2010
76. "Fifth International Workshop on CML and MPN"; Mission Inn, Florida (USA), 7-9 dicembre 2010
77. "I nuovi traguardi nella cura della leucemia mieloide cronica"; Bologna, 20-21 gennaio 2011
78. "9<sup>th</sup> Nilotinib Global Investigators' Meeting"; Izmir, Turchia, 15-16 aprile 2011
79. EICML meeting; Prague, 5-8 maggio 2011
80. "Workshop sulle malattie mieloproliferative croniche"; Spineto (SI), 20-21 maggio 2011
81. "10 anos avanzando juntos en LMC"; Madrid, Spagna, 17-18 giugno 2011
82. EXcel Preceptorship "Treatment and monitoring of CML at the University of Bologna: an interactive clinical journey", Bologna, 8-9 luglio 2011
83. "Le leucemie Ph+ nell'era dei TKIs: quali nuovi traguardi?" Trieste, 16-17 settembre 2011
84. "13<sup>th</sup> ESH-ICMLf International Conference on Chronic Myeloid Leukemia – Biology and Therapy"; Estoril, Portogallo, 22-25 settembre 2011
85. CML Preceptorship "How chronic myeloid leukemia patients are monitored and treated at the University of Bologna. An interactive clinical journey, from bench to bed and back"; Bologna, 14-15 novembre 2011
86. "Conoscere il Genoma per Curare le Leucemie: Potenzialità e Applicazioni della Tecnologia più avanzata di Next Generation Sequencing"; Brescia, 25 novembre 2011



87. "Sixth International Workshop on CML and MPN"; La Jolla, California (USA), 13-14 dicembre 2011
88. "Sindromi mieloproliferative: i vantaggi di un approccio integrato per la cura del paziente" Napoli, 24-25 gennaio 2012
89. "European Hematology Academy Module 2: Leukemia"; Berlino, Germania, 18-19 febbraio 2012
90. "CML GOLS 2012: Progress in CML therapy: selective targeting, response and outcomes" Monaco, Germania, 9-10 Marzo 2012
91. EICML meeting; Madrid, Spagna, 3-6 maggio 2012
92. "Next Generation Sequencing - Nuovi traguardi per la diagnostica e le terapie personalizzate delle leucemie"; Bologna, 11 maggio 2012
93. EXcel Preceptorship "Treatment and monitoring of CML at the University of Bologna: an interactive clinical journey", Bologna, 9-10 luglio 2012
94. "CML Academy: Innovazione nel Management della Leucemia Mieloide Cronica"; Napoli, 10 luglio 2012
95. CML Preceptorship "How chronic myeloid leukemia patients are monitored and treated at the University of Bologna. An interactive clinical journey, from bench to bed and back"; Bologna, 16-17 luglio 2012
96. "14<sup>th</sup> ESH-ICMLf International Conference on Chronic Myeloid Leukemia – Biology and Therapy"; Baltimore, Maryland (USA), 20-23 settembre 2012
97. CML Preceptorship "How chronic myeloid leukemia patients are monitored and treated at the University of Bologna. An interactive clinical journey, from bench to bed and back" Bologna, 8-9 ottobre 2012
98. "20th National Clinic and Transfusion Hematology Conference"; Sinaia, Romania, 11-14 ottobre 2012
99. "CML Academy: Innovazione nel Management della Leucemia Mieloide Cronica"; Napoli, 25 ottobre 2012
100. ELN Frontiers Meeting 2012 "Myeloid Neoplasms: Approaching Cure"; Istanbul, Turchia, 9-11 novembre 2012
101. "Giornata Ematologica del Policlinico di Milano: Focus sulla Leucemia Mieloide Cronica"; Milano, 23 novembre 2012
102. "Aggiornamenti in Ematologia – Leucemia Mieloide Cronica: il prossimo futuro"; Treviso, 24 novembre 2012
103. "Next-Generation Sequencing for Targeted Personalized Therapy of Leukemia"; Bologna, 30 novembre-1° dicembre 2012
104. "Seventh International Workshop on CML and MPN"; Atlanta, Georgia (USA), 11-12 dicembre 2012
105. "CML and MPN GOLS 2013: Navigating advances in CML therapy: Steps toward treatment-free remission" Helsinki, Finlandia, 22-23 febbraio 2013
106. III Preceptorship Latin American Meeting CML Labs Groups; Buenos Aires, Argentina, 17-20 aprile 2013
107. EICML meeting; Weimar, 25-28 aprile 2013
108. EUTOS CML Naples Fellows Days; Napoli, 24-25 maggio 2013
109. All-Russian Scientific Conference "Innovative Technologies in Neuroendocrinology, Neuroscience and Hematology"; San Pietroburgo, Russia, 23-25 maggio 2013
110. "2<sup>nd</sup> International Conference Leukemia 2013"; Genova, 10-11 giugno 2013
111. Genetic Course: Module IV. Molecular genetics – PCR based technologies; Bucharest, Romania, 13-17 maggio 2013

112. CML Preceptorship “How chronic myeloid leukemia patients are monitored and treated at the University of Bologna. An interactive clinical journey, from bench to bed and back” Bologna, 24-25 giugno 2013
113. International CML Workshop/EUTOS meeting; Mannheim, Germania, 28-29 giugno 2013
114. Latin-American CML Preceptorship; Bologna, 1-2 luglio 2013
115. XXVI IACRLRD (International Association for Comparative Research in Leukemias and Related Disorders) Symposium; Torino, 11-14 settembre 2013
116. “15th ESH-ICMLf International Conference on Chronic Myeloid Leukemia – Biology and Therapy”; Estoril, Portogallo, 26-29 settembre 2013
117. “Best to test” Workshop; Bucarest, 24 settembre 2013
118. XXXI Conferenza Nazionale di Citometria; Lucca, 8-11 ottobre 2013
119. ELN Frontiers Meeting 2013 “Myeloid Neoplasms: Approaching Cure”; Praga, Repubblica Ceca, 11-13 ottobre 2013
120. Convegno Regionale SIE, Delegazione Marche: “La Malattia Minima Residua in Ematologia: dalla filosofia alla pratica”; Fano, 15 novembre 2013
121. “Aspetti biomolecolari e mutazionali alla base delle resistenze nelle leucemie Ph+”; Firenze, 22 novembre 2013
122. “First Annual Colloquium on Myeloproliferative Neoplasms: Focus on JAK2”; Bologna, 28 novembre 2013
123. “Eighth International Workshop on CML and MPN”; New Orleans, Louisiana (USA), 10-11 dicembre 2013
124. “Time on advances in haematological disorders; the ‘target’ therapy”; Palermo, 30 gennaio-1 febbraio 2014
125. BMS National standalone “Sprycel – the first choice for long lasting outcomes”; Bucarest, Romania, 22 febbraio 2014
126. EHA-SW Scientific Meeting “New molecular insights in emerging therapeutic strategies in acute lymphoblastic leukemia”; Lisbona, Portogallo, 28 febbraio-2 marzo 2014
127. “SIES - Discutiamone Insieme”; Firenze, 20 marzo 2014
128. “3G (Genes, Genetics and Genomics)” Meeting 2014; Praga, Repubblica Ceca, 11 aprile 2014
129. “Chronic Myeloid Leukemia: dissecting the new challenges”; Bologna, 30 aprile 2014
130. “Chronic Myeloid Leukemia: current treatment paradigms and future perspectives – an educational day for European fellows on behalf of EUTOS for CML”; Napoli, 5-6 maggio 2014
131. CML Academy 2014; Sarteano (SI), 19-20 maggio 2014
132. “Reunion Nacional de la LMC”; Madrid, Spagna, 4-5 luglio 2014
133. “16th Annual John Goldman Conference on CML: Biology and Therapy”; Philadelphia, Pennsylvania, 4-7 settembre 2014 (Keynote speaker)
134. SOHO 2014 Annual Meeting, Houston, Texas, 17-20 settembre 2014
135. Congress of the Romanian Society of Medical Genetics”; Bucarest, Romania, 24-26 settembre 2014
136. “How we treat CML: the GIMEMA CML Working Party Experience”; Preceptorship Bologna, 30 settembre-1 ottobre 2014
137. ELN Frontiers Meeting 2014: where science meets clinical practice”; Berlino (Germania), 16-19 ottobre 2014
138. “Alterazioni molecolari in oncoematologia: dalla diagnosi allo studio della malattia minima residua (MRD)”; Genova, 11 novembre 2014
139. “Ninth International Workshop on CML and MPN”; San Francisco, California (USA), 9-10 dicembre 2014
140. “Strategie terapeutiche nella LMC e nelle LLA Ph+”; Roma, 22-23 gennaio 2015

141. XIIIth Annual Conference on Evidence Based Management of Cancers 2015 (EBM2015): Molecular Haematology: Laboratory Testing for Myeloid Malignancies, TATA Memorial Hospital Mumbai, India, 27 febbraio-1 marzo 2015
142. Workshop for Assay Standardization, Validation and Testing in Myeloid Malignancies, TATA Memorial Hospital Mumbai, India, 1 marzo 2015
143. V Latin American CML Labs Group Meeting, Buenos Aires, Argentina, 19-21 marzo 2015
144. EICML Meeting 2015, Bologna, 7-9 maggio, 2015
145. Russian Genetics Conference, San Pietroburgo, 20-21 maggio 2015
146. CML Academy, Bologna, 25-26 maggio 2015
147. "Leucemia mieloide cronica: lo stato dell'arte tra percorsi terapeutici ed esperienze di pratica clinica", Bologna 30 giugno 2015
148. Annual meeting 2015 of the Hematology Section of the Chinese Medical Doctor Association, Shenyang, Cina, 4 luglio 2015
149. How we treat CML: the experience of the GIMEMA CML working party - an interactive clinical journey at the Bologna University Hospital, 10 settembre 2015
150. From the bench to the bedside. How CML is treated at the institute "Seragnoli", Bologna, 15 settembre 2015
151. XXVII IACRLRD (International Association for Comparative Research in Leukemias and Related Disorders) Symposium; Parigi, Francia, 21-23 settembre 2015
152. "Seminari di aggiornamento in onco-ematologia 2015: Leucemia Mieloide Cronica - Stato dell'arte e News from 20th European Hematology Association Meeting 2015, Wien" Rionero in Vulture, 17 settembre 2015
153. "17th Annual John Goldman Conference on CML: Biology and Therapy", Estoril, Portogallo, 1-4 ottobre 2015
154. 2015 BCR-ABL Workshop, Dubai, UAE, 7 novembre 2015
155. 26th Congress of the Pan-Hellenic Society of Hematology, Atene, Grecia, 12 novembre 2015
156. Società Italiana di Farmacia Ospedaliera (SIFO) "Training regionale per farmacisti ospedalieri su leucemia mieloide cronica (LMC), nuove tecnologie nuovi approcci", Roma, 16 novembre 2015
157. Società Italiana di Farmacia Clinica e Chemioterapia (SIFACT) "Evoluzione dei trattamenti nella leucemia mieloide cronica: Sostenibilità, Appropriatezza e Governance delle nuove terapie target", Padova, 18 novembre 2015
158. "Tenth International Workshop on CML and MPN"; Orlando, Florida (USA), 8-9 dicembre 2015
159. Società Italiana di Farmacia Clinica e Chemioterapia (SIFACT) "Evoluzione dei trattamenti nella leucemia mieloide cronica: Sostenibilità, Appropriatezza e Governance delle nuove terapie target", Bologna, 17 dicembre 2015
160. SIRIC BRIO conference 'Tyrosine Kinase Inhibitors workshop', Bordeaux, Francia, 15 gennaio 2016
161. "Post-Orlando 2015: novità dal meeting della Società Americana di Ematologia", Genova, 11-13 febbraio 2016
162. "Inspire: 10 anni di successi nel trattamento della Leucemia Mieloide Cronica", Milano, 8-9 aprile 2016
163. "CML Academy", Bologna, 18-19 aprile 2016
164. EICML Meeting 2016, Versailles, Francia, 12-14 maggio, 2016
165. 5th International Conference "Leukemia 2016", Santa Margherita Ligure, 20-21 maggio 2016
166. "CML response forum", San Pietroburgo, Russia, 26-27 maggio 2016
167. Emil J Freireich Hematology Grand Rounds, MD Anderson Cancer Center, Houston, Texas (USA), 7 settembre 2016

168. 2016 SOHO Annual Meeting, Houston, Texas (USA), 7-10 settembre 2016
169. 18th Annual John Goldman Conference on Chronic Myeloid leukemia: Biology and Therapy, Houston (TX) 15-18 settembre 2016
170. "How we treat CML: the experience of the GIMEMA CML working party - an interactive clinical journey at the Bologna University Hospital", Bologna 22-23 settembre 2016
171. "Treatment-free remission in the community practice setting"; Milano, 30 settembre-1 ottobre 2016
172. "How we treat CML: the experience of the GIMEMA CML working party - an interactive clinical journey at the Bologna University Hospital", Bologna 13-14 ottobre 2016
173. Meeting of the European Competence Network on Mastocytosis (ECNM), Verona, 27-29 ottobre 2016
174. XX Congresso della Società Portoghese di Ematologia; Espinho, Portogallo, 17 novembre 2016
175. "Eleventh International Workshop on CML and MPN"; La Jolla, California (USA), 6-7 dicembre 2016
176. "Post-San Diego 2015: novità dal meeting della Società Americana di Ematologia", Torino, 10-12 febbraio 2017
177. "Hematology 2017: la medicina di precisione del futuro", Milano, 3-4 marzo 2017
178. "ESH Training Course on WHO Classification: Towards Personalized Medicine in Haematology", 9-11 marzo 2017 - Saggart (Dublin), Irlanda
179. VII Latin American CML Labs Group Meeting, Buenos Aires, Argentina, 4-5 maggio 2017
180. "Educational Meeting on NGS in Ph+ Leukemia". Milano, 17 maggio 2017
181. "Educational Meeting on NGS in Ph+ Leukemia". Roma, 18 maggio 2017
182. "Postgraduate leukemia conference - Leukemia 2017". Roma 19-20 maggio 2017
183. "CML Academy". Bologna, 29-30 maggio 2017
184. "NEXT GENERATION SEQUENCING: il futuro e' routine". Bologna, 8 giugno 2017
185. 2017 SOHO Annual Meeting, Houston, Texas (USA), 13-16 settembre 2017
186. "Terapie personalizzate nelle neoplasie mieloidi". Milano, 25-26 settembre 2017
187. "Approccio olistico della leucemia cronica". Firenze, 28-29 settembre 2017
188. "How We Treat CML and Ph+ ALL: The Experience of the GIMEMA CML Working Party". Bologna, 6-7 ottobre 2017
189. 19th Annual John Goldman Conference on Chronic Myeloid leukemia: Biology and Therapy. Estoril, Portogallo, 12-15 ottobre 2017
190. EHA-AHA Tutorial on Biology and Management of Myeloid Malignancies. Yerevan, Armenia, 20-21 ottobre 2017
191. VI Workshop SIES in Ematologia Traslazionale. Parma, 17 - 18 novembre 2017
192. XII Post-ASH CML-MPN Workshop. Atlanta, 12-13 dicembre 2017
193. "NEXT-in-LEUKEMIA". Bologna, 15-16 dicembre 2017
194. "Post-Atlanta 2017: novità dal meeting della Società Americana di Ematologia". Milano, 8-10 febbraio 2018
195. "Insights in Hematology". Cluj Napoca, Romania, 9-10 marzo 2018
196. "Educational Meeting on NGS in Ph+ Leukemia". Roma, 15 marzo 2018
197. "Educational Meeting on NGS in Ph+ Leukemia". Milano, 16 marzo 2018
198. 15th Annual Symposium of the European LeukemiaNet. Venezia, 21-22 marzo 2018
199. EICML Meeting 2018, Torino, 18-19 maggio, 2018
200. "Revue Biologique et Clinique de la LMC et LAL Ph+". Bordeaux, 25 maggio 2018
201. 'Planning your next move in Ph+ leukemia', satellite symposium during the 23rd Congress of the European Association of Hematology (EHA). Stoccolma, Svezia, 14 giugno 2018
202. "Attualità in Ematologia". Ferrara, 6 luglio 2018

203. 2018 SOHO Annual Meeting, Houston, Texas (USA), 12-15 settembre 2018
204. 20th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy. Miami, Florida, 13-16 settembre 2018
205. "Convegno Inter-Regionale di aggiornamento su Leucemia Linfoblastica Acuta & Leucemia Mielode Cronica". Padova, 25 settembre 2018
206. PROGETTO FORMATIVO SIE "Il nuovo ruolo della Malattia Minima Residua in ematologia". Napoli, 25 ottobre 2018
207. "HOW WE TREAT CML AND Ph+ ALL: THE EXPERIENCE OF THE GIMEMA CML WORKING PARTY" – An interactive clinical journey at the Bologna University Hospital'. Bologna, 26-27 ottobre 2018
208. "Comment mieux orienter LE PATIENT au cœur de la prise en charge thérapeutique ACTUELLE et FUTURE en Hématologie?" Parigi, 9 novembre 2018
209. "Focus on Mastocitosi: approccio diagnostico e terapeutico alla patologia". Bologna, 18 novembre 2018
210. "Midostaurina, UNA STORIA NUOVA" - Milano, 20 novembre 2018
211. "Il trattamento della LMC: Percorso clinico interattivo presso l'Ospedale Universitario di Bologna". Bologna, 22-23 novembre 2018
212. XIII Post-ASH CML-MPN Workshop. San Diego, 4-5 dicembre 2018
213. "CAMPUS CML". Roma, 11-12 gennaio 2019
214. ESH conference 'How to Diagnose and Treat Chronic Myeloid Leukemia / Myeloproliferative Neoplasms'. Saggart, Irlanda, 8-10 marzo 2019
215. International Conference of the Korean Society of Hematology. Seul, Corea, 14-16 marzo 2019
216. "Focus sulla mastocitosi: le novità per un approccio clinico integrato". Faenza, 20 marzo 2019
217. "The European Congress on Leukemias - Between Cutting Edge and Grey Zone Controversies". Vienna, 4-5 aprile 2019
218. Progetto Ematologia Romagna: "Le mastocitosi: acquisizioni biologiche e scenari terapeutici". Ravenna, 13 aprile 2019
219. "Gestione del paziente con leucemia linfoblastica acuta: approcci attuali e sfide future". Bologna, 5 maggio 2019
220. "EICML 2019". Amsterdam, Olanda, 17-18 maggio 2018
221. 'Planning your next move in Ph+ leukemia', satellite symposium during the 24th Congress of the European Association of Hematology (EHA). Amsterdam, Olanda, 13 giugno 2019
222. 'Planning your next move in Ph+ leukemia', satellite symposium during the 21st ESH John Goldman meeting on Chronic Myeloid Leukemia: Biology and Therapy. Bordeaux, Francia, 13 settembre 2019
223. "LXI Congreso Nacional de la Sociedad Espanola de Hematologia y Hemoterapia", Valencia, Spagna, 24-26 ottobre 2019
224. "Application of new technologies for precision medicine of CML and ALL" Praga, Repubblica Ceca, 15 novembre 2019
225. "LMC 2019: un punto sull'oggi e uno sguardo sul domani". Udine, 20 novembre 2019
226. Preceptorship "How we treat CML and Ph+ ALL at Bologna University Hospital – The experience of the GIMEMA CML WP". Bologna, 29-30 novembre 2019
227. "XIV Post-ASH CML and MPN Workshop". Orlando, FL, 10-11 dicembre 2019
228. 1° Convegno Nazionale "ADVANCES IN HEMATOLOGY: il ruolo dei TKI di terza generazione". Napoli, 16-17 dicembre 2019
229. "CAMPUS Chronic Myeloid Leukemia". Roma, 30 gennaio 2020
230. "Neoplasie Mieloproliferative Ph-negative". Bologna, 31 gennaio 2020
231. 4th Annual Davidoff Hematology Conference: Hematology 2020: "To Be or Not to Be MRD

- Negative - That is the Question". Tel Aviv, Israele, 27 febbraio 2020
232. 25<sup>th</sup> Meeting of the European Hematology Association (EHA), virtual. 11-21 giugno 2020
233. 2020 SOHO Annual Virtual Meeting, 9-12 settembre 2020
234. "Leucemia mieloide cronica 20 anni dopo: le nuove sfide" Webinar live - 9 ottobre 2020
235. Progetto Ematologia Romagna: "Le conoscenze in biologia corrono!": Ravenna, 10 ottobre 2020
236. "L'ottimizzazione della gestione del paziente con LLA Ph+ alla luce delle recenti evidenze scientifiche" evento live – 10, 13 e 23 novembre 2020
237. "La mastocitosi sistemica" corso di Formazione a Distanza sincrona, 16 novembre 2020
238. "CAMPUS Chronic Myeloid Leukemia". Webinar. 28-29 gennaio 2021
239. Leukemia AIL 2020-2021. Virtual congress. 26-27 aprile 2021
240. Bio-Rad's Droplet Digital PCR World Global Virtual Symposium 2021. 26 maggio-2 giugno 2021.
241. Workshop educazionale on web: "UPDATE SULLA NMP PH-NEGATIVE E LMC" - 6 luglio 2021.
242. 2021 SOHO Annual Virtual Meeting. 8-11 settembre 2020.
243. Progetto Ematologia Romagna: "Dallo studio del genoma una terapia senza citotossici in ematologia: sogno o realtà?" Ravenna, 18 settembre 2021.
244. SOHO Italy 2021. Roma, 27-30 settembre 2021.
245. "Gestione del paziente con neoplasie mieloproliferative e mastocitosi". Webinar. 23 settembre 2021.
246. 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy. Virtual. 7-10 ottobre 2021.
247. "Alla ricerca della malattia minima residua: un percorso verso la guarigione". Brescia, 8-9 ottobre 2021.
248. International symposium on "New biological insights and novel drugs in chronic myeloid leukemia". Venezia, 12-13 ottobre 2021.
249. The 2nd Virtual Congress on Controversies in Leukemias (Euroleuk2021). 28-29 ottobre 2021.
250. "CML ONE". Madrid, Spagna, 28-30 ottobre 2021.
251. 1° Congresso dell'Associazione RIMA (Rete Italiana Mastocitosi). Verona, 3 dicembre 2021.
252. "Essentials in Hematology 2021". Roma, 20 dicembre 2021.
253. VI Simposio Annual GELMC. Virtual. 23-24 febbraio 2022.
254. 2022 Korean Society of Hematology International Conference and 63<sup>rd</sup> Annual Meeting. Virtual. 31 marzo – 2 aprile 2022.
255. EICML Meeting 2022. Windsor, UK. 20-22 maggio 2022.
256. "In conversation with..." Webinar. 26 maggio 2022.
257. Droplet Digital PCR Scientific Conference 2022 – Italy. Roma. 14 settembre 2022.
258. 2022 SOHO Annual Meeting, Houston, Texas (USA), 28 settembre – 1 ottobre 2022.
259. Tavola Rotonda: "L'evoluzione della terapia della leucemia linfoblastica acuta Ph+: stato dell'arte e direzioni future". Roma. 21 settembre 2022.
260. Tavola Rotonda: "L'evoluzione della terapia della leucemia linfoblastica acuta Ph+: stato dell'arte e direzioni future". Mestre. 30 settembre 2022.
261. CAMPUS CML. Roma. 12-13 ottobre 2022.
262. "Leucemia mieloide cronica: la storia siamo noi". Siena. 19 ottobre 2022.
263. 24th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy. Mandelieu-La Napoule, Francia. 21-23 ottobre 2022.
264. 4<sup>th</sup> SOHO Italy Annual Conference 2022. Roma. 23-26 ottobre 2022.
265. Preceptorship "How we treat CML and PH+ ALL: the experience of the GIMEMA CML

- Working Party". Bologna. 28-29 ottobre 2022
266. "IL ruolo dell'NGS: dalla diagnostica oncoematologica al trapianto di cellule staminali emopoietiche" Piacenza. 14 novembre 2022.
267. CML ONE. Barcellona, Spagna. 18-19 novembre 2022.
268. "WORKSHOP EDUCAZIONALE "on web": Update sulle Mielofibrosi e Leucemia Mieloide Cronica". Virtual. 22 novembre 2022.
269. 2° Congresso dell'Associazione RIMA (Rete Italiana MAstocitosi). Milano, 25 novembre 2022.
270. "Scenari attuali e sfide future nel trattamento delle leucemie Ph+". Udine. 9-10 febbraio 2023.
271. "First international Michele Bacarani Conference on CML and related diseases". Torino. 10-11 febbraio 2023.
272. "43e Congres de la Societé Francaise d'Hematologie (SFH)" Parigi, Francia. 29-31 marzo 2023.
273. "The 1st SOHO – Israel Meeting and 7th International Davidoff Conference: State of the art and next questions." Tel Aviv, Israele. 3-4 maggio 2023.
274. King's CML Academy. Virtual. 4 maggio 2023.
275. EICML Meeting 2023. Napoli. 13-14 maggio 2023.
276. MRD in Oncoematologia. Milano. 27-28 giugno 2023.
277. 2023 SOHO Annual Meeting, Houston, Texas (USA). 6-9 settembre 2023.
278. "10 years of ICLUSIG® (ponatinib): A CML expert-led discussion". Londra. 21 settembre 2023.
279. 23 Annual Meeting of European Competence Network on Mastocytosis (ECNM). Anversa, Belgio. 21-23 settembre 2023.
280. 25th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy. Mandelieu-La Napoule, Francia. 6-8 ottobre 2023.
281. Preceptorship "How we treat CML and PH+ ALL: the experience of the GIMEMA CML Working Party". Bologna. 13-14 ottobre 2023.
282. CAMPUS CML. Roma. 23-24 novembre 2023.
283. 3° Congresso dell'Associazione RIMA (Rete Italiana MAstocitosi). Firenze. 24 novembre 2023.
284. 65th ASH Annual Meeting. San Diego, CA. 9-12 dicembre 2023.
285. 18th Post ASH CML MPN Workshop. San Diego, CA. 12-13 dicembre 2023.
286. "Avapritinib: Drive the change – Guidare il cambiamento per costruire il future della mastocitosi sistemica". Napoli, 29 febbraio-1 marzo 2024.
287. Lettura sponsorizzata nell'ambito del congresso SIES 2024: "La medicina di precisione nella mastocitosi sistemica avanzata: l'analisi molecolare ed il target selettivo di KIT D816V con avapritinib. Firenze, 7 marzo 2024.
288. "Second International Michele Bacarani Conference on CML and Philadelphia-negative myeloproliferative disorders". Brescia, 22-23 marzo 2024.
289. Keynote lecture al 18° Annual Symposium of the European LeukemiaNet. Mannheim, Germania, 18 aprile 2024.
290. EICML 2024. Bordeaux, Francia, 26-28 aprile 2024.
291. "Ruolo dei TKIs nelle leucemie Philadelphia-positive: esperienze a confronto." Milano, 17 maggio 2024.
292. 2nd SOHO Israel Meeting – 8th International Davidoff Conference: State of the Art and Next Questions. Tel Aviv, Israele, 23-24 maggio 2024.

## Allegato 5

### CONGRESSI E CORSI D'AGGIORNAMENTO ORGANIZZATI IN QUALITA' DI MEMBRO DEL COMITATO SCIENTIFICO/SEGRETERIA SCIENTIFICA

---

1. "Next-Generation Sequencing for Targeted Personalized Therapy of Leukemia – I act"  
Bologna, 30 novembre - 1 dicembre 2012
2. "Novità in Oncoematologia al post-AACR 2014", Bologna, 5 giugno 2014
3. Educational Meeting on NGS in Ph+ Leukemia. Milano, 17 maggio 2017
4. Educational Meeting on NGS in Ph+ Leukemia. Roma, 18 maggio 2017
5. NEXT GENERATION SEQUENCING: il futuro e' routine. Bologna, 8 giugno 2017
6. Educational Meeting on NGS in Ph+ Leukemia. Roma, 15 marzo 2018
7. Educational Meeting on NGS in Ph+ Leukemia. Milano, 16 marzo 2018
8. "Focus on Mastocitosi: approccio diagnostico e terapeutico alla patologia". Bologna, 18 novembre 2018
9. "L'ottimizzazione della gestione del paziente con LLA Ph+ alla luce delle recenti evidenze scientifiche" evento live – 10 novembre 2020
10. "L'ottimizzazione della gestione del paziente con LLA Ph+ alla luce delle recenti evidenze scientifiche" evento live – 13 novembre 2020
11. "L'ottimizzazione della gestione del paziente con LLA Ph+ alla luce delle recenti evidenze scientifiche" evento live – 23 novembre 2020



## Allegato 6

### PARTECIPAZIONE A CONGRESSI E CORSI D'AGGIORNAMENTO IN QUALITA' DI DISCENTE

1. "European Hematology Network DG-V RQ-PCR for MRD detection in Leukemia"; Capri (NA), 15-17 ottobre 1999
2. Corso "PCR OVERVIEW"; Bologna, CNR Area della Ricerca, 18 novembre 1999
3. "La vaccinazione antitumorale: una speranza o una realtà?"; Bologna, 21 febbraio 2000
4. "VI Congresso Nazionale della Società Italiana di Ematologia Sperimentale (SIES)"; Bologna, 26-28 settembre 2000
5. "I° Workshop di Analisi Computazionale del Genoma"; Bologna, CINECA, 19 gennaio 2001
6. "VIII<sup>th</sup> International Myeloma Workshop"; Banff, Canada, 4-8 maggio 2001
7. "38° Congresso Nazionale della Società Italiana di Ematologia (SIE)"; Firenze, 7-10 ottobre 2001
8. "43<sup>rd</sup> Annual Meeting of the American Society of Hematology (ASH)"; Orlando, Florida (USA), 8-11 dicembre 2001
9. "7<sup>th</sup> Congress of the European Hematology Association (EHA)"; Firenze, 6-9 giugno 2002
10. "IX<sup>th</sup> International Myeloma Workshop"; Salamanca, Spagna, 23-25 maggio 2003
11. "39° Congresso Nazionale della Società Italiana di Ematologia (SIE)"; Roma, 26-29 ottobre 2003
12. "45<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; San Diego, California (USA), 6-9 dicembre 2003
13. "1<sup>st</sup> MRD Workpackage meeting"; Monaco, Germania, 21 febbraio 2004
14. "9<sup>th</sup> Congress of the European Hematology Association (EHA)"; Ginevra, Svizzera, 10-13 giugno 2004
15. Meeting Discutiamone Insieme "Le basi molecolari dell'emopoiesi normale e patologica"; Firenze, 24 giugno 2004
16. "VIII Congresso Nazionale della Società Italiana di Ematologia Sperimentale (SIES)"; Pavia, 14-16 settembre 2004
17. "46<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; San Diego, California (USA), 4-7 dicembre 2004
18. "2<sup>nd</sup> Symposium of the European LeukemiaNet"; Heidelberg, Germania, 1-3 febbraio 2005
19. "Applicazioni in Medicina Molecolare"; Bologna, 4 aprile 2005
20. "96<sup>th</sup> AACR Annual Meeting"; Anaheim, California (USA), 16-20 aprile 2005
21. "10<sup>th</sup> Congress of the European Hematology Association (EHA)"; Stoccolma, Svezia, 2-5 giugno 2005
22. "40° Congresso Nazionale della Società Italiana di Ematologia (SIE)"; Bergamo, 3-6 luglio 2005
23. "Investigators' Meeting CSTI571K2301"; Berlino, Germania, 14-15 settembre 2005
24. "New Drugs in Hematology"; Bologna, 9-11 ottobre 2005
25. "47<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; Atlanta, Georgia (USA) 10-13 dicembre 2005
26. "3<sup>rd</sup> Annual Symposium of the European LeukemiaNet"; Heidelberg, Germania, 31 gennaio-2 febbraio 2006
27. "11<sup>th</sup> Congress of the European Hematology Association (EHA)"; Amsterdam, Olanda, 15-18 giugno 2006
28. "IX Congresso Nazionale della Società Italiana di Ematologia Sperimentale (SIES)"; Napoli,

20-22 settembre 2006

29. 48<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; Orlando, Florida (USA), 9-12 dicembre 2006
30. "4<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Heidelberg, Germania, 30 gennaio-1 febbraio 2007
31. "AACR Annual Meeting 2007"; Los Angeles, California (USA), 14-18 aprile 2007
32. "12<sup>th</sup> Congress of the European Hematology Association (EHA)"; Vienna, Austria, 7-10 giugno 2007
33. "Copy Number Morning"; Milano, 9 ottobre 2007
34. "49<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; Atlanta, Georgia (USA) 8-11 dicembre 2007
35. "Investigator Meeting Protocollo CML0307"; Bologna, 21 gennaio 2008
36. "5<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Heidelberg, Germania, 29-31 gennaio 2008
37. "La statistica medica: la sperimentazione clinica fra etica e statistica"; Spineto (SI), 29-30 maggio 2008
38. "13<sup>th</sup> Congress of the European Hematology Association (EHA)"; Copenhagen, Danimarca, 12-15 giugno 2008
39. "17<sup>th</sup> International CML-Workshop / EUTOS for CML"; Heidelberg, Germania, 4-5 luglio 2008
40. "New Drugs in Hematology"; Bologna, 5-7 ottobre 2008
41. "50<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; San Francisco, California (USA), 6-9 dicembre 2008
42. "Studi di SNIPS e di genomica nelle LAL-B"; Roma, 13 gennaio 2009
43. "6<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 3-5 febbraio 2009
44. "AACR Annual Meeting 2009"; Denver, Colorado (USA), 18-22 aprile 2009
45. "14<sup>th</sup> Congress of the European Hematology Association (EHA)"; Berlino, Germania, 4-7 giugno 2009
46. "Dalla biologia della cellula leucemica ai nuovi approcci terapeutici"; Bologna, 28 settembre 2009
47. "42° Congresso Nazionale della Società Italiana di Ematologia (SIE)"; Milano, 18-21 ottobre 2009
48. "51<sup>st</sup> Annual Meeting of the American Society of Hematology (ASH)"; New Orleans, Louisiana (USA), 5-8 dicembre 2009
49. "7<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 1-3 febbraio 2010
50. "Discutiamone Insieme"; Firenze, 18 marzo 2010
51. "15<sup>th</sup> Congress of the European Hematology Association (EHA)"; Barcellona, Spagna, 10-13 giugno 2010
52. "XI Congresso Nazionale della Società Italiana di Ematologia Sperimentale (SIES)"; Torino, 6-8 ottobre 2010
53. "52<sup>nd</sup> Annual Meeting of the American Society of Hematology (ASH)"; Orlando, Florida (USA), 4-7 dicembre 2010
54. "8<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 1-3 febbraio 2011
55. "Training course Roche GS Junior"; Bologna, 22-24 marzo 2011
56. "16<sup>th</sup> Congress of the European Hematology Association (EHA)"; Londra, Regno Unito, 9-

12 giugno 2011

57. "43° Congresso Nazionale della Società Italiana di Ematologia (SIE)"; Napoli, 16-19 ottobre 2011
58. "53<sup>rd</sup> Annual Meeting of the American Society of Hematology (ASH)"; San Diego, California (USA), 10-13 dicembre 2011
59. "9<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 31 gennaio-1 febbraio 2012
60. "IRON II Investigator Meeting"; Monaco, Germania, 23-24 maggio 2012
61. "2012 American Society of Clinical Oncology (ASCO) Annual Meeting"; Chicago, Illinois (USA), 1-5 giugno 2012
62. "17<sup>th</sup> Congress of the European Hematology Association (EHA)"; Amsterdam, Olanda, 14-17 giugno 2012
63. "XII Congresso Nazionale della Società Italiana di Ematologia Sperimentale (SIES)"; Roma, 17-19 ottobre 2012
64. "54<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; Atlanta, Georgia (USA), 8-11 dicembre 2012
65. "10<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 4-6 febbraio 2013
66. "AACR Annual Meeting 2013"; Washington, DC (USA), 18-22 aprile 2013
67. "18<sup>th</sup> Congress of the European Hematology Association (EHA)"; Stoccolma, Svezia, 13-16 giugno 2013
68. "55<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; New Orleans, Louisiana (USA), 8-11 dicembre 2013
69. "11<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 4-5 febbraio 2014
70. "19<sup>th</sup> Congress of the European Hematology Association (EHA)"; Milano, 12-15 giugno 2014
71. "56<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; San Francisco, California (USA), 5-8 dicembre 2014
72. "20<sup>th</sup> Congress of the European Hematology Association (EHA)"; Vienna, 11-14 giugno 2015
73. 13<sup>th</sup> Meeting of the European Competence Network on Mastocytosis (ECNM), Monaco di Baviera, Germania, 8-10 ottobre 2015
74. "57<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; Orlando, Florida, (USA), 4-8 dicembre 2015
75. "21<sup>st</sup> Congress of the European Hematology Association (EHA)"; Copenhagen, Danimarca, 9-12 giugno 2016
76. "XIV Congresso Nazionale della Società Italiana di Ematologia Sperimentale (SIES)"; Rimini, 19-21 ottobre 2016
77. "58<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; San Diego, California, (USA), 3-6 dicembre 2016
78. "14<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 4-5 febbraio 2017
79. "22<sup>nd</sup> Congress of the European Hematology Association (EHA)"; Madrid, Spagna 22-25 giugno 2017
80. "59<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; Atlanta, Georgia, (USA), 9-12 dicembre 2017
81. "23<sup>rd</sup> Congress of the European Hematology Association (EHA)"; Stoccolma, Svezia, 14-17 giugno 2018


82. "XV Congresso Nazionale della Società Italiana di Ematologia Sperimentale (SIES)"; Rimini, 18-20 ottobre 2018
83. "60<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; San Diego, California, (USA), 1-4 dicembre 2018
84. "16<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 12 febbraio 2019
85. "24<sup>th</sup> Congress of the European Hematology Association (EHA)"; Amsterdam, Olanda, 13-16 giugno 2019
86. "47° Congresso Nazionale della Società Italiana di Ematologia (SIE)"; Roma, 7-9 ottobre 2019
87. "61<sup>st</sup> Annual Meeting of the American Society of Hematology (ASH)"; Orlando, California, (USA), 7-10 dicembre 2019
88. "25<sup>th</sup> Congress of the European Hematology Association (EHA)", virtual edition; 2020
89. "26<sup>th</sup> Congress of the European Hematology Association (EHA)", virtual edition; 2021
90. "18<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 15 marzo 2022
91. "17° Congresso Nazionale della Società Italiana di Ematologia Sperimentale (SIES)"; Roma, 31 marzo-2 aprile 2022
92. "64<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH)"; New Orleans, Louisiana, (USA), 10-13 dicembre 2022
93. "19<sup>th</sup> Annual Symposium of the European LeukemiaNet"; Mannheim, Germania, 18 aprile 2023
94. "28<sup>th</sup> Congress of the European Hematology Association (EHA)", Francoforte, Germania; 8-11 giugno 2023
95. "29<sup>th</sup> Congress of the European Hematology Association (EHA)", Madrid, Spagna; 13-16 giugno 2024.

La sottoscritta, consapevole delle responsabilità penali previste dagli artt. 75 e 76 del D.P.R. n.445 del 28/12/2000 per le ipotesi di falsità negli atti e dichiarazioni mendaci, dichiara di aver redatto il presente curriculum sotto la propria personale responsabilità, ai sensi degli artt. 46 e 47 del predetto D.P.R. n.445/2000.

Ai sensi del D.LGS. 196/03 e s.m.i. dichiara inoltre il consenso al trattamento dei dati personali contenuti nel presente documento.

Bologna, 16/06/2024

In fede



## **AUTODICHIARAZIONE AI SENSI DEGLI ARTT. 46 E 47 D.P.R. N. 445/2000**

La sottoscritta SIMONA SOVERINI, nata il 03.09.1975 a BOLOGNA (BO),  
residente in CASTEL MAGGIORE (BO), via CAMILLO TORRES 8,  
identificata a mezzo della C.I. nr. AT 8513166,  
rilasciata da COMUNE DI CASTEL MAGGIORE in data 07.05.2013,  
utenza telefonica 339 7688671,  
consapevole delle conseguenze penali previste in caso di dichiarazioni mendaci a pubblico  
ufficiale (art. 495 c.p.)

### **DICHIARA SOTTO LA PROPRIA RESPONSABILITÀ**

- che le informazioni e le dichiarazioni contenute nel presente curriculum vitae corrispondono al vero;
- di essere in possesso di tutti i titoli riportati nel presente curriculum vitae;
- che ogni contenuto relativo a titoli, pubblicazioni e attività svolte riportate nel presente curriculum vitae corrisponde al vero;
- che le copie delle pubblicazioni presentate ai fini della valutazione analitica sono conformi all'originale.

Bologna, 6/02/2024

Firma

